force_id,pt_report,xgb_report,psu_occlusion,pt_psu_gt,gpt_0shot_response,gpt_1shot_response,gpt_2shot_response,gpt_3shot_response,human_assessment0,human_assessment1,human_assessment2,human_assessment3,yesno_gt
BCH-ALDNOR-1," Pt Clinical Surgical History 
 Cardiac diagnosis: Atrioventricular canal defect
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.0
 Patient weight: 68.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7662057085170642
 Heart rate: 85.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Left ventricle end-diastolic volume: 57.7
 Left ventricle end-systolic volume: 33.2
 Left ventricular mass: 35.0
 Right ventricular end-diastolic volume: 134.5
 Right ventricular end-systolic volume: 72.7
 Right ventricle mass: 54.6
 Native aorta flow rate: 5.25
 Ascending aorta, above the Stansel flow rate: 5.25
 Right atrioventricular valve/tricuspid inflow rate: 3.64
 Left atrioventricular valve/mitral inflow rate: 1.19
 Aortic or native aortic regurgitation fraction: 4.0
 Single ventricle ejection fraction 0.4490114464099895
 Single ventricle systolic volume 86.29999999999998
 Body mass index 25.98689224203627
 Mass to height volume indexed on BSA (exp = 2.7) 24.35664523003953
 Systemic ventricle end-systolic volume: 105.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 59.959040721771544
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 50.55245959852313
 Systemic ventricle end-diastolic volume: 192.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.82084633356457
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.74865660846217
 Systemic ventricle mass: 89.6
 Systemic ventricle mass indexed on BSA (exp=1) 50.73021764561595
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.77148611924147
 Systemic ventricle mass to volume ratio: 1.0125337439518596
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5732818884398239
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.48334344837835447
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Large metallic artifacts from stainless steel coils obscuring most of the upper thorax, including the aorta, pulmonary arteries, superior vena cava, atria, Fontan pathways, and pulmonary veins but allowing measurements of ventricular volumes and flow in the aortic and atrioventricular valves.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01098548].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the available data, it is reasonable to predict that the patient does not have a diagnosis of seizures requiring antiepileptic medications (i.e., the occluded outcome is ""no""). The patient exhibits a complex cardiac history with an atrioventricular canal defect and has undergone multiple surgeries but lacks any current neurological issues as noted in their clinical status updates. Additionally, the predicted probability of having seizures, as indicated by the XGBoost model (0.01098548), is quite low, and there are no documented indications of any seizure history. The absence of any neurological complications, alongside the low prediction probability, supports the conclusion that this patient is unlikely to have seizures necessitating treatment with antiepileptic medications.","Based on the provided data and the model's prediction, it is predicted that the main patient does **not have a diagnosis of seizures requiring antiepileptic medications.** This conclusion is supported by the fact that similar patients with comparable surgical histories and MRI findings demonstrated a low prevalence of seizure diagnoses, as indicated by the similar patient's status updates, which uniformly report no history of seizures or the need for antiepileptic medications. Additionally, the XGBoost model gives a very low probability (approximately 1.1%) for the occluded outcome being 'yes', suggesting that the likelihood of this diagnosis is notably low for patients within this cohort. Overall, the clinical and MRI findings of the main patient do not indicate risk factors commonly associated with seizures, further reinforcing the prediction.","Based on the provided information, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The main patient has a complex cardiac history with no recorded instances of seizures, strokes, or other major complications that are often associated with seizure disorders. Moreover, similar patients diagnosed with complex conditions such as hypoplastic left heart syndrome and other single ventricle defects showed low incidence rates of seizures, as indicated by their records. The XGBoost model's predicted probability of seizures being present for the cohort is quite low (0.01098548), which substantiates the inference that seizures are unlikely for this patient. Overall, the combination of the individual patient’s medical background and trends observed in similar patients supports the conclusion that the occluded outcome is likely negative for seizures.","Based on the provided data, the predicted outcome for the main patient regarding the diagnosis of seizures requiring antiepileptic medications is **no**. The main patient has not exhibited any history of seizures, nor have they been listed as requiring antiepileptic treatments. Furthermore, among the similar patients, none have a documented history of seizures, although a small cohort does indicate a possible risk; the XGBoost model's predicted probability reflects a very low likelihood (approximately 1.1%) of such a diagnosis. The model's strong accuracy and AUC also suggest that this is a rare condition within this cohort, reinforcing the likelihood that the main patient does not have a diagnosis of seizures requiring antiepileptic medications.",1,1,1,1,0
BCH-ALDNOR-1," Pt Clinical Surgical History 
 Cardiac diagnosis: Atrioventricular canal defect
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.0
 Patient weight: 68.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7662057085170642
 Heart rate: 85.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Left ventricle end-diastolic volume: 57.7
 Left ventricle end-systolic volume: 33.2
 Left ventricular mass: 35.0
 Right ventricular end-diastolic volume: 134.5
 Right ventricular end-systolic volume: 72.7
 Right ventricle mass: 54.6
 Native aorta flow rate: 5.25
 Ascending aorta, above the Stansel flow rate: 5.25
 Right atrioventricular valve/tricuspid inflow rate: 3.64
 Left atrioventricular valve/mitral inflow rate: 1.19
 Aortic or native aortic regurgitation fraction: 4.0
 Single ventricle ejection fraction 0.4490114464099895
 Single ventricle systolic volume 86.29999999999998
 Body mass index 25.98689224203627
 Mass to height volume indexed on BSA (exp = 2.7) 24.35664523003953
 Systemic ventricle end-systolic volume: 105.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 59.959040721771544
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 50.55245959852313
 Systemic ventricle end-diastolic volume: 192.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.82084633356457
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.74865660846217
 Systemic ventricle mass: 89.6
 Systemic ventricle mass indexed on BSA (exp=1) 50.73021764561595
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.77148611924147
 Systemic ventricle mass to volume ratio: 1.0125337439518596
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5732818884398239
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.48334344837835447
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Large metallic artifacts from stainless steel coils obscuring most of the upper thorax, including the aorta, pulmonary arteries, superior vena cava, atria, Fontan pathways, and pulmonary veins but allowing measurements of ventricular volumes and flow in the aortic and atrioventricular valves.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00078829].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided data about the main patient, I predict that the missing clinical outcome regarding the history of pacemaker placement is **no**. The patient has shown no significant arrhythmias or complications that typically warrant the need for a pacemaker, as indicated by their history of no sustained ventricular tachyarrhythmias and the absence of any reports of atrial arrhythmias. Additionally, the patient's ongoing stable status, as seen in their cardiac MRI findings and treatment regimen (which does not include beta-blockers or other arrhythmia-related medications), supports the conclusion that there has been no need for pacemaker intervention. Furthermore, the extremely low predicted probability of the occluded outcome being 'yes' (0.00078829) aligns with this reasoning, suggesting a very low likelihood of previous pacemaker placement.","Based on the information provided, the prediction for whether the main patient has a history of pacemaker placement is **no**. The patient underwent a complex surgical history, including a lateral tunnel Fontan and has been reported to have mild atrioventricular valve regurgitation and trivial semi-lunar valve regurgitation, which typically suggests preserved ventricular function. Additionally, the similar patients, particularly those with comparable outcomes and surgical histories, predominantly show no history of pacemaker placement unless they exhibited more severe complications, which this patient has not. The XGBoost model further supports this prediction with a very low predicted probability of the outcome being 'yes' (0.00078829), reinforcing the likelihood that this patient is managing well post-surgery without the need for a pacemaker intervention.","Based on the main patient's extensive surgical history and MRI findings, along with similar patients' data, the prediction for whether this patient has a history of pacemaker placement is **no**. The patient has a complex surgical background, including a fenestrated Fontan procedure and interventions that suggest ongoing ventricular function management without the requirement for a pacemaker. 

Moreover, analyzing similar patients reveals a trend where those without significant arrhythmias or complications related to their Fontan status (such as atrial tachyarrhythmias or frequent adjustments to ventricular function) generally did not require pacemakers. The XGBoost model's low predicted probability (0.00078829) for the outcome being 'yes' further supports that this patient is unlikely to have a history of pacemaker placement. Thus, considering both clinical outcomes of similar cohorts and the main patient’s pathology, a pacemaker has not been indicated in their management thus far.","Based on the analysis of the main patient’s data and the trends observed from similar patients, it is predicted that the patient does not have a history of pacemaker placement. The main patient has undergone several surgeries including Fontan surgery and associated interventions, but there is no documented history of a pacemaker placement in their status event updates. Furthermore, similar patients with comparable surgical histories, particularly those with right-dominant morphology like the main patient, have generally shown low incidences of pacemaker placements unless specifically indicated by arrhythmias or conduction abnormalities. Additionally, the low predicted probability from the XGBoost model (0.00078829) further supports this conclusion, suggesting that such an occurrence is quite rare in this patient context.",1,1,1,1,0
BCH-ALDNOR-1," Pt Clinical Surgical History 
 Cardiac diagnosis: Atrioventricular canal defect
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.0
 Patient weight: 68.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7662057085170642
 Heart rate: 85.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Left ventricle end-diastolic volume: 57.7
 Left ventricle end-systolic volume: 33.2
 Left ventricular mass: 35.0
 Right ventricular end-diastolic volume: 134.5
 Right ventricular end-systolic volume: 72.7
 Right ventricle mass: 54.6
 Native aorta flow rate: 5.25
 Ascending aorta, above the Stansel flow rate: 5.25
 Right atrioventricular valve/tricuspid inflow rate: 3.64
 Left atrioventricular valve/mitral inflow rate: 1.19
 Aortic or native aortic regurgitation fraction: 4.0
 Single ventricle ejection fraction 0.4490114464099895
 Single ventricle systolic volume 86.29999999999998
 Body mass index 25.98689224203627
 Mass to height volume indexed on BSA (exp = 2.7) 24.35664523003953
 Systemic ventricle end-systolic volume: 105.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 59.959040721771544
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 50.55245959852313
 Systemic ventricle end-diastolic volume: 192.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.82084633356457
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.74865660846217
 Systemic ventricle mass: 89.6
 Systemic ventricle mass indexed on BSA (exp=1) 50.73021764561595
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.77148611924147
 Systemic ventricle mass to volume ratio: 1.0125337439518596
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5732818884398239
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.48334344837835447
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Large metallic artifacts from stainless steel coils obscuring most of the upper thorax, including the aorta, pulmonary arteries, superior vena cava, atria, Fontan pathways, and pulmonary veins but allowing measurements of ventricular volumes and flow in the aortic and atrioventricular valves.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.03919285].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data for the main patient, I would predict that the patient has **not died**. The key indicators supporting this prediction include the patient's relatively stable clinical history, with no significant adverse events such as cardiac arrest, stroke, or severe complications like protein-losing enteropathy or plastic bronchitis. Additionally, the patient's MRI results indicate moderately preserved heart function with a single ventricle ejection fraction of around 0.45, and no history of significant arrhythmias or thrombus, which suggests a lower risk for mortality. Furthermore, the XGBoost model's predicted probability of the occluded outcome being 'yes' (indicating death) is only approximately 3.92%, which aligns with the overall encouraging clinical parameters of this patient.","Based on the provided data, I predict that the occluded clinical outcome for the main patient, ""Has the patient died?"" is **no**. The main patient has a complex history including a surgical diagnosis of an atrioventricular canal defect and underwent multiple surgeries, including a lateral tunnel Fontan with fenestration. Although the MRI reports indicate some challenges, such as significant metallic artifacts, the overall cardiac function appears stable, with a single ventricle ejection fraction of 0.45 and no significant reported complications like thrombus or enteropathy that are frequent precursors to mortality in this population.

In comparison, the similar patients studied also show consistent outcomes with low mortality rates despite their complex surgical histories. Notably, the XGBoost model suggests a low predicted probability (around 3.92%) for the occluded outcome being 'yes,' which indicates a strong likelihood that similar patients have survived. Given these observations and the main patient's overall clinical stability, it is reasonable to conclude that the answer to whether the patient has died is no.","Based on the provided data, the predicted outcome for the main patient is ""no,"" they have not died. The patient's clinical history indicates they have undergone multiple complex surgeries associated with congenital heart defects, including a lateral tunnel Fontan and have a history of fenestration. Their MRI report shows a preserved ventricular function with a single ventricle ejection fraction of approximately 0.45, suggesting functional capacity is still present. Furthermore, when examining similar patients, especially those with atrioventricular canal defects and similar procedural histories, the majority have not experienced mortality, indicating that while there are risks, the clinical trajectory for such patients often remains stable if without significant postoperative complications. Additionally, the XGBoost model predicts a very low probability of a severe adverse outcome (like death), reinforcing the expectation of survival.","**Predicted Outcome:** No

**Reasoning:** The main patient has undergone multiple successful cardiac interventions, including a lateral tunnel Fontan procedure with the presence of a fenestration, which typically indicates better hemodynamic stability post-surgery. While there are factors such as the history of atrioventricular canal defect and suspected heterotaxy that may be concerning, similar patients with comparable surgical histories and MRI evaluations show a high survival rate post-Fontan, particularly when there are no significant complications reported, as evidenced by the high accuracy (0.96) and AUC (0.87) of the predictive model. The predicted probability of outcomes aligned with death was quite low (3.92%), further supporting the likelihood that this patient has not died based on both their clinical context and the trends observed in similar patient cohorts.",1,1,1,1,0
BCH-ALDNOR-1," Pt Clinical Surgical History 
 Cardiac diagnosis: Atrioventricular canal defect
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.0
 Patient weight: 68.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7662057085170642
 Heart rate: 85.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Left ventricle end-diastolic volume: 57.7
 Left ventricle end-systolic volume: 33.2
 Left ventricular mass: 35.0
 Right ventricular end-diastolic volume: 134.5
 Right ventricular end-systolic volume: 72.7
 Right ventricle mass: 54.6
 Native aorta flow rate: 5.25
 Ascending aorta, above the Stansel flow rate: 5.25
 Right atrioventricular valve/tricuspid inflow rate: 3.64
 Left atrioventricular valve/mitral inflow rate: 1.19
 Aortic or native aortic regurgitation fraction: 4.0
 Single ventricle ejection fraction 0.4490114464099895
 Single ventricle systolic volume 86.29999999999998
 Body mass index 25.98689224203627
 Mass to height volume indexed on BSA (exp = 2.7) 24.35664523003953
 Systemic ventricle end-systolic volume: 105.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 59.959040721771544
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 50.55245959852313
 Systemic ventricle end-diastolic volume: 192.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.82084633356457
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.74865660846217
 Systemic ventricle mass: 89.6
 Systemic ventricle mass indexed on BSA (exp=1) 50.73021764561595
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.77148611924147
 Systemic ventricle mass to volume ratio: 1.0125337439518596
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5732818884398239
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.48334344837835447
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Large metallic artifacts from stainless steel coils obscuring most of the upper thorax, including the aorta, pulmonary arteries, superior vena cava, atria, Fontan pathways, and pulmonary veins but allowing measurements of ventricular volumes and flow in the aortic and atrioventricular valves.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.06742494].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the information provided, I predict that the main patient does **not** have a history of ascites (> trace). This conclusion is supported by the lack of any documented history of complications such as protein-losing enteropathy, significant pleural effusions, or liver dysfunction, all of which are commonly associated with ascites in patients who have undergone Fontan procedures. Additionally, the MRI findings indicating that the patient has only mild atrioventricular valve regurgitation and trivial to mild semilunar valve regurgitation suggest stable hemodynamics, which reduces the likelihood of fluid accumulation such as ascites. The low predicted probability of the occluded outcome (0.0674) further reinforces the expectation that ascites is not a concern for this patient.","Based on the provided data, it is predicted that the main patient does **not** have a history of ascites (> trace). The patient's clinical profile indicates a complex history, including a lateral tunnel Fontan operation and a fenestration, but there are no documented complications such as protein-losing enteropathy or pleural effusions, which often correlate with ascites in single-ventricle patients. Additionally, comparative analysis of similar patients reveals a subset who also exhibited similar surgical histories and MRI characteristics but did not experience significant ascites, aligning with the main patient's clinical status. This trend, combined with a low predicted probability (6.74%) from the XGBoost model of experiencing this outcome, supports the conclusion that the patient likely does not have a history of ascites.","Based on the provided data, the main patient does not have a documented history of ascites (> trace) as indicated by their medical history, and they have not been reported to experience pleural effusions, chylous or otherwise, greater than 30 days after surgery. When comparing to similar patients, those with a history of ascites tended to have complications like protein-losing enteropathy or plastic bronchitis, which were absent in this patient. Furthermore, the low predicted probability from the XGBoost model (0.067) suggests that the likelihood of developing ascites is quite low in this cohort, reinforcing that the patient likely does not have a history of ascites. Therefore, the reasonable conclusion is that the patient's history does not indicate the presence of ascites. Thus, the answer is **no**.","Based on the provided data, it is predicted that the main patient does not have a history of ascites (> trace) as there are no indications in the patient's status update. The similar patients' data also shows a relatively low prevalence of ascites in the cohort, suggesting that a history of ascites is not common among patients with similar surgical histories and MRI findings. Furthermore, the XGBoost model predicts a very low probability (6.74%) of the occluded outcome being 'yes', which reinforces the likelihood that the main patient is also not experiencing this condition given the absence of supporting clinical indicators. Therefore, the most reasonable conclusion is that the main patient does not have a history of ascites.",1,1,1,1,0
BCH-ALDNOR-1," Pt Clinical Surgical History 
 Cardiac diagnosis: Atrioventricular canal defect
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.0
 Patient weight: 68.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7662057085170642
 Heart rate: 85.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Left ventricle end-diastolic volume: 57.7
 Left ventricle end-systolic volume: 33.2
 Left ventricular mass: 35.0
 Right ventricular end-diastolic volume: 134.5
 Right ventricular end-systolic volume: 72.7
 Right ventricle mass: 54.6
 Native aorta flow rate: 5.25
 Ascending aorta, above the Stansel flow rate: 5.25
 Right atrioventricular valve/tricuspid inflow rate: 3.64
 Left atrioventricular valve/mitral inflow rate: 1.19
 Aortic or native aortic regurgitation fraction: 4.0
 Single ventricle ejection fraction 0.4490114464099895
 Single ventricle systolic volume 86.29999999999998
 Body mass index 25.98689224203627
 Mass to height volume indexed on BSA (exp = 2.7) 24.35664523003953
 Systemic ventricle end-systolic volume: 105.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 59.959040721771544
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 50.55245959852313
 Systemic ventricle end-diastolic volume: 192.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.82084633356457
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.74865660846217
 Systemic ventricle mass: 89.6
 Systemic ventricle mass indexed on BSA (exp=1) 50.73021764561595
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.77148611924147
 Systemic ventricle mass to volume ratio: 1.0125337439518596
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5732818884398239
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.48334344837835447
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Large metallic artifacts from stainless steel coils obscuring most of the upper thorax, including the aorta, pulmonary arteries, superior vena cava, atria, Fontan pathways, and pulmonary veins but allowing measurements of ventricular volumes and flow in the aortic and atrioventricular valves.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00292091].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data, it is likely that the patient did not receive a heart transplant (NO). The patient has a history of interventions typical for single-ventricle patients, including bidirectional Glenn and lateral tunnel Fontan procedures. Furthermore, the XGBoost model predicts a very low probability (0.0029) of the occluded outcome being 'yes', indicating a strong likelihood that the patient has not undergone a heart transplant. Additionally, the absence of significant complications such as protein-losing enteropathy or major vascular thrombus, alongside the patient's current NYHA class status, supports the idea that the patient's heart function is being managed effectively without the necessity for transplantation.","Based on the available information, it is likely that the main patient did not receive a heart transplant. The patient's history includes multiple surgeries relevant to their single-ventricle physiology, particularly the successful implementation of the Fontan procedure, which is designed to optimize blood flow in cases of complex congenital heart defects. Given that similar patients with comparable cardiac histories also did not receive heart transplants, along with the extremely low predicted probability (0.0029) from the XGBoost model indicating that the occurrence of receiving a heart transplant is rare, it further supports this conclusion. Additionally, the absence of serious complications or significant declining cardiac status in the main patient suggests stability that typically reduces the need for transplantation.","Based on the information provided, the predicted clinical outcome is **no**, the patient did not receive a heart transplant. The main patient has a number of specific clinical features, including a history of congenital heart disease (atrioventricular canal defect) and other surgical interventions without prior heart transplant listings, which align with patterns observed in similar patients who did not undergo heart transplantation. Additionally, despite the presence of risks associated with single-ventricle physiology, such as a history of protein-losing enteropathy or arrhythmias, the XGBoost model indicates a very low probability (0.0029) of receiving a heart transplant. This suggests that ongoing management strategies may have been prioritized over transplant in this patient cohort. Thus, given the surgical history and low predicted risk, it is reasonable to conclude that the main patient has not undergone a heart transplant.","Based on the provided information, I would predict that the patient did **not** receive a heart transplant. The main patient has a complex surgical history, including an atrioventricular canal defect and multiple cardiac surgeries, which puts them at higher risk for complications. An important note is that the patient's known outcomes, which include additional surgeries like a fenestration intervention and a bidirectional Glenn, are indicative of a management strategy focused on improving hemodynamics rather than transitioning to transplantation. 

Furthermore, among the similar patients, those who did not receive a transplant shared common features like a successful Fontan operation and no subsequent heart transplant, implying that significant complications leading to transplantation were not evident. The low probability (0.29%) predicted by the XGBoost model reinforces the likelihood of avoiding transplant, given the high accuracy of the model in similar cohorts. Hence, the collective evidence suggests that this patient likely did not proceed to receive a heart transplant.",1,1,1,1,0
BCH-BEABEN-1," Pt Clinical Surgical History 
 If other atrioventricular valve procedure please describe: Surg: patch closure of tricuspid valve
 Other relevant surgical or clinical history (optional): SURG (12/1988, NYU Medical Center):  left modified Blalock Taussig shunt 
SURG (9/1991, NYU Medical Center):  atriopulmonary Fontan, Blalock-Taussig shunt takedown, and patent ductus arteriosus ligation
SURG (??NYU Medical Center):  patch closure of tricuspid valve and primary repair of atrial septal fenestration

 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 19.0
 Gadolinium unknown contrast dose: 19.0
 Patient height: 170.0
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4736165014689198
 Heart rate: 75.0
 Upper limb systolic blood pressure: 118.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 92.0
 Left ventricle end-diastolic volume: 125.8
 Left ventricle end-systolic volume: 56.9
 Left ventricular mass: 84.2
 Native aorta flow rate: 3.9
 Ascending aorta, above the Stansel flow rate: 3.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.09
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.09
 Left atrioventricular valve/mitral inflow rate: 4.75
 Aortic or native aortic regurgitation fraction: 5.0
 Mitral or common atrioventricular regurgitation fraction: 18.0
 Single ventricle ejection fraction 0.5476947535771066
 Single ventricle systolic volume 68.9
 Body mass index 16.262975778546714
 Mass to height volume indexed on BSA (exp = 2.7) 20.095554940718102
 Systemic ventricle end-systolic volume: 56.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.612488353164714
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.37260501451259
 Systemic ventricle end-diastolic volume: 125.8
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 85.36820799346434
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.99426556811395
 Systemic ventricle mass: 84.2
 Systemic ventricle mass indexed on BSA (exp=1) 57.138339531396646
 Systemic ventricle mass indexed on BSA (exp=1.3) 50.864206365939545
 Systemic ventricle mass to volume ratio: 0.6693163751987282
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4541998372925012
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.40432596475309657
 Description of late gadolinium enhancement: There is delayed enhancement of the wall of the right atrium and at the inferior insertion point of the RV into the septum.  Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and the basal anterior wall of the infundibulum.=========================Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and 
the basal anterior wall of the infundibulum. 
There is delayed enhancement at the inferior insertion point of the right ventricle into the septum.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.2804787].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided clinical history and MRI report for the main patient, it is predicted that the patient **does not have a history of ascites (> trace)**. The patient has a history of cardiac complications, including intracardiac thrombus and atrial tachyarrhythmias, but there are no indications of fluid retention, liver dysfunction, or related symptoms that often accompany ascites. Additionally, the current medications (i.e., diuretics) could suggest management of any potential fluid imbalances, although the absence of significant symptoms or findings related to ascites in the provided clinical history supports this prediction. The XGBoost model's predicted probability of 0.2804787 for the occluded outcome being 'yes' further supports a lower likelihood of significant fluid accumulation issues like ascites.","Based on the provided information, the prediction for the occluded outcome, whether the main patient has a history of ascites (> trace), is **no**. The main patient's clinical history does not indicate any prior episodes of ascites, nor does it suggest significant fluid accumulation that aligns with conditions that would lead to ascites, such as heart failure or liver dysfunction. Furthermore, the similar patients, including patient #1, displayed diverse outcomes, with the majority not having complications like ascites or thrombus issues, and a specific lack of ascites history noted. Additionally, the XGBoost model predicts a low probability (approximately 28%) for this outcome, which further supports the conclusion that it is unlikely for the main patient to have a history of ascites given their clinical context and comparisons.","Based on the clinical history and data provided, the main patient has no current indications of ascites, as there are no documented cases of ascites or gastrointestinal complications. The similar patients exhibited a range of clinical outcomes, but none indicated significant ascites. The XGBoost model predicts a low probability (0.2804787) for the occluded outcome of ascites being 'yes', which reflects a similar trend where major complications like ascites were not frequently documented among patients analogous to the main patient's profile. Thus, it is reasonable to conclude that the main patient likely does not have a history of ascites (> trace). Therefore, I predict the outcome is **no**.","Based on the provided information, it is more likely that the main patient does not have a history of ascites (> trace). The main patient has a known history of intracardiac thrombus, atrial tachyarrhythmias, and mild regurgitation of the mitral valve, but there are no indications of hepatic dysfunction or significant circulatory complications that would typically lead to ascites. Additionally, similar patients with comparable surgical histories (including multiple surgeries and interventions like the Fontan operation) also do not show a pattern of ascites in their records, which reinforces the idea that this main patient is likely in a health status with no significant fluid accumulation in the abdomen. The XGBoost model output predicting a 28% probability of the outcome indicates that while it's possible, it aligns more with the typical clinical profile that does not suggest ascites. Therefore, it is reasonable to conclude that the main patient does not have a history of ascites.",1,1,1,1,0
BCH-BEABEN-1," Pt Clinical Surgical History 
 If other atrioventricular valve procedure please describe: Surg: patch closure of tricuspid valve
 Other relevant surgical or clinical history (optional): SURG (12/1988, NYU Medical Center):  left modified Blalock Taussig shunt 
SURG (9/1991, NYU Medical Center):  atriopulmonary Fontan, Blalock-Taussig shunt takedown, and patent ductus arteriosus ligation
SURG (??NYU Medical Center):  patch closure of tricuspid valve and primary repair of atrial septal fenestration

 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 19.0
 Gadolinium unknown contrast dose: 19.0
 Patient height: 170.0
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4736165014689198
 Heart rate: 75.0
 Upper limb systolic blood pressure: 118.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 92.0
 Left ventricle end-diastolic volume: 125.8
 Left ventricle end-systolic volume: 56.9
 Left ventricular mass: 84.2
 Native aorta flow rate: 3.9
 Ascending aorta, above the Stansel flow rate: 3.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.09
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.09
 Left atrioventricular valve/mitral inflow rate: 4.75
 Aortic or native aortic regurgitation fraction: 5.0
 Mitral or common atrioventricular regurgitation fraction: 18.0
 Single ventricle ejection fraction 0.5476947535771066
 Single ventricle systolic volume 68.9
 Body mass index 16.262975778546714
 Mass to height volume indexed on BSA (exp = 2.7) 20.095554940718102
 Systemic ventricle end-systolic volume: 56.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.612488353164714
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.37260501451259
 Systemic ventricle end-diastolic volume: 125.8
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 85.36820799346434
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.99426556811395
 Systemic ventricle mass: 84.2
 Systemic ventricle mass indexed on BSA (exp=1) 57.138339531396646
 Systemic ventricle mass indexed on BSA (exp=1.3) 50.864206365939545
 Systemic ventricle mass to volume ratio: 0.6693163751987282
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4541998372925012
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.40432596475309657
 Description of late gadolinium enhancement: There is delayed enhancement of the wall of the right atrium and at the inferior insertion point of the RV into the septum.  Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and the basal anterior wall of the infundibulum.=========================Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and 
the basal anterior wall of the infundibulum. 
There is delayed enhancement at the inferior insertion point of the right ventricle into the septum.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.02138278].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data, the predicted clinical outcome for the main patient is **no**, indicating that the patient has not died. The reasoning behind this prediction stems from several key factors in the patient’s medical history and current evaluations. The patient has undergone multiple surgeries, including a left modified Blalock-Taussig shunt and atriopulmonary Fontan, which shows a history of ongoing care and management. Additionally, cardiac MRI results point to the presence of sub-endocardial delayed enhancement, which suggests some degree of myocardial scarring but does not indicate acute heart failure or impending death. The XGBoost model estimates a very low probability of the occluded outcome being 'yes' (0.021), supporting the prediction that the patient has not died. Collectively, these observations suggest that the patient is being effectively monitored and managed, without evidence for imminent mortality.","Based on the provided data, I predict that the missing clinical outcome for the main patient, *Has the patient died?* is **no**. The main patient has a history of significant interventions including patch closure of the tricuspid valve and a Fontan operation, but does not exhibit evidence of severe complications such as protein-losing enteropathy or catheter-related thrombi, which were prevalent in cases of patients who passed away. Similar patients also showed that those with well-managed ejection fractions and effective cardiac outputs tended to have better survival rates. The XGBoost model's low predicted probability of 0.021 suggests a strong indication that death is unlikely. This aligns with the clinical patterns observed, where most patients with comparable backgrounds and stable statuses continue to live without mortality indicators in recent updates.","Based on the provided data, I predict that **the missing clinical outcome for the main patient is ""no,"" they have not died**. This conclusion is drawn from several observations:

1. **Surgical and Clinical History**: The main patient has undergone multiple surgical interventions related to congenital cardiac conditions, but there is no indication of severe complications that typically correlate with mortality, such as significant post-operative complications or histories indicative of severe decline (e.g., heart transplant listing).

2. **MRI Findings**: Although the main patient presents with some concerning MRI results, such as delayed gadolinium enhancement and some regurgitation, these are common in single-ventricle physiology post-Fontan and do not directly suggest imminent mortality.

3. **Similar Patient Outcomes**: The cohort of similar patients shows a low predicted probability of death based on the XGBoost model outcome (0.0214), along with data indicating that many similar patients with comparable post-surgical profiles and outcomes remain alive. Moreover, similar patients with complex medical histories, such as atrial tachyarrhythmias or intracardiac thrombus without any subsequent deaths, support a lower likelihood of mortality for the main patient, especially without any acute or chronic deteriorative events recorded.

Thus, the overall analysis leads to the conclusion that, considering the absence of direct evidence of a life-threatening condition, the main patient likely still has a favorable status.","Based on the provided clinical data and the XGBoost model's predicted probability of the patient dying — estimated at approximately 2.14% (0.02138278) — it is reasonable to predict that the outcome is ""no,"" the patient has not died. The main patient has undergone multiple surgeries and has a history of atrial tachyarrhythmias and an intracardiac thrombus but no documented severe complications such as protein-losing enteropathy or major vascular embolic events, which could significantly increase mortality risk. Additionally, a review of similar patients shows that none of them report death, and the validation set indicates a high accuracy (96%) in predicting mortality outcomes, further supporting the likelihood of survival for this patient.",1,1,1,1,0
BCH-BEABEN-1," Pt Clinical Surgical History 
 If other atrioventricular valve procedure please describe: Surg: patch closure of tricuspid valve
 Other relevant surgical or clinical history (optional): SURG (12/1988, NYU Medical Center):  left modified Blalock Taussig shunt 
SURG (9/1991, NYU Medical Center):  atriopulmonary Fontan, Blalock-Taussig shunt takedown, and patent ductus arteriosus ligation
SURG (??NYU Medical Center):  patch closure of tricuspid valve and primary repair of atrial septal fenestration

 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 19.0
 Gadolinium unknown contrast dose: 19.0
 Patient height: 170.0
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4736165014689198
 Heart rate: 75.0
 Upper limb systolic blood pressure: 118.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 92.0
 Left ventricle end-diastolic volume: 125.8
 Left ventricle end-systolic volume: 56.9
 Left ventricular mass: 84.2
 Native aorta flow rate: 3.9
 Ascending aorta, above the Stansel flow rate: 3.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.09
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.09
 Left atrioventricular valve/mitral inflow rate: 4.75
 Aortic or native aortic regurgitation fraction: 5.0
 Mitral or common atrioventricular regurgitation fraction: 18.0
 Single ventricle ejection fraction 0.5476947535771066
 Single ventricle systolic volume 68.9
 Body mass index 16.262975778546714
 Mass to height volume indexed on BSA (exp = 2.7) 20.095554940718102
 Systemic ventricle end-systolic volume: 56.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.612488353164714
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.37260501451259
 Systemic ventricle end-diastolic volume: 125.8
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 85.36820799346434
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.99426556811395
 Systemic ventricle mass: 84.2
 Systemic ventricle mass indexed on BSA (exp=1) 57.138339531396646
 Systemic ventricle mass indexed on BSA (exp=1.3) 50.864206365939545
 Systemic ventricle mass to volume ratio: 0.6693163751987282
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4541998372925012
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.40432596475309657
 Description of late gadolinium enhancement: There is delayed enhancement of the wall of the right atrium and at the inferior insertion point of the RV into the septum.  Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and the basal anterior wall of the infundibulum.=========================Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and 
the basal anterior wall of the infundibulum. 
There is delayed enhancement at the inferior insertion point of the right ventricle into the septum.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00061804].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the available clinical history and MRI findings for the patient, it is reasonable to predict that the patient did not receive a heart transplant (no). The patient's surgical history indicates that they have undergone multiple surgeries, including a Fontan procedure and a tricuspid valve repair, but there are no recorded instances of advanced heart failure or transplant interventions in their history. Additionally, while the patient does have a history of intracardiac thrombus and arrhythmias, these issues are managed and do not necessarily imply imminent heart failure or the need for transplant. With a very low predicted probability of 0.00061804 for the event of receiving a transplant, alongside symptom management and ongoing care, it strongly suggests that a heart transplant was not indicated or pursued for this patient.","Based on the data provided, the prediction for whether the main patient received a heart transplant is **No**. The main patient has a history of complex surgeries related to pulmonary atresia, including a patch closure of the tricuspid valve and a Fontan procedure. This specific surgical history, combined with the delayed enhancement observed in the MRI, may suggest cardiac complications but not necessarily an indication for transplant. The data from similar patients shows that while there are a few with transplants, many, including the one closely matching the main patient, did not undergo transplantation, which aligns with the low predicted probability (0.00061804) generated by the XGBoost model. Overall, the absence of a heart transplant history and the clinical indicators suggest that the main patient has managed to maintain function without the need for transplant intervention.","Based on the available data, it is predicted that the main patient did **not** receive a heart transplant (i.e., the outcome is **no**). The main patient has undergone multiple heart surgeries, including a patch closure of the tricuspid valve and an atriopulmonary Fontan procedure, but there is no indication of heart transplant status in their surgical history. 

Furthermore, an analysis of similar patients indicates low rates of transplant in those with comparable surgical histories and outcomes, especially among patients with ongoing ventricular function and no significant complications such as protein-losing enteropathy or severe thrombus formation. The XGBoost model's predicted probability of the outcome being 'yes' (heart transplant) is very low (0.00061804), which further supports the likelihood that the main patient has not received a heart transplant. Thus, given both the clinical context and the statistical evidence, a prediction of ""no"" for heart transplant aligns with these insights.","Based on the provided data, it is likely that the main patient did not receive a heart transplant. The main patient has a complex surgical history, including atriopulmonary Fontan and patch closure of the tricuspid valve, without any indication of a severe decline in heart function typically necessitating a transplant. Additionally, the estimated probability from the XGBoost model (0.00061804) suggests that the likelihood of receiving a heart transplant is extremely low. Similar patients with comparable surgical histories experienced no transplant events, reinforcing the idea that the main patient likely falls into this category as well. Thus, the predicted outcome is ""no.""",1,1,1,1,0
BCH-BEABEN-1," Pt Clinical Surgical History 
 If other atrioventricular valve procedure please describe: Surg: patch closure of tricuspid valve
 Other relevant surgical or clinical history (optional): SURG (12/1988, NYU Medical Center):  left modified Blalock Taussig shunt 
SURG (9/1991, NYU Medical Center):  atriopulmonary Fontan, Blalock-Taussig shunt takedown, and patent ductus arteriosus ligation
SURG (??NYU Medical Center):  patch closure of tricuspid valve and primary repair of atrial septal fenestration

 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 19.0
 Gadolinium unknown contrast dose: 19.0
 Patient height: 170.0
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4736165014689198
 Heart rate: 75.0
 Upper limb systolic blood pressure: 118.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 92.0
 Left ventricle end-diastolic volume: 125.8
 Left ventricle end-systolic volume: 56.9
 Left ventricular mass: 84.2
 Native aorta flow rate: 3.9
 Ascending aorta, above the Stansel flow rate: 3.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.09
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.09
 Left atrioventricular valve/mitral inflow rate: 4.75
 Aortic or native aortic regurgitation fraction: 5.0
 Mitral or common atrioventricular regurgitation fraction: 18.0
 Single ventricle ejection fraction 0.5476947535771066
 Single ventricle systolic volume 68.9
 Body mass index 16.262975778546714
 Mass to height volume indexed on BSA (exp = 2.7) 20.095554940718102
 Systemic ventricle end-systolic volume: 56.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.612488353164714
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.37260501451259
 Systemic ventricle end-diastolic volume: 125.8
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 85.36820799346434
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.99426556811395
 Systemic ventricle mass: 84.2
 Systemic ventricle mass indexed on BSA (exp=1) 57.138339531396646
 Systemic ventricle mass indexed on BSA (exp=1.3) 50.864206365939545
 Systemic ventricle mass to volume ratio: 0.6693163751987282
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4541998372925012
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.40432596475309657
 Description of late gadolinium enhancement: There is delayed enhancement of the wall of the right atrium and at the inferior insertion point of the RV into the septum.  Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and the basal anterior wall of the infundibulum.=========================Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and 
the basal anterior wall of the infundibulum. 
There is delayed enhancement at the inferior insertion point of the right ventricle into the septum.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.09811153].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided information, it is reasonable to predict that the patient does not have a diagnosis of seizures requiring antiepileptic medications (no). The patient's MRI findings show some late gadolinium enhancement, which can indicate myocardial scarring or previous injury, but there is no history of seizure activity documented in the patient's clinical history. Furthermore, the patient's other complications primarily involve cardiac issues (e.g., history of intracardiac thrombus and atrial tachyarrhythmias), and the absence of neurological complications or related medical history, as evident from the lack of mentions regarding seizures or neurologic interventions, supports this conclusion. The estimated probability of a positive outcome from the XGBoost model (approximately 9.8%) aligns with a low likelihood of this diagnosis, reinforcing that seizures are unlikely in this patient.","Based on the available information, the prediction for whether the main patient has a diagnosis of seizures requiring antiepileptic medications is **no**. This conclusion is supported by the absence of any history of seizures or related neurological issues in the main patient's medical details, as well as noting that they also do not exhibit any severe complications commonly associated with seizure disorders. 

In contrast, the similar patients exhibited a relatively high occurrence of seizures, specifically the one with an event update reporting seizures requiring antiepileptic medications, which may correlate with clinical conditions seen in post-Fontan patients. However, considering the XGBoost model's predicted probability of 0.098 for the occluded outcome alongside the dominant clinical history of the main patient, it suggests a low likelihood of seizure history compared to the similar cohort. Therefore, it is more reasonable to assert that this patient does not have a diagnosis of seizures requiring antiepileptic medications.","Based on the main patient's history, there is evidence of intracardiac thrombus formation and a documented history of arrhythmias (atrial tachyarrhythmias), both of which increase the risk of neurological events, such as seizures. In contrast, similar patients exhibited a tendency towards higher incidences of seizure diagnoses, particularly in those requiring antiepileptic medications, as noted in their clinical outcomes. Given the XGBoost model's predicted probability of 0.098 for the patient having seizures, which leans toward a ""no"" outcome but is not definitive, the clinical picture overall provides substantial reasoning to anticipate that this patient may also have related neurological challenges. Therefore, it is reasonable to predict that the main patient likely **does not have a diagnosis of seizures requiring antiepileptic medications**, but this is due to the balancing of risk factors rather than an absence of merit for monitoring neurological health closely.","Based on the provided data, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The main patient has a history of intracardiac thrombus, which may correlate with a variety of complications but does not directly imply seizure activity. Comparing with similar patients, many who had a diagnosis of seizures had additional complications, notably a history of both intracardiac thrombus and atrial tachyarrhythmias, which the main patient does not exhibit. Furthermore, the predicted probability from the XGBoost model (0.098) suggests that, while there may be a low probability for seizures, the absence of documented seizures in this patient and the lack of strong correlations in the similar cohorts leads to the conclusion that seizures requiring treatment are unlikely in this case.",1,1,1,1,0
BCH-BEABEN-1," Pt Clinical Surgical History 
 If other atrioventricular valve procedure please describe: Surg: patch closure of tricuspid valve
 Other relevant surgical or clinical history (optional): SURG (12/1988, NYU Medical Center):  left modified Blalock Taussig shunt 
SURG (9/1991, NYU Medical Center):  atriopulmonary Fontan, Blalock-Taussig shunt takedown, and patent ductus arteriosus ligation
SURG (??NYU Medical Center):  patch closure of tricuspid valve and primary repair of atrial septal fenestration

 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 19.0
 Gadolinium unknown contrast dose: 19.0
 Patient height: 170.0
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4736165014689198
 Heart rate: 75.0
 Upper limb systolic blood pressure: 118.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 92.0
 Left ventricle end-diastolic volume: 125.8
 Left ventricle end-systolic volume: 56.9
 Left ventricular mass: 84.2
 Native aorta flow rate: 3.9
 Ascending aorta, above the Stansel flow rate: 3.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.09
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.09
 Left atrioventricular valve/mitral inflow rate: 4.75
 Aortic or native aortic regurgitation fraction: 5.0
 Mitral or common atrioventricular regurgitation fraction: 18.0
 Single ventricle ejection fraction 0.5476947535771066
 Single ventricle systolic volume 68.9
 Body mass index 16.262975778546714
 Mass to height volume indexed on BSA (exp = 2.7) 20.095554940718102
 Systemic ventricle end-systolic volume: 56.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.612488353164714
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.37260501451259
 Systemic ventricle end-diastolic volume: 125.8
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 85.36820799346434
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.99426556811395
 Systemic ventricle mass: 84.2
 Systemic ventricle mass indexed on BSA (exp=1) 57.138339531396646
 Systemic ventricle mass indexed on BSA (exp=1.3) 50.864206365939545
 Systemic ventricle mass to volume ratio: 0.6693163751987282
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4541998372925012
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.40432596475309657
 Description of late gadolinium enhancement: There is delayed enhancement of the wall of the right atrium and at the inferior insertion point of the RV into the septum.  Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and the basal anterior wall of the infundibulum.=========================Sub-endocardial delayed enhancement along the right ventricular septal and inferior walls, and 
the basal anterior wall of the infundibulum. 
There is delayed enhancement at the inferior insertion point of the right ventricle into the septum.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00101269].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided patient's clinical and MRI data, it can be inferred that the patient likely does not have a history of pacemaker placement. First, the patient has a history of atrial tachyarrhythmias, which may warrant closer monitoring rather than immediate pacemaker intervention, especially in the context of being managed through medication. The absence of significant symptoms indicative of pacemaker dependency, along with the fact that the patient has not had a history of cardiac arrest or severe arrhythmias requiring device placement, supports this prediction. Additionally, the XGBoost model's very low predicted probability (0.00101269) strengthens the likelihood that the patient has not undergone pacemaker placement. Therefore, I predict that the missing clinical outcome is ""no.""","Based on the provided data, it is likely that the main patient does NOT have a history of pacemaker placement. The main patient has a history of atrial tachyarrhythmias, which could increase the need for pacing; however, there is no record of pacemaker placement or associated interventions noted in their surgical history. Additionally, among similar patients, some with atrial arrhythmias also did not require pacemaker placement, suggesting that the presence of arrhythmias does not always correlate with the need for pacing, especially if the arrhythmias are manageable. The XGBoost model's predicted probability of having a history of pacemaker placement is very low (0.001), further supporting the likelihood that the main patient does not have this history.","Based on the provided data, the prediction for whether the main patient has a history of pacemaker placement is **no**. The main patient's surgical history reflects significant interventions such as tricuspid valve patch closure and a Fontan procedure, but there is no mention of pacemaker placement. Additionally, analysis of similar patients indicates that there is no reported history of pacemaker placement among those who underwent similar surgeries, including those with tricuspid valve interventions or Fontan procedures. The very low predicted probability from the XGBoost model (0.00101269) further supports the conclusion that it is highly unlikely the main patient has received a pacemaker, aligning with the absence of such interventions in both their history and that of comparable cases.","Based on the provided data, I predict that the main patient does not have a history of pacemaker placement. This hypothesis is supported by the patient's surgical history and current clinical status, which indicate a lack of significant complications commonly associated with the need for a pacemaker, such as severe arrhythmias or sustained tachyarrhythmias. Furthermore, among the similar patients analyzed—who had comparable surgical histories and outcomes—none showed a prevalent need for a pacemaker, reinforcing the low likelihood of this main patient requiring one. Additionally, the low estimated probability (0.00101269) from the XGBoost model suggests that the factors related to the patient and their cohort do not support a history of pacemaker placement.",1,1,1,1,0
BCH-BYRSAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other modification of superior cavopulmonary connection surgery, please describe: Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
 Please describe additional cardiac pre-Fontan surgery: Atrial septectomy, PA band revision, tricuspid valvuloplasty.
 Other relevant surgical or clinical history (optional): SURG (11/2014, 2m, China): PA band.
SURG (03/2016, 1y 6m, China): Atrial septectomy, PA band revision, tricuspid valvuloplasty.
CATH (10/2017, 3y, Callahan): Hemodynamics.
SURG (10/2017, 3y, Emani): Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
CATH (04/2018, 3y, Esch): APC coiled, Vasodilator testing 
SURG (04/2018, 3y, Emani): Lateral tunnel fenestrated (4 mm) Fontan.
CATH (01/2019, 4y, Callahan): fenestration closed
CATH (6/21, BCH): Hemo
SURG/EP CATH  (6/21, BCH):tricuspid valve repair. Placement of CRT dual-chamber pacemaker system
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Other modification
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 3.5
 Patient height: 111.5
 Patient weight: 17.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.7283518830084269
 Heart rate: 108.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 67.0
 Upper limb mean blood pressure: 79.0
 O2 Saturation: 99
 Left ventricle end-diastolic volume: 81.6
 Left ventricle end-systolic volume: 45.6
 Left ventricular mass: 38.2
 Right ventricular end-diastolic volume: 12.9
 Right ventricular end-systolic volume: 6.2
 Right ventricle mass: 5.1
 Native aorta flow rate: 0.93
 Neo-aorta flow rate: 1.47
 Descending aorta flow rate: 0.67
 Right superior vena cava flow rate: 1.08
 Inferior vena cava, below the fenestration flow rate: 0.62
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.07
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.34
 Total right pulmonary vein flow rate: 1.35
 Total left pulmonary vein flow rate: 0.55
 Right atrioventricular valve/tricuspid inflow rate: 0.28
 Left atrioventricular valve/mitral inflow rate: 3.23
 Mitral or common atrioventricular regurgitation fraction: 44.0
 Single ventricle ejection fraction 0.4411764705882352
 Single ventricle systolic volume 35.99999999999999
 Body mass index 13.91542158499065
 Mass to height volume indexed on BSA (exp = 2.7) 28.47221280456676
 Systemic ventricle end-systolic volume: 45.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 62.60710113311043
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 68.85273895320329
 Systemic ventricle end-diastolic volume: 81.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 112.03375992240814
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 123.2101644425743
 Systemic ventricle mass: 38.2
 Systemic ventricle mass indexed on BSA (exp=1) 52.44717682642146
 Systemic ventricle mass indexed on BSA (exp=1.3) 57.67926815816592
 Systemic ventricle mass to volume ratio: 0.46813725490196084
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6427350101277141
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.7068537764481118
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Metallic artifact from the fenestration occluding device.=========================Minor artifact only
 Other relevant report comments or concerns: Metallic artifact from the fenestration occluding device.
Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.
Probably no significant residual fenestration or baffle leak.
Unobstructed right and left pulmonary arteries.
Unobstructed right pulmonary venous return to the left atrium.
Compression of the left lower pulmonary vein between the atrium and descending aorta.
Modest interatrial communication.
Minimal inflow through the partially oversewn left-sided tricuspid valve.
Severe right-sided mitral regurgitation.
Somewhat small bulboventricular foramen.
Unobstructed left ventricular outflow tract through the neo-aortic valve.
Unobstructed Stansel anastomosis.
Unobstructed left aortic arch.
Trivial semilunar valve regurgitation.
Dilated single left ventricle with mildly reduced ejection fraction.
Suspected abnormal lymphatics.
Enlarged liver and spleen.
No pericardial or pleural effusion. No ascites.

 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0024228].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data, the predicted clinical outcome for the main patient is ""no,"" meaning that the patient has not died. This conclusion is supported by the information showing no history of serious complications such as cardiac arrest, stroke, renal dysfunction, or other life-threatening conditions. Additionally, the patient's MRI report indicates stable hemodynamics with unobstructed vascular pathways and no significant residual fenestration or baffle leak, suggesting that the patient's current circulatory status is adequate. Coupled with the very low predicted probability (0.0024228) of the outcome being 'yes' and the relatively high accuracy and AUC of the model applied to a similar cohort, this reinforces the likelihood of the patient being alive.","Based on the provided information, the prediction for the main patient's outcome regarding whether they have died is **no**. The main patient exhibits a complex surgical history with multiple interventions but has notably avoided significant post-operative complications such as cardiac arrest, thrombus formation, or other forms of acute medical crisis, which would typically be associated with mortality. Additionally, the long-term similarity trends with matched patients indicate low mortality, as similar patients also maintain a stable health status and have not had fatal outcomes. The XGBoost model also suggests a very low probability (0.0024228) for the adverse outcome of death, reinforcing the implication that the patient is likely alive.",,"Based on the provided data, the predicted clinical outcome for the main patient regarding whether they have died is ""no."" The patient's surgical history indicates multiple corrective surgeries, including a lateral tunnel fontan and tricuspid valve repair, signaling a commitment to managing complications intrinsic to single-ventricle anatomy. Additionally, the MRI report suggests no significant residual complications, such as major structural defects or leaks. The statistical model's probability of the occluded outcome being 'yes' is extremely low at approximately 0.002, indicating a strong likelihood that the patient remains alive, especially when similar patients with analogous surgical histories and clinical presentations also demonstrate positive survival outcomes.",1,1,1,1,0
BCH-BYRSAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other modification of superior cavopulmonary connection surgery, please describe: Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
 Please describe additional cardiac pre-Fontan surgery: Atrial septectomy, PA band revision, tricuspid valvuloplasty.
 Other relevant surgical or clinical history (optional): SURG (11/2014, 2m, China): PA band.
SURG (03/2016, 1y 6m, China): Atrial septectomy, PA band revision, tricuspid valvuloplasty.
CATH (10/2017, 3y, Callahan): Hemodynamics.
SURG (10/2017, 3y, Emani): Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
CATH (04/2018, 3y, Esch): APC coiled, Vasodilator testing 
SURG (04/2018, 3y, Emani): Lateral tunnel fenestrated (4 mm) Fontan.
CATH (01/2019, 4y, Callahan): fenestration closed
CATH (6/21, BCH): Hemo
SURG/EP CATH  (6/21, BCH):tricuspid valve repair. Placement of CRT dual-chamber pacemaker system
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Other modification
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 3.5
 Patient height: 111.5
 Patient weight: 17.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.7283518830084269
 Heart rate: 108.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 67.0
 Upper limb mean blood pressure: 79.0
 O2 Saturation: 99
 Left ventricle end-diastolic volume: 81.6
 Left ventricle end-systolic volume: 45.6
 Left ventricular mass: 38.2
 Right ventricular end-diastolic volume: 12.9
 Right ventricular end-systolic volume: 6.2
 Right ventricle mass: 5.1
 Native aorta flow rate: 0.93
 Neo-aorta flow rate: 1.47
 Descending aorta flow rate: 0.67
 Right superior vena cava flow rate: 1.08
 Inferior vena cava, below the fenestration flow rate: 0.62
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.07
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.34
 Total right pulmonary vein flow rate: 1.35
 Total left pulmonary vein flow rate: 0.55
 Right atrioventricular valve/tricuspid inflow rate: 0.28
 Left atrioventricular valve/mitral inflow rate: 3.23
 Mitral or common atrioventricular regurgitation fraction: 44.0
 Single ventricle ejection fraction 0.4411764705882352
 Single ventricle systolic volume 35.99999999999999
 Body mass index 13.91542158499065
 Mass to height volume indexed on BSA (exp = 2.7) 28.47221280456676
 Systemic ventricle end-systolic volume: 45.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 62.60710113311043
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 68.85273895320329
 Systemic ventricle end-diastolic volume: 81.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 112.03375992240814
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 123.2101644425743
 Systemic ventricle mass: 38.2
 Systemic ventricle mass indexed on BSA (exp=1) 52.44717682642146
 Systemic ventricle mass indexed on BSA (exp=1.3) 57.67926815816592
 Systemic ventricle mass to volume ratio: 0.46813725490196084
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6427350101277141
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.7068537764481118
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Metallic artifact from the fenestration occluding device.=========================Minor artifact only
 Other relevant report comments or concerns: Metallic artifact from the fenestration occluding device.
Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.
Probably no significant residual fenestration or baffle leak.
Unobstructed right and left pulmonary arteries.
Unobstructed right pulmonary venous return to the left atrium.
Compression of the left lower pulmonary vein between the atrium and descending aorta.
Modest interatrial communication.
Minimal inflow through the partially oversewn left-sided tricuspid valve.
Severe right-sided mitral regurgitation.
Somewhat small bulboventricular foramen.
Unobstructed left ventricular outflow tract through the neo-aortic valve.
Unobstructed Stansel anastomosis.
Unobstructed left aortic arch.
Trivial semilunar valve regurgitation.
Dilated single left ventricle with mildly reduced ejection fraction.
Suspected abnormal lymphatics.
Enlarged liver and spleen.
No pericardial or pleural effusion. No ascites.

 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00478739].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided data, it is likely that the patient did not receive a heart transplant (no). The clinical history indicates that the patient has undergone multiple complex surgeries related to their condition, including a lateral tunnel Fontan and several interventional procedures. The patient's current MRI suggests a dilated single left ventricle with a mildly reduced ejection fraction, but they have not demonstrated significant chronic complications such as protein-losing enteropathy or life-threatening arrhythmias indicative of end-stage heart failure, which are often conditions leading to the consideration of heart transplantation. Additionally, the very low predicted probability (0.00478739) from the XGBoost model, alongside the high accuracy of the model on similar cohorts, reinforces the likelihood that this patient has not reached a clinical status warranting heart transplant.","Based on the main patient's extensive surgical history, which includes complex procedures such as a lateral tunnel fenestrated Fontan and tricuspid valve repair, along with significant ongoing management of his hypoplastic left ventricle, the likelihood of a heart transplant appears low. The XGBoost model's estimated probability of receiving a heart transplant is notably low at 0.0048, suggesting a very strong indication against it. Additionally, in the cohort of similar patients, none exhibited a strong tendency towards heart transplantation, even after multiple surgeries, indicating that while the risks of complications remain high, the decision for transplantation is not commonly made in this specific patient demographic. Thus, it is reasonable to predict that the main patient did not receive a heart transplant.","Based on the data provided, it is predicted that the main patient did not receive a heart transplant (no). The main patient has a complex surgical history involving five cardiac surgeries, including a Fontan procedure with a fenestration. Despite similar patient profiles with histories of surgeries and outcomes, including tricuspid atresia and double inlet left ventricle, none of the similar patients indicated a heart transplant, and there were only a few cases among them indicating a positive outcome. Moreover, the XGBoost model predicts a low probability (0.0048) of a heart transplant being in play for this patient, suggesting that the likelihood of requiring such intervention is minimal given their clinical trajectory and MRI findings. Thus, the combination of current clinical status, surgical history, and models reinforces a prediction of no heart transplant for this patient.","Based on the information provided, the predicted outcome for the main patient regarding whether they received a heart transplant is **no**. This conclusion is supported by the XGBoost model's estimated low probability of 0.0048 for the occluded outcome being 'yes'. Moreover, the clinical history of the main patient indicates multiple surgeries without a heart transplant, and their ongoing clinical status suggests stability without known complications leading to transplantation, like protein-losing enteropathy or significant cardiovascular events. 

In comparison to the similar patients, despite some having a transplant status, the majority showed no history of receiving a heart transplant after their Fontan procedures, primarily due to overall positive postoperative follow-ups and absence of dire complications like severe heart dysfunction that would necessitate a heart transplant. Thus, considering these factors, it is reasonable to predict that the main patient likely did not undergo a heart transplant.",1,1,1,1,0
BCH-BYRSAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other modification of superior cavopulmonary connection surgery, please describe: Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
 Please describe additional cardiac pre-Fontan surgery: Atrial septectomy, PA band revision, tricuspid valvuloplasty.
 Other relevant surgical or clinical history (optional): SURG (11/2014, 2m, China): PA band.
SURG (03/2016, 1y 6m, China): Atrial septectomy, PA band revision, tricuspid valvuloplasty.
CATH (10/2017, 3y, Callahan): Hemodynamics.
SURG (10/2017, 3y, Emani): Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
CATH (04/2018, 3y, Esch): APC coiled, Vasodilator testing 
SURG (04/2018, 3y, Emani): Lateral tunnel fenestrated (4 mm) Fontan.
CATH (01/2019, 4y, Callahan): fenestration closed
CATH (6/21, BCH): Hemo
SURG/EP CATH  (6/21, BCH):tricuspid valve repair. Placement of CRT dual-chamber pacemaker system
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Other modification
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 3.5
 Patient height: 111.5
 Patient weight: 17.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.7283518830084269
 Heart rate: 108.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 67.0
 Upper limb mean blood pressure: 79.0
 O2 Saturation: 99
 Left ventricle end-diastolic volume: 81.6
 Left ventricle end-systolic volume: 45.6
 Left ventricular mass: 38.2
 Right ventricular end-diastolic volume: 12.9
 Right ventricular end-systolic volume: 6.2
 Right ventricle mass: 5.1
 Native aorta flow rate: 0.93
 Neo-aorta flow rate: 1.47
 Descending aorta flow rate: 0.67
 Right superior vena cava flow rate: 1.08
 Inferior vena cava, below the fenestration flow rate: 0.62
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.07
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.34
 Total right pulmonary vein flow rate: 1.35
 Total left pulmonary vein flow rate: 0.55
 Right atrioventricular valve/tricuspid inflow rate: 0.28
 Left atrioventricular valve/mitral inflow rate: 3.23
 Mitral or common atrioventricular regurgitation fraction: 44.0
 Single ventricle ejection fraction 0.4411764705882352
 Single ventricle systolic volume 35.99999999999999
 Body mass index 13.91542158499065
 Mass to height volume indexed on BSA (exp = 2.7) 28.47221280456676
 Systemic ventricle end-systolic volume: 45.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 62.60710113311043
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 68.85273895320329
 Systemic ventricle end-diastolic volume: 81.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 112.03375992240814
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 123.2101644425743
 Systemic ventricle mass: 38.2
 Systemic ventricle mass indexed on BSA (exp=1) 52.44717682642146
 Systemic ventricle mass indexed on BSA (exp=1.3) 57.67926815816592
 Systemic ventricle mass to volume ratio: 0.46813725490196084
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6427350101277141
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.7068537764481118
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Metallic artifact from the fenestration occluding device.=========================Minor artifact only
 Other relevant report comments or concerns: Metallic artifact from the fenestration occluding device.
Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.
Probably no significant residual fenestration or baffle leak.
Unobstructed right and left pulmonary arteries.
Unobstructed right pulmonary venous return to the left atrium.
Compression of the left lower pulmonary vein between the atrium and descending aorta.
Modest interatrial communication.
Minimal inflow through the partially oversewn left-sided tricuspid valve.
Severe right-sided mitral regurgitation.
Somewhat small bulboventricular foramen.
Unobstructed left ventricular outflow tract through the neo-aortic valve.
Unobstructed Stansel anastomosis.
Unobstructed left aortic arch.
Trivial semilunar valve regurgitation.
Dilated single left ventricle with mildly reduced ejection fraction.
Suspected abnormal lymphatics.
Enlarged liver and spleen.
No pericardial or pleural effusion. No ascites.

 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00754037].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided data, it is predicted that the patient does **not** have a history of ascites (> trace). This conclusion is supported by the MRI report indicating ""No pericardial or pleural effusion"" and ""No ascites,"" which suggests that there are no significant fluid collections in the abdomen at the time of evaluation. Furthermore, the absence of any reported complications typically associated with the Fontan physiology, such as protein-losing enteropathy or congestive symptoms related to heart failure, reinforces this prediction. The very low estimated probability of the occluded outcome being 'yes' (0.00754037) further suggests that it is highly unlikely that the patient has a history of ascites.","Based on the main patient's clinical data, there are signs that suggest they are unlikely to have a history of ascites. The MRI report states “no ascites,” along with details like an enlarged liver and spleen, which can be associated with fluid overload but do not confirm ascitic fluid specifically. Furthermore, the analysis of similar patients shows that fluid-related complications such as pleural effusions are noted, yet none reported a history of ascites. The XGBoost model also indicates a very low probability (0.75%) of the occluded outcome being 'yes,' further supporting the conclusion that the main patient likely does not have a history of ascites. Thus, the predicted outcome for the main patient is ""no"" for a history of ascites.","**Predicted Outcome:** No, the patient does not have a history of ascites (> trace).

**Reasoning:** The main patient's MRI report indicates an enlarged liver and spleen, but there are no noted signs of ascites. Among the similar patients analyzed, those with significant surgical histories, such as the use of fenestrations and procedures related to double inlet left ventricle and tricuspid atresia, frequently reported histories of ascites. However, the top matches demonstrate a low incidence of ascites related to complete Fontan procedures, with only a few cases actually indicating non-chylous effusions. Furthermore, the XGBoost model predicts a low probability (0.0075) of the occluded outcome being 'yes', indicating that ascites is unlikely in the main patient given the prevailing findings in their profile and the similarity trends observed among these patients.","Based on the main patient's comprehensive surgical history and MRI findings, it is unlikely that this patient has a significant history of ascites. The patient has undergone several relevant surgeries, including a lateral tunnel Fontan and interventions addressing regurgitant valvulopathy, which can contribute to fluid retention but did not present significant concerns for fluid overload in recent evaluations. 

Additionally, examining the similar cohort of patients, cases of ascites were more prominently recorded among those with a history of significant pleural effusions or liver complications, such as protein-losing enteropathy. The main patient has no records indicating these complications or a history of liver dysfunction. Therefore, considering the findings from both the individual patient's situation and trends in similar cases, the prediction is that this patient has not experienced a history of ascites (> trace). Thus, the answer is **no**.",1,1,1,1,0
BCH-BYRSAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other modification of superior cavopulmonary connection surgery, please describe: Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
 Please describe additional cardiac pre-Fontan surgery: Atrial septectomy, PA band revision, tricuspid valvuloplasty.
 Other relevant surgical or clinical history (optional): SURG (11/2014, 2m, China): PA band.
SURG (03/2016, 1y 6m, China): Atrial septectomy, PA band revision, tricuspid valvuloplasty.
CATH (10/2017, 3y, Callahan): Hemodynamics.
SURG (10/2017, 3y, Emani): Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
CATH (04/2018, 3y, Esch): APC coiled, Vasodilator testing 
SURG (04/2018, 3y, Emani): Lateral tunnel fenestrated (4 mm) Fontan.
CATH (01/2019, 4y, Callahan): fenestration closed
CATH (6/21, BCH): Hemo
SURG/EP CATH  (6/21, BCH):tricuspid valve repair. Placement of CRT dual-chamber pacemaker system
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Other modification
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 3.5
 Patient height: 111.5
 Patient weight: 17.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.7283518830084269
 Heart rate: 108.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 67.0
 Upper limb mean blood pressure: 79.0
 O2 Saturation: 99
 Left ventricle end-diastolic volume: 81.6
 Left ventricle end-systolic volume: 45.6
 Left ventricular mass: 38.2
 Right ventricular end-diastolic volume: 12.9
 Right ventricular end-systolic volume: 6.2
 Right ventricle mass: 5.1
 Native aorta flow rate: 0.93
 Neo-aorta flow rate: 1.47
 Descending aorta flow rate: 0.67
 Right superior vena cava flow rate: 1.08
 Inferior vena cava, below the fenestration flow rate: 0.62
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.07
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.34
 Total right pulmonary vein flow rate: 1.35
 Total left pulmonary vein flow rate: 0.55
 Right atrioventricular valve/tricuspid inflow rate: 0.28
 Left atrioventricular valve/mitral inflow rate: 3.23
 Mitral or common atrioventricular regurgitation fraction: 44.0
 Single ventricle ejection fraction 0.4411764705882352
 Single ventricle systolic volume 35.99999999999999
 Body mass index 13.91542158499065
 Mass to height volume indexed on BSA (exp = 2.7) 28.47221280456676
 Systemic ventricle end-systolic volume: 45.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 62.60710113311043
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 68.85273895320329
 Systemic ventricle end-diastolic volume: 81.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 112.03375992240814
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 123.2101644425743
 Systemic ventricle mass: 38.2
 Systemic ventricle mass indexed on BSA (exp=1) 52.44717682642146
 Systemic ventricle mass indexed on BSA (exp=1.3) 57.67926815816592
 Systemic ventricle mass to volume ratio: 0.46813725490196084
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6427350101277141
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.7068537764481118
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Metallic artifact from the fenestration occluding device.=========================Minor artifact only
 Other relevant report comments or concerns: Metallic artifact from the fenestration occluding device.
Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.
Probably no significant residual fenestration or baffle leak.
Unobstructed right and left pulmonary arteries.
Unobstructed right pulmonary venous return to the left atrium.
Compression of the left lower pulmonary vein between the atrium and descending aorta.
Modest interatrial communication.
Minimal inflow through the partially oversewn left-sided tricuspid valve.
Severe right-sided mitral regurgitation.
Somewhat small bulboventricular foramen.
Unobstructed left ventricular outflow tract through the neo-aortic valve.
Unobstructed Stansel anastomosis.
Unobstructed left aortic arch.
Trivial semilunar valve regurgitation.
Dilated single left ventricle with mildly reduced ejection fraction.
Suspected abnormal lymphatics.
Enlarged liver and spleen.
No pericardial or pleural effusion. No ascites.

 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.03521026].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided data for this patient, it is reasonable to predict that the occluded clinical outcome of whether the patient has a diagnosis of seizures requiring antiepileptic medications is **no**. The patient has no reported history of neurological events such as strokes or transient ischemic attacks, which would typically increase the likelihood of seizure activity. Furthermore, the current clinical status indicates no prior use of antiepileptic medications, which is often a clear indication of seizure history. The XGBoost model's predicted probability of the occluded outcome being 'yes' (0.035) also supports a low likelihood of requiring such medications, suggesting seizures are unlikely in this case.","Based on the information provided, the predicted clinical outcome for the main patient regarding a diagnosis of seizures requiring antiepileptic medications is **no**. The patient's surgical history and MRI report indicate significant structural heart issues, but there is no mention of neurological complications or a history of seizures. Additionally, similar patients do show variance in neurological diagnoses; however, the overall probability from the XGBoost model suggests a very low likelihood (approximately 3.5%) of this outcome occurring. The high accuracy (94%) and AUC (0.86) of the model on the validation set further support the assertion that it is more likely the main patient does not have a diagnosis of seizures requiring antiepileptic medications, as the clinical history does not align with the patterns seen in patients who were positive for this diagnosis.","Based on the provided information, it is likely that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The patient's MRI report indicates significant cardiac complications such as severe tricuspid regurgitation and modest interatrial communication, but no history of neurological events like seizures or transient ischemic attacks is reported. Additionally, examining similar patients, particularly those with comparable surgical histories, it appears that while some had complications such as ascites and non-chylous pleural effusions, there were no significant incidences of seizures. Furthermore, the XGBoost model yields a low predicted probability (0.035) of the occluded outcome being ""yes,"" suggesting that the risk of this patient developing seizures is low. Hence, it would be reasonable to conclude that the patient does not have a diagnosis of seizures requiring antiepileptic medications.","Based on the information provided, it is predicted that the main patient does not have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model estimates a very low predicted probability (0.0352) for the outcome being 'yes,' indicating a strong inclination towards a 'no' classification. Additionally, trends in the similar patient cohort reflect that while antiepileptic medications are a consideration, the rate of seizures was low among those with similar clinical and surgical histories, particularly in cases with comparable complexities like the main patient's double inlet left ventricle condition and several cardiac surgeries. Thus, considering the low predicted probability and the absence of significant reports of seizures in similar patients, it is reasonable to conclude that seizures are unlikely in this case.",1,1,1,1,0
BCH-BYRSAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other modification of superior cavopulmonary connection surgery, please describe: Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
 Please describe additional cardiac pre-Fontan surgery: Atrial septectomy, PA band revision, tricuspid valvuloplasty.
 Other relevant surgical or clinical history (optional): SURG (11/2014, 2m, China): PA band.
SURG (03/2016, 1y 6m, China): Atrial septectomy, PA band revision, tricuspid valvuloplasty.
CATH (10/2017, 3y, Callahan): Hemodynamics.
SURG (10/2017, 3y, Emani): Damus-Kaye-Stansel anastomosis, right-sided bidirectional Glenn.
CATH (04/2018, 3y, Esch): APC coiled, Vasodilator testing 
SURG (04/2018, 3y, Emani): Lateral tunnel fenestrated (4 mm) Fontan.
CATH (01/2019, 4y, Callahan): fenestration closed
CATH (6/21, BCH): Hemo
SURG/EP CATH  (6/21, BCH):tricuspid valve repair. Placement of CRT dual-chamber pacemaker system
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Other modification
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 3.5
 Patient height: 111.5
 Patient weight: 17.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.7283518830084269
 Heart rate: 108.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 67.0
 Upper limb mean blood pressure: 79.0
 O2 Saturation: 99
 Left ventricle end-diastolic volume: 81.6
 Left ventricle end-systolic volume: 45.6
 Left ventricular mass: 38.2
 Right ventricular end-diastolic volume: 12.9
 Right ventricular end-systolic volume: 6.2
 Right ventricle mass: 5.1
 Native aorta flow rate: 0.93
 Neo-aorta flow rate: 1.47
 Descending aorta flow rate: 0.67
 Right superior vena cava flow rate: 1.08
 Inferior vena cava, below the fenestration flow rate: 0.62
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.07
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.34
 Total right pulmonary vein flow rate: 1.35
 Total left pulmonary vein flow rate: 0.55
 Right atrioventricular valve/tricuspid inflow rate: 0.28
 Left atrioventricular valve/mitral inflow rate: 3.23
 Mitral or common atrioventricular regurgitation fraction: 44.0
 Single ventricle ejection fraction 0.4411764705882352
 Single ventricle systolic volume 35.99999999999999
 Body mass index 13.91542158499065
 Mass to height volume indexed on BSA (exp = 2.7) 28.47221280456676
 Systemic ventricle end-systolic volume: 45.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 62.60710113311043
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 68.85273895320329
 Systemic ventricle end-diastolic volume: 81.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 112.03375992240814
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 123.2101644425743
 Systemic ventricle mass: 38.2
 Systemic ventricle mass indexed on BSA (exp=1) 52.44717682642146
 Systemic ventricle mass indexed on BSA (exp=1.3) 57.67926815816592
 Systemic ventricle mass to volume ratio: 0.46813725490196084
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6427350101277141
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.7068537764481118
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Metallic artifact from the fenestration occluding device.=========================Minor artifact only
 Other relevant report comments or concerns: Metallic artifact from the fenestration occluding device.
Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.
Probably no significant residual fenestration or baffle leak.
Unobstructed right and left pulmonary arteries.
Unobstructed right pulmonary venous return to the left atrium.
Compression of the left lower pulmonary vein between the atrium and descending aorta.
Modest interatrial communication.
Minimal inflow through the partially oversewn left-sided tricuspid valve.
Severe right-sided mitral regurgitation.
Somewhat small bulboventricular foramen.
Unobstructed left ventricular outflow tract through the neo-aortic valve.
Unobstructed Stansel anastomosis.
Unobstructed left aortic arch.
Trivial semilunar valve regurgitation.
Dilated single left ventricle with mildly reduced ejection fraction.
Suspected abnormal lymphatics.
Enlarged liver and spleen.
No pericardial or pleural effusion. No ascites.

 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.97609097].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? yes\n Reason for pacemaker placement: Other\n'],"Based on the provided data, the predicted clinical outcome for the main patient is ""yes,"" they have a history of pacemaker placement. This conclusion is supported by the surgical history, which clearly indicates the placement of a CRT dual-chamber pacemaker system during the electrophysiological procedure in June 2021. Additionally, the patient's complex surgical history—including multiple surgeries such as tricuspid valve repair—suggests a higher likelihood of requiring cardiac device implantation. The XGBoost model's predicted probability of 0.976 indicates a strong likelihood of the patient having a history of pacemaker placement, further corroborating this outcome.","Based on the provided information, it is predicted that the main patient has a history of pacemaker placement (yes). The patient's extensive surgical history involving multiple cardiac procedures, including a tricuspid valve repair and placement of a CRT dual-chamber pacemaker system, strongly suggests the need for rhythm management, which is often facilitated by a pacemaker. Furthermore, the similar patients, particularly those with complex single-ventricle anatomies and a significant history of interventions, indicated that pacemaker placement is common in this cohort, aligning with the patient's clinical profile. Given the high predictive probability from the XGBoost model (0.976) and the characteristics of the similar patients, this outcome appears highly likely.","Based on the provided data, I predict that the main patient **does have a history of pacemaker placement**. The patient's extensive surgical history indicates significant interventions, including tricuspid valve repair and placement of a CRT dual-chamber pacemaker system as recent as June 2021. Additionally, among similar patients, significant valvular and hemodynamic challenges have resulted in similar interventions; this is reflected in the similar patients' data where certain patients received pacemakers or had a history of complex cardiac procedures suggesting the need for rhythm management devices. Furthermore, the high predicted probability of the occluded outcome being 'yes' (97.6% from the XGBoost model) aligns with this reasoning, indicating a strong likelihood of a history of pacemaker placement in patients with comparable profiles to the main patient.","Based on the data provided, the main patient has a significant surgical history, including multiple interventions related to their congenital heart condition. The presence of a tricuspid valve repair and CRT dual-chamber pacemaker system indicates a need for pacing support likely due to previous surgical complications or rhythm disturbances. Additionally, the similar patients exhibit trends in pacing assistance, particularly those with comparable surgery types and outcomes worse than baseline, suggestive of a high probability of requiring pacing devices. Therefore, the evidence strongly supports that the main patient does have a history of pacemaker placement (yes).",1,1,1,1,1
BCH-CASKEV-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 114.0
 Patient weight: 22.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8361655996857873
 Left ventricle end-diastolic volume: 57.9
 Left ventricle end-systolic volume: 25.7
 Single ventricle ejection fraction 0.5561312607944733
 Single ventricle systolic volume 32.2
 Body mass index 16.928285626346568
 Systemic ventricle end-systolic volume: 25.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 30.735538522103152
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 32.43046217220016
 Systemic ventricle end-diastolic volume: 57.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 69.24465682606119
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 73.06318131402291
 Other relevant report comments or concerns: Mild to moderate coarctation.
Unobstructed Fontan pathway and right pulmonary artery.
Mild left pulmonary artery compression.
Unobstructed pulmonary venous return.
Unobstructed Stansel.
Normal left ventricular systolic function.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01061994].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided clinical information, it is predicted that the patient does **not** have a history of ascites (> trace). The patient's MRI report indicates an unobstructed Fontan pathway and pulmonary venous return, along with no documented history of complications typically associated with Fontan physiology, such as ascites. Furthermore, the patient's status shows no indication of protein-losing enteropathy or significant liver dysfunction, both of which commonly contribute to ascites development in this population. Therefore, given these considerations and the low predicted probability (approximately 1%) from the XGBoost model for the patient having a history of ascites, it is reasonable to conclude a negative outcome for this occluded clinical question.","Based on the provided data, I predict that the main patient does not have a history of ascites (> trace). The main patient's surgical history suggests stable post-Fontan physiology, with no histories of significant complications such as pleural effusions or significant liver dysfunction, which are often associated with ascites. Additionally, the similar patients' outcomes indicate a low occurrence of ascites, particularly among those without evident severe complications in their MRI reports. The predicted probability of the occluded outcome being 'yes' is particularly low (0.01061994), which aligns with the clinical trends observed in both the main patient and the similar cohort.","Based on the provided information, the missing clinical outcome for the main patient regarding a history of ascites (> trace) is likely to be ""no."" The main patient has a detailed surgical and MRI history indicating multiple interventions but no mention or history of ascites, pleural effusions, or significant gastrointestinal complications that would suggest fluid accumulation. Furthermore, among similar patients, none reported a history of ascites. The XGBoost model's probability prediction of 0.0106 for the outcome being ""yes"" corroborates the low likelihood of this outcome, indicating that a history of ascites is not a common feature in this cohort. Therefore, combining the main patient's clinical history with the trends from similar patients strongly supports a prediction of ""no.""","Based on the provided data, the main patient exhibits numerous procedural interventions typically associated with complex post-Fontan physiology, including a fenestration during their initial Fontan surgery and a Stansel/Damus procedure. In reviewing the similar patients, there is a notable trend showing that those with a history of significant interventions had varying outcomes related to ascites. Notably, a considerable portion of similar patients with complex histories of surgeries and interventions reported an absence of significant fluid accumulation post-operatively. Additionally, the XGBoost model’s prediction probability of 0.0106 suggests a very low likelihood of the outcome being 'yes,' indicating a similar low incidence in the dataset for a history of ascites. Therefore, it is reasonable to predict that this patient does not have a history of ascites (> trace) given these observations.",1,1,1,1,0
BCH-CASKEV-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 114.0
 Patient weight: 22.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8361655996857873
 Left ventricle end-diastolic volume: 57.9
 Left ventricle end-systolic volume: 25.7
 Single ventricle ejection fraction 0.5561312607944733
 Single ventricle systolic volume 32.2
 Body mass index 16.928285626346568
 Systemic ventricle end-systolic volume: 25.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 30.735538522103152
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 32.43046217220016
 Systemic ventricle end-diastolic volume: 57.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 69.24465682606119
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 73.06318131402291
 Other relevant report comments or concerns: Mild to moderate coarctation.
Unobstructed Fontan pathway and right pulmonary artery.
Mild left pulmonary artery compression.
Unobstructed pulmonary venous return.
Unobstructed Stansel.
Normal left ventricular systolic function.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.03477965].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided data and the XGBoost model's prediction probability of 0.0348 for the occluded outcome, it is likely that the patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The patient's history suggests the presence of atrial tachyarrhythmias and sinus node dysfunction, but there is no documented history of seizures or neurological issues directly related to seizures requiring treatment. Additionally, a low predicted probability in the XGBoost model indicates that the clinical features of this patient, when assessed against the cohort, do not support the presence of a seizure disorder.","Based on the analysis of both the main patient's data and the outcomes of similar patients, it is predicted that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The main patient has a history of atrial tachyarrhythmias and sinus node dysfunction, but there is no documentation of seizures or related neurologic complications. The similar patients with comparable surgical histories and conditions also show no significant incidences of seizures, and the likelihood of epilepsy in this cohort appears low given the overall low probability (3.48%) predicted by the XGBoost model. Therefore, considering the absence of evidence and the trends observed, the likelihood of this patient having such a diagnosis is minimal.","Based on the data provided, it is predicted that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. This conclusion is drawn from the main patient's clinical status, which does not indicate any history of seizures, stroke, or significant neurological events. Furthermore, an analysis of similar patients, particularly those with comparable surgical histories and MRI characteristics, reveals that none of them have a diagnosis of seizures either, suggesting a trend toward lower incidence in this cohort. Additionally, the XGBoost model's predicted probability of 0.03477965 for developing such a diagnosis aligns with the absence of substantial risk factors presented in the patient's profile and those of the matched peers.","Based on the available data, the prediction for whether the main patient has a diagnosis of seizures requiring antiepileptic medications is **no**. The main patient has undergone multiple cardiac surgeries without a documented history of seizure activity, and other complications typically associated with seizure disorders, such as strokes or significant neurological events, are absent. 

Furthermore, the similar patient cohort also reflects a low incidence of antiepileptic medication use, with the prediction probability (0.03477965) indicating a much higher likelihood of a negative outcome for this condition. This combination of findings suggests that it is less likely for the main patient to have a diagnosis of seizures requiring treatment with antiepileptics.",1,1,1,1,0
BCH-CASKEV-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 114.0
 Patient weight: 22.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8361655996857873
 Left ventricle end-diastolic volume: 57.9
 Left ventricle end-systolic volume: 25.7
 Single ventricle ejection fraction 0.5561312607944733
 Single ventricle systolic volume 32.2
 Body mass index 16.928285626346568
 Systemic ventricle end-systolic volume: 25.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 30.735538522103152
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 32.43046217220016
 Systemic ventricle end-diastolic volume: 57.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 69.24465682606119
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 73.06318131402291
 Other relevant report comments or concerns: Mild to moderate coarctation.
Unobstructed Fontan pathway and right pulmonary artery.
Mild left pulmonary artery compression.
Unobstructed pulmonary venous return.
Unobstructed Stansel.
Normal left ventricular systolic function.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01886172].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data for the main patient, it is likely that the patient has not died (outcome: ""no""). This prediction is supported by several key factors: the patient's systemic ventricle shows normal functional metrics with a decent ejection fraction of approximately 55.6%, indicating adequate cardiac performance. Additionally, there is no documented history of severe complications commonly associated with Fontan patients, such as protein-losing enteropathy, plastic bronchitis, or significant arrhythmias that would detrimentally impact survival. Furthermore, the low predicted probability (1.9%) from the XGBoost model further suggests a very low likelihood of mortality in this case, reinforcing the inference that the patient is likely alive.","Based on the information provided, I predict that the main patient has **not** died. The main patient has a history of multiple surgeries, including a successful lateral tunnel Fontan, and exhibits normal left ventricular systolic function, which is critically important for overall outcomes. Furthermore, the data from similar patients, particularly those with comparable surgical histories and cardiac diagnoses (like double inlet right ventricle), show a similar trend of survival, with notable stability in outcomes post-Fontan surgery. The XGBoost model probability of death being only 0.01886172 also suggests a significantly low risk. Overall, these factors indicate a positive prognosis for the main patient, making death unlikely.","Based on the provided data, the predicted clinical outcome for the main patient regarding ""Has the patient died?"" is **no**. Both the main patient and the similar patients have undergone multiple cardiac surgeries and exhibited no significant adverse events such as cardiac arrest or major complications, indicating they have been managing their conditions relatively well. Additionally, the XGBoost model's probability estimate of the occluded outcome being 'yes' is quite low (0.01886172), suggesting that death is unlikely in this cohort. Given the overall clinical context and favorable MRI findings, including normal left ventricular function and no history of critical complications, it is reasonable to conclude that the main patient has not died.","Based on the data available for the main patient, the prediction for the occluded clinical outcome, ""Has the patient died?"" is **no**. The main patient has a surgical history indicative of significant intervention, including multiple surgeries and a lateral tunnel Fontan, with an unobstructed Fontan pathway and normal left ventricular systolic function noted in the MRI report, which favor positive survival outcomes. Additionally, the similar patients within the dataset show a strong trend of survival, where the majority have not succumbed to their conditions—reflecting an overall 96% accuracy in predictions for this outcome across a cohort where several had similar cardiac diagnoses and procedures. Given these indicators and the low predicted probability (1.9%) of the outcome being 'yes' from the XGBoost model, it supports the conclusion that the main patient has not died.",1,1,1,1,0
BCH-CASKEV-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 114.0
 Patient weight: 22.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8361655996857873
 Left ventricle end-diastolic volume: 57.9
 Left ventricle end-systolic volume: 25.7
 Single ventricle ejection fraction 0.5561312607944733
 Single ventricle systolic volume 32.2
 Body mass index 16.928285626346568
 Systemic ventricle end-systolic volume: 25.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 30.735538522103152
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 32.43046217220016
 Systemic ventricle end-diastolic volume: 57.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 69.24465682606119
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 73.06318131402291
 Other relevant report comments or concerns: Mild to moderate coarctation.
Unobstructed Fontan pathway and right pulmonary artery.
Mild left pulmonary artery compression.
Unobstructed pulmonary venous return.
Unobstructed Stansel.
Normal left ventricular systolic function.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00294164].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the available data for the main patient, I predict that the missing clinical outcome, ""Did the patient receive a heart transplant?"" is **no**. The patient's surgical history indicates a total of three cardiac surgeries, including a lateral tunnel Fontan and a Stansel/Damus procedure, suggesting a stable surgical management of their condition without the immediate need for transplantation. Additionally, the patient's current status shows no significant complications such as protein-losing enteropathy or arrhythmias that would typically lead to worsening heart function, which could necessitate transplantation. The low predicted probability of heart transplantation (0.00294164) further supports this conclusion, indicating a very low likelihood that this patient has undergone a heart transplant compared to the similar cohort studied.","Based on the available information, I predict that the main patient did **not** receive a heart transplant. The patient's extensive surgical history—including multiple cardiac interventions, a fenestrated lateral tunnel Fontan, and stable hemodynamics indicated by unobstructed pathways—suggests stability typical of patients who might avoid transplantation if they have effectively managed their conditions. The similar patients also illustrate a pattern where none with analogous cardiac surgeries and outcomes received a transplant, and only 2.94% predicted probability in the XGBoost model further supports the likelihood that transplantation is not indicated for the main patient. Given these findings, it is reasonable to conclude that the main patient has maintained sufficient cardiovascular function to forgo a heart transplant.","Based on the available data, I predict that the main patient did not receive a heart transplant. The probability of the occluded outcome being 'yes' is very low (0.00294164), which correlates with the high accuracy and precision shown in the model trained on similar patients. Additionally, none of the similar patients who underwent comparable surgical interventions or had similar clinical outcomes indicated a heart transplant. Specifically, the main patient’s history of atrial tachyarrhythmias and sinus node dysfunction, alongside the absence of any significant transplant-related complications or previous transplant candidacy (indicated by their outcomes), further supports the likelihood of not receiving a transplant.","Based on the provided data, the prediction for whether the main patient received a heart transplant is ""no."" The main patient has undergone multiple surgeries, including complex interventions like a lateral tunnel Fontan with fenestration, which suggests a high level of medical management to address their condition without progressing to a transplant. Additionally, analysis of similar patients reveals that despite comparable surgical histories and the complexity of their congenital conditions, none of the similar patients were listed for or received a heart transplant, aligning with the even lower probability of the main patient undergoing this drastic treatment, as indicated by an XGBoost model estimate of 0.00294164 for ""yes,"" suggesting a very slim likelihood. These insights collectively support the conclusion that the patient did not receive a heart transplant.",1,1,1,1,0
BCH-CASKEV-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 114.0
 Patient weight: 22.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8361655996857873
 Left ventricle end-diastolic volume: 57.9
 Left ventricle end-systolic volume: 25.7
 Single ventricle ejection fraction 0.5561312607944733
 Single ventricle systolic volume 32.2
 Body mass index 16.928285626346568
 Systemic ventricle end-systolic volume: 25.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 30.735538522103152
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 32.43046217220016
 Systemic ventricle end-diastolic volume: 57.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 69.24465682606119
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 73.06318131402291
 Other relevant report comments or concerns: Mild to moderate coarctation.
Unobstructed Fontan pathway and right pulmonary artery.
Mild left pulmonary artery compression.
Unobstructed pulmonary venous return.
Unobstructed Stansel.
Normal left ventricular systolic function.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.9987472].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? yes\n Reason for pacemaker placement: Other\n'],"Based on the provided data, the predicted clinical outcome for the patient regarding the history of pacemaker placement is ""yes."" This conclusion is supported by several factors: the patient has a history of atrial tachyarrhythmias and sinus node dysfunction, both of which often necessitate the placement of a pacemaker to manage rhythm disturbances and maintain adequate heart rates. Additionally, the high predicted probability of 0.9987472 suggests a strong likelihood that the patient has undergone this intervention, indicating the presence of clinical indications for pacemaker placement. Finally, the well-documented surgical history, including multiple surgeries and the presence of a lateral tunnel Fontan, heightens the likelihood of complications that could lead to the need for pacing devices.","Based on the provided data, the prediction for the main patient regarding the history of pacemaker placement is **no**. The main patient has a complex surgical history, including multiple surgeries and interventions, but no recorded history of a pacemaker placement, unlike some of the similar patients who either have a pacemaker or had various interventions. Furthermore, the similar patients' outcomes show no such pattern of required pacing, particularly in those with analogous conditions and treatments, which might indicate that the absence of such a history is consistent within this cohort. The XGBoost model’s high predicted probability of the occluded outcome supports the interpretation that the patient does not require a pacemaker at this point in their care.","Based on the information provided, I predict that the main patient **does not have a history of pacemaker placement (no)**. The patient's current medical records indicate atrial tachyarrhythmias and sinus node dysfunction, which can often lead to the need for pacing, yet no explicit history of pacemaker placement is documented, suggesting adequate management of these issues without the need for pacing. Additionally, the cohort of similar patients shows that most who experienced similar arrhythmias did not require pacemaker installations, and the low prevalence of such interventions in the comparable cohort reinforces this assessment. Moreover, the high predictive probability from the XGBoost model further supports the likelihood that this patient may not have a pacemaker, given that most patients without this history were accurately identified in the training set.","**Prediction**: Yes, the patient likely has a history of pacemaker placement.

**Reasoning**: The main patient has a complex cardiac surgical history, including atrial tachyarrhythmias and sinus node dysfunction, which are often indications for pacemaker placement in single-ventricle patients following Fontan surgery. Among the similar patients, a notable trend exists where those with similar surgical histories and complications like arrhythmias often required additional interventions such as pacemaker insertion. Moreover, the XGBoost model indicates a very high probability (0.9987472) of the outcome being positive, suggesting a strong statistical correlation with similar patient profiles who have undergone pacemaker implantation. Thus, the combination of clinical history and predictive modeling supports the likelihood of this patient having a history of pacemaker placement.",1,0,0,1,1
BCH-CIPEMI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 153.5
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4151676276431957
 Heart rate: 90.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 70.0
 Upper limb mean blood pressure: 85.0
 Right ventricular end-diastolic volume: 129.5
 Right ventricular end-systolic volume: 71.6
 Right ventricle mass: 105.9
 Single ventricle ejection fraction 0.4471042471042471
 Single ventricle systolic volume 57.900000000000006
 Body mass index 19.947161243090115
 Mass to height volume indexed on BSA (exp = 2.7) 33.29686418060451
 Systemic ventricle end-systolic volume: 71.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 50.59471302296664
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.58928398019045
 Systemic ventricle end-diastolic volume: 129.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 91.50859408483491
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 82.45547870718804
 Systemic ventricle mass: 105.9
 Systemic ventricle mass indexed on BSA (exp=1) 74.83212442922022
 Systemic ventricle mass indexed on BSA (exp=1.3) 67.42884320533756
 Systemic ventricle mass to volume ratio: 0.8177606177606178
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5778542426966812
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.5206860479176646
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The previously placed Clamshell device causes a very large susceptibility artifact that obscures the Fontan pathways and entire base of the heart, including the basal portion of the ventricles. The study is very limited due to this artifact.
The quantitative assessment of right ventricular function is only moderately reliable due to the artifact. The RV ejection fraction is probably in the range of 40-45%.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: superior mesenteric vein thrombosis extending to the portal splenic confluence and mean portal vein seen on CT after car accident
 Please provide any known details regarding the death: Presumed EP arrest secondary to heart failure
She was found dead at home in her bed. She was seen the week prior in clinic, with stable but significant respiratory distress and pedal edema. ""We were slowly increasing her diuretic regime. She had a history of arrhythmias. Dr. Freed who had followed for years felt it was likely an arrhythmic event. She was NYHA class 2-3 when I saw her.""
 Has the patient died? yes
 If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest
  diagnosis of seizures requiring antiepileptic medications? yes
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00752878].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided information, I predict that the patient did **not** receive a heart transplant. The main patient has a complex surgical history including multiple cardiac surgeries and a Lateral Tunnel Fontan, along with significant complications such as arrhythmias and intracardiac thrombus. The low predicted probability (0.00752878) from the XGBoost model suggests that the likelihood of receiving a heart transplant is very low. Furthermore, the presence of a chronic condition like heart failure leading to malignant arrhythmia and the management of symptoms without surgical intervention imply the patient’s condition may have been managed without opting for transplantation.","Based on the given data, the predicted outcome for the main patient is *no*, the patient did not receive a heart transplant. The main patient has undergone 4 cardiac surgeries, including a lateral tunnel Fontan procedure with a history of arrhythmias and intracardiac thrombus, which raises concerns about transplant eligibility and the complexities of rehabilitation. Additionally, the similar patients, particularly those with comparable surgical histories, mainly did not receive transplants, indicating a trend where patients with significant surgical interventions and complications are often managed conservatively rather than progressing to transplantation. The XGBoost model also suggests a very low probability (0.0075) for receiving a transplant, strengthening the prediction that the main patient likely did not undergo this procedure.","Based on the provided data, the predicted outcome is ""No,"" the patient did not receive a heart transplant. The main patient has a surgical history that includes multiple interventions and an overall clinical profile suggesting stability despite significant underlying cardiovascular challenges, as evident from their cardiac surgeries and management of arrhythmias. The similar patients also had predominantly non-transplant outcomes, correlating with the prediction model's output that shows a very low probability (0.0075) of the occluded outcome being 'yes' (indicating a transplant). The majority of similar cases did not progress to heart transplantation, with a robust model showing high accuracy and a low false-negative rate, further supporting the conclusion that heart transplant was not warranted in this scenario.","Based on the data provided, it is predicted that the main patient did NOT receive a heart transplant. The patient has a complex surgical history typical of a single-ventricle anatomy and has undergone multiple surgeries including a Fontan procedure, indicated by the placement of a lateral tunnel and a fenestration. The similar cohort of patients, despite their varying heart conditions, did not demonstrate a high incidence of heart transplants, particularly in those with significant comorbidities such as atrial arrhythmias and the history of prolonged cardiac issues. Additionally, the XGBoost model estimates a 0.75% probability of the outcome being ""yes,"" which strongly suggests it is more likely that the main patient remained within a suitable range for continued management without advancing to transplant.",1,1,1,1,0
BCH-CIPEMI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 153.5
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4151676276431957
 Heart rate: 90.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 70.0
 Upper limb mean blood pressure: 85.0
 Right ventricular end-diastolic volume: 129.5
 Right ventricular end-systolic volume: 71.6
 Right ventricle mass: 105.9
 Single ventricle ejection fraction 0.4471042471042471
 Single ventricle systolic volume 57.900000000000006
 Body mass index 19.947161243090115
 Mass to height volume indexed on BSA (exp = 2.7) 33.29686418060451
 Systemic ventricle end-systolic volume: 71.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 50.59471302296664
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.58928398019045
 Systemic ventricle end-diastolic volume: 129.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 91.50859408483491
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 82.45547870718804
 Systemic ventricle mass: 105.9
 Systemic ventricle mass indexed on BSA (exp=1) 74.83212442922022
 Systemic ventricle mass indexed on BSA (exp=1.3) 67.42884320533756
 Systemic ventricle mass to volume ratio: 0.8177606177606178
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5778542426966812
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.5206860479176646
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The previously placed Clamshell device causes a very large susceptibility artifact that obscures the Fontan pathways and entire base of the heart, including the basal portion of the ventricles. The study is very limited due to this artifact.
The quantitative assessment of right ventricular function is only moderately reliable due to the artifact. The RV ejection fraction is probably in the range of 40-45%.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: superior mesenteric vein thrombosis extending to the portal splenic confluence and mean portal vein seen on CT after car accident
  diagnosis of seizures requiring antiepileptic medications? yes
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.3674904].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,"[' Please provide any known details regarding the death: Presumed EP arrest secondary to heart failure\r\nShe was found dead at home in her bed. She was seen the week prior in clinic, with stable but significant respiratory distress and pedal edema. ""We were slowly increasing her diuretic regime. She had a history of arrhythmias. Dr. Freed who had followed for years felt it was likely an arrhythmic event. She was NYHA class 2-3 when I saw her.""\n Has the patient died? yes\n If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest\n']","Based on the provided data and longitudinal health information regarding this single-ventricle patient who underwent Fontan surgery, it is predicted that the patient has not died (""no""). The patient has a history of multiple surgeries and complications including intracardiac thrombus, seizures, and arrhythmias, but importantly, there is no indication of a recent serious event leading to mortality, such as a heart transplant or sustained cardiac arrest. The XGBoost model's predicted probability of the occluded outcome being ‘yes’ (indicating death) is 0.367, which suggests that the likelihood of death is relatively low compared to the overall health issues and surgical history. Additionally, the excellent accuracy of the model on a similar cohort and the management of current medications and interventions imply ongoing medical oversight, further supporting the prediction of survival.","Based on the provided data, I would predict that the missing clinical outcome for the main patient is **no** regarding whether the patient has died. The main patient has undergone multiple cardiac surgeries, including a successful initial Fontan procedure with a fenestration, and has a relatively stable single ventricle ejection fraction around 44.7%, indicating some degree of heart function. 

Moreover, similar patients with comparable clinical and surgical histories, including those who also underwent Fontan procedures and had similar complications, exhibited a higher survival probability despite their challenges. Given that the XGBoost model predicts a probability of only 36.7% for the occluded outcome being 'yes' (indicating death), combined with successful medical management and the absence of additional severe complications in the main patient, suggests a favorable prognosis.","Based on the provided data, it is reasonable to predict that the main patient has **not died**. The patient's condition involves a complex surgical history with multiple interventions, including a lateral tunnel Fontan and fenestration, which have been successfully performed without significant complications noted in the surgical updates. Furthermore, among the similar patients, there is a notable trend of survival despite severe clinical histories, as indicated by their outcomes and treatments. The XGBoost model predicts a moderate probability (approximately 36.7%) for the outcome of death; however, given the overall clinical picture, history of extensive monitoring and interventions, and the common outcomes seen in counterparts, it suggests that the patient remains alive.","Based on the information provided, I would predict that the main patient **has not died**. The patient has undergone a series of complex surgeries, including a Lateral Tunnel Fontan and a Stansel/Damus procedure, which are critical indicators of ongoing management in congenital heart disease. The similar patients share a comparable surgical history and have not experienced mortality; additionally, there is a notable trend where the patients with multiple surgeries and procedural interventions, like the ones seen in this main patient, generally have better outcomes due to proactive medical management and advancements in care. The XGBoost model's estimated probability of 0.3674904 (indicative of a relatively low likelihood of negative outcomes) further supports the prediction that the patient has survived, alongside the encouraging clinical management strategies observed in similar cases.",0,0,0,0,1
BCH-CIPEMI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 153.5
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4151676276431957
 Heart rate: 90.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 70.0
 Upper limb mean blood pressure: 85.0
 Right ventricular end-diastolic volume: 129.5
 Right ventricular end-systolic volume: 71.6
 Right ventricle mass: 105.9
 Single ventricle ejection fraction 0.4471042471042471
 Single ventricle systolic volume 57.900000000000006
 Body mass index 19.947161243090115
 Mass to height volume indexed on BSA (exp = 2.7) 33.29686418060451
 Systemic ventricle end-systolic volume: 71.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 50.59471302296664
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.58928398019045
 Systemic ventricle end-diastolic volume: 129.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 91.50859408483491
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 82.45547870718804
 Systemic ventricle mass: 105.9
 Systemic ventricle mass indexed on BSA (exp=1) 74.83212442922022
 Systemic ventricle mass indexed on BSA (exp=1.3) 67.42884320533756
 Systemic ventricle mass to volume ratio: 0.8177606177606178
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5778542426966812
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.5206860479176646
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The previously placed Clamshell device causes a very large susceptibility artifact that obscures the Fontan pathways and entire base of the heart, including the basal portion of the ventricles. The study is very limited due to this artifact.
The quantitative assessment of right ventricular function is only moderately reliable due to the artifact. The RV ejection fraction is probably in the range of 40-45%.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: superior mesenteric vein thrombosis extending to the portal splenic confluence and mean portal vein seen on CT after car accident
 Please provide any known details regarding the death: Presumed EP arrest secondary to heart failure
She was found dead at home in her bed. She was seen the week prior in clinic, with stable but significant respiratory distress and pedal edema. ""We were slowly increasing her diuretic regime. She had a history of arrhythmias. Dr. Freed who had followed for years felt it was likely an arrhythmic event. She was NYHA class 2-3 when I saw her.""
 Has the patient died? yes
 If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.6338589].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? yes\n'],"**Prediction:** Yes, the patient has a diagnosis of seizures requiring antiepileptic medications.

**Reasoning:** The patient has a history of significant cardiac events, including arrhythmias and a prior stroke, which can be indicative of a compromised neurological state—often a precursor to seizures. Additionally, the presence of intracardiac thrombus and the resulting complications could contribute to cerebrovascular incidents, potentially leading to seizure activity. Given the estimated probability of 0.63 from the XGBoost model, along with relevant historical context from similar patients, this outcome appears plausible.","Based on the data provided, it is predicted that the main patient does have a diagnosis of seizures requiring antiepileptic medications. This conclusion is supported by the patient’s complex surgical history, which includes multiple cardiac surgeries and the presence of significant complications such as arrhythmias and a history of intracardiac thrombus, both of which are known risk factors for seizures. Furthermore, the similar patients exhibit varied outcomes but show some histories of significant neurological issues, suggesting a pattern where seizures could be more prevalent in this high-risk population. Additionally, the estimated probability of 0.634 for having seizures further indicates a likelihood that aligns with these observations.","Based on the provided data, I predict that the main patient **does not have a diagnosis of seizures requiring antiepileptic medications**. The patient's surgical history and MRI report do not indicate significant neurological complications, and their primary issues relate to cardiac function and arrhythmias rather than neurological conditions. In examining similar patients, particularly those who also underwent fontan surgeries, a notable trend is the absence of seizure diagnoses among those without significant neurological histories, particularly when other serious complications—such as arrhythmias or protein-losing enteropathy—are documented. Additionally, the XGBoost model gives a probability of 0.6338589 for a 'yes' response, which indicates some uncertainty; however, this model's performance is based on a broader cohort, likely skewing toward findings more common in patients with other comorbidities. Thus, the absence of any seizure history in the main patient and similar profiles leads to this conclusion.","Based on the provided data and the XGBoost model's predictive probability of 0.6338589 for the occluded outcome of seizures requiring antiepileptic medications, there is a moderate likelihood that the main patient could be diagnosed with seizures. Analyzing the similar patients, none reported a diagnosis of seizures, which may suggest a lower prevalence within this population. However, the main patient has a complex medical history, including significant cardiac surgeries and arrhythmias, which could predispose them to seizures as a secondary complication. The combination of these factors supports the hypothesis that while the risk exists, the final determination should take into account clinical evaluations and monitoring. Therefore, the recommendation would be to assess further whether the patient might indeed qualify for a diagnosis of seizures requiring treatment.",1,1,0,1,1
BCH-CIPEMI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 153.5
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4151676276431957
 Heart rate: 90.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 70.0
 Upper limb mean blood pressure: 85.0
 Right ventricular end-diastolic volume: 129.5
 Right ventricular end-systolic volume: 71.6
 Right ventricle mass: 105.9
 Single ventricle ejection fraction 0.4471042471042471
 Single ventricle systolic volume 57.900000000000006
 Body mass index 19.947161243090115
 Mass to height volume indexed on BSA (exp = 2.7) 33.29686418060451
 Systemic ventricle end-systolic volume: 71.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 50.59471302296664
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.58928398019045
 Systemic ventricle end-diastolic volume: 129.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 91.50859408483491
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 82.45547870718804
 Systemic ventricle mass: 105.9
 Systemic ventricle mass indexed on BSA (exp=1) 74.83212442922022
 Systemic ventricle mass indexed on BSA (exp=1.3) 67.42884320533756
 Systemic ventricle mass to volume ratio: 0.8177606177606178
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5778542426966812
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.5206860479176646
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The previously placed Clamshell device causes a very large susceptibility artifact that obscures the Fontan pathways and entire base of the heart, including the basal portion of the ventricles. The study is very limited due to this artifact.
The quantitative assessment of right ventricular function is only moderately reliable due to the artifact. The RV ejection fraction is probably in the range of 40-45%.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: superior mesenteric vein thrombosis extending to the portal splenic confluence and mean portal vein seen on CT after car accident
 Please provide any known details regarding the death: Presumed EP arrest secondary to heart failure
She was found dead at home in her bed. She was seen the week prior in clinic, with stable but significant respiratory distress and pedal edema. ""We were slowly increasing her diuretic regime. She had a history of arrhythmias. Dr. Freed who had followed for years felt it was likely an arrhythmic event. She was NYHA class 2-3 when I saw her.""
 Has the patient died? yes
 If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest
  diagnosis of seizures requiring antiepileptic medications? yes
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.15205666].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided data, I predict that the patient does **not** have a history of ascites (> trace). The patient has a documented history of respiratory distress and pedal edema, which may suggest fluid overload or heart failure rather than ascites specifically. Additionally, the absence of chronic conditions known to contribute to ascites, such as protein-losing enteropathy or significant liver dysfunction, supports this conclusion. Furthermore, the low estimated probability (0.152) from the XGBoost model indicates that there is only a small likelihood of the patient experiencing ascites, reinforcing the prediction that the outcome is 'no'.","Based on the provided data, it is likely that the main patient does not have a history of ascites (> trace). The patient's surgical history indicates a series of complex cardiac interventions, which can sometimes lead to complications such as ascites, but there is no documented history of pleural effusions or ascites beyond trace levels in the main patient's report. Additionally, among the similar patients, two did not have any records of ascites despite undergoing comparable surgeries, reflecting an overall trend where ascites was not a prevalent complication following the surgeries observed in the selected cohort. Moreover, the low predicted probability of 0.15205666 from the XGBoost model further supports this inference, indicating a lower likelihood of the occluded outcome being 'yes' for ascites. Thus, it is reasonable to predict that the answer is ""no,"" the patient does not have a significant history of ascites.","**Prediction:** The patient does not have a history of ascites (> trace) (no).

**Reasoning:** The main patient's surgical history indicates complexity with potential complications, such as the presence of a single ventricle and various interventions, including a lateral tunnel Fontan with a fenestration. However, despite the significant surgical history, there is no direct indication of ascites mentioned or any supportive data in the MRI report. In contrast, most of the similar patients, despite their varied histories, do not show any records of ascites either. Additionally, the predicted probability of the occluded outcome being 'yes' is low at 15.21%, suggesting that complications like ascites might indeed be rare in such a context; thus, it is reasonable to conclude that the main patient likely does not have a history of ascites.","Based on the data provided, I predict that the main patient does **not** have a history of ascites (> trace). The main patient has undergone multiple surgeries, including a lateral tunnel Fontan and a Stansel procedure, and utilizes diuretics, which may indicate effective management of fluid status. In contrast, among the similar patients, the majority do not report a history of ascites. Additionally, the predicted probability of the occluded outcome being 'yes' is relatively low at 15.2%, suggesting that the likelihood of ascites in this cohort is minimized. Hence, combining clinical history and outcome correlations, it suggests that the main patient likely did not experience significant ascites.",1,1,1,1,0
BCH-CIPEMI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 153.5
 Patient weight: 47.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4151676276431957
 Heart rate: 90.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 70.0
 Upper limb mean blood pressure: 85.0
 Right ventricular end-diastolic volume: 129.5
 Right ventricular end-systolic volume: 71.6
 Right ventricle mass: 105.9
 Single ventricle ejection fraction 0.4471042471042471
 Single ventricle systolic volume 57.900000000000006
 Body mass index 19.947161243090115
 Mass to height volume indexed on BSA (exp = 2.7) 33.29686418060451
 Systemic ventricle end-systolic volume: 71.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 50.59471302296664
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.58928398019045
 Systemic ventricle end-diastolic volume: 129.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 91.50859408483491
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 82.45547870718804
 Systemic ventricle mass: 105.9
 Systemic ventricle mass indexed on BSA (exp=1) 74.83212442922022
 Systemic ventricle mass indexed on BSA (exp=1.3) 67.42884320533756
 Systemic ventricle mass to volume ratio: 0.8177606177606178
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5778542426966812
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.5206860479176646
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The previously placed Clamshell device causes a very large susceptibility artifact that obscures the Fontan pathways and entire base of the heart, including the basal portion of the ventricles. The study is very limited due to this artifact.
The quantitative assessment of right ventricular function is only moderately reliable due to the artifact. The RV ejection fraction is probably in the range of 40-45%.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Trivial or trivial to mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: superior mesenteric vein thrombosis extending to the portal splenic confluence and mean portal vein seen on CT after car accident
 Please provide any known details regarding the death: Presumed EP arrest secondary to heart failure
She was found dead at home in her bed. She was seen the week prior in clinic, with stable but significant respiratory distress and pedal edema. ""We were slowly increasing her diuretic regime. She had a history of arrhythmias. Dr. Freed who had followed for years felt it was likely an arrhythmic event. She was NYHA class 2-3 when I saw her.""
 Has the patient died? yes
 If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest
  diagnosis of seizures requiring antiepileptic medications? yes
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00105251].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided clinical data, the prediction for the missing clinical outcome, **""Does the patient have a history of pacemaker placement?""** is **no**. This conclusion is primarily supported by the absence of information regarding any chronic pacing issues or the need for a pacemaker, despite the patient's history of arrhythmias. The fact that the patient had significant respiratory distress and pedal edema prior to their death, along with existing non-sustained ventricular tachyarrhythmias, suggests they may have been managed through medications and monitoring rather than the need for pacing. Moreover, no mention is made of a pacemaker in the surgical history or interventions, reinforcing the prediction. Given the very low predicted probability (0.00105251) of this outcome being ""yes,"" it aligns with the rationale that the patient has not required a pacemaker placement historically.","Based on the information provided, I predict that the main patient does **not** have a history of pacemaker placement. This conclusion is supported by the patient’s existing clinical and surgical history, which does not indicate interventions typically associated with pacemaker use, such as significant arrhythmias requiring chronic pacing management. Furthermore, when comparing this patient with similar cases, especially the one with a comparable procedural background, there were no documented instances of pacemaker utilization, reflecting a trend in this cohort that suggests functional stability without electrical management devices. The low predicted probability of 'yes' from the XGBoost model (0.00105251) further supports the likelihood of a 'no' outcome regarding pacemaker placement history.","Based on the provided data, the missing clinical outcome indicating whether the main patient has a history of pacemaker placement is **""no.""** The main patient has experienced multiple surgeries and complications, including arrhythmias, but there is no record of prior pacemaker placement. Furthermore, similar patients with a comparable surgical history, particularly those with a similar cardiac diagnosis and operational procedures, generally did not require pacemakers either, as indicated by their status updates. This aligns with the low probability of complications leading to the need for a pacemaker, reflected in the XGBoost model's prediction that the occluded outcome would likely be ""no,"" coupled with a minimal estimated probability of requiring such an intervention.","Based on the data provided, the main patient has undergone multiple complex cardiac surgeries and shows significant cardiac morbidity, including a history of severe arrhythmias (non-sustained ventricular tachyarrhythmias and atrial tachyarrhythmias). While the similar patients, especially those with comparable surgical histories involving multiple stages of Fontan procedures and interventions, tend to show a notable prevalence of pacemaker placements due to arrhythmias and other complications, this specific patient has no records indicating a pacemaker intervention. Given the low predicted probability (0.00105251) from the XGBoost model for a positive outcome (which suggests a history of pacemaker placement), it is reasonable to conclude that the main patient likely does not have a history of pacemaker placement. Therefore, the prediction for the missing clinical outcome is **""no.""**",1,1,1,1,0
BCH-COBJAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 10.0
 Gadolinium unknown contrast dose: 10.0
 Patient height: 127.0
 Patient weight: 22.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.887562197264406
 Heart rate: 95.0
 Upper limb systolic blood pressure: 92.0
 Upper limb diastolic blood pressure: 50.0
 Upper limb mean blood pressure: 64.0
 Left ventricle end-diastolic volume: 81.0
 Left ventricle end-systolic volume: 27.8
 Left ventricular mass: 51.0
 Right ventricular end-diastolic volume: 24.0
 Right ventricular end-systolic volume: 13.0
 Right ventricle mass: 15.3
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 0.8
 Single ventricle ejection fraction 0.6114285714285714
 Single ventricle systolic volume 64.2
 Body mass index 14.074028148056296
 Mass to height volume indexed on BSA (exp = 2.7) 34.77310579168444
 Systemic ventricle end-systolic volume: 40.8
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 45.96860944027523
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 47.64328818747134
 Systemic ventricle end-diastolic volume: 105.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.30156841247302
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 122.61140342363949
 Systemic ventricle mass: 66.3
 Systemic ventricle mass indexed on BSA (exp=1) 74.69899034044725
 Systemic ventricle mass indexed on BSA (exp=1.3) 77.42034330464094
 Systemic ventricle mass to volume ratio: 1.2671296296296297
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.4276516434962023
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.4796623067482422
 Description of veno-venous collaterals: A small, 2mm in size collateral vessel extends to the left upper lobe pulmonary vein from the left superolateral and anterior pleura consistent with a systemic venous to pulmonary venous collateral. 
 Description of aortopulmonary collaterals: Two small aortopulmonary artery collaterals course superiorly from the abdominal aorta at the level of the celiac axis to either lower lobe.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Susceptibility artifact from the coil in the left superior mediastinum obscure the transverse arch and proximal arteries to the head and neck.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.02666651].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data, it is predicted that the patient has not died (outcome = ""no""). The patient's clinical history does not indicate any severe post-operative complications such as major vascular thrombus, significant arrhythmias, or critical incidents beyond a history of stroke, which is relatively common in a population with single-ventricle physiology. Additionally, the relatively low predicted probability of mortality (2.67%) from the XGBoost model further supports this prediction, indicating a low likelihood of death compared to the cohort's outcomes. Overall, considering the absence of life-threatening conditions and the favorable metrics derived from imaging and previous interventions, it's reasonable to conclude that the patient is alive.","Based on the data provided, it is reasonable to predict that the main patient has not died. The MRI report indicates a relatively stable hemodynamic status, including a single ventricle ejection fraction of 0.61 and absence of significant ventricular hypertrophy or valve regurgitation. Furthermore, similar patients with comparable surgical histories and characteristics have generally experienced positive outcomes, with the majority remaining alive despite the complexity of their conditions. The XGBoost model's predicted probability of 0.026, indicating a low likelihood of poor outcome such as death, further supports this conclusion. Therefore, while clinical trajectories can vary, the indicators from the main patient's MRI findings and the trends in similar patients suggest that the likelihood of survival is high.","Based on the provided data, it is predicted that the main patient has not died (answer: *no*). The patient has a strong surgical history, having undergone three cardiac surgeries, including a successful lateral tunnel Fontan and a Bidirectional Glenn procedure, with no significant complications reported so far, such as stroke or cardiac arrhythmias. In contrast, the similar patient cohort primarily consists of individuals who experienced more severe comorbidities, with lower ejection fractions and higher incidences of negative outcomes linked to their surgical histories. Additionally, the XGBoost model predicted a low probability (0.027) of the adverse outcome—suggesting that given the absence of severe previous complications, the main patient's prognosis appears stable, further supporting the prediction that the patient has not died.","Based on the clinical features of the main patient, along with the data from similar patients, it can be predicted that the main patient is likely to have **not died**. The patient's surgical history indicates they have undergone a lateral tunnel Fontan and have not had significant complications like cardiac arrest or major thrombus, which suggest a relatively stable status post-surgery. Additionally, the prediction probability of 0.0267 indicates a low risk of mortality; when combined with the validation set's high accuracy and the outcomes of analogous patients, this supports the inference that this patient likely falls into the non-fatal category. Moreover, similar patients who have a comparable surgical history and clinical characteristics generally exhibit survival rates aligned with the low mortality prediction provided by the model.",1,1,1,1,0
BCH-COBJAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 10.0
 Gadolinium unknown contrast dose: 10.0
 Patient height: 127.0
 Patient weight: 22.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.887562197264406
 Heart rate: 95.0
 Upper limb systolic blood pressure: 92.0
 Upper limb diastolic blood pressure: 50.0
 Upper limb mean blood pressure: 64.0
 Left ventricle end-diastolic volume: 81.0
 Left ventricle end-systolic volume: 27.8
 Left ventricular mass: 51.0
 Right ventricular end-diastolic volume: 24.0
 Right ventricular end-systolic volume: 13.0
 Right ventricle mass: 15.3
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 0.8
 Single ventricle ejection fraction 0.6114285714285714
 Single ventricle systolic volume 64.2
 Body mass index 14.074028148056296
 Mass to height volume indexed on BSA (exp = 2.7) 34.77310579168444
 Systemic ventricle end-systolic volume: 40.8
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 45.96860944027523
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 47.64328818747134
 Systemic ventricle end-diastolic volume: 105.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.30156841247302
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 122.61140342363949
 Systemic ventricle mass: 66.3
 Systemic ventricle mass indexed on BSA (exp=1) 74.69899034044725
 Systemic ventricle mass indexed on BSA (exp=1.3) 77.42034330464094
 Systemic ventricle mass to volume ratio: 1.2671296296296297
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.4276516434962023
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.4796623067482422
 Description of veno-venous collaterals: A small, 2mm in size collateral vessel extends to the left upper lobe pulmonary vein from the left superolateral and anterior pleura consistent with a systemic venous to pulmonary venous collateral. 
 Description of aortopulmonary collaterals: Two small aortopulmonary artery collaterals course superiorly from the abdominal aorta at the level of the celiac axis to either lower lobe.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Susceptibility artifact from the coil in the left superior mediastinum obscure the transverse arch and proximal arteries to the head and neck.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00946598].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided data, it is highly unlikely that the patient has a history of ascites (> trace). The patient's MRI report does not indicate any significant hepatic or abdominal complications, and there are no records of protein-losing enteropathy or a positive fibrosure for liver fibrosis, both of which are commonly associated with ascites in patients with Fontan physiology. Additionally, the model prediction probability of 0.00947 suggests a very low likelihood of this clinical outcome occurring in the patient, which aligns with the absence of any supportive clinical features in the patient's history. Therefore, the predicted outcome is ""no"" for a history of ascites.","Based on the data provided, I predict that the main patient does **not** have a history of ascites (> trace). Firstly, the main patient has no documented history of pleural effusion or any notable post-operative complications such as protein-losing enteropathy or significant liver issues, both of which are often associated with ascites. In comparison, the similar patient cohort, especially the one with a high similarity score, shows a notable finding of positive fibrosure tests indicating potential liver fibrosis, which could suggest a higher risk for complications like ascites. Given the low predicted probability of the occluded outcome being 'yes' (0.0095) and the lack of similar historical findings, the evidence leans towards the absence of ascites in this patient.","Based on the provided data, the prediction for the main patient having a history of ascites (> trace) is **no**. The main patient's surgical history and MRI reports indicate there have been no significant complications such as pleural effusions or any indications of fluid overload. Additionally, among similar patients with comparable surgical histories and CMR results, ascites has been noted in some cases; however, those patients often presented with more significant pleural effusions or higher pressures in the vascular system. Furthermore, the XGBoost model predicts a very low likelihood (approximately 0.0095) of the patient having this condition, aligning with the clinical context supporting a “no” outcome. Thus, it reinforces that the main patient is unlikely to have experienced ascites based on the patterns observed.","Based on the provided information, it is predicted that the main patient does **not** have a history of ascites (> trace). This conclusion is supported by the fact that similar patients with comparable conditions, such as undergoing Fontan procedures and having documented histories of surgeries, show a low incidence of ascites post-operation when both have fenestrated Fontan anatomy (as seen in the main patient). Additionally, considering that the XGBoost model predicted only a 0.009 probability of the occluded outcome being 'yes', it implies a strong tendency against the occurrence of ascites in this patient profile. Therefore, correlating the main patient's clinical history with that of similar patients suggests a reasonable expectation that they have not experienced significant ascites.",1,1,1,1,0
BCH-COBJAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 10.0
 Gadolinium unknown contrast dose: 10.0
 Patient height: 127.0
 Patient weight: 22.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.887562197264406
 Heart rate: 95.0
 Upper limb systolic blood pressure: 92.0
 Upper limb diastolic blood pressure: 50.0
 Upper limb mean blood pressure: 64.0
 Left ventricle end-diastolic volume: 81.0
 Left ventricle end-systolic volume: 27.8
 Left ventricular mass: 51.0
 Right ventricular end-diastolic volume: 24.0
 Right ventricular end-systolic volume: 13.0
 Right ventricle mass: 15.3
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 0.8
 Single ventricle ejection fraction 0.6114285714285714
 Single ventricle systolic volume 64.2
 Body mass index 14.074028148056296
 Mass to height volume indexed on BSA (exp = 2.7) 34.77310579168444
 Systemic ventricle end-systolic volume: 40.8
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 45.96860944027523
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 47.64328818747134
 Systemic ventricle end-diastolic volume: 105.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.30156841247302
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 122.61140342363949
 Systemic ventricle mass: 66.3
 Systemic ventricle mass indexed on BSA (exp=1) 74.69899034044725
 Systemic ventricle mass indexed on BSA (exp=1.3) 77.42034330464094
 Systemic ventricle mass to volume ratio: 1.2671296296296297
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.4276516434962023
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.4796623067482422
 Description of veno-venous collaterals: A small, 2mm in size collateral vessel extends to the left upper lobe pulmonary vein from the left superolateral and anterior pleura consistent with a systemic venous to pulmonary venous collateral. 
 Description of aortopulmonary collaterals: Two small aortopulmonary artery collaterals course superiorly from the abdominal aorta at the level of the celiac axis to either lower lobe.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Susceptibility artifact from the coil in the left superior mediastinum obscure the transverse arch and proximal arteries to the head and neck.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00105511].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided data, I predict that the missing clinical outcome—whether the patient has a history of pacemaker placement—is ""no."" This prediction is substantiated by the fact that the patient exhibits no documented arrhythmias, such as atrial or ventricular tachycardias, which are commonly associated with the need for pacemaker placement. Moreover, the patient has a single ventricle ejection fraction of 61.1% and a normal heart rate of 95 bpm, indicating adequate cardiac function without significant conduction abnormalities that would necessitate pacing. Additionally, the absence of relevant historical interventions, such as a post-Fontan electrophysiologic study or any mention of arrhythmia management, further suggests that a pacemaker would not have been required.","Based on the information provided, it is highly unlikely that the main patient has a history of pacemaker placement. The patient's MRI findings indicate a relatively stable cardiac function, with a single ventricle ejection fraction around 61%, and no documented history of arrhythmias that typically necessitate pacemaker placement. Additionally, the cohort of similar patients shows a trend of higher outcomes related to those requiring pacemaker placements, often tied to complications like significant arrhythmias or poor ventricular function, which are not highlighted in the main patient's data. Furthermore, the low predicted probability of the occluded outcome being 'yes' (0.00105) suggests that placement of a pacemaker is not a common intervention for this patient's profile, indicating a likely answer of ""no"" for the history of pacemaker placement.","Based on the information provided, it is reasonably expected that the main patient does **not** have a history of pacemaker placement. The patient's surgical history indicates they have undergone a lateral tunnel Fontan surgery with a fenestration but no additional surgeries that typically necessitate pacing support. Furthermore, the majority of similar patients, particularly those with comparable cardiac diagnoses and interventions, also show no history of pacemaker placement. The XGBoost model's prediction probability of 0.00105511 suggests a very low likelihood of other serious complications linked to the need for a pacemaker, further supporting that the patient likely does not require one. Thus, considering both the main patient's clinical details and the trends in outcomes among similar patients, it is logical to conclude they likely do not have a history of pacemaker placement.","Based on the information provided, the predicted outcome for whether the patient has a history of pacemaker placement is **""no.""** The main patient has undergone a series of complex surgeries associated with single-ventricle physiology and has notable features such as a lateral tunnel Fontan and the presence of collaterals, yet there is no documented history of arrhythmias that would typically necessitate a pacemaker. 

In addition, the similar patients' data indicates that despite similar surgical histories and characteristics, many did not have a history of pacemaker placement. The XGBoost model also suggests a very low predicted probability (0.00105511) for this outcome being 'yes,' reinforcing that the main patient likely does not have a history of pacemaker placement. In summary, given the lack of arrhythmias, the patient's clinical profile, and the outcomes of similar patients, it is reasonable to conclude that the patient does not have a history of pacemaker placement.",1,1,1,1,0
BCH-COBJAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 10.0
 Gadolinium unknown contrast dose: 10.0
 Patient height: 127.0
 Patient weight: 22.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.887562197264406
 Heart rate: 95.0
 Upper limb systolic blood pressure: 92.0
 Upper limb diastolic blood pressure: 50.0
 Upper limb mean blood pressure: 64.0
 Left ventricle end-diastolic volume: 81.0
 Left ventricle end-systolic volume: 27.8
 Left ventricular mass: 51.0
 Right ventricular end-diastolic volume: 24.0
 Right ventricular end-systolic volume: 13.0
 Right ventricle mass: 15.3
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 0.8
 Single ventricle ejection fraction 0.6114285714285714
 Single ventricle systolic volume 64.2
 Body mass index 14.074028148056296
 Mass to height volume indexed on BSA (exp = 2.7) 34.77310579168444
 Systemic ventricle end-systolic volume: 40.8
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 45.96860944027523
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 47.64328818747134
 Systemic ventricle end-diastolic volume: 105.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.30156841247302
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 122.61140342363949
 Systemic ventricle mass: 66.3
 Systemic ventricle mass indexed on BSA (exp=1) 74.69899034044725
 Systemic ventricle mass indexed on BSA (exp=1.3) 77.42034330464094
 Systemic ventricle mass to volume ratio: 1.2671296296296297
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.4276516434962023
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.4796623067482422
 Description of veno-venous collaterals: A small, 2mm in size collateral vessel extends to the left upper lobe pulmonary vein from the left superolateral and anterior pleura consistent with a systemic venous to pulmonary venous collateral. 
 Description of aortopulmonary collaterals: Two small aortopulmonary artery collaterals course superiorly from the abdominal aorta at the level of the celiac axis to either lower lobe.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Susceptibility artifact from the coil in the left superior mediastinum obscure the transverse arch and proximal arteries to the head and neck.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00757991].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the information provided, it is highly likely that the patient did not receive a heart transplant, as indicated by the predicted probability of the occluded outcome being 'yes' at only 0.00757991, which is very low. The patient's surgical history also reveals that they underwent three cardiac surgeries, including a Fontan procedure, and had various interventions, but there is no mention of a heart transplant in their medical history. Additionally, the patient's clinical status, including the lack of major complications like sustained arrhythmias or severe dysfunctions (indicated by their current NYHA class status), further suggests that transplantation was not pursued as a treatment option. Thus, the reasonable prediction would be that the patient did not receive a heart transplant (no).","Based on the provided data, the prediction for whether the main patient received a heart transplant is ""no."" The patient's surgical history indicates that they have undergone multiple surgeries related to their single-ventricle condition, including a lateral tunnel Fontan and a bidirectional Glenn procedure, yet they have not had a heart transplant, which is consistent with their clinical stability as evident from their MRI findings. Additionally, the similarity analysis of other patients suggests that while some with comparable conditions underwent transplantation, those with similar clinical characteristics and MRI findings typically managed their outcomes without it. Furthermore, the XGBoost model predicts a very low probability (0.0076) of heart transplantation, reinforcing this conclusion.","Based on the provided data, the predicted outcome for the main patient regarding whether they received a heart transplant is **""no.""** The main patient's surgical history does not indicate any severe complications or deterioration in health that would typically necessitate a heart transplant; they have not faced issues such as significant ventricular dysfunction, severe protein-losing enteropathy, or recurrent thromboembolic events, which are often precursors to transplantation in this population. 

Additionally, examining similar patients suggests a pattern where those who received transplants exhibited either higher instances of severe complications or specific clinical markers which are not present in the main patient. The XGBoost model further supports this prediction, as the estimated probability of the occluded outcome being 'yes' is exceedingly low (0.00757991), indicating a strong likelihood of 'no' in alignment with both clinical and historical data.","Based on the provided information, I predict that the main patient did not receive a heart transplant. The patient's clinical and surgical history indicates that they have undergone three cardiac surgeries, including a Lateral Tunnel Fontan surgery, which typically aims to optimize the circulation for single-ventricle physiology rather than leading to transplantation. Furthermore, the similar patients, who also had significant cardiac surgeries, showed no history of undergoing heart transplantation, particularly those with comparable surgical interventions and demographic profiles. The XGBoost model suggests a very low probability (0.0076) of the patient having received a transplant, aligning with the observations of outcomes for analogous patient cohorts. Overall, these factors suggest that the likelihood of heart transplantation in this patient is minimal.",1,1,1,1,0
BCH-COBJAM-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 10.0
 Gadolinium unknown contrast dose: 10.0
 Patient height: 127.0
 Patient weight: 22.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.887562197264406
 Heart rate: 95.0
 Upper limb systolic blood pressure: 92.0
 Upper limb diastolic blood pressure: 50.0
 Upper limb mean blood pressure: 64.0
 Left ventricle end-diastolic volume: 81.0
 Left ventricle end-systolic volume: 27.8
 Left ventricular mass: 51.0
 Right ventricular end-diastolic volume: 24.0
 Right ventricular end-systolic volume: 13.0
 Right ventricle mass: 15.3
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 0.8
 Single ventricle ejection fraction 0.6114285714285714
 Single ventricle systolic volume 64.2
 Body mass index 14.074028148056296
 Mass to height volume indexed on BSA (exp = 2.7) 34.77310579168444
 Systemic ventricle end-systolic volume: 40.8
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 45.96860944027523
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 47.64328818747134
 Systemic ventricle end-diastolic volume: 105.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.30156841247302
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 122.61140342363949
 Systemic ventricle mass: 66.3
 Systemic ventricle mass indexed on BSA (exp=1) 74.69899034044725
 Systemic ventricle mass indexed on BSA (exp=1.3) 77.42034330464094
 Systemic ventricle mass to volume ratio: 1.2671296296296297
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.4276516434962023
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.4796623067482422
 Description of veno-venous collaterals: A small, 2mm in size collateral vessel extends to the left upper lobe pulmonary vein from the left superolateral and anterior pleura consistent with a systemic venous to pulmonary venous collateral. 
 Description of aortopulmonary collaterals: Two small aortopulmonary artery collaterals course superiorly from the abdominal aorta at the level of the celiac axis to either lower lobe.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Susceptibility artifact from the coil in the left superior mediastinum obscure the transverse arch and proximal arteries to the head and neck.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? yes
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.43401805].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided data, it is reasonable to predict that the patient does **not** have a diagnosis of seizures requiring antiepileptic medications (no). Although the patient has a history of stroke, which is sometimes associated with seizure disorders, there is no documented history of seizures or the use of antiepileptic medications in the patient's clinical history. Moreover, considering the predicted probability of the occluded outcome being 'yes' is relatively low at 0.43401805, this further supports the conclusion that the patient is unlikely to qualify for a seizure diagnosis that necessitates treatment. Overall, the absence of evidence for seizures in the clinical history and the low probability weight against the outcome indicate that the patient likely does not require antiepileptic medications.","Based on the provided data, it is likely that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The main patient has a history of stroke (peri-op) but does not exhibit any additional neurological complications that could indicate a higher risk for seizures. In contrast, the similar patient cohort shows a very low prevalence of seizure disorders, with no similar patients reporting such a diagnosis. Additionally, the XGBoost model predicts a probability of 0.43 for the occluded outcome being 'yes', and given the strong accuracy (94%) and AUC (0.86) of the model on the validation set, it suggests that the risk of seizures in this patient may be low compared to the feature set from the similar cohort. Therefore, it is reasonable to conclude that the main patient likely does not require antiepileptic medications.","Based on the provided data and analysis, the prediction for the main patient is **""no""** for a diagnosis of seizures requiring antiepileptic medications. The main patient does have a history of a non-perioperative stroke, which could be associated with neurological issues; however, none of the similar patients with comparable surgical histories or anatomical profiles have reported a diagnosis of seizures. Additionally, the XGBoost model's predicted probability of 43.4% suggests that while there is a notable risk for seizure diagnosis, a strong negative trend is suggested through the similar patient outcomes, indicating that seizures may not be prevalent among this population. Thus, the data supports a lower likelihood for the main patient having a diagnosis of seizures requiring antiepileptic treatment.","Based on the provided data, the main patient has a complex surgical and medical history, including a history of stroke (peri-operative) and veno-venous collaterals, but exhibits no history of seizures or the need for antiepileptic medications. In examining the similar patients, while features like the history of stroke correlate with a potential risk of seizures, the overall low prevalence of seizures in similar patients (only two instances found in a patient cohort with extensive cardiac backgrounds) suggests that the risk for this main patient tends to be lower. Despite the predicted probability of 0.434 for having seizures, which indicates a moderate likelihood, the combined evidence from their current clinical status and observations from similar patients leads me to conclude that this main patient likely does not have a diagnosis of seizures requiring antiepileptic medications. Therefore, the predicted outcome is ""no.""",1,1,1,1,0
BCH-COFRAC-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURG 1/1988- Stage 1 Norwood Procedure  w/ RmBTS and modified arch repair, direct anastomosis of descending aorta to MPA and ascending aorta anastomosis
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 30.0
 Gadolinium unknown contrast dose: 30.0
 Patient height: 154.0
 Patient weight: 70.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7649453814966805
 Right ventricular end-diastolic volume: 157.0
 Right ventricular end-systolic volume: 91.6
 Right ventricle mass: 96.4
 Native aorta flow rate: 6.2
 Ascending aorta, above the Stansel flow rate: 6.2
 Right superior vena cava flow rate: 1.3
 Inferior vena cava, below the fenestration flow rate: 2.28
 Single ventricle ejection fraction 0.41656050955414015
 Single ventricle systolic volume 65.4
 Body mass index 29.811097992916178
 Mass to height volume indexed on BSA (exp = 2.7) 30.044922468426407
 Systemic ventricle end-systolic volume: 91.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.899623048007776
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 43.766802828787256
 Systemic ventricle end-diastolic volume: 157.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.9545940888343
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.01515332008297
 Systemic ventricle mass: 96.4
 Systemic ventricle mass indexed on BSA (exp=1) 54.619253950086794
 Systemic ventricle mass indexed on BSA (exp=1.3) 46.06025974557961
 Systemic ventricle mass to volume ratio: 0.6140127388535033
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.34789333726169935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.29337745060878734
 Description of veno-venous collaterals: There is suggestion of a venous collateral, which extends horizontally from the anterior chest wall posteriorly to the right lower lobe pulmonary vein.
 Description of aortopulmonary collaterals:  A few tiny aortopulmonary collateral vessels extend from the distal descending thoracic aorta to the right lower lobe. The internal mammary arteries are also prominent bilaterally. No major APCs are identified.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Artifact from coils in the mediastinum obscures the majority of the cavopulmonary anastomosis and right pulmonary artery. In
addition, the proximal connection of the pulmonary veins to the left atrium are obscured due to the artifact. The proximal left pulmonary artery to cavopulmonary anastomosis is fairly well visualized and unobstructed. The left pulmonary artery is normal in caliber with normal branching to the hilum.=========================Artifact limited anatomy
 Other relevant report comments or concerns: Mild focal narrowing of the distal trachea at the level of the cavopulmonary anastomosis above the level of the carina. The trachea measures 0.9cm at the thoracic inlet and narrows to 0.6cm.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? yes
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.5943146].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? yes\n'],"Based on the provided data, it is reasonable to predict that the main patient **does not have a history of ascites** (yes or no: **no**). The patient's clinical history shows the presence of pleural effusions, but these were non-chylous and did not result in significant complications following surgery. Additionally, the patient has documented liver issues, including elevated fibrosis tests and renal dysfunction, which typically correlate with a risk of ascites development; however, the absence of any specific mentions of ascites itself strongly supports the prediction that ascites is not present. The model's predicted probability of 0.5943146 also indicates a likelihood near the threshold, but overall clinical context aligns more with the absence of this condition.","Based on the provided information, I predict that the main patient does not have a history of ascites (> trace). This reasoning is supported by the clinical data indicating that the patient has no reported history of chylous pleural effusion and significant liver disease suggested by elevated liver fibrosis tests. Furthermore, when looking at the similar patients, particularly similar patient #1, there was also a lack of history regarding ascites, despite their complex surgical history and known liver issues; this suggests that patients with similar profiles often do not develop this condition. The XGBoost model's predicted probability of the occluded outcome being 'yes' is 0.5943146, which indicates uncertainty but aligns more with a likelihood of 'no' given the absence of strong clinical indicators in the main patient's data.","Based on the provided data, I predict that the main patient **does not have a history of ascites (> trace)**. Although the main patient does have a history of pleural effusions, it is indicated that they do not have a history of protein-losing enteropathy, which is often associated with ascites. Looking at the similar patients’ data, those with a history of ascites tended to have additional complications, including diagnoses like protein-losing enteropathy or more severe cardiac issues, which do not align with the main patient's relatively stable status as per the MRI findings. Additionally, the XGBoost model's predicted probability of 0.5943146 suggests a moderate likelihood, but the trends from similar patients and the absence of aggravating diagnoses lean towards a conclusion of no ascites.","Based on the data provided for the main patient, it is likely that they do not have a history of ascites. The patient's history indicates a history of pleural effusions but specifically notes that there is no mention of ascites greater than trace, which suggests proper management of fluid-related complications since completion of surgeries. Additionally, among the similar patients, none demonstrated ascites as a significant concern; they showed other complications such as arrhythmias or liver function issues. The predicted probability of 0.5943146 from the XGBoost model suggests a slight likelihood of 'yes,' but the overall context of the main patient's findings, including clinical history and outcomes of similar patients, reinforces the likelihood that the patient does not exhibit a significant problem with ascites at this time. Thus, the prediction is that the main patient does not have a history of ascites (> trace): **No**.",0,0,0,0,1
BCH-COFRAC-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURG 1/1988- Stage 1 Norwood Procedure  w/ RmBTS and modified arch repair, direct anastomosis of descending aorta to MPA and ascending aorta anastomosis
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 30.0
 Gadolinium unknown contrast dose: 30.0
 Patient height: 154.0
 Patient weight: 70.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7649453814966805
 Right ventricular end-diastolic volume: 157.0
 Right ventricular end-systolic volume: 91.6
 Right ventricle mass: 96.4
 Native aorta flow rate: 6.2
 Ascending aorta, above the Stansel flow rate: 6.2
 Right superior vena cava flow rate: 1.3
 Inferior vena cava, below the fenestration flow rate: 2.28
 Single ventricle ejection fraction 0.41656050955414015
 Single ventricle systolic volume 65.4
 Body mass index 29.811097992916178
 Mass to height volume indexed on BSA (exp = 2.7) 30.044922468426407
 Systemic ventricle end-systolic volume: 91.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.899623048007776
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 43.766802828787256
 Systemic ventricle end-diastolic volume: 157.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.9545940888343
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.01515332008297
 Systemic ventricle mass: 96.4
 Systemic ventricle mass indexed on BSA (exp=1) 54.619253950086794
 Systemic ventricle mass indexed on BSA (exp=1.3) 46.06025974557961
 Systemic ventricle mass to volume ratio: 0.6140127388535033
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.34789333726169935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.29337745060878734
 Description of veno-venous collaterals: There is suggestion of a venous collateral, which extends horizontally from the anterior chest wall posteriorly to the right lower lobe pulmonary vein.
 Description of aortopulmonary collaterals:  A few tiny aortopulmonary collateral vessels extend from the distal descending thoracic aorta to the right lower lobe. The internal mammary arteries are also prominent bilaterally. No major APCs are identified.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Artifact from coils in the mediastinum obscures the majority of the cavopulmonary anastomosis and right pulmonary artery. In
addition, the proximal connection of the pulmonary veins to the left atrium are obscured due to the artifact. The proximal left pulmonary artery to cavopulmonary anastomosis is fairly well visualized and unobstructed. The left pulmonary artery is normal in caliber with normal branching to the hilum.=========================Artifact limited anatomy
 Other relevant report comments or concerns: Mild focal narrowing of the distal trachea at the level of the cavopulmonary anastomosis above the level of the carina. The trachea measures 0.9cm at the thoracic inlet and narrows to 0.6cm.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? yes
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.07526835].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"**Prediction: No, the patient does not have a diagnosis of seizures requiring antiepileptic medications.**

**Reasoning:** The patient's clinical history shows significant cardiac and non-cardiac complexities, including a history of atrial tachyarrhythmias and renal dysfunction, as well as the need for pacemaker placement. Despite these issues, no direct indication of a seizure disorder or the use of antiepileptic medications is mentioned in the history. Additionally, the XGBoost model indicates a low predicted probability (7.53%) of the occluded outcome being 'yes', suggesting that seizures are likely not a significant issue for this patient based on existing patterns in similar cohorts.","Based on the information provided, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The patient's surgical history demonstrates a complex cardiac condition with prior surgeries, but no direct mention of neurological issues or seizures. Additionally, in the data from the similar patients, while some presented with a diagnosis of seizures, many did not, and the high negative rate of 94% in the XGBoost model's validation set for the negative class further supports that the likelihood of seizure diagnosis generally appears low among such cases. Given the predicted probability of only approximately 7.5% for an affirmative outcome, this further substantiates that it is unlikely the main patient has this diagnosis.","Based on the provided data and the similarity of the main patient's clinical and surgical history to those of similar patients, I predict that the missing clinical outcome is **no**, that the patient does not have a diagnosis of seizures requiring antiepileptic medications. The main patient has a complex history characterized by multiple surgeries and the unique challenges of hypoplastic left heart syndrome, yet there is no mention of neurological issues in their history. In contrast, the similar patient cohort shows a higher incidence of seizure diagnosis, especially among those with significant complications such as elevated liver fibrosis tests and renal dysfunction; however, the prediction model suggests a low probability (7.5%) for this outcome. This indicates that even among similar patients, the overall risk for seizures requiring medication remains low, reinforcing the notion that the main patient is less likely to have such a diagnosis.","Based on the analysis of the main patient's clinical and surgical history, as well as the data from similar patients, it appears unlikely that this patient has a diagnosis of seizures requiring antiepileptic medications. The main patient has a history of atrial tachyarrhythmias and some renal dysfunction, but there is no recorded history of intracranial events, stroke, or seizures. 

In contrast, the similar patient cohort shows a mixed trend: some have a history of seizures, while others, despite having comparable surgical interventions and similar anatomical presentations (like atrial and ventricular morphologies), do not. The XGBoost model’s low probability estimate of 0.075 suggests a high likelihood that the main patient does not have this diagnosis. Thus, considering the main patient's lack of relevant symptoms from previous evaluations and aligning with the trends of the similar cohort, the prediction would be ""no"" for a diagnosis of seizures requiring antiepileptic medications.",1,1,1,1,0
BCH-COFRAC-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURG 1/1988- Stage 1 Norwood Procedure  w/ RmBTS and modified arch repair, direct anastomosis of descending aorta to MPA and ascending aorta anastomosis
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 30.0
 Gadolinium unknown contrast dose: 30.0
 Patient height: 154.0
 Patient weight: 70.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7649453814966805
 Right ventricular end-diastolic volume: 157.0
 Right ventricular end-systolic volume: 91.6
 Right ventricle mass: 96.4
 Native aorta flow rate: 6.2
 Ascending aorta, above the Stansel flow rate: 6.2
 Right superior vena cava flow rate: 1.3
 Inferior vena cava, below the fenestration flow rate: 2.28
 Single ventricle ejection fraction 0.41656050955414015
 Single ventricle systolic volume 65.4
 Body mass index 29.811097992916178
 Mass to height volume indexed on BSA (exp = 2.7) 30.044922468426407
 Systemic ventricle end-systolic volume: 91.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.899623048007776
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 43.766802828787256
 Systemic ventricle end-diastolic volume: 157.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.9545940888343
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.01515332008297
 Systemic ventricle mass: 96.4
 Systemic ventricle mass indexed on BSA (exp=1) 54.619253950086794
 Systemic ventricle mass indexed on BSA (exp=1.3) 46.06025974557961
 Systemic ventricle mass to volume ratio: 0.6140127388535033
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.34789333726169935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.29337745060878734
 Description of veno-venous collaterals: There is suggestion of a venous collateral, which extends horizontally from the anterior chest wall posteriorly to the right lower lobe pulmonary vein.
 Description of aortopulmonary collaterals:  A few tiny aortopulmonary collateral vessels extend from the distal descending thoracic aorta to the right lower lobe. The internal mammary arteries are also prominent bilaterally. No major APCs are identified.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Artifact from coils in the mediastinum obscures the majority of the cavopulmonary anastomosis and right pulmonary artery. In
addition, the proximal connection of the pulmonary veins to the left atrium are obscured due to the artifact. The proximal left pulmonary artery to cavopulmonary anastomosis is fairly well visualized and unobstructed. The left pulmonary artery is normal in caliber with normal branching to the hilum.=========================Artifact limited anatomy
 Other relevant report comments or concerns: Mild focal narrowing of the distal trachea at the level of the cavopulmonary anastomosis above the level of the carina. The trachea measures 0.9cm at the thoracic inlet and narrows to 0.6cm.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.97162825].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? yes\n Reason for pacemaker placement: Other\n'],"Based on the provided data for the main patient, I predict that the patient **does have a history of pacemaker placement** ('yes'). This prediction is supported by several factors: the patient's complex surgical history includes a high number of surgeries and modifications to cardiac anatomy, notably the Stansel/Damus procedure which can sometimes lead to arrhythmias. Moreover, the patient displays a history of atrial tachyarrhythmias, which may necessitate the use of a pacemaker for rhythm management. Additionally, considering the high predicted probability (0.97162825) from the XGBoost model, it indicates a strong likelihood of the patient having a pacemaker placement history, as such interventions are common in patients with this type of cardiac history.","Based on the available data, I predict that the main patient does **not** have a history of pacemaker placement. In the surgical history, the patient has a complex background, including multiple procedures related to their single ventricle status, yet there are no mentions of pacemaker placement or related interventions. Similar patients who underwent Fontan procedures indicated varied histories, but none had prominent issues associated with prolonged arrhythmias requiring pacing devices. Furthermore, no evidence of significant ventricular tachycardias or other complications that often necessitate pacemaker intervention was noted in either the main patient's status or the similar cohorts. The XGBoost model's high confidence (0.97 probability) further supports that a history of pacemaker placement is unlikely in this case.","Based on the analysis of the main patient's clinical history and MRI findings, it is reasonable to predict that the patient does *not* have a history of pacemaker placement. The patient has undergone various surgical interventions, including a Stansel/Damus/DKS procedure and atrioventricular valve procedure, but there is no mention of a pacemaker or indication of severe arrhythmias that typically necessitate such an intervention. Additionally, the similar patients with a high degree of similarity showed a low prevalence of pacemaker placements, particularly in cases without significant arrhythmias that warranted such a device. The XGBoost model's prediction further supports this, as it indicates a high probability of the main patient having a normal cardiac rhythm without requiring pacing support in the past.","**Prediction:** Yes, the patient has a history of pacemaker placement.

**Reasoning:** The main patient has undergone multiple cardiac surgeries, including Stansel and other complex interventions, which often predispose individuals to arrhythmias and other conduction disturbances, thus increasing the likelihood of requiring a pacemaker. Furthermore, the similar patients, especially those with comparable surgical histories and features (e.g., similar types of repaired congenital heart defects and history of ventricular tachyarrhythmias), have shown a significant trend wherein many have opted for pacemaker placement due to similar complications. Given the high probability (97.16%) provided by the XGBoost model regarding the likelihood of positive outcomes for this patient category and the specific risks associated with the complexities of their cardiac repair, it is reasonable to conclude that this patient likely has a history of pacemaker placement.",1,0,0,1,1
BCH-COFRAC-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURG 1/1988- Stage 1 Norwood Procedure  w/ RmBTS and modified arch repair, direct anastomosis of descending aorta to MPA and ascending aorta anastomosis
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 30.0
 Gadolinium unknown contrast dose: 30.0
 Patient height: 154.0
 Patient weight: 70.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7649453814966805
 Right ventricular end-diastolic volume: 157.0
 Right ventricular end-systolic volume: 91.6
 Right ventricle mass: 96.4
 Native aorta flow rate: 6.2
 Ascending aorta, above the Stansel flow rate: 6.2
 Right superior vena cava flow rate: 1.3
 Inferior vena cava, below the fenestration flow rate: 2.28
 Single ventricle ejection fraction 0.41656050955414015
 Single ventricle systolic volume 65.4
 Body mass index 29.811097992916178
 Mass to height volume indexed on BSA (exp = 2.7) 30.044922468426407
 Systemic ventricle end-systolic volume: 91.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.899623048007776
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 43.766802828787256
 Systemic ventricle end-diastolic volume: 157.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.9545940888343
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.01515332008297
 Systemic ventricle mass: 96.4
 Systemic ventricle mass indexed on BSA (exp=1) 54.619253950086794
 Systemic ventricle mass indexed on BSA (exp=1.3) 46.06025974557961
 Systemic ventricle mass to volume ratio: 0.6140127388535033
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.34789333726169935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.29337745060878734
 Description of veno-venous collaterals: There is suggestion of a venous collateral, which extends horizontally from the anterior chest wall posteriorly to the right lower lobe pulmonary vein.
 Description of aortopulmonary collaterals:  A few tiny aortopulmonary collateral vessels extend from the distal descending thoracic aorta to the right lower lobe. The internal mammary arteries are also prominent bilaterally. No major APCs are identified.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Artifact from coils in the mediastinum obscures the majority of the cavopulmonary anastomosis and right pulmonary artery. In
addition, the proximal connection of the pulmonary veins to the left atrium are obscured due to the artifact. The proximal left pulmonary artery to cavopulmonary anastomosis is fairly well visualized and unobstructed. The left pulmonary artery is normal in caliber with normal branching to the hilum.=========================Artifact limited anatomy
 Other relevant report comments or concerns: Mild focal narrowing of the distal trachea at the level of the cavopulmonary anastomosis above the level of the carina. The trachea measures 0.9cm at the thoracic inlet and narrows to 0.6cm.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? yes
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.19102933].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the information provided, the predicted clinical outcome for the main patient is ""no"" (the patient has not died). The patient's history includes multiple cardiac surgeries, with a successful Fontan procedure, and no indications of severe complications leading to mortality, such as protein-losing enteropathy, major thrombus, or severe arrhythmias requiring interventions. Additionally, the reported MRI findings show only mild complications such as atrioventricular valve regurgitation and veno-venous collaterals, which typically do not lead to immediate mortality. The model's predicted probability of 0.191 indicates a relatively low likelihood of death, further supporting the conclusion that the patient is likely alive.","Based on the provided data, I predict that the main patient has **not** died. The main patient has undergone multiple cardiac surgeries, including a Stansel/Damus/DKS procedure, and despite having complex condition factors such as Fontan physiology, their overall cardiac metrics, including a single ventricle ejection fraction of approximately 41.7% and no significant complications listed (e.g., thrombus or chronic conditions), suggest relative stability. 

Furthermore, similar patients tended to survive despite significant complications; notably, one patient with a lower cardiac output and a history of sustained ventricular arrhythmias has also not died, though they did report significant comorbidities. The predicted probability of dying based on XGBoost of approximately 19.1% is relatively low, indicating that, overall, the risk factors in this cohort do not strongly imply mortality at this time.","Based on the provided data for the main patient and the similar patients, the predicted outcome for ""Has the patient died?"" is **no**. The main patient has undergone several complex cardiac surgeries, and while they exhibit significant medical history, including arrhythmias and some vascular complications, their MRI data reflects reasonably stable cardiac function with a single ventricle ejection fraction of approximately 0.42 and no major acute events reported. 

Additionally, the similar patients' profiles suggest that those with comparable surgical histories had relatively stable outcomes despite undergoing similar surgical paths. The XGBoost model predicts a probability of only 19.1% for the adverse outcome, which further supports that the main patient, while facing considerable medical challenges, is likely to remain alive based on the current clinical and MRI evaluations.","Based on the data provided, it is predicted that the missing clinical outcome for the main patient, ""Has the patient died?"", is likely **no**. This conclusion is supported by the patient's relatively stable clinical history and surgical history, including a series of successful surgeries without revisions or significant complications. Additionally, the similar patients, particularly those with comparable surgical interventions and MRI findings, have generally shown a low incidence of mortality. The model's predicted probability of 0.191, while highlighting some risk, suggests that given the patient's overall profile, survival is more probable than not, especially considering the high accuracy and AUC observed in the model's validation.",1,1,1,1,0
BCH-COFRAC-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURG 1/1988- Stage 1 Norwood Procedure  w/ RmBTS and modified arch repair, direct anastomosis of descending aorta to MPA and ascending aorta anastomosis
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 30.0
 Gadolinium unknown contrast dose: 30.0
 Patient height: 154.0
 Patient weight: 70.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7649453814966805
 Right ventricular end-diastolic volume: 157.0
 Right ventricular end-systolic volume: 91.6
 Right ventricle mass: 96.4
 Native aorta flow rate: 6.2
 Ascending aorta, above the Stansel flow rate: 6.2
 Right superior vena cava flow rate: 1.3
 Inferior vena cava, below the fenestration flow rate: 2.28
 Single ventricle ejection fraction 0.41656050955414015
 Single ventricle systolic volume 65.4
 Body mass index 29.811097992916178
 Mass to height volume indexed on BSA (exp = 2.7) 30.044922468426407
 Systemic ventricle end-systolic volume: 91.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.899623048007776
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 43.766802828787256
 Systemic ventricle end-diastolic volume: 157.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.9545940888343
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.01515332008297
 Systemic ventricle mass: 96.4
 Systemic ventricle mass indexed on BSA (exp=1) 54.619253950086794
 Systemic ventricle mass indexed on BSA (exp=1.3) 46.06025974557961
 Systemic ventricle mass to volume ratio: 0.6140127388535033
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.34789333726169935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.29337745060878734
 Description of veno-venous collaterals: There is suggestion of a venous collateral, which extends horizontally from the anterior chest wall posteriorly to the right lower lobe pulmonary vein.
 Description of aortopulmonary collaterals:  A few tiny aortopulmonary collateral vessels extend from the distal descending thoracic aorta to the right lower lobe. The internal mammary arteries are also prominent bilaterally. No major APCs are identified.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Artifact from coils in the mediastinum obscures the majority of the cavopulmonary anastomosis and right pulmonary artery. In
addition, the proximal connection of the pulmonary veins to the left atrium are obscured due to the artifact. The proximal left pulmonary artery to cavopulmonary anastomosis is fairly well visualized and unobstructed. The left pulmonary artery is normal in caliber with normal branching to the hilum.=========================Artifact limited anatomy
 Other relevant report comments or concerns: Mild focal narrowing of the distal trachea at the level of the cavopulmonary anastomosis above the level of the carina. The trachea measures 0.9cm at the thoracic inlet and narrows to 0.6cm.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? yes
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01764377].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data, it is predicted that the patient did not receive a heart transplant (no). The patient's surgical history indicates they have undergone a total of four cardiac surgeries, including a Stansel procedure and a lateral tunnel Fontan, which are often performed with the intent of managing the single ventricle circulation without necessitating a heart transplant. Additionally, the presence of significant cardiac abnormalities, such as a mild atrioventricular valve regurgitation and veno-venous collaterals, along with the patient's current use of anticoagulants and heart rhythm management through a pacemaker, suggests that the patient has been managed successfully without resorting to transplantation. The XGBoost model's predicted probability of 0.0176 for receiving a transplant further supports this, indicating a very low likelihood of the occluded outcome being 'yes.'","Based on the data provided, it is predicted that the main patient **did not receive a heart transplant**. The patient's complex surgical history, including multiple cardiac interventions and a total of four surgeries without a recorded heart transplant, suggests a management path focused on surgical corrections compatible with single-ventricle physiology rather than proceeding to transplantation. The similar patients exhibit a low incidence of heart transplants within the shared characteristics, as seen from the XGBoost model's prediction of only a 1.76% likelihood. This aligns with the historical trends for patients with Hypoplastic Left Heart Syndrome (HLHS), typically managed with palliative surgical options instead of early transplantation.","Based on the information provided, it is reasonable to predict that the main patient did **not** receive a heart transplant. The patient's surgical history reveals multiple cardiac surgeries and complex anatomical issues associated with hypoplastic left heart syndrome, yet none of the recorded similar patients with comparable profiles and clinical outcomes underwent a heart transplant either. Furthermore, the XGBoost model indicates a very low predicted probability (1.76%) for the occluded outcome of receiving a heart transplant, further supporting this conclusion. Monitoring factors like the mild atrioventricular valve regurgitation and the presence of veno-venous collaterals indicates some chronic changes in hemodynamics, which are associated with ongoing management rather than necessitating transplantation in this cohort. Thus, the main patient's case aligns more with patients who are managed conservatively rather than those who proceed to heart transplant.","Based on the data provided, I predict that the main patient did **not** receive a heart transplant. The longitudinal MRI report highlights several complications common in single-ventricle patients post-Fontan, such as renal dysfunction, arrhythmias, and mechanical interventions like those associated with veno-venous collaterals and pacemaker placement. Additionally, the XGBoost model predicts a low probability (1.76%) of the outcome being 'yes' for heart transplant, which is consistent with the high AUC (0.93) illustrating the ability of the model to distinguish outcomes effectively. Furthermore, the similar patients also show a diversity of surgical histories and complications without heart transplant necessity, indicating that many similar individuals can manage their conditions without requiring transplantation.",1,1,1,1,0
BCH-DACKEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt conduit
 Other relevant surgical or clinical history (optional): CATH 1/70- Hemodynamics
SURG 1/70- Pott's shunt 
CATH 1/72- Hemodynamics
CATH 4/1984- Hemodynamics
SURG 8/1984- Lung byopsy and waterston shunt
CATH 8/1985- Hemodynamics
SURG 11/1985- Central shunt conduit
SURG 11/1985- RA-PA Fontan, tricuspid valvectomy
CATH 9/2016, BWH-hemodynamic

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 40.0
 Gadolinium unknown contrast dose: 40.0
 Patient height: 157.1
 Patient weight: 56.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5723626749875916
 Heart rate: 72.0
 Upper limb mean blood pressure: 78.0
 Left ventricle end-diastolic volume: 168.8
 Left ventricle end-systolic volume: 77.91
 Left ventricular mass: 109.6
 Right ventricular end-diastolic volume: 55.9
 Right ventricular end-systolic volume: 38.3
 Right ventricle mass: 31.2
 Single ventricle ejection fraction 0.4828215398308857
 Single ventricle systolic volume 108.49000000000002
 Body mass index 22.77109659037269
 Mass to height volume indexed on BSA (exp = 2.7) 41.58406635923462
 Systemic ventricle end-systolic volume: 116.21
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 73.90788515182547
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 64.52454600044103
 Systemic ventricle end-diastolic volume: 224.70000000000002
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.90596156626094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 124.76263218569059
 Systemic ventricle mass: 140.79999999999998
 Systemic ventricle mass indexed on BSA (exp=1) 89.54677075447057
 Systemic ventricle mass indexed on BSA (exp=1.3) 78.17791994546164
 Systemic ventricle mass to volume ratio: 1.207428634409787
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7679072097150332
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6704137721643922
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.9928019].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? yes\n Reason for pacemaker placement: Other\n'],"Based on the provided data, it is highly probable that the main patient has a history of pacemaker placement (prediction: **yes**). The patient's surgical and clinical history indicates significant cardiac interventions and a complex clinical course, including atrial tachyarrhythmias, sinus node dysfunction, and frequent arrhythmias. These conditions often necessitate pacing interventions for rhythm management, particularly in patients with a single ventricle anatomy who are at higher risk for conduction disturbances and subsequent arrhythmias. The high probability prediction of 0.9928019 from the XGBoost model further supports this likelihood, suggesting that similar patients in the cohort frequently required pacemaker placement due to comparable clinical features.","Based on the provided information, I predict that the main patient **does not** have a history of pacemaker placement. The patient's surgical history reveals multiple interventions without indication of significant rhythm disturbances that would typically necessitate a pacemaker. Furthermore, similar patients with high similarities, particularly those exhibiting arrhythmias, have had varied outcomes regarding pacemaker placements; however, the XGBoost model's high predicted probability suggests a strong likelihood of a negative outcome for pacemaker placement among this cohort. Coupled with the absence of reported episodes of significant arrhythmias or syncopal events in the main patient's documentation, it is reasonable to conclude that the patient has not required a pacemaker thus far.","**Prediction:** Yes, the patient likely has a history of pacemaker placement.

**Reasoning:** The main patient has a complex surgical history with multiple cardiac interventions and has exhibited symptoms that may necessitate pacing support, such as atrial tachyarrhythmias and sinus node dysfunction. Additionally, among the similar patients, there is a shared pattern of complex arrhythmias leading to pacemaker placement, especially in those with similar cardiac diagnoses and surgical histories, reinforcing the probability of arrhythmia management with pacing. The high predicted probability (0.9928) from the XGBoost model coupled with the consistent outcomes observed in similar patients further supports the likelihood that this main patient has indeed undergone pacemaker placement.","Based on the provided data and the analysis of similar patients, it is likely that the main patient does have a history of pacemaker placement. The main patient has several significant clinical factors, such as a history of arrhythmias including atrial tachyarrhythmias and sinus node dysfunction, both of which could predispose to the need for a pacemaker. Additionally, among the similar patients, there is a consistent pattern where those with similar cardiac diagnoses and arrhythmias have undergone pacemaker placements as part of their management strategies. Furthermore, the XGBoost model predicts a very high probability (0.9928) of the occluded outcome being 'yes', supporting the contention that this patient likely falls within the same clinical trajectory as those with known pacemaker placements in the similar cohort.",1,0,1,1,1
BCH-DACKEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt conduit
 Other relevant surgical or clinical history (optional): CATH 1/70- Hemodynamics
SURG 1/70- Pott's shunt 
CATH 1/72- Hemodynamics
CATH 4/1984- Hemodynamics
SURG 8/1984- Lung byopsy and waterston shunt
CATH 8/1985- Hemodynamics
SURG 11/1985- Central shunt conduit
SURG 11/1985- RA-PA Fontan, tricuspid valvectomy
CATH 9/2016, BWH-hemodynamic

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 40.0
 Gadolinium unknown contrast dose: 40.0
 Patient height: 157.1
 Patient weight: 56.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5723626749875916
 Heart rate: 72.0
 Upper limb mean blood pressure: 78.0
 Left ventricle end-diastolic volume: 168.8
 Left ventricle end-systolic volume: 77.91
 Left ventricular mass: 109.6
 Right ventricular end-diastolic volume: 55.9
 Right ventricular end-systolic volume: 38.3
 Right ventricle mass: 31.2
 Single ventricle ejection fraction 0.4828215398308857
 Single ventricle systolic volume 108.49000000000002
 Body mass index 22.77109659037269
 Mass to height volume indexed on BSA (exp = 2.7) 41.58406635923462
 Systemic ventricle end-systolic volume: 116.21
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 73.90788515182547
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 64.52454600044103
 Systemic ventricle end-diastolic volume: 224.70000000000002
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.90596156626094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 124.76263218569059
 Systemic ventricle mass: 140.79999999999998
 Systemic ventricle mass indexed on BSA (exp=1) 89.54677075447057
 Systemic ventricle mass indexed on BSA (exp=1.3) 78.17791994546164
 Systemic ventricle mass to volume ratio: 1.207428634409787
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7679072097150332
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6704137721643922
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.5020602].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? yes\n'],"Based on the provided clinical information, I predict that the patient does have a history of ascites. This conclusion is supported by the presence of significant complications in the patient's history, including renal dysfunction and a positive liver fibrosis test, both of which can contribute to fluid accumulation and the development of ascites. Additionally, the patient has experienced hemoptysis and atrial tachyarrhythmias, which can further suggest systemic venous congestion, often associated with conditions like ascites in the context of single-ventricle physiology post-Fontan. The XGBoost model's prediction probability of 0.5020602 indicates uncertainty but leans towards a higher chance of the presence of the outcome, further supporting the assertion of ascites history.","Based on the provided data, I predict that the main patient does **not** have a history of ascites (> trace). Although the patient has experienced significant cardiac interventions and has an elevated risk profile indicated by their medical history, including renal dysfunction and elevated liver fibrosis, neither their surgical history nor their MRI findings suggest fluid retention issues typically associated with ascites. Furthermore, when comparing with similar patients, where some exhibited ascites, those had different surgical histories and outcomes that included more significant cardiac complications. The XGBoost model indicates a 50% probability for the occluded outcome, which supports the idea that while there's a notable risk, the specific markers in the main patient's clinical picture and the historical absence of ascites lean toward a ""no"" outcome.","Prediction: Yes, the patient has a history of ascites (> trace).

Reasoning: The main patient exhibits significant cardiovascular challenges, including a history of structural heart issues and multiple surgeries, which increases the likelihood of complications such as ascites due to poor hepatic venous return or high systemic pressures. Furthermore, among the similar patients, there is evidence of ascites and liver-related issues, including elevated liver fibrosis tests, which also suggests that complications like ascites may be common in this patient population. The XGBoost model predicts a 50.2% probability of the occluded outcome being ""yes,"" aligning with the patterns observed in similar patients. This combined evidence supports a higher likelihood of ascites being present.","Based on the main patient's extensive surgical history and significant clinical background, including the presence of a positive fibrosure and renal dysfunction, it is likely that they have a history of ascites. Similar patients with comparable conditions often exhibit similar complications, especially given that those with prior cardiac surgeries frequently face challenges such as fluid retention and elevated pressures. Additionally, among the cohort of similar patients, many exhibited a history of ascites, suggesting that this complication is relatively common among this population following Fontan surgery. The predicted probability for the occluded outcome being 'yes' is around 50.2%, aligning with these observations, indicating that there is a substantial likelihood that the patient has experienced ascites. Thus, I predict that the patient does have a history of ascites (> trace).",1,0,1,1,1
BCH-DACKEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt conduit
 Other relevant surgical or clinical history (optional): CATH 1/70- Hemodynamics
SURG 1/70- Pott's shunt 
CATH 1/72- Hemodynamics
CATH 4/1984- Hemodynamics
SURG 8/1984- Lung byopsy and waterston shunt
CATH 8/1985- Hemodynamics
SURG 11/1985- Central shunt conduit
SURG 11/1985- RA-PA Fontan, tricuspid valvectomy
CATH 9/2016, BWH-hemodynamic

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 40.0
 Gadolinium unknown contrast dose: 40.0
 Patient height: 157.1
 Patient weight: 56.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5723626749875916
 Heart rate: 72.0
 Upper limb mean blood pressure: 78.0
 Left ventricle end-diastolic volume: 168.8
 Left ventricle end-systolic volume: 77.91
 Left ventricular mass: 109.6
 Right ventricular end-diastolic volume: 55.9
 Right ventricular end-systolic volume: 38.3
 Right ventricle mass: 31.2
 Single ventricle ejection fraction 0.4828215398308857
 Single ventricle systolic volume 108.49000000000002
 Body mass index 22.77109659037269
 Mass to height volume indexed on BSA (exp = 2.7) 41.58406635923462
 Systemic ventricle end-systolic volume: 116.21
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 73.90788515182547
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 64.52454600044103
 Systemic ventricle end-diastolic volume: 224.70000000000002
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.90596156626094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 124.76263218569059
 Systemic ventricle mass: 140.79999999999998
 Systemic ventricle mass indexed on BSA (exp=1) 89.54677075447057
 Systemic ventricle mass indexed on BSA (exp=1.3) 78.17791994546164
 Systemic ventricle mass to volume ratio: 1.207428634409787
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7679072097150332
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6704137721643922
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00538816].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data, it is predicted that the patient did **not** receive a heart transplant. This conclusion is supported by the patient's clinical history, which reveals no acute rejection of the Fontan pathway, minimal complications such as no history of protein-losing enteropathy, and a stable function of ventricles evidenced by normal systolic and diastolic volumes, as well as no significant regurgitation issues. Furthermore, the low probability (0.0054) generated by the XGBoost model for receiving a transplant suggests that, given the overall stability and management of the patient's condition, the likelihood of a transplant being necessary is extremely low.","Based on the provided data, I predict that the main patient did **not** receive a heart transplant. This conclusion stems from the main patient's extensive surgical history, which includes multiple interventions, but specifically no record of past heart transplant or prior listing for one. Furthermore, the similar patients showed a distinct trend: the two highlighted patients with relevant similar diagnoses, surgeries, and outcomes also did not undergo heart transplantation, suggesting that the likelihood for the main patient in this cohort is low. Finally, the predicted probability from the XGBoost model reflects a minimal risk (0.0054) of having received a transplant, further supporting the conclusion that this main patient likely did not receive one.","Based on the data provided, it is predicted that the main patient did **not** receive a heart transplant. The patient's history indicates multiple cardiac surgeries, including a Fontan procedure, and a known genetic diagnosis, which suggests a complex cardiac condition. Additionally, the similar patients, though they experienced a range of outcomes, show a lower likelihood of heart transplantation in patients with comparable characteristics and histories. The XGBoost model further supports this prediction with a very low estimated probability (0.00538816) of the outcome being 'yes', indicating that the odds of the patient having undergone a heart transplant are exceedingly low relative to the overall cohort that was analyzed, strongly favoring the conclusion that the patient did not receive a transplant.","Based on the analysis of the main patient's clinical data and the results from similar patients, it is likely that the main patient did not receive a heart transplant. The similar cohort shows a very low predicted probability (0.00538816) for receiving a heart transplant, indicating that this outcome is rare in the patient population typically seen. Furthermore, the main patient has a history of significant complications such as stroke (non-peri-op), renal dysfunction, and elevated liver fibrosis test, which are known risk factors that typically preclude transplant eligibility. Similar patients generally did not receive heart transplants either, indicating that the issues faced by such patients often lead them to manage their conditions without surgical intervention through transplantation. Therefore, the predicted outcome is that the main patient did **not** receive a heart transplant.",1,1,1,1,0
BCH-DACKEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt conduit
 Other relevant surgical or clinical history (optional): CATH 1/70- Hemodynamics
SURG 1/70- Pott's shunt 
CATH 1/72- Hemodynamics
CATH 4/1984- Hemodynamics
SURG 8/1984- Lung byopsy and waterston shunt
CATH 8/1985- Hemodynamics
SURG 11/1985- Central shunt conduit
SURG 11/1985- RA-PA Fontan, tricuspid valvectomy
CATH 9/2016, BWH-hemodynamic

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 40.0
 Gadolinium unknown contrast dose: 40.0
 Patient height: 157.1
 Patient weight: 56.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5723626749875916
 Heart rate: 72.0
 Upper limb mean blood pressure: 78.0
 Left ventricle end-diastolic volume: 168.8
 Left ventricle end-systolic volume: 77.91
 Left ventricular mass: 109.6
 Right ventricular end-diastolic volume: 55.9
 Right ventricular end-systolic volume: 38.3
 Right ventricle mass: 31.2
 Single ventricle ejection fraction 0.4828215398308857
 Single ventricle systolic volume 108.49000000000002
 Body mass index 22.77109659037269
 Mass to height volume indexed on BSA (exp = 2.7) 41.58406635923462
 Systemic ventricle end-systolic volume: 116.21
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 73.90788515182547
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 64.52454600044103
 Systemic ventricle end-diastolic volume: 224.70000000000002
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.90596156626094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 124.76263218569059
 Systemic ventricle mass: 140.79999999999998
 Systemic ventricle mass indexed on BSA (exp=1) 89.54677075447057
 Systemic ventricle mass indexed on BSA (exp=1.3) 78.17791994546164
 Systemic ventricle mass to volume ratio: 1.207428634409787
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7679072097150332
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6704137721643922
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.06291912].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided data, it appears unlikely that the patient has a diagnosis of seizures requiring antiepileptic medications. Although the patient does have a history of a non-perioperative stroke, which may indicate a potential for seizure activity, their clinical status does not include any mention of anticonvulsant medication usage. Furthermore, the XGBoost model's predicted probability of 0.0629 for a 'yes' outcome indicates a low likelihood of this diagnosis. Given the patient's overall medical history and absence of antiepileptic medications, it is reasonable to predict that they do not have a diagnosis of seizures requiring such treatment. Thus, the predicted outcome for the patient is ""no.""","Based on the information provided, the predicted outcome for the main patient regarding a diagnosis of seizures requiring antiepileptic medications is likely ""no"". The main patient has a history of stroke, which could potentially increase the risk of seizures, but their current medications do not include antiepileptic drugs, which suggests no ongoing seizure activity requiring treatment. 

Moreover, when examining the similar patients, particularly similar patient #1 who has no history of seizures or the need for antiepileptic medications and shared patient characteristics—such as similar volumes and surgical histories—this reinforces the likelihood that the main patient does not possess the same diagnosis. Furthermore, the XGBoost model output shows a low predicted probability (0.0629) for seizures being present, supporting the conclusion that seizures are unlikely in the main patient.","Based on the data provided, the main patient has a history of stroke (non-perioperative), which may indicate a predisposition to neurological complications, including seizures. The model's predicted probability for the occluded outcome being positive ('yes') is relatively low at approximately 6.29%, which suggests that seizures are less likely in this patient. Additionally, similar patients with stroke history and keeping in mind their overall clinical profiles show a varied prevalence of seizures. However, considering the significant ratio of patients without seizures in the similar cohort, along with the lack of seizure diagnosis mentioned in the main patient's history, it would be reasonable to conclude that the patient does not have a diagnosis of seizures requiring antiepileptic medications. Hence, I would predict **no** for the missing clinical outcome.","Based on the provided data, the prediction for the main patient regarding the diagnosis of seizures requiring antiepileptic medications is **no**. The main patient has a history of stroke but has not reported any seizures requiring such treatment. Additionally, the similar patients exhibited a tendency for seizure diagnoses associated with significant cardiac complications, such as atrial arrhythmias or structural anomalies resulting from their cardiac history. Given that the main patient does not share these conditions to the same severity, and the XGBoost model indicates a low probability (6.29%) of having seizures, it is reasonable to conclude that the patient likely does not have this diagnosis.",1,1,1,1,0
BCH-DACKEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt conduit
 Other relevant surgical or clinical history (optional): CATH 1/70- Hemodynamics
SURG 1/70- Pott's shunt 
CATH 1/72- Hemodynamics
CATH 4/1984- Hemodynamics
SURG 8/1984- Lung byopsy and waterston shunt
CATH 8/1985- Hemodynamics
SURG 11/1985- Central shunt conduit
SURG 11/1985- RA-PA Fontan, tricuspid valvectomy
CATH 9/2016, BWH-hemodynamic

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 40.0
 Gadolinium unknown contrast dose: 40.0
 Patient height: 157.1
 Patient weight: 56.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5723626749875916
 Heart rate: 72.0
 Upper limb mean blood pressure: 78.0
 Left ventricle end-diastolic volume: 168.8
 Left ventricle end-systolic volume: 77.91
 Left ventricular mass: 109.6
 Right ventricular end-diastolic volume: 55.9
 Right ventricular end-systolic volume: 38.3
 Right ventricle mass: 31.2
 Single ventricle ejection fraction 0.4828215398308857
 Single ventricle systolic volume 108.49000000000002
 Body mass index 22.77109659037269
 Mass to height volume indexed on BSA (exp = 2.7) 41.58406635923462
 Systemic ventricle end-systolic volume: 116.21
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 73.90788515182547
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 64.52454600044103
 Systemic ventricle end-diastolic volume: 224.70000000000002
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.90596156626094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 124.76263218569059
 Systemic ventricle mass: 140.79999999999998
 Systemic ventricle mass indexed on BSA (exp=1) 89.54677075447057
 Systemic ventricle mass indexed on BSA (exp=1.3) 78.17791994546164
 Systemic ventricle mass to volume ratio: 1.207428634409787
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7679072097150332
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6704137721643922
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? yes
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.24075049].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided information, the prediction for the missing clinical outcome—whether the patient has died—is likely ""no."" The patient's clinical history reveals that they have not undergone a heart transplant, have a history of stroke, renal dysfunction, and atrial tachyarrhythmias; however, they show no signs of acute life-threatening events like cardiac arrest or major thrombotic incidents. The XGBoost model gives a predicted probability of 0.2407 for the outcome being 'yes,' which, while not insignificant, indicates that there is a more substantial likelihood of survival given the context of their clinical management and reasonably stable MRI findings despite past complications. This suggests the patient is surviving post-Fontan and managing chronic conditions without immediate mortality risk.","Based on the provided data, the predicted clinical outcome for the main patient, specifically whether they have died, is ""no."" The main patient has a complex surgical history with several procedures, a balanced dominant ventricular morphology, and appropriate hemodynamic status as indicated by their recent MRI findings. Additionally, similar patients in the cohort also show a relatively high survival rate despite facing challenges such as protein-losing enteropathy or arrhythmias. The estimated probability of 0.24075049 suggests a lower risk of mortality, aligning with the lack of reported death in similar patients and overall positive clinical indicators from the MRI results.","Based on the available data and analysis, it is predicted that the main patient has not died. The patient has a significant surgical history, including an atrio-pulmonary Fontan procedure, without any reported history of cardiac arrest, death, or complications indicative of imminent demise, such as major vascular thrombus or severe complications post-surgery. Furthermore, the similar patients, who have undergone comparable surgical interventions and have a similar clinical profile, show a trend of surviving despite various challenges. The XGBoost model's predicted probability of 0.2407 indicates a moderate risk for a poor outcome, but the high validation accuracy and AUC reflect that most patients with similar features have fared well, reinforcing the conclusion that this patient is likely alive.","Based on the provided data, it is predicted that the outcome ""Has the patient died?"" for the main patient is **no**. The main patient's clinical history, including multiple cardiac surgeries and management of associated complications, indicates a complex but managed clinical picture. Notably, the presence of issues such as a history of stroke (non-perioperative), atrial arrhythmias, and renal dysfunction may increase the risk; however, similar patients with analogous profiles (particularly those with stroke history) have shown no deaths, especially when receiving appropriate medical management. The predicted probability from the XGBoost model (24.08%) suggests that while there is risk, it is not high enough to indicate impending mortality, especially considering the validation metrics that demonstrate a high prediction accuracy for long-term survival in similar patients.",1,1,1,1,0
BCH-FIECOU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): critical AS, small left sided structures 

FETAL INTERVENTION (9/13, 28 weeks gestation)- aortic valve balloon dilation

CATH (12/13, BCH)- sequential balloon dilation of the aortic valve and PFO balloon dilation. Complications:  Catheter-related SVT --> spontaneously resolved.
SURG (12/13, BCH)-Stage 1 Norwood with resection of coarctation and reconstruction with pulmonary homograft, 5 mm ring Gore-Tex RV to RPA conduit banded to 4 mm, partial resection of atrial septum, and division of PDA
CATH (5/14, BCH)-Coil occlusion of RIMA, LIMA, and large right bronchial artery
SURG (5/14, BCH)-Right-sided bidirectional Glenn with azygous vein ligation, central PA plasty with bovine pericardium, aortic valvotomy, mitral valvotomy, LV EFE resection, partial ASD closure, and left radial artery cut-down
CATH (11/16, BCH)-gelfoam/coil occlusion of 7 APCs (2 from DescAo, 4 from RSCA, 1 from LSCA).
SURG (11/16, BCH)-18 mm GoreTex extracardiac Fontan with 4 mm fenestration, atrial septectomy with coronary sinus unroofing, and aortic valve repair with commissural closure
          a) Complicated by thrombotic occlusion of fenestration and depressed cardiac function
          b) Prolonged hospital course, initiation of sildenafil
CATH (11/16, BCH)-fenestration balloon dilation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bilateral bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 4.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 4.7
 Patient height: 116.0
 Patient weight: 31.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.0194835142132124
 Heart rate: 103.0
 Upper limb systolic blood pressure: 78.0
 Upper limb diastolic blood pressure: 36.0
 Upper limb mean blood pressure: 49.0
 Left ventricle end-diastolic volume: 26.6
 Left ventricle end-systolic volume: 20.6
 Left ventricular mass: 18.1
 Right ventricular end-diastolic volume: 135.3
 Right ventricular end-systolic volume: 80.41
 Right ventricle mass: 73.0
 Native aorta flow rate: 6.1
 Ascending aorta, above the Stansel flow rate: 6.1
 Descending aorta flow rate: 1.63
 Right superior vena cava flow rate: 1.55
 Inferior vena cava, below the fenestration flow rate: 0.99
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.94
 Total right pulmonary vein flow rate: 3.09
 Total left pulmonary vein flow rate: 1.54
 Single ventricle ejection fraction 0.3760963557751699
 Single ventricle systolic volume 60.890000000000015
 Body mass index 23.335315101070154
 Mass to height volume indexed on BSA (exp = 2.7) 61.02134923778084
 Systemic ventricle end-systolic volume: 101.00999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 99.07958156435181
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 98.50768242218997
 Systemic ventricle end-diastolic volume: 161.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 158.80590293306167
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 157.8892563523667
 Systemic ventricle mass: 91.1
 Systemic ventricle mass indexed on BSA (exp=1) 89.35897317604643
 Systemic ventricle mass indexed on BSA (exp=1.3) 88.84318254293146
 Systemic ventricle mass to volume ratio: 1.219992886873503
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1966774056322373
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.1897700411589525
 Contrast type: Gadavist
 Description of aortopulmonary collaterals: Evidence for massive aortopulmonary collateral flow. Multiple small APCs seen on the MR angiogram.
 Description of late gadolinium enhancement: Focal region of dense transmural late gadolinium enhancement seen in apical-inferior wall with associated dyskinesis. Additional dyskinesis and late gadolinium enhancement at prior Sano insertion site.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Trivial or trivial to mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: thrombotic occlusion of fenestration 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00710511].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the patient's data, it is predicted that the patient did **not** receive a heart transplant. The primary reasons for this conclusion include the patient’s complex history of cardiac surgeries, including a successful Fontan procedure and a complicated postoperative course characterized by thrombotic occlusion of the fenestration and depressed cardiac function. Additionally, the XGBoost model indicates a very low probability (0.0071) for the occluded outcome of having received a transplant, suggesting that the likelihood of the patient having undergone such a procedure is extremely limited, especially considering their ongoing management with anticoagulants and pulmonary vasodilators, which are often used in patients who have not received transplants.","Based on the data provided for the main patient, who has a complex surgical history related to hypoplastic left heart syndrome and has undergone multiple cardiac interventions, it is reasonable to predict that this patient did **not** receive a heart transplant. The patient’s ongoing management has focused on interventions like catheterizations and surgical revisions related to their Fontan physiology, without documentation of a heart transplant. Furthermore, similar patients with hypoplastic left heart syndrome and a comparable surgical history who underwent Fontan surgery also show a low incidence of transplantation, as indicated by the model's probability estimate (0.0071), which suggests that the occluded outcome of receiving a heart transplant is unlikely given the patient’s circumstances and past interventions. Therefore, the most fitting prediction for the main patient is ""no"" regarding heart transplantation.","Based on the provided information, I predict that the main patient did **not receive a heart transplant**. Firstly, the main patient's complex surgical history, including multiple procedures and interventions related to hypoplastic left heart syndrome, indicates a high level of medical management without necessitating a transplant at this stage. Secondly, in the context of the similar patients, none received a heart transplant; they managed their conditions through surgeries like Fontan and associated interventions, reflecting similar clinical trajectories. Additionally, the XGBoost model's predicted probability of transplant being 'yes' at only 0.007 suggests a very low likelihood of this outcome, reinforcing the notion that ongoing management without transplantation is more characteristic for patients with comparable profiles. Thus, considering these trends and the individual clinical details, the conclusion is supported that the patient has not undergone a heart transplant.","Based on the provided data, it is predicted that the main patient did not receive a heart transplant (outcome: 'no'). The patient has undergone multiple intricate surgeries, including a Fontan procedure with complicated outcomes, such as thrombotic occlusion and depressed cardiac function. In reviewing the data from similar patients, those with comparable surgical histories and cardiac anatomy had low transplant rates, particularly among patients with high surgical interventions and declining systemic function. Additionally, the XGBoost model predicts a very low probability (approximately 0.71%) for the heart transplant outcome, further corroborating that the current clinical situation may lean toward non-transplant management given the complexities involved.",1,1,1,1,0
BCH-FIECOU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): critical AS, small left sided structures 

FETAL INTERVENTION (9/13, 28 weeks gestation)- aortic valve balloon dilation

CATH (12/13, BCH)- sequential balloon dilation of the aortic valve and PFO balloon dilation. Complications:  Catheter-related SVT --> spontaneously resolved.
SURG (12/13, BCH)-Stage 1 Norwood with resection of coarctation and reconstruction with pulmonary homograft, 5 mm ring Gore-Tex RV to RPA conduit banded to 4 mm, partial resection of atrial septum, and division of PDA
CATH (5/14, BCH)-Coil occlusion of RIMA, LIMA, and large right bronchial artery
SURG (5/14, BCH)-Right-sided bidirectional Glenn with azygous vein ligation, central PA plasty with bovine pericardium, aortic valvotomy, mitral valvotomy, LV EFE resection, partial ASD closure, and left radial artery cut-down
CATH (11/16, BCH)-gelfoam/coil occlusion of 7 APCs (2 from DescAo, 4 from RSCA, 1 from LSCA).
SURG (11/16, BCH)-18 mm GoreTex extracardiac Fontan with 4 mm fenestration, atrial septectomy with coronary sinus unroofing, and aortic valve repair with commissural closure
          a) Complicated by thrombotic occlusion of fenestration and depressed cardiac function
          b) Prolonged hospital course, initiation of sildenafil
CATH (11/16, BCH)-fenestration balloon dilation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bilateral bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 4.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 4.7
 Patient height: 116.0
 Patient weight: 31.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.0194835142132124
 Heart rate: 103.0
 Upper limb systolic blood pressure: 78.0
 Upper limb diastolic blood pressure: 36.0
 Upper limb mean blood pressure: 49.0
 Left ventricle end-diastolic volume: 26.6
 Left ventricle end-systolic volume: 20.6
 Left ventricular mass: 18.1
 Right ventricular end-diastolic volume: 135.3
 Right ventricular end-systolic volume: 80.41
 Right ventricle mass: 73.0
 Native aorta flow rate: 6.1
 Ascending aorta, above the Stansel flow rate: 6.1
 Descending aorta flow rate: 1.63
 Right superior vena cava flow rate: 1.55
 Inferior vena cava, below the fenestration flow rate: 0.99
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.94
 Total right pulmonary vein flow rate: 3.09
 Total left pulmonary vein flow rate: 1.54
 Single ventricle ejection fraction 0.3760963557751699
 Single ventricle systolic volume 60.890000000000015
 Body mass index 23.335315101070154
 Mass to height volume indexed on BSA (exp = 2.7) 61.02134923778084
 Systemic ventricle end-systolic volume: 101.00999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 99.07958156435181
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 98.50768242218997
 Systemic ventricle end-diastolic volume: 161.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 158.80590293306167
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 157.8892563523667
 Systemic ventricle mass: 91.1
 Systemic ventricle mass indexed on BSA (exp=1) 89.35897317604643
 Systemic ventricle mass indexed on BSA (exp=1.3) 88.84318254293146
 Systemic ventricle mass to volume ratio: 1.219992886873503
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1966774056322373
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.1897700411589525
 Contrast type: Gadavist
 Description of aortopulmonary collaterals: Evidence for massive aortopulmonary collateral flow. Multiple small APCs seen on the MR angiogram.
 Description of late gadolinium enhancement: Focal region of dense transmural late gadolinium enhancement seen in apical-inferior wall with associated dyskinesis. Additional dyskinesis and late gadolinium enhancement at prior Sano insertion site.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Trivial or trivial to mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: thrombotic occlusion of fenestration 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0010774].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided data, the predicted outcome for the patient regarding the history of pacemaker placement is ""no."" The patient's surgical history and MRI findings indicate significant cardiac interventions, particularly the complex anatomy and multiple surgeries (e.g., Fontan, Glenn procedures) addressing critical aortic stenosis and other structural issues. Additionally, although there are mentions of arrhythmias (atrial tachyarrhythmias), the absence of any history of prolonged ventricular tachycardia or bradyarrhythmias that would typically necessitate pacemaker insertion suggests that pacing has not been required. Moreover, the predicted probability of needing a pacemaker, indicated by the XGBoost model's low estimated probability of the occluded outcome being 'yes,' supports this conclusion.","Based on the information provided, it is reasonable to predict that the main patient does not have a history of pacemaker placement. The main patient has a complex surgical history and has undergone multiple interventions, but there is no documented placement of a pacemaker, nor are there indications of severe arrhythmias that would typically necessitate one. 

When analyzing the similar patients, while some had a history of arrhythmias, the specific need for a pacemaker placement was not widespread, and most did not report such an intervention. Additionally, the absence of life-threatening arrhythmias or pacemaker placement in the specific similar cases reviewed, alongside the main patient's stable post-operative status, suggests that placement is unlikely. Given the low predicted probability (0.0010774) from the XGBoost model indicating minimal risk, we can conclude there is no compelling evidence to suggest this patient requires a pacemaker based on their profile and those of comparable patients. Thus, the predicted outcome is **no**.","Based on the information provided, I predict that the main patient does not have a history of pacemaker placement. The main patient has undergone multiple complex surgeries associated with hypoplastic left heart syndrome and has a documented history of intracardiac thrombus. Such complications could generally indicate a high likelihood of arrhythmias, which often necessitate intervention such as a pacemaker. However, among the similar patients, particularly those with comparable surgical histories and outcomes, there has been no documented pacemaker placement. Additionally, the XGBoost model output suggests a very low probability (0.0010774) for the occluded outcome, supporting the conclusion that the likelihood of needing a pacemaker is minimal in this case. Thus, these factors lead to a rational deduction that this patient has not undergone pacemaker placement.","Based on the information provided, I predict that the main patient does **not** have a history of pacemaker placement. The main patient has undergone multiple cardiac interventions, including a Fontan procedure and multiple catheterizations, but there is no documented use of a pacemaker in their surgical or clinical history. 

In comparison, the similar patients predominantly exhibit either the absence of pacemaker placement or have histories that intersect with known complications, such as atrial arrhythmias. In those similar patients with significant atrial issues or substantial intervention history, pacemaker use is indicated. However, the low risk of developing severe complications in the main patient’s context, combined with the likelihood of vigilant post-operative monitoring, leads to a lower probability of pacemaker placement. Additionally, the XGBoost model predicts a very low probability (0.0010774) of related complications which further supports this conclusion. ",1,1,1,1,0
BCH-FIECOU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): critical AS, small left sided structures 

FETAL INTERVENTION (9/13, 28 weeks gestation)- aortic valve balloon dilation

CATH (12/13, BCH)- sequential balloon dilation of the aortic valve and PFO balloon dilation. Complications:  Catheter-related SVT --> spontaneously resolved.
SURG (12/13, BCH)-Stage 1 Norwood with resection of coarctation and reconstruction with pulmonary homograft, 5 mm ring Gore-Tex RV to RPA conduit banded to 4 mm, partial resection of atrial septum, and division of PDA
CATH (5/14, BCH)-Coil occlusion of RIMA, LIMA, and large right bronchial artery
SURG (5/14, BCH)-Right-sided bidirectional Glenn with azygous vein ligation, central PA plasty with bovine pericardium, aortic valvotomy, mitral valvotomy, LV EFE resection, partial ASD closure, and left radial artery cut-down
CATH (11/16, BCH)-gelfoam/coil occlusion of 7 APCs (2 from DescAo, 4 from RSCA, 1 from LSCA).
SURG (11/16, BCH)-18 mm GoreTex extracardiac Fontan with 4 mm fenestration, atrial septectomy with coronary sinus unroofing, and aortic valve repair with commissural closure
          a) Complicated by thrombotic occlusion of fenestration and depressed cardiac function
          b) Prolonged hospital course, initiation of sildenafil
CATH (11/16, BCH)-fenestration balloon dilation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bilateral bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 4.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 4.7
 Patient height: 116.0
 Patient weight: 31.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.0194835142132124
 Heart rate: 103.0
 Upper limb systolic blood pressure: 78.0
 Upper limb diastolic blood pressure: 36.0
 Upper limb mean blood pressure: 49.0
 Left ventricle end-diastolic volume: 26.6
 Left ventricle end-systolic volume: 20.6
 Left ventricular mass: 18.1
 Right ventricular end-diastolic volume: 135.3
 Right ventricular end-systolic volume: 80.41
 Right ventricle mass: 73.0
 Native aorta flow rate: 6.1
 Ascending aorta, above the Stansel flow rate: 6.1
 Descending aorta flow rate: 1.63
 Right superior vena cava flow rate: 1.55
 Inferior vena cava, below the fenestration flow rate: 0.99
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.94
 Total right pulmonary vein flow rate: 3.09
 Total left pulmonary vein flow rate: 1.54
 Single ventricle ejection fraction 0.3760963557751699
 Single ventricle systolic volume 60.890000000000015
 Body mass index 23.335315101070154
 Mass to height volume indexed on BSA (exp = 2.7) 61.02134923778084
 Systemic ventricle end-systolic volume: 101.00999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 99.07958156435181
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 98.50768242218997
 Systemic ventricle end-diastolic volume: 161.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 158.80590293306167
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 157.8892563523667
 Systemic ventricle mass: 91.1
 Systemic ventricle mass indexed on BSA (exp=1) 89.35897317604643
 Systemic ventricle mass indexed on BSA (exp=1.3) 88.84318254293146
 Systemic ventricle mass to volume ratio: 1.219992886873503
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1966774056322373
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.1897700411589525
 Contrast type: Gadavist
 Description of aortopulmonary collaterals: Evidence for massive aortopulmonary collateral flow. Multiple small APCs seen on the MR angiogram.
 Description of late gadolinium enhancement: Focal region of dense transmural late gadolinium enhancement seen in apical-inferior wall with associated dyskinesis. Additional dyskinesis and late gadolinium enhancement at prior Sano insertion site.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Trivial or trivial to mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: thrombotic occlusion of fenestration 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.1187084].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided data, the patient most likely does not have a history of ascites (> trace). The patient's surgical history indicates complex cardiac interventions related to Hypoplastic Left Heart Syndrome and subsequent Fontan surgery, including management of coagulation issues but no indications of significant stasis or fluid retention typically associated with ascites. Additionally, the absence of reported complications like protein-losing enteropathy or significant pleural effusion suggests that fluid overload has been adequately managed or has not progressed to cause notable ascites. The low predicted probability (approximately 0.12) of the occluded outcome also implies a lesser likelihood of this condition occurring.","Based on the provided data, I predict that the main patient does **not** have a history of ascites (> trace). The main patient exhibits significant cardiac history, including critical anatomical defects and multiple surgeries, but there are no explicit indications of fluid retention or cardiovascular complications leading to ascites, such as chronic heart failure or liver dysfunction, noted in their clinical history. 

In contrast, the similar patients show varied outcomes regarding ascites, but none had a history of ascites reported. The model’s predicted probability of the occluded outcome being 'yes' is relatively low at around 12%, indicating that the prevalence of ascites among similar patients is low. This reinforces the notion that the main patient is unlikely to have developed ascites, especially with no documented cases of significant liver issues or pleural effusions. Thus, it is reasonable to conclude the absence of ascites based on the data available.","**Prediction**: No

The main patient has undergone multiple surgeries related to hypoplastic left heart syndrome and presented with significant complications, including thrombotic occlusion of the fenestration and depressed cardiac function following the Fontan procedure. An analysis of the similar patients shows a low frequency of ascites, especially among those with complex surgical histories and better ventricular function. Additionally, the XGBoost model indicates a low predicted probability (11.87%) of the occluded outcome being 'yes', suggesting that the likelihood of the patient experiencing ascites is low, particularly given the absence of other risk factors or diagnoses like protein-losing enteropathy or heart failure typically associated with ascites. Overall, these data points strongly suggest that the patient likely does not have a history of ascites.","Based on the information provided, it is reasonable to predict that the main patient does **not** have a history of ascites (> trace). The main patient has undergone multiple surgeries related to hypoplastic left heart syndrome but shows no indication of significant complications typically associated with ascites, like severe cardiac dysfunction or significant liver problems. 

Moreover, similar patients with a more severe surgical history but without a diagnosis of ascites further support this prediction. The XGBoost model predicts a low probability (approximately 11.87%) for the occluded outcome of having ascites, which aligns with the clinical features of both the main patient and the similar cohort, who also did not exhibit signs indicating ascites. Therefore, considering the main patient’s stable post-surgical state and the clinical history of similar patients, the prediction leans towards a negative for the presence of ascites.",1,1,1,1,0
BCH-FIECOU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): critical AS, small left sided structures 

FETAL INTERVENTION (9/13, 28 weeks gestation)- aortic valve balloon dilation

CATH (12/13, BCH)- sequential balloon dilation of the aortic valve and PFO balloon dilation. Complications:  Catheter-related SVT --> spontaneously resolved.
SURG (12/13, BCH)-Stage 1 Norwood with resection of coarctation and reconstruction with pulmonary homograft, 5 mm ring Gore-Tex RV to RPA conduit banded to 4 mm, partial resection of atrial septum, and division of PDA
CATH (5/14, BCH)-Coil occlusion of RIMA, LIMA, and large right bronchial artery
SURG (5/14, BCH)-Right-sided bidirectional Glenn with azygous vein ligation, central PA plasty with bovine pericardium, aortic valvotomy, mitral valvotomy, LV EFE resection, partial ASD closure, and left radial artery cut-down
CATH (11/16, BCH)-gelfoam/coil occlusion of 7 APCs (2 from DescAo, 4 from RSCA, 1 from LSCA).
SURG (11/16, BCH)-18 mm GoreTex extracardiac Fontan with 4 mm fenestration, atrial septectomy with coronary sinus unroofing, and aortic valve repair with commissural closure
          a) Complicated by thrombotic occlusion of fenestration and depressed cardiac function
          b) Prolonged hospital course, initiation of sildenafil
CATH (11/16, BCH)-fenestration balloon dilation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bilateral bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 4.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 4.7
 Patient height: 116.0
 Patient weight: 31.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.0194835142132124
 Heart rate: 103.0
 Upper limb systolic blood pressure: 78.0
 Upper limb diastolic blood pressure: 36.0
 Upper limb mean blood pressure: 49.0
 Left ventricle end-diastolic volume: 26.6
 Left ventricle end-systolic volume: 20.6
 Left ventricular mass: 18.1
 Right ventricular end-diastolic volume: 135.3
 Right ventricular end-systolic volume: 80.41
 Right ventricle mass: 73.0
 Native aorta flow rate: 6.1
 Ascending aorta, above the Stansel flow rate: 6.1
 Descending aorta flow rate: 1.63
 Right superior vena cava flow rate: 1.55
 Inferior vena cava, below the fenestration flow rate: 0.99
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.94
 Total right pulmonary vein flow rate: 3.09
 Total left pulmonary vein flow rate: 1.54
 Single ventricle ejection fraction 0.3760963557751699
 Single ventricle systolic volume 60.890000000000015
 Body mass index 23.335315101070154
 Mass to height volume indexed on BSA (exp = 2.7) 61.02134923778084
 Systemic ventricle end-systolic volume: 101.00999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 99.07958156435181
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 98.50768242218997
 Systemic ventricle end-diastolic volume: 161.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 158.80590293306167
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 157.8892563523667
 Systemic ventricle mass: 91.1
 Systemic ventricle mass indexed on BSA (exp=1) 89.35897317604643
 Systemic ventricle mass indexed on BSA (exp=1.3) 88.84318254293146
 Systemic ventricle mass to volume ratio: 1.219992886873503
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1966774056322373
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.1897700411589525
 Contrast type: Gadavist
 Description of aortopulmonary collaterals: Evidence for massive aortopulmonary collateral flow. Multiple small APCs seen on the MR angiogram.
 Description of late gadolinium enhancement: Focal region of dense transmural late gadolinium enhancement seen in apical-inferior wall with associated dyskinesis. Additional dyskinesis and late gadolinium enhancement at prior Sano insertion site.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Trivial or trivial to mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: thrombotic occlusion of fenestration 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0552157].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided information, I predict that the missing clinical outcome regarding whether the patient has a diagnosis of seizures requiring antiepileptic medications is ""no."" Although the patient has a complex surgical history involving critical aortic stenosis and multiple cardiac procedures, there is no indication of a direct history of seizures or neurological complications in the status event update. Additionally, the XGBoost model prediction reflects a low probability (0.0552) of seizures being present, suggesting that, while seizures can occur in this demographic, this patient is unlikely to be affected based on the available data. Furthermore, the absence of any documented episodes of neurological events such as transient ischemic attacks or cardiac arrest strengthens the conclusion that seizures are not a current diagnosis for this patient.","Based on the provided data, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The patient has a history of multiple cardiac surgeries, including complex procedures related to hypoplastic left heart syndrome, but there is no indication of seizures or related neurological complications in their medical history. Moreover, among the similar patients analyzed, particularly similar patient #1 who shares a comparable surgical history and cardiac anatomy, there is no documented diagnosis of seizures, which further suggests that the risk is low in this cohort. The XGBoost model also indicates a low probability (0.0552157) of the occluded outcome being 'yes', corroborating the suspicion that the main patient is likely not suffering from seizures requiring treatment.","Based on the provided data, it is predicted that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The main patient has a history of complex cardiac surgeries, which include significant interventions that could contribute to brain injury or dysfunction, but there's no mention of seizures in their medical history. 

Additionally, the similarities with the matched cohort patients reveal that only a small minority had a diagnosis of seizures despite a high overall complexity of cardiac issues. Specifically, among the similar patients evaluated, none reported a seizure history, further supporting the likelihood that this specific outcome may not manifest in the main patient. Furthermore, given the low predicted probability of 0.055 from the XGBoost model, the data suggests a strong trend against this outcome.","Based on the information provided, the main patient has a complex surgical history related to hypoplastic left heart syndrome, with multiple interventions including a Fontan procedure and significant atrial arrhythmias, which may predispose them to complications such as seizures. From the similar cohort, many patients with comparable cardiac history and surgical profiles experienced seizures, particularly under circumstances of surgical stress or a background of arrhythmias. The model's prediction probability of 0.0552 indicates a very low likelihood of a positive outcome (diagnosis of seizures requiring antiepileptic medication), yet it doesn't completely eliminate the possibility of such occurrences in a medically complex patient. Therefore, despite the weak model prediction, the clinical complexity associated with this patient's history and the experiences of similar patients suggest a heightened risk, leading to the conclusion that it would be reasonable to predict **""Yes""**, that this patient has a diagnosis of seizures requiring antiepileptic medications.",1,1,1,0,0
BCH-FIECOU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): critical AS, small left sided structures 

FETAL INTERVENTION (9/13, 28 weeks gestation)- aortic valve balloon dilation

CATH (12/13, BCH)- sequential balloon dilation of the aortic valve and PFO balloon dilation. Complications:  Catheter-related SVT --> spontaneously resolved.
SURG (12/13, BCH)-Stage 1 Norwood with resection of coarctation and reconstruction with pulmonary homograft, 5 mm ring Gore-Tex RV to RPA conduit banded to 4 mm, partial resection of atrial septum, and division of PDA
CATH (5/14, BCH)-Coil occlusion of RIMA, LIMA, and large right bronchial artery
SURG (5/14, BCH)-Right-sided bidirectional Glenn with azygous vein ligation, central PA plasty with bovine pericardium, aortic valvotomy, mitral valvotomy, LV EFE resection, partial ASD closure, and left radial artery cut-down
CATH (11/16, BCH)-gelfoam/coil occlusion of 7 APCs (2 from DescAo, 4 from RSCA, 1 from LSCA).
SURG (11/16, BCH)-18 mm GoreTex extracardiac Fontan with 4 mm fenestration, atrial septectomy with coronary sinus unroofing, and aortic valve repair with commissural closure
          a) Complicated by thrombotic occlusion of fenestration and depressed cardiac function
          b) Prolonged hospital course, initiation of sildenafil
CATH (11/16, BCH)-fenestration balloon dilation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bilateral bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 4.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 4.7
 Patient height: 116.0
 Patient weight: 31.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.0194835142132124
 Heart rate: 103.0
 Upper limb systolic blood pressure: 78.0
 Upper limb diastolic blood pressure: 36.0
 Upper limb mean blood pressure: 49.0
 Left ventricle end-diastolic volume: 26.6
 Left ventricle end-systolic volume: 20.6
 Left ventricular mass: 18.1
 Right ventricular end-diastolic volume: 135.3
 Right ventricular end-systolic volume: 80.41
 Right ventricle mass: 73.0
 Native aorta flow rate: 6.1
 Ascending aorta, above the Stansel flow rate: 6.1
 Descending aorta flow rate: 1.63
 Right superior vena cava flow rate: 1.55
 Inferior vena cava, below the fenestration flow rate: 0.99
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.94
 Total right pulmonary vein flow rate: 3.09
 Total left pulmonary vein flow rate: 1.54
 Single ventricle ejection fraction 0.3760963557751699
 Single ventricle systolic volume 60.890000000000015
 Body mass index 23.335315101070154
 Mass to height volume indexed on BSA (exp = 2.7) 61.02134923778084
 Systemic ventricle end-systolic volume: 101.00999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 99.07958156435181
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 98.50768242218997
 Systemic ventricle end-diastolic volume: 161.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 158.80590293306167
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 157.8892563523667
 Systemic ventricle mass: 91.1
 Systemic ventricle mass indexed on BSA (exp=1) 89.35897317604643
 Systemic ventricle mass indexed on BSA (exp=1.3) 88.84318254293146
 Systemic ventricle mass to volume ratio: 1.219992886873503
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1966774056322373
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.1897700411589525
 Contrast type: Gadavist
 Description of aortopulmonary collaterals: Evidence for massive aortopulmonary collateral flow. Multiple small APCs seen on the MR angiogram.
 Description of late gadolinium enhancement: Focal region of dense transmural late gadolinium enhancement seen in apical-inferior wall with associated dyskinesis. Additional dyskinesis and late gadolinium enhancement at prior Sano insertion site.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Trivial or trivial to mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: thrombotic occlusion of fenestration 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01601037].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data for this single-ventricle patient who has undergone Fontan surgery, it is predicted that the patient has **not died**. The XGBoost model indicates a very low probability (0.016) of the outcome being 'yes' (i.e., the patient having died), which suggests that the risk of mortality in this instance is minimal. Additionally, the patient’s clinical history, including complications such as thrombotic occlusion of the fenestration, atrial tachyarrhythmias, and the management with anticoagulants and pulmonary vasodilators, suggests that despite challenges, they are currently receiving appropriate medical interventions to stabilize their condition. Furthermore, no information is present in the clinical records indicating any acute or terminal issues that would typically precede such an outcome.","**Prediction:** No, the patient has not died.

**Reasoning:** The main patient has undergone multiple cardiac surgeries, including a successful Fontan procedure with a significant surgical history, which is often associated with ongoing management and monitoring rather than mortality. While there are indications of complications such as thrombotic occlusion during the Fontan surgery and the presence of late gadolinium enhancement, these factors are not uncommon among similar patients who have also experienced adverse outcomes yet survived. The prediction model indicates a low probability (0.016) for the occluded outcome indicating death, and the similar patients, though experiencing various complications, did not report mortality, suggesting a pattern of survival in this cohort despite significant clinical challenges.","Based on the data provided for the main patient and the trends observed in similar patients, it is predicted that this patient has not died (no). The main patient has undergone multiple surgeries and interventions, albeit complicated, particularly with a history of thrombotic occlusion and depressed cardiac function post-Fontan surgery. Importantly, among the similar patients, those with comparable surgical histories (such as hypoplastic left heart syndrome) did not show a high mortality rate, particularly with successful management of complications. Furthermore, the XGBoost model predicts a low probability (1.6%) of adverse outcomes like death, aligning with the overall clinical history of similar patients who continue to survive with appropriate medical follow-up. Thus, the likelihood suggests that this patient remains alive.","Based on the available data, I predict that the main patient has not died. The patient's MRI report indicates significant cardiac interventions and a history of a fenestrated extracardiac Fontan procedure, which generally improve survival outcomes. Additionally, the XGBoost model predicts a very low probability (1.6%) of adverse outcomes relating to mortality, aligning with a clinical context where many similar patients have survived multiple surgical episodes. Moreover, the successful management of thrombotic events and the absence of other critical complications like severe arrhythmias or extensive end-organ failure suggest a stable status. While the risk cannot be completely ruled out, the evidence leans towards survival in this case.",1,1,1,1,0
BCH-GRIJAH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 6.0
 Gadobutrol (Gadavist, Gadovist) contrast dose: 6.0
 Patient height: 150.0
 Patient weight: 39.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.2823305439824881
 Heart rate: 81.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 89.0
 Left ventricle end-diastolic volume: 112.5
 Left ventricle end-systolic volume: 49.1
 Left ventricular mass: 59.1
 Right ventricular end-diastolic volume: 7.43
 Right ventricular end-systolic volume: 3.04
 Right ventricle mass: 4.5
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Descending aorta flow rate: 2.2
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.5
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.9
 Left atrioventricular valve/mitral inflow rate: 3.3
 Single ventricle ejection fraction 0.5635555555555556
 Single ventricle systolic volume 63.4
 Body mass index 17.688888888888886
 Mass to height volume indexed on BSA (exp = 2.7) 19.776119669777824
 Systemic ventricle end-systolic volume: 49.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.28965958146165
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.53706111364036
 Systemic ventricle end-diastolic volume: 112.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 87.73089007972372
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 81.42401986322893
 Systemic ventricle mass: 59.1
 Systemic ventricle mass indexed on BSA (exp=1) 46.08796092188153
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.774751768149606
 Systemic ventricle mass to volume ratio: 0.5253333333333333
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.40967076375005806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.38022001571688535
 Contrast type: Gadavist
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.07208246].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided patient data, I predict that the missing clinical outcome, whether the patient has a diagnosis of seizures requiring antiepileptic medications, is ""no."" The MRI report indicates a well-functioning single ventricle with a reasonable ejection fraction of approximately 56%, and there is no documented history of stroke, significant arrhythmias, or other neurological complications that could predispose this patient to seizures. Furthermore, the XGBoost model predicts a very low probability (approximately 7.2%) for the occluded outcome, aligning with the absence of relevant clinical red flags in the history, which supports the conclusion that the likelihood of seizure diagnosis in this case is low.","Based on the information provided, it is reasonable to predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications (""no""). The main patient has not exhibited any significant neurological complications such as strokes or transient ischemic attacks, which are often associated with seizure diagnoses. Additionally, the similar patients' cohort shows a very low incidence of seizures (only one out of several similar patients reported it), indicating that such outcomes are relatively rare in this specific population. Furthermore, the XGBoost model predicts a low probability (0.072) for the occluded outcome, which supports the hypothesis that seizures are unlikely to be a concern for this patient.","Based on the information provided, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The main patient has undergone multiple cardiac surgeries, including Fontan surgery, but has a robust clinical status without any noted complications such as stroke or arrhythmias. In the cohort of similar patients, while some had diagnoses of intracardiac thrombus and other complications, the majority did not present with seizure diagnoses, and the majority had a favorable outcome post-surgery. Additionally, the XGBoost model predicts a low probability (7.2%) of the occluded outcome being 'yes', which aligns with the absence of significant neurological issues in the main patient's history. Thus, considering these factors, the likelihood of seizure diagnosis seems low.","Based on the provided information, the prediction for the main patient is **""No""**, indicating they do not have a diagnosis of seizures requiring antiepileptic medications. This conclusion is reinforced by the absence of any documented history of seizures or related complications in the main patient's clinical status updates. 

Furthermore, examining the similar patients reveals patterns; specifically, none had a history of seizures despite presenting with other cardiac complications, which suggests that seizures are not a common issue within this cohort. Moreover, the low predicted probability of the occluded outcome being 'yes' (0.072) from the XGBoost model corroborates the likelihood that the main patient is also not diagnosed with seizures. Thus, the evidence from the main patient's records and the comparative analysis with similar patients supports this outcome prediction.",1,1,1,1,0
BCH-GRIJAH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 6.0
 Gadobutrol (Gadavist, Gadovist) contrast dose: 6.0
 Patient height: 150.0
 Patient weight: 39.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.2823305439824881
 Heart rate: 81.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 89.0
 Left ventricle end-diastolic volume: 112.5
 Left ventricle end-systolic volume: 49.1
 Left ventricular mass: 59.1
 Right ventricular end-diastolic volume: 7.43
 Right ventricular end-systolic volume: 3.04
 Right ventricle mass: 4.5
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Descending aorta flow rate: 2.2
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.5
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.9
 Left atrioventricular valve/mitral inflow rate: 3.3
 Single ventricle ejection fraction 0.5635555555555556
 Single ventricle systolic volume 63.4
 Body mass index 17.688888888888886
 Mass to height volume indexed on BSA (exp = 2.7) 19.776119669777824
 Systemic ventricle end-systolic volume: 49.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.28965958146165
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.53706111364036
 Systemic ventricle end-diastolic volume: 112.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 87.73089007972372
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 81.42401986322893
 Systemic ventricle mass: 59.1
 Systemic ventricle mass indexed on BSA (exp=1) 46.08796092188153
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.774751768149606
 Systemic ventricle mass to volume ratio: 0.5253333333333333
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.40967076375005806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.38022001571688535
 Contrast type: Gadavist
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00099053].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided information, it is predicted that the main patient did not receive a heart transplant (no). This conclusion is supported by the fact that the patient has undergone a total of three cardiac surgeries culminating in an extracardiac Fontan, which often serves as the definitive palliation for single-ventricle patients. Additionally, the nature of the cardiac morphology—pulmonary atresia with intact septum and no significant complications such as a history of thrombus, heart failure, or progressive decline indicated in the patient's status—further corroborates the low likelihood of transplant necessity. The XGBoost model's predicted probability of the occluded outcome being 'yes' is extremely low (0.00099053), suggesting that a heart transplant is not indicated for this patient at this time.","Based on the available data, it is predicted that the main patient did **not** receive a heart transplant. The patient's significant surgical history, including multiple cardiac interventions and a successful initial Fontan surgery with fenestration, suggests a focus on improving hemodynamics rather than transplantation. Furthermore, the model indicates a very low predicted probability (0.00099) of requiring a transplant, aligning with the outcomes observed in similar patients who share comparable surgical histories and clinical characteristics. The similar patients generally did not receive transplants either, as indicated by their stable statuses, which further supports the likelihood that the main patient remains a candidate for non-transplant management.","Based on the data for the main patient, who has undergone multiple cardiac surgeries including a bidirectional Glenn and an extracardiac Fontan with a fenestration, and has no indications of severe complications such as thrombus or significant pleural effusions, it is reasonable to predict that this patient did not receive a heart transplant. The similar patients, while having some variations in their surgical histories, did not show a consistent pattern of undergoing transplant if they presented with significant surgical complexities managed effectively through their existing treatments. Additionally, the estimated probability of the occluded outcome being 'yes' to receiving a heart transplant is extremely low (0.00099), further supporting that the most likely answer is 'no'. 

Therefore, the predicted outcome is **No**, the patient did not receive a heart transplant.","Based on the provided data and the analysis of the similar patients, it is predicted that the main patient did not receive a heart transplant. The primary factors supporting this prediction are the low probability (0.00099053) of the occluded outcome being 'yes', suggesting that the event is rare among patients with comparable profiles. Additionally, in related cases, particularly those with similar surgical histories (like the extracardiac Fontan and the presence of a fenestration), the known outcomes indicate that heart transplants were infrequent. Most similar patients did not receive heart transplants and had varying degrees of management for their conditions, further reinforcing the likelihood that the main patient also did not transition to transplantation.",1,1,1,1,0
BCH-GRIJAH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 6.0
 Gadobutrol (Gadavist, Gadovist) contrast dose: 6.0
 Patient height: 150.0
 Patient weight: 39.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.2823305439824881
 Heart rate: 81.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 89.0
 Left ventricle end-diastolic volume: 112.5
 Left ventricle end-systolic volume: 49.1
 Left ventricular mass: 59.1
 Right ventricular end-diastolic volume: 7.43
 Right ventricular end-systolic volume: 3.04
 Right ventricle mass: 4.5
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Descending aorta flow rate: 2.2
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.5
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.9
 Left atrioventricular valve/mitral inflow rate: 3.3
 Single ventricle ejection fraction 0.5635555555555556
 Single ventricle systolic volume 63.4
 Body mass index 17.688888888888886
 Mass to height volume indexed on BSA (exp = 2.7) 19.776119669777824
 Systemic ventricle end-systolic volume: 49.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.28965958146165
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.53706111364036
 Systemic ventricle end-diastolic volume: 112.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 87.73089007972372
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 81.42401986322893
 Systemic ventricle mass: 59.1
 Systemic ventricle mass indexed on BSA (exp=1) 46.08796092188153
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.774751768149606
 Systemic ventricle mass to volume ratio: 0.5253333333333333
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.40967076375005806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.38022001571688535
 Contrast type: Gadavist
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00088999].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided data, I predict that the patient does not have a history of pacemaker placement (answer: no). This conclusion is supported by the absence of any documented arrhythmias or significant cardiac events (such as sustained ventricular tachycardia or atrial fibrillation) that would typically warrant pacemaker placement in such clinical contexts. Additionally, the patient is currently classified with good functional capacity (current NYHA class is not explicitly reported as reduced), and there are no interventions related to pacing indicated in their surgical history or clinical status, further suggesting that the rhythm has remained stable. The very low estimated probability (0.00088999) of having a negative outcome related to cardiac interventions strengthens the assumption that the patient is managed well without the need for a pacemaker.","Based on the analysis, I predict that the main patient does **not** have a history of pacemaker placement. The main patient has a history of complex surgeries consistent with single-ventricle physiology and some intervention history (e.g., they had a fenestration during the initial Fontan surgery), but there are no indications of arrhythmias or electrical pathologies that would necessitate a pacemaker. Moreover, the similar patient's data shows that the majority of comparable patients without significant arrhythmias do not have a pacemaker placement, which supports the prediction. The XGBoost model’s low probability for the occluded outcome being 'yes' aligns with this reasoning, suggesting that the occurrence of pacemaker placement is rare among these patients given their current condition and surgical history.","Based on the provided data, the main patient is less likely to have a history of pacemaker placement. While the patient has undergone multiple cardiac surgeries, including procedures related to a single ventricle physiology, there are no indications of arrhythmias or other complications that typically necessitate pacemaker implantation, as evidenced by the lack of recorded histories of sustained or non-sustained ventricular tachyarrhythmias, atrial fibrillation, or other significant arrhythmias.

Furthermore, reviewing the similar patients, particularly those with comparable surgical histories and outcomes, most did not require a pacemaker, and only one of the similar patients with a history of cardiac interventions had pacemaker placement attributed to arrhythmias. The model's estimated low probability of a 'yes' outcome for history of pacemaker placement in this cohort further supports the conclusion. Therefore, I would predict that the main patient does not have a history of pacemaker placement.","Based on the information provided, I predict that the main patient does not have a history of pacemaker placement. This inference is supported by the absence of reported arrhythmias in the main patient's clinical history, as well as the results from the MRI report showing no signs of significant complications that might warrant such an intervention. Additionally, none of the similar patients with a comparable surgical history, particularly those who underwent Fontan procedures and had a history of similar clinical features, reported pacemaker placements either, indicating a trend against the need for this intervention in such cases. The low predicted probability (0.00088999) from the XGBoost model further suggests that the likelihood of the patient requiring a pacemaker is minimal, reinforcing this conclusion.",1,1,1,1,0
BCH-GRIJAH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 6.0
 Gadobutrol (Gadavist, Gadovist) contrast dose: 6.0
 Patient height: 150.0
 Patient weight: 39.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.2823305439824881
 Heart rate: 81.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 89.0
 Left ventricle end-diastolic volume: 112.5
 Left ventricle end-systolic volume: 49.1
 Left ventricular mass: 59.1
 Right ventricular end-diastolic volume: 7.43
 Right ventricular end-systolic volume: 3.04
 Right ventricle mass: 4.5
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Descending aorta flow rate: 2.2
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.5
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.9
 Left atrioventricular valve/mitral inflow rate: 3.3
 Single ventricle ejection fraction 0.5635555555555556
 Single ventricle systolic volume 63.4
 Body mass index 17.688888888888886
 Mass to height volume indexed on BSA (exp = 2.7) 19.776119669777824
 Systemic ventricle end-systolic volume: 49.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.28965958146165
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.53706111364036
 Systemic ventricle end-diastolic volume: 112.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 87.73089007972372
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 81.42401986322893
 Systemic ventricle mass: 59.1
 Systemic ventricle mass indexed on BSA (exp=1) 46.08796092188153
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.774751768149606
 Systemic ventricle mass to volume ratio: 0.5253333333333333
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.40967076375005806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.38022001571688535
 Contrast type: Gadavist
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00079606].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data, the predicted outcome for the main patient regarding whether they have died is ""no."" The patient's MRI report indicates stable ventricular function, with an ejection fraction of 56% and no significant regurgitation or other complications such as thrombus or arrhythmias reported. Furthermore, the patient has not experienced any serious adverse events post-surgery, such as seizures or organ dysfunction, suggesting good overall health. The XGBoost model also predicts a very low probability (0.0008) of the occluded outcome being 'yes,' supporting the conclusion that the patient is likely still alive.","Based on the provided data, the predicted outcome for whether the main patient has died is **no**. The main patient has undergone a total of three cardiac surgeries, including a successful Fontan procedure, and has not exhibited significant postoperative complications such as thrombus formation or other serious conditions that could lead to death. 

When reviewing the similar patients, the survival rate appears high as many have survived despite having diverse surgical histories, including one patient who had an intracardiac thrombus but ultimately did not die. Additionally, the XGBoost model's predicted probability of the occluded outcome being 'yes' is extremely low (0.00079606), suggesting a very low likelihood of the patient having died. Thus, integrating the clinical history and patient outcomes from the similar cohort supports the conclusion that the main patient has not died.","Based on the provided information, the prediction for the missing clinical outcome ""Has the patient died?"" is **no**. The main patient exhibits a comprehensive surgical history with multiple corrective procedures, including a successful Fontan surgery with a fenestration, which often correlates with better long-term outcomes. Additionally, the MRI findings suggest stability with no significant abnormalities (e.g., no late gadolinium enhancement or large volume issues), further supporting a favorable prognosis. 

In comparison, similar patients who have undergone comparable surgical interventions and whose outcomes are documented also show high survival rates, despite some complications. The XGBoost model also indicates a very low predicted probability (0.00079606) for a negative outcome (death), which echoes the trends observed in both the main patient and the similar cohort. Thus, these combined indicators lead to the conclusion that the main patient has not died.","Based on the available data, it is predicted that the main patient has **not** died. The main patient has a relatively stable clinical profile with no history of significant complications post-surgery, such as thrombus formation, protein-losing enteropathy, or arrhythmias which are commonly associated with mortality in single-ventricle patients post-Fontan procedure. Furthermore, the similar patients had diverse surgical histories and outcomes, but none indicated mortality, especially those with comparable profiles who did not exhibit severe post-operative issues. Additionally, the XGBoost model estimates a very low probability (0.00079606) of the occluded outcome (death) being 'yes,' further supporting the prediction that the patient is alive.",1,1,1,1,0
BCH-GRIJAH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Pulmonary atresia with intact ventricular septum
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 6.0
 Gadobutrol (Gadavist, Gadovist) contrast dose: 6.0
 Patient height: 150.0
 Patient weight: 39.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.2823305439824881
 Heart rate: 81.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 78.0
 Upper limb mean blood pressure: 89.0
 Left ventricle end-diastolic volume: 112.5
 Left ventricle end-systolic volume: 49.1
 Left ventricular mass: 59.1
 Right ventricular end-diastolic volume: 7.43
 Right ventricular end-systolic volume: 3.04
 Right ventricle mass: 4.5
 Native aorta flow rate: 3.4
 Ascending aorta, above the Stansel flow rate: 3.4
 Descending aorta flow rate: 2.2
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.9
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.5
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.9
 Left atrioventricular valve/mitral inflow rate: 3.3
 Single ventricle ejection fraction 0.5635555555555556
 Single ventricle systolic volume 63.4
 Body mass index 17.688888888888886
 Mass to height volume indexed on BSA (exp = 2.7) 19.776119669777824
 Systemic ventricle end-systolic volume: 49.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 38.28965958146165
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.53706111364036
 Systemic ventricle end-diastolic volume: 112.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 87.73089007972372
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 81.42401986322893
 Systemic ventricle mass: 59.1
 Systemic ventricle mass indexed on BSA (exp=1) 46.08796092188153
 Systemic ventricle mass indexed on BSA (exp=1.3) 42.774751768149606
 Systemic ventricle mass to volume ratio: 0.5253333333333333
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.40967076375005806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.38022001571688535
 Contrast type: Gadavist
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00930508].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the available information, I predict that the patient does not have a history of ascites (> trace) (no). The patient's cardiovascular magnetic resonance imaging report shows no signs of significant structural or functional abnormalities, such as elevated end-diastolic or end-systolic volumes that could suggest heart failure or fluid retention. Additionally, the patient has no documented incidents of conditions that commonly accompany ascites, such as protein-losing enteropathy or hepatocellular dysfunction. The low predicted probability of the occluded outcome being 'yes' (only 0.0093) further supports the conclusion that ascites is unlikely to be present in this patient.","Based on the available data, it is likely that the main patient does not have a history of ascites (> trace). The surgical history shows that the patient underwent multiple cardiac procedures, including an Extracardiac Fontan and a fenestration, which can influence hemodynamics favorably. In the similar cohort of patients, many had histories of significant complications related to Fontan physiology, including those with ascites. However, the average flow rates in the main patient’s pulmonary and systemic circuits are relatively well-maintained, coupled with a low predicted probability (0.0093) from the XGBoost model for the occluded outcome, suggesting a lower risk profile for developing complications like ascites compared to some peers. Thus, it is reasonable to conclude that the main patient likely does not have a history of clinically significant ascites.","Based on the data provided for the main patient and the trends observed in similar patients, it is predicted that this patient does not have a history of ascites (> trace) (no). The main patient shows no indication of complications typically associated with Fontan physiology, such as protein-losing enteropathy or significant pleural effusions, which could lead to ascites. Furthermore, among the similar patients, those with a history of ascites often had coexisting conditions, like elevated liver fibrosis tests or other significant post-surgical complications; the main patient does not present with these issues. The XGBoost model's prediction probability of 0.0093 supports a very low likelihood of the missing outcome being 'yes', which aligns with the overall clinical picture observed in both the main patient and the similar cohort.","Based on the provided data, the predicted clinical outcome for the main patient regarding whether they have a history of ascites (> trace) is **no**. The main patient’s MRI and surgical history indicate no prior interventions or complications like protein-losing enteropathy or chylous pleural effusions, which often accompany conditions leading to ascites. Furthermore, similar patients who have a history of ascites generally exhibit concerning features such as elevated liver fibrosis tests, which are not reported for the main patient. Additionally, the predicted probability from the XGBoost model being low (0.0093) further supports that the likelihood of the main patient developing ascites is minimal when compared to the cohort that displays positive outcomes for such a complication.",1,1,1,1,0
BCH-GUYCOR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: Loosening of PAB (due to patients low sats) 13 days after initial surgery
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Lateral tunnel Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 35.0
 Gadolinium unknown contrast dose: 35.0
 Patient height: 176.5
 Patient weight: 66.1
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.796777264024984
 Heart rate: 92.0
 Left ventricle end-diastolic volume: 88.0
 Left ventricle end-systolic volume: 41.0
 Left ventricular mass: 103.0
 Right ventricular end-diastolic volume: 40.6
 Right ventricular end-systolic volume: 18.0
 Right ventricle mass: 50.0
 Native aorta flow rate: 4.63
 Ascending aorta, above the Stansel flow rate: 4.63
 Right superior vena cava flow rate: 4.63
 Inferior vena cava, below the fenestration flow rate: 3.06
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.83
 Single ventricle ejection fraction 0.5412130637636081
 Single ventricle systolic volume 69.6
 Body mass index 21.218371064690352
 Mass to height volume indexed on BSA (exp = 2.7) 32.9974754607999
 Systemic ventricle end-systolic volume: 59.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 32.83656866173459
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 27.542889204311262
 Systemic ventricle end-diastolic volume: 128.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 71.57258864235708
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 60.03416189278692
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 85.15245771602359
 Systemic ventricle mass indexed on BSA (exp=1.3) 71.42478047897666
 Systemic ventricle mass to volume ratio: 2.4019816390506046
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.336827712117135
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.121313799240013
 Description of veno-venous collaterals: Multiple tortuous venous structures extend from the innominate vein into the left side of the mediastinum. The left internal jugular vein has a very small caliber and is connected via dilated anterior neck veins to the right internal jugular vein. One small 3mm in size vessel extends from the region of the innominate vein to the left upper lobe pulmonary vein consistent with a systemic to pulmonary venous collateral
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum. The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum.=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? yes
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: no
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.1640789].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the patient's clinical history, including episodes of stroke and neurological complications, there is a concerning pattern that suggests the possibility of seizures. The patient's atrial tachyarrhythmias and history of clot formation may contribute to neurological deficits, increasing the likelihood of seizure activity. Additionally, the presence of anticoagulation treatment and the notation of a positive fibrosure indicating potential liver issues could position this patient at a higher risk for neurological sequelae, including seizures. Therefore, considering these factors and the predicted probability of the occluded outcome being low (0.164), it is reasonable to conclude that the patient likely does **have a diagnosis of seizures requiring antiepileptic medications** (yes).","Based on the analysis of the main patient's clinical and MRI data, alongside information from similar patients, it is predicted that the patient does not have a diagnosis of seizures requiring antiepileptic medications. The main patient has a history of stroke, both peri-operative and non-peri-operative, which is related but not directly indicative of seizures. Additionally, among the similar patients, none reported a diagnosis of seizures, despite having cardiac complexities. The XGBoost model output indicates a lower probability (16.4%) of the occluded outcome being 'yes,' suggesting that seizures may be uncommon in this clinical context, especially given the absence of neurological issues in the matched cohort. Therefore, it is reasonable to conclude that the main patient likely does not have a diagnosis of seizures requiring antiepileptic medications.","The predicted outcome for the main patient regarding a diagnosis of seizures requiring antiepileptic medications is **no**. This conclusion is drawn from the main patient’s surgical history and clinical status, where a notable event history of strokes is documented but no explicit seizure diagnosis or treatment with antiepileptic medications is recorded. 

When examining similar patients, there is a clear trend indicating that the presence of significant neurological events, such as strokes, led to a diagnosis of seizures in some cases. However, the similar patients who did not have seizures or required antiepileptic medications either did not have a history of stroke or had other supportive health parameters. The XGBoost model’s predicted low probability for an adverse seizure outcome (0.164) further supports the inference that the main patient is less likely to be diagnosed with seizures requiring medication. Thus, given the patient's unique history and the data trends, it is reasonable to assert a prediction of **no** for the diagnosis of seizures requiring antiepileptic medications.","Based on the provided data for the main patient, there is a concerning history of stroke along with non-perioperative strokes noted, which may suggest some underlying neurological issues or complications. Additionally, the presence of atrial tachyarrhythmias could be linked to a higher risk for seizures due to potential embolic events. In the similar cohort, particularly those with comparable clinical characteristics, none reported seizures, with a negative correlation to the history of thrombus formation, suggesting that while the risk for seizures exists, it is not definitive. However, the XGBoost model indicates a very low probability (0.16) for the outcome of seizures being positive, leading to a more cautious conclusion. Therefore, it is reasonable to predict that the main patient likely does **not** have a diagnosis of seizures requiring antiepileptic medications, but the risk cannot be entirely dismissed without further assessment.",0,1,1,1,0
BCH-GUYCOR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: Loosening of PAB (due to patients low sats) 13 days after initial surgery
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Lateral tunnel Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 35.0
 Gadolinium unknown contrast dose: 35.0
 Patient height: 176.5
 Patient weight: 66.1
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.796777264024984
 Heart rate: 92.0
 Left ventricle end-diastolic volume: 88.0
 Left ventricle end-systolic volume: 41.0
 Left ventricular mass: 103.0
 Right ventricular end-diastolic volume: 40.6
 Right ventricular end-systolic volume: 18.0
 Right ventricle mass: 50.0
 Native aorta flow rate: 4.63
 Ascending aorta, above the Stansel flow rate: 4.63
 Right superior vena cava flow rate: 4.63
 Inferior vena cava, below the fenestration flow rate: 3.06
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.83
 Single ventricle ejection fraction 0.5412130637636081
 Single ventricle systolic volume 69.6
 Body mass index 21.218371064690352
 Mass to height volume indexed on BSA (exp = 2.7) 32.9974754607999
 Systemic ventricle end-systolic volume: 59.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 32.83656866173459
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 27.542889204311262
 Systemic ventricle end-diastolic volume: 128.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 71.57258864235708
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 60.03416189278692
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 85.15245771602359
 Systemic ventricle mass indexed on BSA (exp=1.3) 71.42478047897666
 Systemic ventricle mass to volume ratio: 2.4019816390506046
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.336827712117135
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.121313799240013
 Description of veno-venous collaterals: Multiple tortuous venous structures extend from the innominate vein into the left side of the mediastinum. The left internal jugular vein has a very small caliber and is connected via dilated anterior neck veins to the right internal jugular vein. One small 3mm in size vessel extends from the region of the innominate vein to the left upper lobe pulmonary vein consistent with a systemic to pulmonary venous collateral
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum. The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum.=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of hepatocellular carcinoma? yes
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: no
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.5239016].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? yes\n'],"Based on the provided information, I predict that the missing clinical outcome is ""no,"" the patient does not have a history of ascites (> trace). This prediction is supported by the absence of significant indicators of ascites in the patient's clinical status and history, including a lack of reports concerning pleural effusions or significant liver dysfunction at this time. Additionally, the patient's history shows that they have significant issues such as a thrombus and elevated liver fibrosis tests, but it does not suggest the presence of ascites, which would typically be a notable finding in a patient with worsening hepatic function or volume overload. The XGBoost model predicting a 52.4% probability of the risky outcome, while indicating some concern, does not provide strong enough evidence for the presence of ascites based on the overall clinical context presented.","Based on the data provided for the main patient and the information from similar patients, it is likely that the main patient does not have a history of ascites (> trace). The main patient exhibits several relevant clinical indicators, such as a history of intracardiac thrombus and some elevated markers for liver issues indicated by a positive fibrosure, but no direct mention of ascites was reported. In the cohort of similar patients, incidents of ascites were not observed, and given the overall high accuracy of the model predicting outcomes, alongside the lower prevalence of ascites in patients similar to our main patient, we conclude that it is plausible the main patient does not have significant ascites. Thus, I predict that the outcome for the main patient is ""no.""","Based on the provided data, it is predicted that the main patient does **not** have a history of ascites (> trace). The main patient has a complex surgical history with multiple interventions, but there is no documented history of complications such as pleural effusions, protein-losing enteropathy, or significant liver dysfunction that would typically contribute to the development of ascites. Moreover, similar patients who also underwent multiple cardiac surgeries and presented with veno-venous collaterals demonstrated a lack of ascites, indicating a trend that aligns with the main patient's clinical profile. Although there is a moderate probability (52.39%) of a positive occluded outcome according to the XGBoost model, the other clinical histories and MRI findings for both the main patient and the similar patients collectively suggest that the likelihood of ascites is low.","Based on the data provided, I predict that the main patient does **not** have a history of ascites (> trace). The main patient has a known history of elevated liver fibrosis but no documented ascites, which suggests that their liver condition may not yet have led to significant fluid accumulation. Additionally, similar patients who experienced ascites historically had elevated risks associated with underlying liver issues, and among the similar patients analyzed, none displayed ascites even with varying underlying conditions; this trend indicates that while there are risks, they are not universally present. The XGBoost model's predicted probability of 0.5239016 suggests uncertainty, but the combination of clinical history and supporting trends from similar patients leads to a reasonable conclusion of no current ascitic history.",0,0,0,0,1
BCH-GUYCOR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: Loosening of PAB (due to patients low sats) 13 days after initial surgery
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Lateral tunnel Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 35.0
 Gadolinium unknown contrast dose: 35.0
 Patient height: 176.5
 Patient weight: 66.1
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.796777264024984
 Heart rate: 92.0
 Left ventricle end-diastolic volume: 88.0
 Left ventricle end-systolic volume: 41.0
 Left ventricular mass: 103.0
 Right ventricular end-diastolic volume: 40.6
 Right ventricular end-systolic volume: 18.0
 Right ventricle mass: 50.0
 Native aorta flow rate: 4.63
 Ascending aorta, above the Stansel flow rate: 4.63
 Right superior vena cava flow rate: 4.63
 Inferior vena cava, below the fenestration flow rate: 3.06
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.83
 Single ventricle ejection fraction 0.5412130637636081
 Single ventricle systolic volume 69.6
 Body mass index 21.218371064690352
 Mass to height volume indexed on BSA (exp = 2.7) 32.9974754607999
 Systemic ventricle end-systolic volume: 59.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 32.83656866173459
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 27.542889204311262
 Systemic ventricle end-diastolic volume: 128.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 71.57258864235708
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 60.03416189278692
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 85.15245771602359
 Systemic ventricle mass indexed on BSA (exp=1.3) 71.42478047897666
 Systemic ventricle mass to volume ratio: 2.4019816390506046
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.336827712117135
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.121313799240013
 Description of veno-venous collaterals: Multiple tortuous venous structures extend from the innominate vein into the left side of the mediastinum. The left internal jugular vein has a very small caliber and is connected via dilated anterior neck veins to the right internal jugular vein. One small 3mm in size vessel extends from the region of the innominate vein to the left upper lobe pulmonary vein consistent with a systemic to pulmonary venous collateral
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum. The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum.=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? yes
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: no
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.03200265].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data for the main patient, it is predicted that the patient did **not** receive a heart transplant. The critical factors influencing this prediction include the patient's clinical history of five cardiac surgeries, including a successful Fontan procedure and subsequent revisions, which suggests ongoing management of their condition rather than a transition to a heart transplant. Additionally, the patient's low estimated probability (0.032) for the outcome being 'yes' from the XGBoost model further supports this conclusion, indicating a low likelihood of having undergone a transplant. Furthermore, observable complications such as intracardiac thrombus and positive liver fibrosis tests suggest significant existing challenges, which may preclude transplant candidacy.","Based on the provided data, I predict that the main patient did **not** receive a heart transplant. The patient has a history of significant complications, including an intracardiac thrombus and a positive fibrosure for elevated liver fibrosis, which typically raises the risk profile for transplant candidacy. Additionally, the similar patients exhibited a low incidence of heart transplants, and those with similar surgical histories and outcomes tended not to have undergone transplants. The XGBoost model's predicted probability (0.032) further supports this prediction, suggesting a much higher likelihood that this patient is not a transplant recipient.","Based on the provided information, I predict that the main patient did **not** receive a heart transplant. This prediction is supported by the patient's clinical and surgical history, which reveals multiple cardiac interventions (five total surgeries) including a Fontan procedure and revisions, but no indication of receiving a heart transplant. Additionally, among the similar patient cohort, only a limited number (16 out of 711) received a transplant, with the model predicting a low probability (0.032) for a heart transplant outcome for this patient. The high accuracy and AUC of the XGBoost model, coupled with the clinical realities of managing single-ventricle patients, suggest it is unlikely this particular patient has undergone transplantation given the outlined circumstances.","Based on the provided data, it is likely that the main patient did not receive a heart transplant (predicted outcome: no). The patient has a complex surgical background with multiple interventions, including a Fontan revision and evidence of atrial tachyarrhythmias and intracardiac thrombus, which are significant risk factors that complicate transplant candidacy. Additionally, the analysis of similar patients shows a low incidence of heart transplant among those with comparable surgical histories and features, with very few in that cohort having received one. Coupled with the XGBoost prediction model, which indicates only a 3.2% probability of transplant likelihood, it aligns well with the understanding that such patients often face significant barriers to receiving a cardiac transplant.",1,1,1,1,0
BCH-GUYCOR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: Loosening of PAB (due to patients low sats) 13 days after initial surgery
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Lateral tunnel Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 35.0
 Gadolinium unknown contrast dose: 35.0
 Patient height: 176.5
 Patient weight: 66.1
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.796777264024984
 Heart rate: 92.0
 Left ventricle end-diastolic volume: 88.0
 Left ventricle end-systolic volume: 41.0
 Left ventricular mass: 103.0
 Right ventricular end-diastolic volume: 40.6
 Right ventricular end-systolic volume: 18.0
 Right ventricle mass: 50.0
 Native aorta flow rate: 4.63
 Ascending aorta, above the Stansel flow rate: 4.63
 Right superior vena cava flow rate: 4.63
 Inferior vena cava, below the fenestration flow rate: 3.06
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.83
 Single ventricle ejection fraction 0.5412130637636081
 Single ventricle systolic volume 69.6
 Body mass index 21.218371064690352
 Mass to height volume indexed on BSA (exp = 2.7) 32.9974754607999
 Systemic ventricle end-systolic volume: 59.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 32.83656866173459
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 27.542889204311262
 Systemic ventricle end-diastolic volume: 128.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 71.57258864235708
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 60.03416189278692
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 85.15245771602359
 Systemic ventricle mass indexed on BSA (exp=1.3) 71.42478047897666
 Systemic ventricle mass to volume ratio: 2.4019816390506046
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.336827712117135
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.121313799240013
 Description of veno-venous collaterals: Multiple tortuous venous structures extend from the innominate vein into the left side of the mediastinum. The left internal jugular vein has a very small caliber and is connected via dilated anterior neck veins to the right internal jugular vein. One small 3mm in size vessel extends from the region of the innominate vein to the left upper lobe pulmonary vein consistent with a systemic to pulmonary venous collateral
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum. The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum.=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? yes
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: no
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.13145462].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data and the estimated probability from the XGBoost model (0.13145462) suggesting a low likelihood of the occluded outcome being 'yes', it is reasonable to predict that the patient has not died (i.e., the outcome is 'no'). Additionally, the patient's clinical history shows a range of ongoing health challenges including episodes of thrombus, arrhythmia, and a positive fibrosure, but no severe acute events like cardiac arrest or end-stage conditions such as severe protein-losing enteropathy or major organ failure that typically lead to mortality in similar patient cohorts. Considering the patient's continued management of their health conditions and the absence of imminent life-threatening issues recorded, the prediction aligns with the clinical picture presented.","Based on the analysis of the main patient's clinical history and MRI data, along with the outcomes of similar patients, it is likely that the patient has not died. The patient's history indicates multiple interventions, including a recent Fontan revision and management of veno-venous collaterals, which suggest an active approach to care that typically aims to prolong life. Furthermore, the XGBoost model predicts a low probability (approximately 13.1%) of the occluded outcome (death) being 'yes,' which aligns with the overall low mortality rates observed in well-managed single-ventricle patients. Lastly, the similar patients show a trend of surviving with persistent medical management, particularly those without severe complications or significant thrombus events. Thus, the accumulated information leads us to predict that the main patient has not died.","Based on the provided information, the predicted outcome for the main patient regarding whether they have died is **no**. The patient has undergone multiple cardiac surgeries, including a Fontan procedure and revisions, without significant predictors of early mortality such as severe ventricular dysfunction or recurrent thromboembolic events indicated in their history. An analysis of similar patients also shows that outcomes such as elevated liver fibrosis scores and the presence of veno-venous collaterals, while concerning, do not correlate strongly with mortality when managed effectively. Additionally, the XGBoost model predicts a low probability (approximately 13%) of the occluded outcome (death), further supporting the conclusion that the patient's status is likely stable, leading us to infer they are alive.","Based on the available data, I predict that the main patient has **not died**. Key indicators supporting this assessment include the patient's relatively stable clinical status, as reflected in the absence of significant cardiovascular events such as cardiac arrest or severe arrhythmias, despite a history of stroke, intracardiac thrombus, and other complications. Furthermore, similar patients with comparable surgical histories and MRI characteristics often show a lower mortality rate, particularly when they exhibit preserved ventricular function and manageable symptoms, as is the case here. The predicted probability of the occluded outcome (death) being only 13.14% aligns with the positive clinical indicators from the main patient and the outcomes of the similar cohort.",1,1,1,1,0
BCH-GUYCOR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: Loosening of PAB (due to patients low sats) 13 days after initial surgery
 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Lateral tunnel Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 35.0
 Gadolinium unknown contrast dose: 35.0
 Patient height: 176.5
 Patient weight: 66.1
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.796777264024984
 Heart rate: 92.0
 Left ventricle end-diastolic volume: 88.0
 Left ventricle end-systolic volume: 41.0
 Left ventricular mass: 103.0
 Right ventricular end-diastolic volume: 40.6
 Right ventricular end-systolic volume: 18.0
 Right ventricle mass: 50.0
 Native aorta flow rate: 4.63
 Ascending aorta, above the Stansel flow rate: 4.63
 Right superior vena cava flow rate: 4.63
 Inferior vena cava, below the fenestration flow rate: 3.06
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.83
 Single ventricle ejection fraction 0.5412130637636081
 Single ventricle systolic volume 69.6
 Body mass index 21.218371064690352
 Mass to height volume indexed on BSA (exp = 2.7) 32.9974754607999
 Systemic ventricle end-systolic volume: 59.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 32.83656866173459
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 27.542889204311262
 Systemic ventricle end-diastolic volume: 128.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 71.57258864235708
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 60.03416189278692
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 85.15245771602359
 Systemic ventricle mass indexed on BSA (exp=1.3) 71.42478047897666
 Systemic ventricle mass to volume ratio: 2.4019816390506046
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.336827712117135
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.121313799240013
 Description of veno-venous collaterals: Multiple tortuous venous structures extend from the innominate vein into the left side of the mediastinum. The left internal jugular vein has a very small caliber and is connected via dilated anterior neck veins to the right internal jugular vein. One small 3mm in size vessel extends from the region of the innominate vein to the left upper lobe pulmonary vein consistent with a systemic to pulmonary venous collateral
 Any significant metallic artifact that obscures anatomy? If yes, please describe: The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum. The left lower lobe pulmonary vein is obscured due to artifact from coils in the posterior mediastinum.=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? yes
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? yes
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: no
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00645357].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided clinical history and current status of the patient, it is reasonable to predict that the patient does **not** have a history of pacemaker placement. The patient has a complex surgical history, including five cardiac surgeries and interventions, but there is no documented indication of heart block or significant arrhythmias necessitating a pacemaker. Additionally, the absence of sustained ventricular tachycardia or critical findings from the electrophysiologic study further supports this reasoning. The predicted probability of a severe outcome related to electrical function, as indicated by the XGBoost model, is also very low at approximately 0.645%, suggesting that a significant issue that would require a pacemaker is unlikely in this case.","Based on the provided information, the most reasonable prediction for the main patient is **no**, they do not have a history of pacemaker placement. The main patient has undergone multiple cardiac surgeries with a complex surgical history but does not display any indications of arrhythmias that typically require pacing, unlike similar patients who have had pacemaker placements. The similar patients exhibited a history of arrhythmias leading to device placement, while the main patient has not documented any history of sustained ventricular tachyarrhythmias or significant sinus node dysfunction. Furthermore, the low predicted probability (0.0064) of the outcome being 'yes,' despite the high accuracy and AUC of the model, reinforces the likelihood that a pacemaker was not needed in this case.","Based on the data provided, it is likely that the main patient does **not** have a history of pacemaker placement. The patient's significant surgical history, including multiple cardiac surgeries and a history of intracardiac thrombus and arrhythmias, raises concern for complications, yet these conditions did not seem to necessitate a pacemaker placement, as indicated by their status updates which specifically state ""no"" for such history. Additionally, trends from similar patients show that while many experienced arrhythmias or other cardiac issues, the majority did not end up requiring a pacemaker. The XGBoost model prediction, showing a very low probability (0.00645) for the occluded outcome (having a pacemaker history), further supports this conclusion. Thus, it is reasonable to predict that the main patient does not have a history of pacemaker placement.","Based on the provided information, I predict that the main patient does **not** have a history of pacemaker placement. The main patient exhibits multiple cardiac surgeries, including a Fontan procedure and associated revisions, yet there is no documentation indicating the need for a pacemaker. Furthermore, similar patients, particularly those with a history of complex single or dual ventricle surgeries, mostly exhibit no pacemaker requirement unless there are recurrent arrhythmias or ventricular dysfunction. In this case, the similar cohort shows a low incidence of pacemaker placement, supporting the conclusion that the main patient likely falls within this trend. Thus, it is reasonable to conclude that the main patient does not have a history of pacemaker placement.",1,1,1,1,0
BCH-HOHMIL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Please describe additional cardiac pre-Fontan surgery: PAB placement
 Other relevant surgical or clinical history (optional): SURG (11/2000, Germany):  PAB placement.
SURG (3/2002, Germany):  DKS, fenestrated lateral tunnel, direct closure of PA bifurcation, and PAB takedown.
CATH (2/2007):  fenestration enlargement, followed ultimately by fenestration closure.
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 12.0
 Gadolinium unknown contrast dose: 12.0
 Patient height: 125.0
 Patient weight: 24.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9269822828488816
 Heart rate: 67.0
 Upper limb systolic blood pressure: 115.0
 Upper limb diastolic blood pressure: 62.0
 Upper limb mean blood pressure: 80.0
 Left ventricle end-diastolic volume: 81.1
 Left ventricle end-systolic volume: 33.12
 Left ventricular mass: 38.4
 Right ventricular end-diastolic volume: 28.46
 Right ventricular end-systolic volume: 8.4
 Right ventricle mass: 14.7
 Ascending aorta, above the Stansel flow rate: 2.63
 Inferior vena cava, below the fenestration flow rate: 0.641
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.901
 Aortic or native aortic regurgitation fraction: 2.0
 Single ventricle ejection fraction 0.6210295728368018
 Single ventricle systolic volume 68.04
 Body mass index 15.936
 Mass to height volume indexed on BSA (exp = 2.7) 29.069494916880423
 Systemic ventricle end-systolic volume: 41.519999999999996
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.79050006478782
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.82099135252458
 Systemic ventricle end-diastolic volume: 109.56
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.18996115361644
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 120.9091477018929
 Systemic ventricle mass: 53.099999999999994
 Systemic ventricle mass indexed on BSA (exp=1) 57.28264820424454
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.60054529911019
 Systemic ventricle mass to volume ratio: 0.9900039252963252
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.067985811178354
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.09255687138652
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0933895].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided clinical and MRI data, the predicted outcome for the patient regarding the diagnosis of seizures requiring antiepileptic medications is ""no."" This conclusion is supported by multiple factors: the patient does not have any history of neurological complications such as stroke or transient ischemic attacks, which are often associated with an increased risk of seizures. Furthermore, there is no mention of currently using antiepileptic medications or any relevant history of seizures, suggesting a lack of neurological issues. The low predicted probability of 0.0934 from the XGBoost model further corroborates the likelihood of the patient not suffering from this condition.","Based on the available data, I predict that the main patient does not have a diagnosis of seizures requiring antiepileptic medications (no). This conclusion is drawn from the absence of any recorded history of seizures in both the main patient's data and in the similar patients, none of whom reported any seizure-related conditions. Furthermore, the XGBoost model estimates a low predicted probability (approximately 9.34%) for the occluded outcome being 'yes', suggesting that the likelihood of seizure diagnosis is quite low among this cohort. Combined with the fact that similar patients with comparable clinical profiles also did not have a history of seizures, it indicates a trend where seizure diagnoses are uncommon in this patient population.","Based on the data provided, I predict that the main patient does not have a diagnosis of seizures requiring antiepileptic medications. The main patient exhibits a history free from significant neurological issues such as stroke or history of seizures, which is a positive indicator. Furthermore, when analyzing similar patients, none of the individuals with comparable surgical histories and MRI findings exhibited any history of seizures, thus reinforcing the trend that seizure occurrences are relatively rare among this cohort. Finally, the estimated probability of 9.34% from the XGBoost model suggests a low likelihood of such a diagnosis, adding further confidence to the prediction.","Based on the data provided for the main patient, there is no documented history of seizures or antiepileptic medications, which suggests a low likelihood of this diagnosis. Additionally, the similar patient cohort also exhibited very low overall seizure rates, with none of the patients reporting this diagnosis, and the majority demonstrating no significant neurological complications. The predicted probability of the occluded outcome being 'yes' is low (0.093), indicating that seizures are relatively uncommon in this population. Therefore, it is reasonable to conclude that the main patient likely does not have a diagnosis of seizures requiring antiepileptic medications.",1,1,1,1,0
BCH-HOHMIL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Please describe additional cardiac pre-Fontan surgery: PAB placement
 Other relevant surgical or clinical history (optional): SURG (11/2000, Germany):  PAB placement.
SURG (3/2002, Germany):  DKS, fenestrated lateral tunnel, direct closure of PA bifurcation, and PAB takedown.
CATH (2/2007):  fenestration enlargement, followed ultimately by fenestration closure.
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 12.0
 Gadolinium unknown contrast dose: 12.0
 Patient height: 125.0
 Patient weight: 24.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9269822828488816
 Heart rate: 67.0
 Upper limb systolic blood pressure: 115.0
 Upper limb diastolic blood pressure: 62.0
 Upper limb mean blood pressure: 80.0
 Left ventricle end-diastolic volume: 81.1
 Left ventricle end-systolic volume: 33.12
 Left ventricular mass: 38.4
 Right ventricular end-diastolic volume: 28.46
 Right ventricular end-systolic volume: 8.4
 Right ventricle mass: 14.7
 Ascending aorta, above the Stansel flow rate: 2.63
 Inferior vena cava, below the fenestration flow rate: 0.641
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.901
 Aortic or native aortic regurgitation fraction: 2.0
 Single ventricle ejection fraction 0.6210295728368018
 Single ventricle systolic volume 68.04
 Body mass index 15.936
 Mass to height volume indexed on BSA (exp = 2.7) 29.069494916880423
 Systemic ventricle end-systolic volume: 41.519999999999996
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.79050006478782
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.82099135252458
 Systemic ventricle end-diastolic volume: 109.56
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.18996115361644
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 120.9091477018929
 Systemic ventricle mass: 53.099999999999994
 Systemic ventricle mass indexed on BSA (exp=1) 57.28264820424454
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.60054529911019
 Systemic ventricle mass to volume ratio: 0.9900039252963252
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.067985811178354
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.09255687138652
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0526533].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided data, I predict that the patient does **not** have a history of ascites (>trace). This prediction is supported by the absence of documented complications such as protein-losing enteropathy, pleural effusions, renal dysfunction, and liver fibrosis, which could all contribute to fluid accumulation and ascites. Additionally, the patient's single ventricle ejection fraction (approximately 62%) indicates reasonable ventricular function, and various cardiac volumes suggest the patient is managing circulatory dynamics effectively post-Fontan. The XGBoost model's estimated probability of 0.0526533 further supports the likelihood of a negative outcome for ascites, aligning with the low incidence of this condition in other similar cases.","Based on the information provided, I predict that the main patient does **not** have a history of ascites (> trace). The main patient presents with a relatively stable clinical profile and no reported complications such as pleural effusions or fluid-related issues that often accompany ascites in similar patient profiles. 

In contrast, the similar patients were noted to have varying outcomes, with one noted to have experienced pleural effusions and ascites, correlating with other complications commonly found in patients who have undergone similar surgeries. Additionally, the estimated probability from the XGBoost model (0.0526533) suggests a low likelihood of the occluded outcome, further supporting the assumption that the main patient likely does not have significant fluid retention issues such as ascites.","Based on the data provided, I predict that the main patient does **not** have a history of ascites (> trace). The main patient's surgical history and clinical metrics do not indicate any previous complications that would typically be associated with ascites, such as significant cardiac or hepatic dysfunction. Furthermore, in the cohort of similar patients, those who displayed certain characteristics—including a history of Fenestration interventions or variations in systemic flow rates—may be more prone to developing ascites. Given that our main patient shows a single-ventricle function with stable parameters, as evident in the echocardiographic findings, the likelihood of developing ascites appears diminished relative to the observed trends in the similar patient cohort. The XGBoost model probability of the occluded outcome being positive (0.0526533) further supports that ascites is an uncommon issue for this patient.","Based on the analysis of the main patient’s clinical data and the trends observed in similar patients, it is predicted that the main patient does **not** have a history of ascites (> trace). The main patient has undergone several surgeries including pulmonary artery banding and a lateral tunnel Fontan, but there are no indications of complications such as pleural effusions or ascites in their status updates. Moreover, the similar patients with successful Fontan procedures that had histories of ascites typically showed additional complications or conditions, suggesting a correlation between complicated surgical histories and the development of ascites. Overall, the predicted probability of the occluded outcome being 'yes' (0.0526533) further supports the idea that the likelihood of ascites in this patient is low given the absence of associated risk factors evident in both the main patient and the similar cohort.",1,1,1,1,0
BCH-HOHMIL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Please describe additional cardiac pre-Fontan surgery: PAB placement
 Other relevant surgical or clinical history (optional): SURG (11/2000, Germany):  PAB placement.
SURG (3/2002, Germany):  DKS, fenestrated lateral tunnel, direct closure of PA bifurcation, and PAB takedown.
CATH (2/2007):  fenestration enlargement, followed ultimately by fenestration closure.
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 12.0
 Gadolinium unknown contrast dose: 12.0
 Patient height: 125.0
 Patient weight: 24.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9269822828488816
 Heart rate: 67.0
 Upper limb systolic blood pressure: 115.0
 Upper limb diastolic blood pressure: 62.0
 Upper limb mean blood pressure: 80.0
 Left ventricle end-diastolic volume: 81.1
 Left ventricle end-systolic volume: 33.12
 Left ventricular mass: 38.4
 Right ventricular end-diastolic volume: 28.46
 Right ventricular end-systolic volume: 8.4
 Right ventricle mass: 14.7
 Ascending aorta, above the Stansel flow rate: 2.63
 Inferior vena cava, below the fenestration flow rate: 0.641
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.901
 Aortic or native aortic regurgitation fraction: 2.0
 Single ventricle ejection fraction 0.6210295728368018
 Single ventricle systolic volume 68.04
 Body mass index 15.936
 Mass to height volume indexed on BSA (exp = 2.7) 29.069494916880423
 Systemic ventricle end-systolic volume: 41.519999999999996
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.79050006478782
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.82099135252458
 Systemic ventricle end-diastolic volume: 109.56
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.18996115361644
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 120.9091477018929
 Systemic ventricle mass: 53.099999999999994
 Systemic ventricle mass indexed on BSA (exp=1) 57.28264820424454
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.60054529911019
 Systemic ventricle mass to volume ratio: 0.9900039252963252
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.067985811178354
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.09255687138652
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00583627].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided information, it is likely that the patient did not receive a heart transplant. The patient has undergone two surgeries, including a lateral tunnel Fontan, and their current cardiac status, as indicated by MRI data, suggests stable cardiac function (single ventricle ejection fraction of approximately 62% and absence of significant valve regurgitation). Furthermore, the predicted probability of the occluded outcome (heart transplant) being 'yes' is extremely low at 0.00583627, indicating that the model's findings also support the conclusion that a transplantation is unlikely. Thus, the overall evidence suggests the patient remains with their current cardiac anatomy post-Fontan, which aligns with a ""no"" response regarding heart transplantation.","Based on the provided data, it is predicted that the main patient did **not** receive a heart transplant. The main patient's surgical history includes multiple procedures often associated with single-ventricle pathologies, such as pulmonary artery banding and modifications to the Fontan pathway, which indicates a course of management without the need for a transplant. Furthermore, analysis of the similar patients reveals that despite various interventions, none necessitated a heart transplant, as evidenced by their documented outcomes, including ongoing management and successful interventions for complications without transplantation. The XGBoost model supports this prediction with a very low probability of a transplant occurring (0.0058), aligning with the historical data trends observed in this cohort. Thus, the combination of these factors strongly suggests that the patient did not receive a heart transplant.","Based on the provided data, I predict that the main patient did **not** receive a heart transplant. The main patient has a surgical history indicative of managed congenital heart disease, specifically tricuspid atresia, and has undergone significant interventions but shows no acute complications or indications leading to transplant consideration, such as severe ventricular dysfunction or other end-stage heart disease signs. Comparing to the similar patients, there was a notable trend: those with a history of receiving a heart transplant frequently exhibited higher severity in complications, such as significant renal dysfunction or cardiac arrhythmias, which are absent in the main patient’s profile. Additionally, the XGBoost model's predicted probability of the occluded outcome being ""yes"" was very low (0.0058), supporting the conclusion that it is unlikely the patient received a transplant.","Based on the provided data, it is predicted that the main patient **did not receive a heart transplant**. This conclusion is supported by the fact that the patient has a complex surgical history, including a lateral tunnel Fontan and previous surgical interventions such as pulmonary artery banding and a Stansel/Damus procedure, indicative of a serious but well-managed single-ventricle condition. Notably, the similar cohort of patients, while facing similar challenges, also displayed a low incidence of heart transplant (as denoted by the low support count for the 'yes' outcome in the classification report). The XGBoost model probability of 0.0058 for transplant suggests that the likelihood of this patient receiving a transplant is extremely low, aligning with the trend observed in the similar patients’ outcomes.",1,1,1,1,0
BCH-HOHMIL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Please describe additional cardiac pre-Fontan surgery: PAB placement
 Other relevant surgical or clinical history (optional): SURG (11/2000, Germany):  PAB placement.
SURG (3/2002, Germany):  DKS, fenestrated lateral tunnel, direct closure of PA bifurcation, and PAB takedown.
CATH (2/2007):  fenestration enlargement, followed ultimately by fenestration closure.
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 12.0
 Gadolinium unknown contrast dose: 12.0
 Patient height: 125.0
 Patient weight: 24.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9269822828488816
 Heart rate: 67.0
 Upper limb systolic blood pressure: 115.0
 Upper limb diastolic blood pressure: 62.0
 Upper limb mean blood pressure: 80.0
 Left ventricle end-diastolic volume: 81.1
 Left ventricle end-systolic volume: 33.12
 Left ventricular mass: 38.4
 Right ventricular end-diastolic volume: 28.46
 Right ventricular end-systolic volume: 8.4
 Right ventricle mass: 14.7
 Ascending aorta, above the Stansel flow rate: 2.63
 Inferior vena cava, below the fenestration flow rate: 0.641
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.901
 Aortic or native aortic regurgitation fraction: 2.0
 Single ventricle ejection fraction 0.6210295728368018
 Single ventricle systolic volume 68.04
 Body mass index 15.936
 Mass to height volume indexed on BSA (exp = 2.7) 29.069494916880423
 Systemic ventricle end-systolic volume: 41.519999999999996
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.79050006478782
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.82099135252458
 Systemic ventricle end-diastolic volume: 109.56
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.18996115361644
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 120.9091477018929
 Systemic ventricle mass: 53.099999999999994
 Systemic ventricle mass indexed on BSA (exp=1) 57.28264820424454
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.60054529911019
 Systemic ventricle mass to volume ratio: 0.9900039252963252
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.067985811178354
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.09255687138652
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0152536].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided information, the predicted outcome for the patient regarding whether they have died is **""no.""** The probabilities generated by the XGBoost model indicate a low likelihood (0.015) of the occluded outcome (death) occurring. Additionally, the patient's clinical history shows no significant complications, including no history of stroke, transplant, or cardiac arrest—all of which could indicate a higher risk of mortality. Furthermore, the patient's current NYHA class and absence of severe outcomes, combined with a relatively high single-ventricle ejection fraction (0.62), suggest a stable clinical status, further indicating that death is unlikely.","Based on the data for the main patient and the outcomes of similar patients, it is predicted that the main patient has not died. The main patient exhibits a relatively stable clinical history, including no significant complications post-Fontan and an absence of severe conditions such as protein-losing enteropathy or significant thrombus history. Additionally, similar patients with comparable surgical histories and MRI findings tend to demonstrate a low incidence of mortality, as evidenced by their ongoing management without severe complications. The XGBoost model's predicted probability of the occluded outcome being 'yes' (indicating death) is extremely low at 0.015, further supporting the conclusion that this patient is likely alive.","Based on the data provided for the main patient and the similar patients, it is predicted that the outcome ""Has the patient died?"" is ""no"". The main patient has undergone several surgeries, including a lateral tunnel Fontan, and has demonstrated stable cardiovascular function with several indicators of good health, such as normal ventricular volumes and ejection fraction. The similar patients, who share a comparable surgical history and MRI findings, have also shown no instances of mortality, despite having undergone similar procedures and having various risk factors. Additionally, the XGBoost model predicts a very low probability (0.0152536) of the occluded outcome being 'yes', suggesting that mortality is unlikely. Together, these data points strongly indicate that the patient is alive.","Based on the provided data, it is predicted that the main patient has not died. The patient has undergone multiple interventions related to their cardiac anatomy, specifically a Fontan procedure and subsequent fenestration interventions, which suggest that they have a plan for managing potential complications commonly associated with single-ventricle physiology. Additionally, the patient's MRI reports indicate a reasonably stable systemic ventricle function, including a single ventricle ejection fraction of 0.621 and overall favorable hemodynamics, which align with the patterns of other similar patients who have also maintained life status post-Fontan. 

Furthermore, similar patients with analogous surgical histories and cardiac diagnoses also demonstrate a high survival rate, as supported by the validation set showing that the model accurately predicts death with an AUC of 0.87. The low estimated probability (0.0152536) of the occluded outcome—indicative of the patient dying—reinforces the conclusion that the patient has likely not died, especially in relation to the stable status and history of medical management observed in similar cases.",1,1,1,1,0
BCH-HOHMIL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Please describe additional cardiac pre-Fontan surgery: PAB placement
 Other relevant surgical or clinical history (optional): SURG (11/2000, Germany):  PAB placement.
SURG (3/2002, Germany):  DKS, fenestrated lateral tunnel, direct closure of PA bifurcation, and PAB takedown.
CATH (2/2007):  fenestration enlargement, followed ultimately by fenestration closure.
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 12.0
 Gadolinium unknown contrast dose: 12.0
 Patient height: 125.0
 Patient weight: 24.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9269822828488816
 Heart rate: 67.0
 Upper limb systolic blood pressure: 115.0
 Upper limb diastolic blood pressure: 62.0
 Upper limb mean blood pressure: 80.0
 Left ventricle end-diastolic volume: 81.1
 Left ventricle end-systolic volume: 33.12
 Left ventricular mass: 38.4
 Right ventricular end-diastolic volume: 28.46
 Right ventricular end-systolic volume: 8.4
 Right ventricle mass: 14.7
 Ascending aorta, above the Stansel flow rate: 2.63
 Inferior vena cava, below the fenestration flow rate: 0.641
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.901
 Aortic or native aortic regurgitation fraction: 2.0
 Single ventricle ejection fraction 0.6210295728368018
 Single ventricle systolic volume 68.04
 Body mass index 15.936
 Mass to height volume indexed on BSA (exp = 2.7) 29.069494916880423
 Systemic ventricle end-systolic volume: 41.519999999999996
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.79050006478782
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 45.82099135252458
 Systemic ventricle end-diastolic volume: 109.56
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 118.18996115361644
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 120.9091477018929
 Systemic ventricle mass: 53.099999999999994
 Systemic ventricle mass indexed on BSA (exp=1) 57.28264820424454
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.60054529911019
 Systemic ventricle mass to volume ratio: 0.9900039252963252
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.067985811178354
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.09255687138652
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00113855].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided information, it can be predicted that the patient **does not have a history of pacemaker placement**. This conclusion stems from the absence of any intervention related to arrhythmias in the patient's surgical history or status updates. Moreover, key indicators from the MRI report suggest a well-maintained heart function—such as a single ventricle ejection fraction of approximately 62.1% and the absence of any recorded arrhythmias or cardiac arrest—further supporting the prediction that they have likely not required pacing support. Additionally, the very low predicted probability (0.00113855) from the XGBoost model indicates a strong likelihood that the patient does not have this history.","**Prediction**: No, the patient does not have a history of pacemaker placement.

**Reasoning**: The main patient has undergone multiple cardiac surgeries and interventions, but there is no recorded history of complications that would typically necessitate pacemaker placement, such as sustained arrhythmias or significant conduction abnormalities. Furthermore, the profile of similar patients indicates that while some had a pacemaker or defibrillator placement, many others did not, particularly those with similar surgical histories and outcomes; hence, the absence of indications for such interventions in the main patient’s records reinforces the prediction of ""no."" Additionally, the XGBoost model's prediction probability for the occluded outcome being 'yes' (0.00113855) suggests a very low likelihood, aligning with the absence of pacemaker placement in other comparable cases.","Based on the information provided, the main patient has undergone multiple cardiac surgeries, including the placement and takedown of a pulmonary artery band, as well as a Stansel procedure, but there is no mention of any history of pacemaker placement in the surgical or clinical history. In examining the similar patients, we note that outcomes related to the necessity of pacemaker placement appear to correlate with complex surgical histories and certain cardiovascular complications. 

Considering the overall stability of the patient (with no records of significant complications like thrombus, arrhythmias, or heart failure requiring a pacemaker), combined with the predicted probability of the occluded outcome being only 0.00113855 (indicating a very low likelihood of complications such as needing a pacemaker), it is reasonable to conclude that the main patient does not have a history of pacemaker placement. Therefore, the prediction for the missing clinical outcome is ""no.""","Based on the provided data for the main patient, alongside the insights from similar patients, it is reasonable to predict that the main patient does **not** have a history of pacemaker placement. The main patient has undergone multiple surgeries and interventions typical of a Fontan patient with a tricuspid atresia diagnosis but does not report any history suggestive of rhythm disturbances, which often lead to pacemaker placement. Furthermore, the similar patients, who share comparable surgical histories and outcomes, consistently show no history of pacemaker placement, reinforcing the likelihood that the main patient has also not required this intervention. Lastly, the low predicted probability (0.00113855) from the XGBoost model for the occluded outcome further suggests that complications typically requiring a pacemaker are unlikely in this specific case.",1,1,1,1,0
BCH-KATNAT-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Other relevant surgical or clinical history (optional): SURG (6/1991, CHB)- bilateral bidirectional Glenn + lat tunnel fontan
SURG (2/1992)-  subaortic stenosis resection (enlargement of BVF)
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 20.0
 Gadolinium unknown contrast dose: 20.0
 Patient height: 162.0
 Patient weight: 44.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.39534273920476
 Left ventricle end-diastolic volume: 166.6
 Left ventricle end-systolic volume: 56.0
 Left ventricular mass: 90.6
 Native aorta flow rate: 5.47
 Ascending aorta, above the Stansel flow rate: 5.47
 Single ventricle ejection fraction 0.6638655462184874
 Single ventricle systolic volume 110.6
 Body mass index 16.76573693034598
 Mass to height volume indexed on BSA (exp = 2.7) 24.628482788410505
 Systemic ventricle end-systolic volume: 56.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 40.1335087262616
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 36.31640587200917
 Systemic ventricle end-diastolic volume: 166.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 119.39718846062826
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 108.04130746922729
 Systemic ventricle mass: 90.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.9302837607018
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.754756642929124
 Systemic ventricle mass to volume ratio: 0.5438175270108043
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.38973759760325216
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.35266960770065503
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01033198].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the information provided, it is reasonable to predict that the patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The longitudinal data indicates no history of significant neurological events such as stroke or transient ischemic attacks, which could be interconnected with seizure activity. Additionally, although the patient has a history of atrial arrhythmias and non-sustained ventricular tachyarrhythmias, there is no direct mention of any seizure activity or the use of antiepileptic medications in the patient's medication history. Furthermore, the XGBoost model output suggests that the probability of a positive outcome (having seizures) is very low (0.01033), reinforcing the conclusion that the patient likely does not have this diagnosis.","Based on the information provided, it is predicted that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. This conclusion is supported by the patient's medical history, which does not mention any prior neurological issues or seizures—significantly, there are no recorded diagnoses or incidents related to seizures throughout the patient's journey. 

Additionally, evaluating the profile of similar patients, particularly the one with documented surgeries and treatment histories, reveals no instances of significant incidentals such as seizures or the need for antiepileptic drugs, suggesting a trend that indicates a relatively low prevalence of this diagnosis among similar patients. Finally, the XGBoost model's predictions, alongside the high accuracy and calibration observed (with a predicted probability of the occluded outcome being 'yes' at only 0.0103), further supports the assertion that it is unlikely for the main patient to be diagnosed with seizures requiring medication.","Based on the provided data, the prediction for the main patient regarding the diagnosis of seizures requiring antiepileptic medications is ""no."" The main patient has a documented history of atrial tachyarrhythmias, as well as non-sustained ventricular tachyarrhythmias, but notably lacks a history of seizures or any other neurological complications. In contrast, the similar patients exhibit a broader range of cardiac issues but also show a predominance of negative outcomes related to seizure history, suggesting that such complications are not common among patients with similar surgical and MRI profiles. Furthermore, the low predicted probability of 0.0103 for the occluded outcome from the XGBoost model aligns with a low likelihood of seizures in this population, thus reinforcing the conclusion that this patient likely does not have a diagnosis of seizures requiring antiepileptic medications.","Based on the information provided, the prediction for the main patient regarding the diagnosis of seizures requiring antiepileptic medications is **no**. The main patient has a history of atrial tachyarrhythmias and non-sustained ventricular tachyarrhythmias, but there is no indication of previous seizures, stroke or other related complications that elevate seizure risk. Furthermore, looking at the similar patients, particularly those with a common diagnosis of tricuspid atresia, none of them were noted to have a diagnosis of seizures, and only a minority displayed significant arrhythmic complications. Additionally, the estimated probability of the occluded outcome being 'yes' is very low (0.0103), and the model accuracy indicates that the vast majority of similar cases did not have seizures leading to a reliable conclusion.",1,1,1,1,0
BCH-KATNAT-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Other relevant surgical or clinical history (optional): SURG (6/1991, CHB)- bilateral bidirectional Glenn + lat tunnel fontan
SURG (2/1992)-  subaortic stenosis resection (enlargement of BVF)
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 20.0
 Gadolinium unknown contrast dose: 20.0
 Patient height: 162.0
 Patient weight: 44.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.39534273920476
 Left ventricle end-diastolic volume: 166.6
 Left ventricle end-systolic volume: 56.0
 Left ventricular mass: 90.6
 Native aorta flow rate: 5.47
 Ascending aorta, above the Stansel flow rate: 5.47
 Single ventricle ejection fraction 0.6638655462184874
 Single ventricle systolic volume 110.6
 Body mass index 16.76573693034598
 Mass to height volume indexed on BSA (exp = 2.7) 24.628482788410505
 Systemic ventricle end-systolic volume: 56.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 40.1335087262616
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 36.31640587200917
 Systemic ventricle end-diastolic volume: 166.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 119.39718846062826
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 108.04130746922729
 Systemic ventricle mass: 90.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.9302837607018
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.754756642929124
 Systemic ventricle mass to volume ratio: 0.5438175270108043
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.38973759760325216
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.35266960770065503
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.02826067].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided information, it is unlikely that the patient has a history of ascites (which would suggest significant fluid retention and liver dysfunction). The MRI report shows no significant heart failure markers, such as pleural effusions, liver fibrosis, or other complications commonly associated with ascites, and the patient has normal function in various cardiovascular metrics, including a single ventricle ejection fraction of approximately 66%. Additionally, the patient's history does not mention symptoms or diagnoses typically associated with ascites, such as protein-losing enteropathy or significant liver complications. Given the low predicted probability of the occluded outcome being 'yes' (0.028), this reinforces the conclusion that the patient likely does not have a history of ascites.","**Prediction:** No, the patient does not have a history of ascites (> trace).

**Reasoning:** The main patient has a known history of atrial tachyarrhythmias but no indications of fluid accumulation or related conditions such as pleural effusions or protein-losing enteropathy, which can sometimes lead to ascites. Additionally, similar patients who have undergone comparable surgical procedures and have similar morphologies also do not appear to report a history of ascites, despite having other complications. Furthermore, the XGBoost model predicts a very low probability (2.83%) for the outcome being 'yes', suggesting that ascites is rare among his matched peers and likely not indicative of the main patient's condition either.","Based on the provided data, I predict that the main patient does **not** have a history of ascites (> trace). The main patient shows a robust clinical status with no reported complications such as protein-losing enteropathy or significant pleural effusions, which are often associated with ascites. The similar patients, particularly those with tricuspid atresia who have undergone Fontan procedures, showed varied outcomes, but trends indicate that the patients with a history of ascites often had concurrent complications such as significant liver fibrosis or related conditions, which are absent in the main patient’s profile. Furthermore, the XGBoost model's predicted probability of 0.028 suggests a low likelihood of the patient developing this outcome, aligning with the clinical histories provided.","Based on the information provided, the predicted clinical outcome for the main patient regarding a history of ascites (> trace) is **no**. The main patient does not have any documented instances of pleural effusions or ascites following surgery, indicating stable fluid levels post-Fontan. Additionally, the similar patient cohort data reveals a low occurrence of ascites in patients with comparable surgical histories and outcomes. The XGBoost model's estimated probability of the occluded outcome being 'yes' is quite low at 2.83%, further suggesting that ascites is not a prominent concern in this specific case. Therefore, considering the main patient's surgical history, clinical observations, and trends from similar patients, it is reasonable to conclude that the main patient does not have a history of ascites.",1,1,1,1,0
BCH-KATNAT-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Other relevant surgical or clinical history (optional): SURG (6/1991, CHB)- bilateral bidirectional Glenn + lat tunnel fontan
SURG (2/1992)-  subaortic stenosis resection (enlargement of BVF)
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 20.0
 Gadolinium unknown contrast dose: 20.0
 Patient height: 162.0
 Patient weight: 44.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.39534273920476
 Left ventricle end-diastolic volume: 166.6
 Left ventricle end-systolic volume: 56.0
 Left ventricular mass: 90.6
 Native aorta flow rate: 5.47
 Ascending aorta, above the Stansel flow rate: 5.47
 Single ventricle ejection fraction 0.6638655462184874
 Single ventricle systolic volume 110.6
 Body mass index 16.76573693034598
 Mass to height volume indexed on BSA (exp = 2.7) 24.628482788410505
 Systemic ventricle end-systolic volume: 56.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 40.1335087262616
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 36.31640587200917
 Systemic ventricle end-diastolic volume: 166.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 119.39718846062826
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 108.04130746922729
 Systemic ventricle mass: 90.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.9302837607018
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.754756642929124
 Systemic ventricle mass to volume ratio: 0.5438175270108043
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.38973759760325216
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.35266960770065503
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01826304].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data, it is predicted that the missing clinical outcome — whether the patient has died — is ""no."" The patient's clinical history reveals no significant complications such as protein-losing enteropathy, plastic bronchitis, or thromboembolic events, which are commonly associated with poorer outcomes in Fontan patients. Additionally, while the patient has experienced some arrhythmias, there have been no indications of life-threatening complications that would suggest a high risk for mortality. The low predicted probability (1.83%) from the XGBoost model further supports this conclusion, indicating a very slim chance of a fatal outcome for this patient.","Based on the provided information, I predict that the main patient has **not died**. The main patient’s surgical history indicates a prior successful lateral tunnel Fontan procedure and a lack of significant complications, such as protein-losing enteropathy, heart transplant, or major thromboembolic events, which are known risk factors for mortality in single-ventricle patients. Additionally, the model's predicted probability of the occluded outcome being 'yes' is very low (0.018), suggesting that the likelihood of death is minimal. Furthermore, similar patients show a trend towards survival, even those with more complex surgical histories, suggesting that the main patient has a favorable prognosis.","Based on the available data and information, I would predict that the main patient has **not died**. The main patient has a cardiac history of tricuspid atresia, underwent a bilateral bidirectional Glenn and lateral tunnel Fontan, and currently exhibits no significant complications, as reflected in their MRI report and surgical history. Additionally, similar patients with comparable profiles generally show low mortality, and given the XGBoost model predicts a very low probability (approximately 1.83%) for a negative outcome like death, it further corroborates the idea that the patient is likely still alive. Furthermore, there have been no reported serious complications (e.g., stroke or cardiac arrest) that would significantly elevate mortality risk in this cohort.","Based on the information provided, I predict that the missing clinical outcome for the main patient is ""no,"" meaning the patient has not died. The main patient has a history of successful surgeries and currently does not exhibit severe complications, such as heart failure, significant arrhythmias, or major adverse events that often contribute to mortality in this cohort. Additionally, the similar patients included in the analysis show that the majority have not experienced mortality, and the model estimates a low probability (1.83%) of the occluded outcome being associated with death. Furthermore, with a strong accuracy of 0.96 in the validation set and an ROC AUC of 0.87, the predictive model supports the conclusion that this patient is likely stable and alive.",1,1,1,1,0
BCH-KATNAT-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Other relevant surgical or clinical history (optional): SURG (6/1991, CHB)- bilateral bidirectional Glenn + lat tunnel fontan
SURG (2/1992)-  subaortic stenosis resection (enlargement of BVF)
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 20.0
 Gadolinium unknown contrast dose: 20.0
 Patient height: 162.0
 Patient weight: 44.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.39534273920476
 Left ventricle end-diastolic volume: 166.6
 Left ventricle end-systolic volume: 56.0
 Left ventricular mass: 90.6
 Native aorta flow rate: 5.47
 Ascending aorta, above the Stansel flow rate: 5.47
 Single ventricle ejection fraction 0.6638655462184874
 Single ventricle systolic volume 110.6
 Body mass index 16.76573693034598
 Mass to height volume indexed on BSA (exp = 2.7) 24.628482788410505
 Systemic ventricle end-systolic volume: 56.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 40.1335087262616
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 36.31640587200917
 Systemic ventricle end-diastolic volume: 166.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 119.39718846062826
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 108.04130746922729
 Systemic ventricle mass: 90.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.9302837607018
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.754756642929124
 Systemic ventricle mass to volume ratio: 0.5438175270108043
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.38973759760325216
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.35266960770065503
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00105299].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided data, it is likely that the patient does not have a history of pacemaker placement (predicted outcome: no). The patient’s MRI findings indicate a relatively preserved single-ventricle ejection fraction (0.66) and no substantial structural heart issues or significant arrhythmias that would typically lead to pacemaker placement, since the history indicates only non-sustained ventricular tachyarrhythmias and some atrial tachyarrhythmias, which were addressed without a defibrillator or further invasive measures. Additionally, the absence of a history of severe bradycardia or conduction abnormalities further supports the absence of a pacemaker. The low predicted probability (0.001) of a positive outcome from the XGBoost model reinforces the assertion that the patient is unlikely to have undergone pacemaker placement.","Based on the provided data, it is reasonable to predict that the main patient does not have a history of pacemaker placement. The patient underwent two surgeries, including a Fontan procedure, but does not seem to have any substantial arrhythmias or other complications that would typically necessitate a pacemaker; while there is a documented history of atrial tachyarrhythmias, there is no mention of sustained ventricular tachycardia or other severe electrical disturbances. Additionally, examining similar patients, it appears that many have varying conditions and interventions; however, the accuracy of the model predicting a low probability of 'yes' (0.00105299) for having a pacemaker placement aligns well with the clinical context that pacemakers are often employed only when necessary, especially in patients without more severe arrhythmias. Therefore, it is anticipated that the outcome would be 'no' for the main patient regarding a history of pacemaker placement.","Based on the data provided for the main patient and the similar patients, I predict that the main patient does **not** have a history of pacemaker placement. The main patient has a history of atrial tachyarrhythmias and non-sustained ventricular tachyarrhythmias but has not undergone significant interventions such as pacemaker placement, as indicated in their clinical history. Furthermore, the similar patients with comparable conditions and histories, such as those diagnosed with tricuspid atresia or who underwent Fontan surgery, generally have a low rate of pacemaker placements, especially given the relatively better cardiac function indicated by the main patient's MRI results (ejection fraction of 0.66). Additionally, the model's predicted probability of the occluded outcome being 'yes' (indicative of a history of pacemaker placement) is extremely low (0.00105299), reinforcing the likelihood that the patient does not have such a history.","Based on the available data, I predict that the main patient does **not** have a history of pacemaker placement. Notably, the main patient has been documented with atrial tachyarrhythmias and has undergone a post-Fontan electrophysiologic study without requiring a pacemaker placement, which suggests that their arrhythmias may have been managed without the need for such intervention. Additionally, among the similar patients, those with comparable surgical histories (notably Fontan procedures and the presence of left ventricular dominance) did not report histories of pacemaker placement, supporting the idea that this patient might not exhibit severe arrhythmias necessitating a pacemaker. Furthermore, the XGBoost model indicates a very low probability (0.00105299) of the occluded outcome being 'yes', which aligns with the main patient’s observable characteristics and historical management trends.",1,1,1,1,0
BCH-KATNAT-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Other relevant surgical or clinical history (optional): SURG (6/1991, CHB)- bilateral bidirectional Glenn + lat tunnel fontan
SURG (2/1992)-  subaortic stenosis resection (enlargement of BVF)
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 20.0
 Gadolinium unknown contrast dose: 20.0
 Patient height: 162.0
 Patient weight: 44.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.39534273920476
 Left ventricle end-diastolic volume: 166.6
 Left ventricle end-systolic volume: 56.0
 Left ventricular mass: 90.6
 Native aorta flow rate: 5.47
 Ascending aorta, above the Stansel flow rate: 5.47
 Single ventricle ejection fraction 0.6638655462184874
 Single ventricle systolic volume 110.6
 Body mass index 16.76573693034598
 Mass to height volume indexed on BSA (exp = 2.7) 24.628482788410505
 Systemic ventricle end-systolic volume: 56.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 40.1335087262616
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 36.31640587200917
 Systemic ventricle end-diastolic volume: 166.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 119.39718846062826
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 108.04130746922729
 Systemic ventricle mass: 90.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.9302837607018
 Systemic ventricle mass indexed on BSA (exp=1.3) 58.754756642929124
 Systemic ventricle mass to volume ratio: 0.5438175270108043
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.38973759760325216
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.35266960770065503
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Unable to determine
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00545165].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data and the low estimated probability (0.00545165) from the XGBoost model, it is highly probable that the main patient did not receive a heart transplant. The patient has a history of tricuspid atresia and a complex surgical history that includes a bilateral bidirectional Glenn procedure and a lateral tunnel Fontan, but there are no indications of complications such as severe heart failure or deteriorating cardiac function that typically lead to transplantation. Additionally, the absence of significant findings such as severe arrhythmias or cardiac dysfunction in both the MRI report and clinical status further supports that the patient is likely managing well under their current treatment without necessitating a transplant. Thus, the predicted outcome is ""no,"" the patient did not receive a heart transplant.","Based on the provided data, I predict that the main patient did **not** receive a heart transplant. The main patient has undergone two significant cardiac surgeries, including a Fontan procedure, and exhibits a profile of complications wherein heart transplant is typically considered when there is severe failure of the Fontan physiology or life-threatening complications. However, they have a stable condition reflected by the absence of significant functional declines and no history of protein-losing enteropathy or thrombus, which are often indicators for transplant consideration. 

Moreover, the XGBoost model estimates a low probability (0.00545) of the occluded outcome being 'yes', further supporting the notion that transplant is unlikely. The similar patients, while having some variations in surgical history and complications, also show trends that indicate that most remained stable post-Fontan without undergoing transplantation, aligning with the main patient's clinical state. Thus, the aggregated data leads to the conclusion that heart transplant is not required for this patient.","Based on the provided data, the prediction of whether the main patient received a heart transplant is ""no."" The main patient has undergone two cardiac surgeries, including a lateral tunnel Fontan, and their clinical status shows no significant complications such as protein-losing enteropathy or significant arrhythmias that often predict further intervention or transplant candidacy. 

When examining the similar patients, most associated with lower severity clinical histories and without significant escalations in their surgical procedures or concerning adverse outcomes, tend to trend away from needing a transplant. Additionally, the XGBoost model's predicted probability of the occluded outcome being 'yes' is extremely low at 0.00545165, supporting that the main patient's condition, while managed, does not necessitate a transplant at this point. Thus, there is a consensus across both the patient data and the predictive modeling suggesting that the main patient did not receive a heart transplant.","Based on the provided data, I predict that the main patient did **not** receive a heart transplant. The patient has a complex history of tricuspid atresia, two surgical interventions including a lateral tunnel Fontan, and a fenestration, indicating a management pathway typical for patients who may not progress to transplantation. Additionally, the XGBoost model estimates a very low probability (0.0054) of the patient receiving a heart transplant, supporting the likelihood that the outcome is ""no."" An examination of similar patients shows that while some had more severe outcomes leading to transplantation, the majority did not, highlighting a trend where similar patients with comparable surgical histories and characteristics remain managed conservatively without transplant.",1,1,1,1,0
BCH-LEOJUL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: tricuspid valvuloplasty for severe tricuspid regurgitation 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 151.0
 Patient weight: 46.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4027651807434258
 Heart rate: 69.0
 Upper limb systolic blood pressure: 102.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 82.0
 Left ventricle end-diastolic volume: 16.8
 Left ventricle end-systolic volume: 13.2
 Left ventricular mass: 16.4
 Right ventricular end-diastolic volume: 225.0
 Right ventricular end-systolic volume: 105.5
 Right ventricle mass: 64.83
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right atrioventricular valve/tricuspid inflow rate: 11.3
 Tricuspid regurgitation fraction: 60.0
 Single ventricle ejection fraction 0.5311111111111111
 Single ventricle systolic volume 119.5
 Body mass index 20.525415551949475
 Mass to height volume indexed on BSA (exp = 2.7) 21.307782934372497
 Systemic ventricle end-systolic volume: 105.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 75.20859617009312
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 67.94726637769602
 Systemic ventricle end-diastolic volume: 225.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 160.39747998361094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 144.91123161120007
 Systemic ventricle mass: 64.83
 Systemic ventricle mass indexed on BSA (exp=1) 46.215860565944425
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.75375620157377
 Systemic ventricle mass to volume ratio: 0.28813333333333335
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2054038247375308
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.18557224978477235
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Study was truncated due to severe patient anxiety and discomfort. Patient was offered and declined anxiolysis.
Image quality is somewhat degraded due to movement and quantitative data should be viewed as approximate.=========================Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: exaggerated sinus node behavior and was started on ivabradine
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.05793077].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data, it is predicted that the patient has **not** died. Several factors support this conclusion: the patient has undergone multiple surgeries including a successful Fontan procedure and has no documented history of critical complications, such as renal dysfunction, protein-losing enteropathy, or major stroke events. Additionally, the predicted probability of death according to the XGBoost model is only 0.0579, indicating a low likelihood of this outcome. Furthermore, the current medical status shows that the patient is receiving appropriate medical management (including anticoagulants and beta-blockers) and does not have significant acute complications that could lead to mortality.","Based on the provided data, the predicted outcome for the main patient regarding death is ""no."" The main patient's history of cardiac surgeries and ongoing management suggests a level of stability; they have not demonstrated critical complications typically associated with mortality post-Fontan procedures, such as heart failure or significant arrhythmias requiring interventions like pacemaker placement. Furthermore, the analysis of similar patients indicates an overall positive survival trend, as none experienced mortality, despite some having complications like pleural effusions or arrhythmias. Additionally, the low probability (5.79%) estimated by the XGBoost model for the occluded outcome being 'yes' further supports the prediction of survival for this patient, indicating a minor likelihood of mortality in their clinical context.","Based on the information provided, the predicted outcome for the main patient is **no**, the patient has not died. This conclusion is supported by several factors: the patient has undergone multiple successful surgeries including a lateral tunnel Fontan with a fenestration, which typically allows for better management of pressures and blood flow in single ventricle physiology. Furthermore, similar patients who had varying degrees of surgical interventions and managed thoracic anatomy without experiencing mortality have shown that while complications like atrial arrhythmias and late effects occur, survival is often maintained. The XGBoost model probability indicates a very low likelihood of death (approximately 5.8%), which aligns with the generally favorable management outcomes seen in patients with comparable profiles.","**Prediction: No, the patient has not died.**

The main patient has undergone multiple complex cardiac surgeries and has a significant medical history, including a Fontan procedure with fenestration and no recorded history of severe complications like protein-losing enteropathy, major thrombus, or plastic bronchitis. Furthermore, the analysis of similar patients shows that those with extensive surgical histories and without severe complications tended to have better outcomes, with many living without significant morbidity. The modeled estimated probability (5.79%) of the outcome being 'yes' (the patient has died) is low, reflecting the generally favorable prognosis seen in this cohort of patients, particularly when controlled for similar characteristics and lack of severe adverse events. Thus, based on the available data, it is reasonable to conclude that this patient has survived.",1,1,1,1,0
BCH-LEOJUL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: tricuspid valvuloplasty for severe tricuspid regurgitation 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 151.0
 Patient weight: 46.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4027651807434258
 Heart rate: 69.0
 Upper limb systolic blood pressure: 102.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 82.0
 Left ventricle end-diastolic volume: 16.8
 Left ventricle end-systolic volume: 13.2
 Left ventricular mass: 16.4
 Right ventricular end-diastolic volume: 225.0
 Right ventricular end-systolic volume: 105.5
 Right ventricle mass: 64.83
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right atrioventricular valve/tricuspid inflow rate: 11.3
 Tricuspid regurgitation fraction: 60.0
 Single ventricle ejection fraction 0.5311111111111111
 Single ventricle systolic volume 119.5
 Body mass index 20.525415551949475
 Mass to height volume indexed on BSA (exp = 2.7) 21.307782934372497
 Systemic ventricle end-systolic volume: 105.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 75.20859617009312
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 67.94726637769602
 Systemic ventricle end-diastolic volume: 225.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 160.39747998361094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 144.91123161120007
 Systemic ventricle mass: 64.83
 Systemic ventricle mass indexed on BSA (exp=1) 46.215860565944425
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.75375620157377
 Systemic ventricle mass to volume ratio: 0.28813333333333335
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2054038247375308
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.18557224978477235
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Study was truncated due to severe patient anxiety and discomfort. Patient was offered and declined anxiolysis.
Image quality is somewhat degraded due to movement and quantitative data should be viewed as approximate.=========================Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: exaggerated sinus node behavior and was started on ivabradine
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01177647].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data, I would predict that the patient did **not** receive a heart transplant. The patient's surgical history indicates multiple interventions, including a successful Fontan procedure with a fenestration, interventions on the atrioventricular valve, and management of tricuspid regurgitation. Furthermore, the relatively low predicted probability of the occluded outcome being 'yes' (0.0118) suggests that the majority of similar patients do not end up requiring a heart transplant, particularly given the success of the various surgical procedures and absence of significant complications historically associated with transplant. Additionally, the absence of critical outcomes such as protein-losing enteropathy or significant heart failure symptoms reinforces the likelihood that the patient could sustain improved quality of life without resorting to transplantation at this time.","Based on the information provided, I would predict that the main patient did **not** receive a heart transplant. The patient's cardiac history indicates multiple surgeries, including a successful Fontan procedure with a lateral tunnel, and previous interventions related to tricuspid valve regurgitation and pulmonary artery issues. Additionally, the clinical outcomes of similar patients show a low frequency of heart transplants among those with comparable characteristics, indicated by the XGBoost model's low predicted probability of the occluded outcome being 'yes' (0.01177647). Moreover, none of the similar patients received a heart transplant, suggesting that the main patient's condition is likely managed without transplantation at this stage.","Based on the data provided for the main patient, it is likely that they did not receive a heart transplant (prediction: **No**). The main patient has undergone multiple surgeries including a comprehensive surgical history surrounding complex conditions such as hypoplastic left heart syndrome. They exhibit a fair cardiac function with a single ventricle ejection fraction of approximately 0.53 and significant tricuspid regurgitation but no direct indications of prior transplants or severe complications such as end-stage heart failure that might necessitate transplantation. 

Trends observed in similar patients reveal that most did not receive transplants either; many exhibited significant comorbidities like atrial arrhythmias or underwent additional interventions without moving to transplantation. Moreover, the XGBoost model's predicted probability of 0.01177647 for transplantation suggests a markedly low likelihood of the main patient having undergone such a procedure based on their clinical and MRI profile. This combination of factors leads to the conclusion that heart transplantation was not part of the main patient's treatment trajectory.","Based on the provided clinical data and MRI findings for the main patient, it is likely that the missing clinical outcome—whether the patient received a heart transplant—is ""no."" The main patient presents with complex surgical history, including a total of five cardiac surgeries, and the Fontan procedure is marked by severe tricuspid regurgitation, which typically places patients at a higher risk for complications rather than necessitating a transplant. Additionally, analysis of similar patients shows that those with comparable surgical histories, such as multiple interventions and chronic heart conditions, predominantly did not undergo transplantation despite severe outcomes. The model's estimated probability (0.01177647) reinforces this notion, indicating a very low likelihood of a heart transplant being required in this patient cohort.",1,1,1,1,0
BCH-LEOJUL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: tricuspid valvuloplasty for severe tricuspid regurgitation 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 151.0
 Patient weight: 46.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4027651807434258
 Heart rate: 69.0
 Upper limb systolic blood pressure: 102.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 82.0
 Left ventricle end-diastolic volume: 16.8
 Left ventricle end-systolic volume: 13.2
 Left ventricular mass: 16.4
 Right ventricular end-diastolic volume: 225.0
 Right ventricular end-systolic volume: 105.5
 Right ventricle mass: 64.83
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right atrioventricular valve/tricuspid inflow rate: 11.3
 Tricuspid regurgitation fraction: 60.0
 Single ventricle ejection fraction 0.5311111111111111
 Single ventricle systolic volume 119.5
 Body mass index 20.525415551949475
 Mass to height volume indexed on BSA (exp = 2.7) 21.307782934372497
 Systemic ventricle end-systolic volume: 105.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 75.20859617009312
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 67.94726637769602
 Systemic ventricle end-diastolic volume: 225.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 160.39747998361094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 144.91123161120007
 Systemic ventricle mass: 64.83
 Systemic ventricle mass indexed on BSA (exp=1) 46.215860565944425
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.75375620157377
 Systemic ventricle mass to volume ratio: 0.28813333333333335
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2054038247375308
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.18557224978477235
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Study was truncated due to severe patient anxiety and discomfort. Patient was offered and declined anxiolysis.
Image quality is somewhat degraded due to movement and quantitative data should be viewed as approximate.=========================Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: exaggerated sinus node behavior and was started on ivabradine
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.02474691].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the available data, it is predicted that the patient does **not** have a history of ascites (> trace). The patient's surgical history, particularly with multiple significant surgeries including a lateral tunnel Fontan, indicates a complex single-ventricle physiology, which often predisposes patients to complications such as fluid overload. However, the absence of any recorded diagnoses such as protein-losing enteropathy or significant pleural effusion, along with a low probability of the occluded outcome being 'yes' (0.0247), suggests a lower likelihood of ascites. Additionally, the patient currently does not exhibit symptoms or interventions commonly associated with ascites, reinforcing this prediction.","Based on the data provided for the main patient, the prediction for the question ""Does the patient have a history of ascites (> trace)?"" is **no**. The main patient exhibits several cardiovascular challenges typical of single-ventricle physiology, such as severe tricuspid regurgitation and a significant volume of cardiac surgeries, which may lead to complications like heart failure, but there is no documented history of ascites. Additionally, examining similar patients reveals that although some experienced pleural effusions and atrial tachyarrhythmias, none reported a history of ascites, indicating that this may not be a prevalent issue among comparable cohorts. Furthermore, the low predicted probability (0.0247) from the XGBoost model supports the conclusion that it is unlikely for this patient to have a significant history of ascites.","Based on the available information, the predicted outcome for the main patient regarding the history of ascites is ""no."" This conclusion is driven by the main patient's multiple heart surgeries and the presence of several risk factors, including severe tricuspid regurgitation and atrial arrhythmias, but a lack of documented history of ascites aligns with other similar patients who also did not report ascites in their medical history. Furthermore, the similar patients exhibited a mix of cardiac histories but recorded a higher prevalence of pleural effusion rather than ascites, indicating that while fluid accumulation could occur post-Fontan, it may not manifest as ascites. The XGBoost model's estimated low probability (0.0247) of the occluded outcome suggests a less than favorable condition that typically is not associated with ascites formation, reinforcing the prediction that the main patient does not have a history of ascites.","Based on the provided data, the main patient does not have a history of ascites (> trace). This conclusion is supported by the fact that the patient has reported no instances of pleural effusion, chylous or non-chylous, and there's no mention of ascites in the clinical history. Additionally, the similar patients typically show a range of outcomes, but the ones reporting ascites either had a diagnosis of protein-losing enteropathy or were otherwise managed differently. The XGBoost model prediction, which indicates a low probability (approximately 2.47%) of the occluded outcome being 'yes', further reinforces that significant complications like ascites are less likely for this patient, especially given the overall high accuracy and AUC of the model on validation.",1,1,1,1,0
BCH-LEOJUL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: tricuspid valvuloplasty for severe tricuspid regurgitation 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 151.0
 Patient weight: 46.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4027651807434258
 Heart rate: 69.0
 Upper limb systolic blood pressure: 102.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 82.0
 Left ventricle end-diastolic volume: 16.8
 Left ventricle end-systolic volume: 13.2
 Left ventricular mass: 16.4
 Right ventricular end-diastolic volume: 225.0
 Right ventricular end-systolic volume: 105.5
 Right ventricle mass: 64.83
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right atrioventricular valve/tricuspid inflow rate: 11.3
 Tricuspid regurgitation fraction: 60.0
 Single ventricle ejection fraction 0.5311111111111111
 Single ventricle systolic volume 119.5
 Body mass index 20.525415551949475
 Mass to height volume indexed on BSA (exp = 2.7) 21.307782934372497
 Systemic ventricle end-systolic volume: 105.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 75.20859617009312
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 67.94726637769602
 Systemic ventricle end-diastolic volume: 225.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 160.39747998361094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 144.91123161120007
 Systemic ventricle mass: 64.83
 Systemic ventricle mass indexed on BSA (exp=1) 46.215860565944425
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.75375620157377
 Systemic ventricle mass to volume ratio: 0.28813333333333335
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2054038247375308
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.18557224978477235
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Study was truncated due to severe patient anxiety and discomfort. Patient was offered and declined anxiolysis.
Image quality is somewhat degraded due to movement and quantitative data should be viewed as approximate.=========================Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: exaggerated sinus node behavior and was started on ivabradine
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.02611402].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Given the provided data on the main patient, I predict that the patient does not have a diagnosis of seizures requiring antiepileptic medications (no). This prediction is supported by the patient’s clinical history and current status; there is no mention of seizures or the use of antiepileptic drugs in the medication data. Additionally, the presence of significant arrhythmias, as indicated by the history of atrial tachyarrhythmias and non-sustained ventricular tachycardia, might suggest potential neurological concerns. However, these types of cardiac issues do not inherently lead to a diagnosis of seizures, especially in the absence of a direct indication of seizure activity or treatment in the reported medications, which also include various heart-related treatments but exclude antiepileptic medication. Furthermore, the predicted probability of the occluded outcome being 'yes' is low (approximately 2.6%), indicating that such a diagnosis is unlikely given the patient's overall profile in the similar cohort context.","Based on the provided data, the predicted outcome for the main patient regarding the diagnosis of seizures requiring antiepileptic medications is ""no."" The main patient demonstrates significant cardiac issues, including a history of atrial tachyarrhythmias and requires various cardiac interventions, but there is no evident direct link or documented history related to seizures. Moreover, analysis of similar patients reveals that those with significant cardiac histories often do not report seizure disorders, reinforcing a possible trend that patients in similar health categories may also be less likely to have seizure diagnoses. Furthermore, the calculated probability of having a seizure diagnosis based on the XGBoost model is quite low (0.0261), indicating a very minimal likelihood of this outcome for the main patient.","Based on the provided data, I would predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The patient’s cardiac history shows significant interventions for complex congenital heart disease but does not indicate any previous seizures. Additionally, among the similar patients, those with a history of seizures frequently also had associated complications like protein-losing enteropathy or plastic bronchitis, which are not documented for the main patient. The low predicted probability of seizures from the XGBoost model (0.0261) further supports this inference, suggesting that seizures are unlikely in this context given the overall performance of the model on similar patients.","Based on the data for the main patient, it appears they have a history of atrial tachyarrhythmias and have received treatment through cardioversion, which may correlate with neurological stressors, such as seizures. Additionally, the similar patients show varying outcomes regarding seizure diagnoses, but one notable case with a history of atrial flutter required anticoagulation while another had transient ischemic attacks, suggesting a potential link between cardiac rhythm disturbances and neurological events. Given the low predicted probability of receiving a seizure diagnosis (0.026) from the XGBoost model, which reflects the overall cohort where seizures are quite rare, it supports the conclusion that the main patient likely does not have a diagnosis of seizures requiring antiepileptic medications. Thus, I would predict that the answer is ""no.""",1,1,1,1,0
BCH-LEOJUL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Please describe additional cardiac pre-Fontan surgery: tricuspid valvuloplasty for severe tricuspid regurgitation 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 151.0
 Patient weight: 46.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4027651807434258
 Heart rate: 69.0
 Upper limb systolic blood pressure: 102.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 82.0
 Left ventricle end-diastolic volume: 16.8
 Left ventricle end-systolic volume: 13.2
 Left ventricular mass: 16.4
 Right ventricular end-diastolic volume: 225.0
 Right ventricular end-systolic volume: 105.5
 Right ventricle mass: 64.83
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right atrioventricular valve/tricuspid inflow rate: 11.3
 Tricuspid regurgitation fraction: 60.0
 Single ventricle ejection fraction 0.5311111111111111
 Single ventricle systolic volume 119.5
 Body mass index 20.525415551949475
 Mass to height volume indexed on BSA (exp = 2.7) 21.307782934372497
 Systemic ventricle end-systolic volume: 105.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 75.20859617009312
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 67.94726637769602
 Systemic ventricle end-diastolic volume: 225.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 160.39747998361094
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 144.91123161120007
 Systemic ventricle mass: 64.83
 Systemic ventricle mass indexed on BSA (exp=1) 46.215860565944425
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.75375620157377
 Systemic ventricle mass to volume ratio: 0.28813333333333335
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2054038247375308
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.18557224978477235
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Study was truncated due to severe patient anxiety and discomfort. Patient was offered and declined anxiolysis.
Image quality is somewhat degraded due to movement and quantitative data should be viewed as approximate.=========================Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: exaggerated sinus node behavior and was started on ivabradine
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? yes
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00112648].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided data and the XGBoost model's predicted probability, the most likely prediction for the missing clinical outcome, ""Does the patient have a history of pacemaker placement?"" would be **no**. The patient's MRI report indicates significant issues such as severe tricuspid regurgitation and atrial tachyarrhythmias, which could lead to the need for pacing, yet there is no mention of pacemaker placement in the surgical history or current medications. Additionally, the low predicted probability (0.00112648) from the model suggests that the occurrence of a pacemaker placement in this patient is highly unlikely. Therefore, taking into account the clinical history and the model's findings, it is reasonable to conclude that the patient does not have a history of pacemaker placement.","Based on the data presented, it is likely that the main patient does not have a history of pacemaker placement (“no”). The patient's significant medical history indicates that they have not experienced severe complications typically associated with the need for a pacemaker, such as sustained arrhythmias, cardiac arrest, or severe conduction abnormalities. Moreover, similar patients who required pacemakers tend to have a documented history of more severe complications or arrhythmias than those present in the main patient, who has only reported non-sustained ventricular tachyarrhythmias and appropriate treatment with anti-arrhythmic medications. Therefore, in conjunction with the estimated low probability (0.00112648) of them having such a history, it suggests that the absence of evident severe complications leads to the conclusion that pacemaker placement is not likely needed in this case.","Based on the provided data, I predict that the main patient **does not have a history of pacemaker placement**. The main patient's clinical history indicates significant surgical interventions, including atrioventricular valve procedures and Fenestration during FonTan surgery, but no mention of a pacemaker. In comparison, similar patients who displayed a history of pacemaker placement generally had more advanced arrhythmias or complications, which were absent in the main patient’s reported events. The low predicted probability (0.00112648) of the occluded outcome being 'yes' further supports that the absence of a pacemaker placement is consistent with their overall clinical trajectory.","Based on the analysis of the main patient's surgical history and the MRI report, the patient has undergone multiple significant cardiac interventions, including a series of surgeries and procedures consistent with complex congenital heart disease. Importantly, similar patients who experienced comparable surgical pathways and complications often showed a history of pacemaker placement, particularly when dealing with atrial tachyarrhythmias, which the main patient has also documented. The XGBoost model's predicted probability of 0.00112648 for a positive pacemaker history aligns with the overall low incidence in the dataset, but given the specific context of multiple surgeries, known arrhythmias, and accrued similar patient outcomes, this leans the inference toward a positive outcome for pacemaker placement. Thus, it is reasonable to conclude that the main patient likely has a history of pacemaker placement (""yes"").",1,1,0,0,0
BCH-MANYOH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Please describe additional cardiac pre-Fontan surgery: tighten PAB as part of Glenn
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 25.0
 Gadolinium unknown contrast dose: 25.0
 Patient height: 169.0
 Patient weight: 85.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 2.0308211204077598
 Heart rate: 50.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 49.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 192.3
 Left ventricle end-systolic volume: 97.3
 Left ventricular mass: 104.3
 Right ventricular end-diastolic volume: 18.7
 Right ventricular end-systolic volume: 6.9
 Right ventricle mass: 10.0
 Descending aorta flow rate: 2.41
 Right superior vena cava flow rate: 1.43
 Inferior vena cava, below the fenestration flow rate: 3.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.39
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.64
 Total right pulmonary vein flow rate: 1.86
 Total left pulmonary vein flow rate: 1.76
 Right atrioventricular valve/tricuspid inflow rate: 1.53
 Left atrioventricular valve/mitral inflow rate: 2.28
 Qp/Qs (enter a number, not a ratio): 0.8
 Single ventricle ejection fraction 0.5061611374407583
 Single ventricle systolic volume 106.8
 Body mass index 30.005952172542983
 Mass to height volume indexed on BSA (exp = 2.7) 27.717376934904255
 Systemic ventricle end-systolic volume: 104.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.30929502007451
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 41.48532971988829
 Systemic ventricle end-diastolic volume: 211.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.89886035734857
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 84.00580202395805
 Systemic ventricle mass: 114.3
 Systemic ventricle mass indexed on BSA (exp=1) 56.28265279073432
 Systemic ventricle mass indexed on BSA (exp=1.3) 45.506460527670164
 Systemic ventricle mass to volume ratio: 1.0771410535565806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5303968147329028
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.42884406681019765
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Moderate sized artifact from a presumed aortopulmonary collateral coil in the left superior thorax which obscures the aortic root and ascending aorta. Mild localized artifact from the fenestration device.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: swelling and boils on right leg after percutaneous sclerotherapy procedure. Later He went to the OR with IR for an incision and drainage of the clot burden.
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00734286].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the information provided, the patient has undergone multiple cardiac surgeries, including a Fontan procedure with a fenestration, indicating that they are being closely managed for their complex cardiac condition. The XGBoost model predicts a very low probability of the occluded outcome being 'yes' (0.0073), suggesting that the likelihood of death is extremely low based on similar cases in the dataset. Additionally, the patient's ongoing issues such as intracardiac thrombus and atrial arrhythmias do not necessarily indicate imminent mortality, and the lack of history of significant complications (e.g., stroke or heart failure) further supports a favorable prognosis. Therefore, I would predict that the missing clinical outcome is ""no,"" indicating the patient has not died.","Based on the provided information, the main patient is less likely to have died (prediction: ""no""). Key factors supporting this conclusion include the patient's management of intracardiac thrombus and their specific surgical history. While similar patients exhibited severe complications leading to mortality—often having undergone multiple cardiac surgeries and presenting with significant comorbidities such as protein-losing enteropathy—the main patient has a more stable report with no known history of such debilitating conditions. The calculated probability of the occluded outcome being 'yes' (0.0073) further suggests a much higher likelihood of survival, aligned with the main patient’s relatively better prognostic indicators compared to the similar cohorts.","Based on the provided data, it is reasonable to predict that the main patient has not died. Although the patient has undergone multiple cardiac surgeries, including the Fontan procedure, their current clinical profile does not exhibit critical complications often seen in similar patients, such as major recurring thrombus formations or severe arrhythmias leading to cardiac arrest. Moreover, the estimated probability of the occluded outcome being yes is very low (0.0073), which indicates that the risk of death is minimal according to the model. In contrast, the similar patients tended to have poorer outcomes due to complications like cardiac transplant needs, protein-losing enteropathy, and prolonged hospitalizations, none of which are reported in the main patient's clinical history at this time.","Based on the provided data, I predict that the missing clinical outcome for the main patient is ""no,"" meaning the patient has not died. While the patient has undergone multiple cardiac interventions and has a complex surgical history, he also exhibits stability in key cardiac metrics such as a single ventricle ejection fraction of approximately 0.51 and a relatively low Qp/Qs ratio of 0.8. The similar patients identified show a higher fatality rate, especially in those with severe complications such as protein-losing enteropathy and the need for multiple surgeries leading to death. However, the main patient lacks these severe complications and has not received a heart transplant, which correlates with better survival rates among similar non-transplanted patients. Additionally, the low predicted probability (0.0073) of the outcome being 'yes' indicates a strong model confidence that the patient is likely alive.",1,1,1,1,0
BCH-MANYOH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Please describe additional cardiac pre-Fontan surgery: tighten PAB as part of Glenn
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 25.0
 Gadolinium unknown contrast dose: 25.0
 Patient height: 169.0
 Patient weight: 85.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 2.0308211204077598
 Heart rate: 50.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 49.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 192.3
 Left ventricle end-systolic volume: 97.3
 Left ventricular mass: 104.3
 Right ventricular end-diastolic volume: 18.7
 Right ventricular end-systolic volume: 6.9
 Right ventricle mass: 10.0
 Descending aorta flow rate: 2.41
 Right superior vena cava flow rate: 1.43
 Inferior vena cava, below the fenestration flow rate: 3.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.39
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.64
 Total right pulmonary vein flow rate: 1.86
 Total left pulmonary vein flow rate: 1.76
 Right atrioventricular valve/tricuspid inflow rate: 1.53
 Left atrioventricular valve/mitral inflow rate: 2.28
 Qp/Qs (enter a number, not a ratio): 0.8
 Single ventricle ejection fraction 0.5061611374407583
 Single ventricle systolic volume 106.8
 Body mass index 30.005952172542983
 Mass to height volume indexed on BSA (exp = 2.7) 27.717376934904255
 Systemic ventricle end-systolic volume: 104.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.30929502007451
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 41.48532971988829
 Systemic ventricle end-diastolic volume: 211.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.89886035734857
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 84.00580202395805
 Systemic ventricle mass: 114.3
 Systemic ventricle mass indexed on BSA (exp=1) 56.28265279073432
 Systemic ventricle mass indexed on BSA (exp=1.3) 45.506460527670164
 Systemic ventricle mass to volume ratio: 1.0771410535565806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5303968147329028
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.42884406681019765
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Moderate sized artifact from a presumed aortopulmonary collateral coil in the left superior thorax which obscures the aortic root and ascending aorta. Mild localized artifact from the fenestration device.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: swelling and boils on right leg after percutaneous sclerotherapy procedure. Later He went to the OR with IR for an incision and drainage of the clot burden.
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01843921].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided data for the main patient, I predict that the missing clinical outcome—whether the patient has a history of ascites (> trace)—is ""no."" The patient's surgical history indicates multiple interventions, including a lateral tunnel Fontan, which typically aims to optimize hemodynamics and reduce the risk of complications such as ascites. Additionally, the MRI report shows a moderate ventricular function, with a single ventricle ejection fraction of approximately 50.6%, which suggests better overall circulation. Furthermore, the absence of other complications such as protein-losing enteropathy or chylous effusion, coupled with the low predicted probability (1.84%) of having significant issues that could lead to ascites, reinforces this conclusion.","Based on the data provided, I predict that the main patient does not have a history of ascites (> trace). This assessment is supported by the fact that none of the similar patients, including those with complex surgical histories and significant comorbidities, reported a history of ascites. Additionally, the main patient has no documented history of pleural effusions or other signs frequently associated with ascites, such as renal dysfunction or protein-losing enteropathy, which could contribute to fluid retention. Furthermore, the XGBoost model predicts a low probability (approximately 1.84%) for the occluded outcome being 'yes,' reinforcing the likelihood that this patient has not experienced clinically significant ascites.","Based on the provided data, it is reasonable to predict that the main patient does **not** have a history of ascites (> trace). The patient's clinical and surgical history, including signs of previous interventions and their MRI findings, suggests a well-managed post-Fontan anatomy with controlled hemodynamics, especially with a low Qp/Qs ratio (0.8) and favorable systemic ventricle metrics. 

Moreover, examining similar patients, we find that those with a history of ascites often had comorbidities such as severe heart failure and additional complications, none of which seem prominent in this patient's report. Additionally, the XGBoost model output shows a very low predicted probability (approximately 1.84%) for the occluded outcome (history of ascites), reinforcing that the available clinical evidence does not support a significant likelihood of ascites for this patient.","Based on the provided data, the main patient likely does **not** have a history of ascites (> trace). This patient exhibits a complex surgical history with significant cardiac interventions, including a Fontan procedure, but no indication of ascites is recorded in their history. In comparison, among the similar patients, those who presented with ascites (historically related to fluid management issues and Fontan physiology) displayed a notable presence of cardiac dysfunction and complications. The XGBoost model indicates a low probability (1.84%) for the presence of ascites, aligning with the observed trends in similar patients, where ascites were frequently associated with additional severe complications such as protein-losing enteropathy or significant heart failure. Thus, considering these patterns and the data available, the prediction leans towards a negative history of ascites for the main patient.",1,1,1,1,0
BCH-MANYOH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Please describe additional cardiac pre-Fontan surgery: tighten PAB as part of Glenn
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 25.0
 Gadolinium unknown contrast dose: 25.0
 Patient height: 169.0
 Patient weight: 85.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 2.0308211204077598
 Heart rate: 50.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 49.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 192.3
 Left ventricle end-systolic volume: 97.3
 Left ventricular mass: 104.3
 Right ventricular end-diastolic volume: 18.7
 Right ventricular end-systolic volume: 6.9
 Right ventricle mass: 10.0
 Descending aorta flow rate: 2.41
 Right superior vena cava flow rate: 1.43
 Inferior vena cava, below the fenestration flow rate: 3.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.39
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.64
 Total right pulmonary vein flow rate: 1.86
 Total left pulmonary vein flow rate: 1.76
 Right atrioventricular valve/tricuspid inflow rate: 1.53
 Left atrioventricular valve/mitral inflow rate: 2.28
 Qp/Qs (enter a number, not a ratio): 0.8
 Single ventricle ejection fraction 0.5061611374407583
 Single ventricle systolic volume 106.8
 Body mass index 30.005952172542983
 Mass to height volume indexed on BSA (exp = 2.7) 27.717376934904255
 Systemic ventricle end-systolic volume: 104.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.30929502007451
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 41.48532971988829
 Systemic ventricle end-diastolic volume: 211.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.89886035734857
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 84.00580202395805
 Systemic ventricle mass: 114.3
 Systemic ventricle mass indexed on BSA (exp=1) 56.28265279073432
 Systemic ventricle mass indexed on BSA (exp=1.3) 45.506460527670164
 Systemic ventricle mass to volume ratio: 1.0771410535565806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5303968147329028
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.42884406681019765
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Moderate sized artifact from a presumed aortopulmonary collateral coil in the left superior thorax which obscures the aortic root and ascending aorta. Mild localized artifact from the fenestration device.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: swelling and boils on right leg after percutaneous sclerotherapy procedure. Later He went to the OR with IR for an incision and drainage of the clot burden.
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00085787].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided clinical data and the predicted probability of 0.00085787 for receiving a heart transplant, it is highly unlikely that the patient has undergone this procedure. The patient has a complex cardiac history, including multiple surgeries, a diagnosed intracardiac thrombus, and a significant medical history of arrhythmias and sinus node dysfunction, which poses considerable risks for transplant candidacy. Furthermore, the absence of a history of major complications such as protein-losing enteropathy or significant ventricular arrhythmias suggests relative stability of the Fontan physiology, supporting that the patient likely remains managed without the need for transplantation. Therefore, the predicted outcome is that the patient did **not** receive a heart transplant.","Based on the available data, the prediction for the main patient is **no**, the patient did not receive a heart transplant. The main patient has a relatively low ejection fraction of 50.6% and a history of atrial tachyarrhythmias, which may suggest some cardiac instability but does not warrant immediate transplant consideration. Moreover, similar patients’ data indicated that the presence of significant comorbidities, such as protein-losing enteropathy and a history of heart transplants, correlates with worse outcomes; patient #1 suffered major complications and ultimately passed away post-transplant. Given the current patient's positive management (no reports of severe complications) and low predicted probability from the XGBoost model (0.00085787), it implies a lower likelihood of transplant necessity at this time.","Given the provided information, I predict that the main patient did **not receive a heart transplant**. The patient has a complex surgical history with a total of three cardiac surgeries, including a lateral tunnel Fontan, and exhibits conditions such as intracardiac thrombus and atrial tachyarrhythmias, which are common complications that can negatively influence transplant candidacy. The predicted probability from the XGBoost model for receiving a transplant is very low (0.00085787), indicating that the likelihood of this outcome is minimal based on the patient's features. Additionally, in reviewing the similar patient cohort, many instances of heart transplant occurred in cases with more severe complications, and the patient’s parameters suggest a chronic status that may limit eligibility for transplantation. Overall, the main patient's profile points towards a challenging clinical scenario with sustained pulmonary circulation issues rather than a path toward successful transplantation.","Based on the data provided, the prediction for whether the main patient received a heart transplant is ""no."" This conclusion is supported by the patient's surgical history, which includes three cardiac surgeries and a history of atrial tachyarrhythmias and sinus node dysfunction, indicating a challenging clinical status without the need for transplant at present. Additionally, the XGBoost model estimates a very low probability (~0.0009) of the outcome being ""yes,"" which aligns with the clinical presentation suggesting that transplantation may not be imminent or necessary based on current health indicators. 

When examining similar patients, several underwent heart transplants due to significant complications, including those linked to Fontan failure, atrial tachyarrhythmias, and plastic bronchitis. However, the main patient does not exhibit severe indicators such as protein-losing enteropathy or a history of multiple failed cardiac interventions leading to transplant necessity that were common among similar patients who did receive transplants. Thus, synthesizing these insights, the current prediction leans towards no heart transplant received.",1,1,1,1,0
BCH-MANYOH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Please describe additional cardiac pre-Fontan surgery: tighten PAB as part of Glenn
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 25.0
 Gadolinium unknown contrast dose: 25.0
 Patient height: 169.0
 Patient weight: 85.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 2.0308211204077598
 Heart rate: 50.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 49.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 192.3
 Left ventricle end-systolic volume: 97.3
 Left ventricular mass: 104.3
 Right ventricular end-diastolic volume: 18.7
 Right ventricular end-systolic volume: 6.9
 Right ventricle mass: 10.0
 Descending aorta flow rate: 2.41
 Right superior vena cava flow rate: 1.43
 Inferior vena cava, below the fenestration flow rate: 3.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.39
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.64
 Total right pulmonary vein flow rate: 1.86
 Total left pulmonary vein flow rate: 1.76
 Right atrioventricular valve/tricuspid inflow rate: 1.53
 Left atrioventricular valve/mitral inflow rate: 2.28
 Qp/Qs (enter a number, not a ratio): 0.8
 Single ventricle ejection fraction 0.5061611374407583
 Single ventricle systolic volume 106.8
 Body mass index 30.005952172542983
 Mass to height volume indexed on BSA (exp = 2.7) 27.717376934904255
 Systemic ventricle end-systolic volume: 104.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.30929502007451
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 41.48532971988829
 Systemic ventricle end-diastolic volume: 211.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.89886035734857
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 84.00580202395805
 Systemic ventricle mass: 114.3
 Systemic ventricle mass indexed on BSA (exp=1) 56.28265279073432
 Systemic ventricle mass indexed on BSA (exp=1.3) 45.506460527670164
 Systemic ventricle mass to volume ratio: 1.0771410535565806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5303968147329028
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.42884406681019765
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Moderate sized artifact from a presumed aortopulmonary collateral coil in the left superior thorax which obscures the aortic root and ascending aorta. Mild localized artifact from the fenestration device.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: swelling and boils on right leg after percutaneous sclerotherapy procedure. Later He went to the OR with IR for an incision and drainage of the clot burden.
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.07493094].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided patient data, it is predicted that the patient does **not** have a diagnosis of seizures requiring antiepileptic medications (outcome: ""no""). This reasoning stems from the absence of any documented history of seizures or neurological events in the patient's status event update, as well as the specific mention of no history of stroke or transient ischemic attacks, which may often coincide with or indicate seizure activity. Additionally, while the patient has a history of atrial tachyarrhythmias and sinus node dysfunction, these primarily cardiac issues do not suggest a predisposition to seizures. The XGBoost model's predicted probability of 0.0749 for the occluded outcome aligns with this reasoning, indicating a low likelihood of seizure diagnosis in line with the patient's clinical profile.","**Prediction:** No, the patient does not have a diagnosis of seizures requiring antiepileptic medications.

**Reasoning:** The main patient has a history of atrial tachyarrhythmias and sinus node dysfunction, which can sometimes lead to neurological complications. However, there is no documented history of seizures or a need for antiepileptic medications. Comparing this to similar patients, we observe that one of the top matches had a critical medical condition and a significant number of surgeries, yet also did not exhibit any history of seizures. Additionally, the estimated probability of the occluded outcome (0.07493094 or approximately 7.5%) indicates a low likelihood of this outcome, suggesting that seizures requiring antiepileptic medications may not be a concern in the main patient's clinical profile.","**Prediction:** Yes, the patient has a diagnosis of seizures requiring antiepileptic medications.

**Reasoning:** The main patient exhibits significant cardiac and surgical history, including a complicated course involving multiple surgeries related to a complex congenital heart defect. This complexity is often associated with neurological complications, including seizures, especially given the patient's prior history that may elevate their risk — particularly in the context of cardiac stressors. Notably, the similar patients displayed trends towards neurological issues, and among those with similar cardiac conditions, 10% were documented to have diagnoses involving seizures. Despite the XGBoost model predicting a low probability, the overarching context of the clinical history and similar patients’ profiles suggests that the answer leans towards a diagnosis of seizures requiring treatment.","Based on the available data, I predict that the main patient does not have a diagnosis of seizures requiring antiepileptic medications. The main patient has a history of atrial tachyarrhythmias and sinus node dysfunction, which are common in single-ventricle patients but do not inherently suggest a seizure disorder. In the similar cohort, a significant number of patients diagnosed with seizures were found to have additional complications (e.g., history of ECMO or transplants), while our main patient lacks additional severe complications or interventions that are often associated with seizure disorders. The XGBoost model also indicates a low predicted probability (0.0749) for the occluded outcome being 'yes', reinforcing my conclusion that the likelihood of seizure diagnosis requiring treatment is low for this patient.",1,1,0,1,0
BCH-MANYOH-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Please describe additional cardiac pre-Fontan surgery: tighten PAB as part of Glenn
 Cardiac diagnosis: Double inlet right ventricle
 Suspected heterotaxy: Yes
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 25.0
 Gadolinium unknown contrast dose: 25.0
 Patient height: 169.0
 Patient weight: 85.7
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 2.0308211204077598
 Heart rate: 50.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 49.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 192.3
 Left ventricle end-systolic volume: 97.3
 Left ventricular mass: 104.3
 Right ventricular end-diastolic volume: 18.7
 Right ventricular end-systolic volume: 6.9
 Right ventricle mass: 10.0
 Descending aorta flow rate: 2.41
 Right superior vena cava flow rate: 1.43
 Inferior vena cava, below the fenestration flow rate: 3.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.39
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.64
 Total right pulmonary vein flow rate: 1.86
 Total left pulmonary vein flow rate: 1.76
 Right atrioventricular valve/tricuspid inflow rate: 1.53
 Left atrioventricular valve/mitral inflow rate: 2.28
 Qp/Qs (enter a number, not a ratio): 0.8
 Single ventricle ejection fraction 0.5061611374407583
 Single ventricle systolic volume 106.8
 Body mass index 30.005952172542983
 Mass to height volume indexed on BSA (exp = 2.7) 27.717376934904255
 Systemic ventricle end-systolic volume: 104.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 51.30929502007451
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 41.48532971988829
 Systemic ventricle end-diastolic volume: 211.0
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.89886035734857
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 84.00580202395805
 Systemic ventricle mass: 114.3
 Systemic ventricle mass indexed on BSA (exp=1) 56.28265279073432
 Systemic ventricle mass indexed on BSA (exp=1.3) 45.506460527670164
 Systemic ventricle mass to volume ratio: 1.0771410535565806
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5303968147329028
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.42884406681019765
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Moderate sized artifact from a presumed aortopulmonary collateral coil in the left superior thorax which obscures the aortic root and ascending aorta. Mild localized artifact from the fenestration device.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: swelling and boils on right leg after percutaneous sclerotherapy procedure. Later He went to the OR with IR for an incision and drainage of the clot burden.
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00215312].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided data and clinical context, it is highly likely that the patient does not have a history of pacemaker placement. The patient's surgical history includes multiple cardiac interventions, particularly a Fontan surgery and associated procedures, but there is no indication of any identified need for pacing, such as significant bradycardia or heart block that would typically necessitate pacemaker placement. Furthermore, the patient's heart rate during the MRI was recorded at 50 bpm, which could be concerning, but the overall clinical picture does not suggest ongoing management with a pacemaker. Additionally, the patient's reported history of sinus node dysfunction and atrial tachyarrhythmias could prompt closer monitoring rather than definitive pacemaker placement. Given the very low predicted probability of the occluded outcome being 'yes' (0.00215312), it reinforces the conclusion that the likelihood of there being a history of pacemaker placement is minimal.","Based on the evaluation of the main patient's MRI report and surgical history, as well as insights from the similar patients, it is reasonable to predict that the main patient does **not** have a history of pacemaker placement (i.e., ""no""). The main patient has a background of atrial tachyarrhythmias and sinus node dysfunction, but there is no documented case of pacemaker placement, which suggests that either the arrhythmias have been managed through other means or the condition hasn't necessitated a device. 

Furthermore, analyzing the similar patients reveals that none of them (including patient #1 with extensive surgical history) had a pacemaker placement, aligning with the findings of other patients who have undergone comparable cardiac surgeries and exhibited similar complications without requiring such interventions. Additionally, the XGBoost model's low predicted probability (0.00215312) for the outcome strongly indicates that a history of pacemaker placement is unlikely in this cohort, further supporting the conclusion for the main patient.","Based on the data provided for the main patient, there are indications that the patient has experienced significant cardiac events, including a history of atrial tachyarrhythmias and sinus node dysfunction, which may predispose them to the need for pacing support. However, the absence of any mention of prior pacemaker placement suggests it was not necessary for the patient thus far. 

When examining the similar patients, those who suffered from complications such as more severe forms of arrhythmias, frequent hospitalizations, or progressive heart failure were more likely to have undergone pacemaker placement. Since the main patient does not exhibit similar escalated clinical management needs and has not had any prior interventions listed related to a pacemaker, it can be reasonably concluded that this patient does **not** have a history of pacemaker placement. The predicted probability from the XGBoost model, being extremely low (0.00215312), reinforces this assessment, indicating a very low likelihood of having undergone such an intervention. Therefore, the final prediction is **no**, the patient does not have a history of pacemaker placement.","Based on the information provided, the predicted outcome for the main patient regarding the history of pacemaker placement is **no**. The main patient has consistent evidence of significant cardiac surgeries—including a lateral tunnel Fontan and additional interventions—without prior mention of a pacemaker being used, alongside a history of atrial tachyarrhythmias but not documented sinus node dysfunction necessitating one. 

In examining the similar patients, many had varied surgical histories but no significant correlation was found between complex surgical histories and pacemaker placement; in fact, the majority had not received pacemakers, only those in more critical states or who underwent specific treatments (like post-Fontan electrophysiological studies and management of specific arrhythmias) did. Given these trends, along with the very low probability (0.2%) from the XGBoost model predicting the occluded outcome, it aligns with the conclusion that the main patient likely does not have a prior history of pacemaker placement.",1,1,1,1,0
BCH-MOLFRA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Other relevant surgical or clinical history (optional): {S,L,L} TGA, VSD, superior inferior ventricles, hypoplastic and dysplastic TV, LAA with NB


BIVENTRICULAR REPAIR 10/2018

SURG (12/2013, 1m 10 days, Buenos Aires): modified stage I surgery with what they called a""palliative arterial switch operation"", Stansel anastomosis + 5 mm Sano (RV to PA) conduit + atrial septectomy. This was complicated by cyanosis, so shortly thereafter a 4 mm RMBTS was placed and the Sano conduit was ligated.
SURG (12/2013, 1m, Buenos Aires): BDG with ligation of the azygous vein and a ""small"" LSVC. Complicated by mediastinitis requiring lavage and extended antibiotic course
 CATH (03/2014, 4m, Buenos Aires): Coil occlusion RIMA and LIMA. Device occlusion of LSVC to CS.
 CATH (09/2016, 2y 10m, OSH): Hemodynamics, APCs occluded
SURG (11/2016, 3y, Buenos Aires): Extracardiac fenestrated Fontan (16mm GoreTex).
 CATH (08/2017, 3y, Porras): VVC and APC coil occlusion.
 CATH (10/2018, 4y, Porras): VVC and APC coil with coil and plug embolization of two big VVC.
SURG (10/2018, 4y DelNido): Biventricular conversion: takedown of extracardiac fontan, hemi-mustard baffle IVC flow to TV with bovine pericardium, pulmonary veins to MV, VSD closure with LV to NeoAo baffle using dacron patch, patch plasty of central PA with bovine pericardium and RV-PA conduit with 15mm aortic homograft, Restriction of Glenn flow to LPA via external suture ligature sized around 6mm Hegar.
CATH (1/20, 6 y, Porras): HD

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 2.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 2.7
 Patient height: 99.0
 Patient weight: 13.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6152860368906081
 Heart rate: 87.0
 Upper limb systolic blood pressure: 75.0
 Upper limb diastolic blood pressure: 27.0
 Upper limb mean blood pressure: 46.0
 Left ventricle end-diastolic volume: 66.4
 Left ventricle end-systolic volume: 25.5
 Left ventricular mass: 33.6
 Right ventricular end-diastolic volume: 30.7
 Right ventricular end-systolic volume: 8.2
 Right ventricle mass: 10.0
 Native aorta flow rate: 4.48
 Ascending aorta, above the Stansel flow rate: 4.48
 Descending aorta flow rate: 1.08
 Right superior vena cava flow rate: 1.24
 Inferior vena cava, below the fenestration flow rate: 0.59
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.63
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.44
 Total right pulmonary vein flow rate: 2.13
 Total left pulmonary vein flow rate: 1.45
 Right atrioventricular valve/tricuspid inflow rate: 2.0
 Left atrioventricular valve/mitral inflow rate: 2.32
 Single ventricle ejection fraction 0.6529351184346035
 Single ventricle systolic volume 63.400000000000006
 Body mass index 14.080195898377717
 Mass to height volume indexed on BSA (exp = 2.7) 44.79932431978035
 Systemic ventricle end-systolic volume: 33.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.771273813241976
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.36212349011767
 Systemic ventricle end-diastolic volume: 97.10000000000001
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 157.8127800375607
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 182.56564364660017
 Systemic ventricle mass: 43.6
 Systemic ventricle mass indexed on BSA (exp=1) 70.8613512836009
 Systemic ventricle mass indexed on BSA (exp=1.3) 81.97592237890593
 Systemic ventricle mass to volume ratio: 0.8317569954083435
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.3518216659225468
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.5638542865528988
 Contrast type: Gadavist
 Description of late gadolinium enhancement: There are 2 small regions of late gadolinium enhancement in the mid anterior wall; the more basal one is associated with regional hypokinesis.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: device related artifact=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00801779].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided information and the model's predicted probability of the occluded outcome being 'yes' (0.00801779), it is highly unlikely that this patient received a heart transplant. The main patient has undergone multiple surgeries including a complex biventricular repair following Fontan, indicating that the cardiac condition had been managed without necessitating a transplant up to this point. Furthermore, the absence of significant complications such as protein-losing enteropathy or a history of adverse events associated with Fontan physiology strengthens the rationale for a 'no' prediction regarding heart transplant necessity. Consequently, it seems that the patient has maintained sufficient cardiac function through their surgical interventions and does not appear to be a candidate for transplant at this time.","**Prediction: No, the patient did not receive a heart transplant.**

The main patient's surgical history indicates a progression through numerous complex surgical interventions, with a significant focus on managing a single ventricle condition and ultimately undergoing a biventricular conversion. Although some similar patients did receive heart transplants, it appears they had more severe complications or end-stage heart failure, which were not evident in the main patient’s status or surgical history. Additionally, the XGBoost model estimates a very low probability (0.008) of the occluded outcome being 'yes,' suggesting that given their current medical status and prior interventions, the likelihood of requiring a heart transplant remains low. Finally, there is no indication of conditions typically leading to a heart transplant, such as severe ventricular dysfunction or significant arrhythmias, observed in this patient’s data.","Based on the provided data, the predicted outcome for the main patient regarding whether they received a heart transplant is ""no."" Analyzing the main patient's extensive surgical history, including multiple interventions and a revision to a biventricular repair following Fontan surgery, it appears that the patient has been managed with complex surgical strategies rather than opting for a heart transplant. Moreover, the similar patients show trends where heart transplantation was often correlated with deteriorating conditions, including protein-losing enteropathy or other post-surgical complications, which do not appear to be present in the main patient’s clinical history. Additionally, the XGBoost model's estimated probability of 0.00801779 indicates a very low likelihood of the occluded outcome (heart transplant status) being positive, reinforcing the conclusion that this patient is unlikely to have received a transplant.","Based on the provided information, I predict that the main patient did not receive a heart transplant. Although the patient has a complex cardiac history that includes multiple surgeries and interventions, there is currently no indication of being listed for a heart transplant or having undergone any transplant surgery. 

Furthermore, examining the similar patients reveals a notable pattern: similar patients who eventually received transplants often had indicators such as significant ventricular dysfunction or other severe post-operative complications. While the XGBoost model output shows a low probability of the occluded outcome being ""yes"" (0.00801779), the main patient has relatively better ejection fraction metrics and does not show evidence of severe complications like some of the similar cases that resulted in transplantation, supporting the conclusion that the patient likely did not receive a transplant.",1,1,1,1,0
BCH-MOLFRA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Other relevant surgical or clinical history (optional): {S,L,L} TGA, VSD, superior inferior ventricles, hypoplastic and dysplastic TV, LAA with NB


BIVENTRICULAR REPAIR 10/2018

SURG (12/2013, 1m 10 days, Buenos Aires): modified stage I surgery with what they called a""palliative arterial switch operation"", Stansel anastomosis + 5 mm Sano (RV to PA) conduit + atrial septectomy. This was complicated by cyanosis, so shortly thereafter a 4 mm RMBTS was placed and the Sano conduit was ligated.
SURG (12/2013, 1m, Buenos Aires): BDG with ligation of the azygous vein and a ""small"" LSVC. Complicated by mediastinitis requiring lavage and extended antibiotic course
 CATH (03/2014, 4m, Buenos Aires): Coil occlusion RIMA and LIMA. Device occlusion of LSVC to CS.
 CATH (09/2016, 2y 10m, OSH): Hemodynamics, APCs occluded
SURG (11/2016, 3y, Buenos Aires): Extracardiac fenestrated Fontan (16mm GoreTex).
 CATH (08/2017, 3y, Porras): VVC and APC coil occlusion.
 CATH (10/2018, 4y, Porras): VVC and APC coil with coil and plug embolization of two big VVC.
SURG (10/2018, 4y DelNido): Biventricular conversion: takedown of extracardiac fontan, hemi-mustard baffle IVC flow to TV with bovine pericardium, pulmonary veins to MV, VSD closure with LV to NeoAo baffle using dacron patch, patch plasty of central PA with bovine pericardium and RV-PA conduit with 15mm aortic homograft, Restriction of Glenn flow to LPA via external suture ligature sized around 6mm Hegar.
CATH (1/20, 6 y, Porras): HD

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 2.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 2.7
 Patient height: 99.0
 Patient weight: 13.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6152860368906081
 Heart rate: 87.0
 Upper limb systolic blood pressure: 75.0
 Upper limb diastolic blood pressure: 27.0
 Upper limb mean blood pressure: 46.0
 Left ventricle end-diastolic volume: 66.4
 Left ventricle end-systolic volume: 25.5
 Left ventricular mass: 33.6
 Right ventricular end-diastolic volume: 30.7
 Right ventricular end-systolic volume: 8.2
 Right ventricle mass: 10.0
 Native aorta flow rate: 4.48
 Ascending aorta, above the Stansel flow rate: 4.48
 Descending aorta flow rate: 1.08
 Right superior vena cava flow rate: 1.24
 Inferior vena cava, below the fenestration flow rate: 0.59
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.63
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.44
 Total right pulmonary vein flow rate: 2.13
 Total left pulmonary vein flow rate: 1.45
 Right atrioventricular valve/tricuspid inflow rate: 2.0
 Left atrioventricular valve/mitral inflow rate: 2.32
 Single ventricle ejection fraction 0.6529351184346035
 Single ventricle systolic volume 63.400000000000006
 Body mass index 14.080195898377717
 Mass to height volume indexed on BSA (exp = 2.7) 44.79932431978035
 Systemic ventricle end-systolic volume: 33.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.771273813241976
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.36212349011767
 Systemic ventricle end-diastolic volume: 97.10000000000001
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 157.8127800375607
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 182.56564364660017
 Systemic ventricle mass: 43.6
 Systemic ventricle mass indexed on BSA (exp=1) 70.8613512836009
 Systemic ventricle mass indexed on BSA (exp=1.3) 81.97592237890593
 Systemic ventricle mass to volume ratio: 0.8317569954083435
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.3518216659225468
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.5638542865528988
 Contrast type: Gadavist
 Description of late gadolinium enhancement: There are 2 small regions of late gadolinium enhancement in the mid anterior wall; the more basal one is associated with regional hypokinesis.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: device related artifact=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.05004829].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided data, it is predicted that the patient does not have a history of ascites (> trace). Key factors supporting this conclusion include the patient's multiple surgeries and interventions that have been performed without significant complications related to fluid retention, such as pleural effusions or chylous effusions, which are often associated with ascites. Additionally, the patient's current status report indicates no history of significant liver dysfunction, which could have contributed to ascites, and the relatively low predicted probability of 0.050 forming a part of the model suggests a low risk for this outcome. Hence, the available clinical history and MRI findings collectively reinforce this prediction.","Based on the information provided, I predict that the main patient does not have a history of ascites (> trace). The patient's surgical history, including multiple catheterizations and the biventricular repair, along with their MRI findings (which reveal late gadolinium enhancement but no significant regurgitation or other complications), suggest a relatively stable hemodynamic status. Additionally, examining the similar patients, none reported ascites, and given the low predicted probability (0.050) from the XGBoost model indicating a low likelihood of this outcome across the cohort, this further supports the conclusion that the main patient is unlikely to have developed ascites.","Based on the available data, it is predicted that the main patient does not have a history of ascites (> trace). The patient's surgical history is significant for complex interventions, including multiple surgeries and catheterizations, but no documented presence of ascites has been reported. In contrast, similar patients, particularly those who exhibited complications following Fontan procedures, have shown elevated instances of ascites as a complication; however, they also had more severe cardiac conditions and outcomes. The XGBoost model predicts a low probability (approximately 5%) of the occluded outcome being 'yes', which further supports the inference that the main patient's history likely does not include significant ascites, particularly given their surgery outcomes and current clinical status.","Based on the available information, it is predicted that the main patient does **not** have a history of ascites (> trace). The main patient has undergone multiple complex cardiac surgeries, including a biventricular conversion and an extracardiac fenestrated Fontan, but has no documentation of complications such as ascites or protein-losing enteropathy, which are often associated with fluid accumulation. 

In reviewing the similar patient cohort, many patients with a history of ascites also had diagnoses that tend to involve more severe hepatic complications or restrictive physiologies, which this patient does not appear to have. Furthermore, the low predicted probability of 0.05004829 from the XGBoost model suggests that, based on their clinical features and surgical history, the likelihood of either developing or having a history of significant ascites remains very low. Thus, the comprehensive analysis of both the specific and similar patient histories supports the conclusion that this patient likely does not have a history of ascites.",1,1,1,1,0
BCH-MOLFRA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Other relevant surgical or clinical history (optional): {S,L,L} TGA, VSD, superior inferior ventricles, hypoplastic and dysplastic TV, LAA with NB


BIVENTRICULAR REPAIR 10/2018

SURG (12/2013, 1m 10 days, Buenos Aires): modified stage I surgery with what they called a""palliative arterial switch operation"", Stansel anastomosis + 5 mm Sano (RV to PA) conduit + atrial septectomy. This was complicated by cyanosis, so shortly thereafter a 4 mm RMBTS was placed and the Sano conduit was ligated.
SURG (12/2013, 1m, Buenos Aires): BDG with ligation of the azygous vein and a ""small"" LSVC. Complicated by mediastinitis requiring lavage and extended antibiotic course
 CATH (03/2014, 4m, Buenos Aires): Coil occlusion RIMA and LIMA. Device occlusion of LSVC to CS.
 CATH (09/2016, 2y 10m, OSH): Hemodynamics, APCs occluded
SURG (11/2016, 3y, Buenos Aires): Extracardiac fenestrated Fontan (16mm GoreTex).
 CATH (08/2017, 3y, Porras): VVC and APC coil occlusion.
 CATH (10/2018, 4y, Porras): VVC and APC coil with coil and plug embolization of two big VVC.
SURG (10/2018, 4y DelNido): Biventricular conversion: takedown of extracardiac fontan, hemi-mustard baffle IVC flow to TV with bovine pericardium, pulmonary veins to MV, VSD closure with LV to NeoAo baffle using dacron patch, patch plasty of central PA with bovine pericardium and RV-PA conduit with 15mm aortic homograft, Restriction of Glenn flow to LPA via external suture ligature sized around 6mm Hegar.
CATH (1/20, 6 y, Porras): HD

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 2.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 2.7
 Patient height: 99.0
 Patient weight: 13.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6152860368906081
 Heart rate: 87.0
 Upper limb systolic blood pressure: 75.0
 Upper limb diastolic blood pressure: 27.0
 Upper limb mean blood pressure: 46.0
 Left ventricle end-diastolic volume: 66.4
 Left ventricle end-systolic volume: 25.5
 Left ventricular mass: 33.6
 Right ventricular end-diastolic volume: 30.7
 Right ventricular end-systolic volume: 8.2
 Right ventricle mass: 10.0
 Native aorta flow rate: 4.48
 Ascending aorta, above the Stansel flow rate: 4.48
 Descending aorta flow rate: 1.08
 Right superior vena cava flow rate: 1.24
 Inferior vena cava, below the fenestration flow rate: 0.59
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.63
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.44
 Total right pulmonary vein flow rate: 2.13
 Total left pulmonary vein flow rate: 1.45
 Right atrioventricular valve/tricuspid inflow rate: 2.0
 Left atrioventricular valve/mitral inflow rate: 2.32
 Single ventricle ejection fraction 0.6529351184346035
 Single ventricle systolic volume 63.400000000000006
 Body mass index 14.080195898377717
 Mass to height volume indexed on BSA (exp = 2.7) 44.79932431978035
 Systemic ventricle end-systolic volume: 33.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.771273813241976
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.36212349011767
 Systemic ventricle end-diastolic volume: 97.10000000000001
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 157.8127800375607
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 182.56564364660017
 Systemic ventricle mass: 43.6
 Systemic ventricle mass indexed on BSA (exp=1) 70.8613512836009
 Systemic ventricle mass indexed on BSA (exp=1.3) 81.97592237890593
 Systemic ventricle mass to volume ratio: 0.8317569954083435
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.3518216659225468
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.5638542865528988
 Contrast type: Gadavist
 Description of late gadolinium enhancement: There are 2 small regions of late gadolinium enhancement in the mid anterior wall; the more basal one is associated with regional hypokinesis.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: device related artifact=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00267014].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided information and longitudinal data concerning the main patient, I predict that the patient does not have a history of pacemaker placement (no). The surgical and clinical history indicates complex surgeries, including a biventricular conversion and prior interventions like the Fontan surgery, but there is no mention of any arrhythmias that would typically necessitate a pacemaker, such as sinus node dysfunction or tachyarrhythmias. Furthermore, the patient is currently classified under medication management, which does not indicate the need for pacing, supporting the likelihood of no prior pacemaker placement. Finally, the model's predicted probability of an adverse outcome related to pacemaker needs is extremely low (0.0027), aligning with this interpretation.","Based on the details provided for the main patient, there is no indication or documented history of pacemaker placement. The patient's extensive surgical history, including multiple interventions related to their complex congenital heart disease, does not mention complications or arrhythmias that typically require such devices. The similar patients exhibited varying outcomes, with some showing a history of pacemaker placement, but they usually had clinical signs or arrhythmias warranting it. Additionally, the XGBoost model predicts a very low probability (0.00267014) of experiencing significant arrhythmias that could lead to pacemaker placement, suggesting that the main patient is unlikely to need a pacemaker. Thus, I predict the outcome to be ""no,"" indicating that the patient does not have a history of pacemaker placement.","Based on the provided data, it is predicted that the main patient does **not** have a history of pacemaker placement. The main patient's extensive surgical history indicates he has undergone several complex cardiac procedures, including a biventricular repair and multiple interventions related to collateral vessels. In contrast, similar patients with a history of complex surgeries, such as the ones outlined, exhibited varied outcomes, with some having received pacemakers. However, given the specific details of the main patient's interventions, the absence of arrhythmias or significant systemic dysfunction points towards a likelihood that pacing was not required. Additionally, the XGBoost model’s low probability estimate of 0.00267014 reinforces the unlikely nature of a pacemaker being necessary in this clinical scenario. Thus, the evidence suggests that the main patient has not required a pacemaker, aligning with both clinical features and patterns seen in analogous cases.","Based on the analysis of the main patient's surgical history and MRI report, it appears that this patient has a complex cardiac history with multiple interventions, including Fontan surgery and the use of collaterals. Importantly, the absence of explicit documentation regarding pacemaker placement in the main patient's records raises the possibility that they have not undergone such a procedure. 

Comparatively, similar patients exhibit a varying incidence of pacemaker utilization; however, the current patient's detailed surgical history does not include any indications of specific rhythm issues that typically necessitate a pacemaker. Furthermore, the XGBoost model estimates a very low probability (0.00267) for the occluded outcome indicating a ""yes"" response for history of pacemaker placement. Consequently, it is reasonable to predict that the main patient does **not** have a history of pacemaker placement.",1,1,1,1,0
BCH-MOLFRA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Other relevant surgical or clinical history (optional): {S,L,L} TGA, VSD, superior inferior ventricles, hypoplastic and dysplastic TV, LAA with NB


BIVENTRICULAR REPAIR 10/2018

SURG (12/2013, 1m 10 days, Buenos Aires): modified stage I surgery with what they called a""palliative arterial switch operation"", Stansel anastomosis + 5 mm Sano (RV to PA) conduit + atrial septectomy. This was complicated by cyanosis, so shortly thereafter a 4 mm RMBTS was placed and the Sano conduit was ligated.
SURG (12/2013, 1m, Buenos Aires): BDG with ligation of the azygous vein and a ""small"" LSVC. Complicated by mediastinitis requiring lavage and extended antibiotic course
 CATH (03/2014, 4m, Buenos Aires): Coil occlusion RIMA and LIMA. Device occlusion of LSVC to CS.
 CATH (09/2016, 2y 10m, OSH): Hemodynamics, APCs occluded
SURG (11/2016, 3y, Buenos Aires): Extracardiac fenestrated Fontan (16mm GoreTex).
 CATH (08/2017, 3y, Porras): VVC and APC coil occlusion.
 CATH (10/2018, 4y, Porras): VVC and APC coil with coil and plug embolization of two big VVC.
SURG (10/2018, 4y DelNido): Biventricular conversion: takedown of extracardiac fontan, hemi-mustard baffle IVC flow to TV with bovine pericardium, pulmonary veins to MV, VSD closure with LV to NeoAo baffle using dacron patch, patch plasty of central PA with bovine pericardium and RV-PA conduit with 15mm aortic homograft, Restriction of Glenn flow to LPA via external suture ligature sized around 6mm Hegar.
CATH (1/20, 6 y, Porras): HD

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 2.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 2.7
 Patient height: 99.0
 Patient weight: 13.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6152860368906081
 Heart rate: 87.0
 Upper limb systolic blood pressure: 75.0
 Upper limb diastolic blood pressure: 27.0
 Upper limb mean blood pressure: 46.0
 Left ventricle end-diastolic volume: 66.4
 Left ventricle end-systolic volume: 25.5
 Left ventricular mass: 33.6
 Right ventricular end-diastolic volume: 30.7
 Right ventricular end-systolic volume: 8.2
 Right ventricle mass: 10.0
 Native aorta flow rate: 4.48
 Ascending aorta, above the Stansel flow rate: 4.48
 Descending aorta flow rate: 1.08
 Right superior vena cava flow rate: 1.24
 Inferior vena cava, below the fenestration flow rate: 0.59
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.63
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.44
 Total right pulmonary vein flow rate: 2.13
 Total left pulmonary vein flow rate: 1.45
 Right atrioventricular valve/tricuspid inflow rate: 2.0
 Left atrioventricular valve/mitral inflow rate: 2.32
 Single ventricle ejection fraction 0.6529351184346035
 Single ventricle systolic volume 63.400000000000006
 Body mass index 14.080195898377717
 Mass to height volume indexed on BSA (exp = 2.7) 44.79932431978035
 Systemic ventricle end-systolic volume: 33.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.771273813241976
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.36212349011767
 Systemic ventricle end-diastolic volume: 97.10000000000001
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 157.8127800375607
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 182.56564364660017
 Systemic ventricle mass: 43.6
 Systemic ventricle mass indexed on BSA (exp=1) 70.8613512836009
 Systemic ventricle mass indexed on BSA (exp=1.3) 81.97592237890593
 Systemic ventricle mass to volume ratio: 0.8317569954083435
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.3518216659225468
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.5638542865528988
 Contrast type: Gadavist
 Description of late gadolinium enhancement: There are 2 small regions of late gadolinium enhancement in the mid anterior wall; the more basal one is associated with regional hypokinesis.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: device related artifact=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0661893].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the information provided, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The patient's cardiac history is complex but does not indicate any neurological complications such as seizures. Furthermore, the clinical outcomes indicate no history of stroke or other significant CNS events which could contribute to seizure activity. The low probability (0.0661893) estimated by the XGBoost model for the occluded outcome suggests that seizures are relatively unlikely in this case, aligning with the lack of neurological history in the patient’s records.","Based on the data provided, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The main patient's comprehensive surgical history includes multiple surgical interventions but no documented history of seizures or neurological complications, which aligns with their current stable status in various functional assessments. While the similar patient cohort shows a small proportion (60% precision but only 7% recall for seizures) indicating some had this diagnosis, the overall low incidence (only 46 out of 711 patients) suggests that seizures are relatively rare in this population. Additionally, the XGBoost model's predicted probability of 0.0661893 further supports this reasoning by suggesting a low likelihood of seizure diagnosis in the main patient’s context.","Based on the longitudinal data provided, the prediction for the missing clinical outcome, whether the patient has a diagnosis of seizures requiring antiepileptic medications, is **""no.""** The main patient’s history does not indicate any neurological complications or any mention of seizures, despite undergoing multiple surgeries and interventions related to congenital heart disease. 

Moreover, when examining the similar patients, while some exhibited complications like protein-losing enteropathy and notable mortality associated with heart transplant and cardiac events, none of the similar cases explicitly reported a history of seizures requiring medication, further suggesting that such an outcome is not prevalent in this patient cohort. Lastly, the XGBoost model’s predicted probability of 0.0661893 indicates a low likelihood of a positive diagnosis for seizures in this group, reinforcing the conclusion that the main patient is less likely to have this diagnosis.","Based on the provided data, it is reasonable to predict that the main patient does not have a diagnosis of seizures requiring antiepileptic medications. The main patient has undergone complex cardiac surgeries and has a substantial surgical history, including a biventricular conversion and multiple catheterizations, but does not indicate any history of seizures or related complications. 

Reviewing the similar patients, while some have experienced seizures, there is a trend of higher seizure prevalence in cases with more significant complications or neurologic deficits, which is not evident in the primary patient’s clinical history. Furthermore, the XGBoost model estimates a low probability (around 6.6%) for the occluded outcome being 'yes,' reinforcing the likelihood that the main patient remains seizure-free based on both patient-specific data and patterns observed in similar cohorts. Thus, the likely outcome for the main patient is that they do not have a diagnosis of seizures requiring antiepileptic medications.",1,1,1,1,0
BCH-MOLFRA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 Other relevant surgical or clinical history (optional): {S,L,L} TGA, VSD, superior inferior ventricles, hypoplastic and dysplastic TV, LAA with NB


BIVENTRICULAR REPAIR 10/2018

SURG (12/2013, 1m 10 days, Buenos Aires): modified stage I surgery with what they called a""palliative arterial switch operation"", Stansel anastomosis + 5 mm Sano (RV to PA) conduit + atrial septectomy. This was complicated by cyanosis, so shortly thereafter a 4 mm RMBTS was placed and the Sano conduit was ligated.
SURG (12/2013, 1m, Buenos Aires): BDG with ligation of the azygous vein and a ""small"" LSVC. Complicated by mediastinitis requiring lavage and extended antibiotic course
 CATH (03/2014, 4m, Buenos Aires): Coil occlusion RIMA and LIMA. Device occlusion of LSVC to CS.
 CATH (09/2016, 2y 10m, OSH): Hemodynamics, APCs occluded
SURG (11/2016, 3y, Buenos Aires): Extracardiac fenestrated Fontan (16mm GoreTex).
 CATH (08/2017, 3y, Porras): VVC and APC coil occlusion.
 CATH (10/2018, 4y, Porras): VVC and APC coil with coil and plug embolization of two big VVC.
SURG (10/2018, 4y DelNido): Biventricular conversion: takedown of extracardiac fontan, hemi-mustard baffle IVC flow to TV with bovine pericardium, pulmonary veins to MV, VSD closure with LV to NeoAo baffle using dacron patch, patch plasty of central PA with bovine pericardium and RV-PA conduit with 15mm aortic homograft, Restriction of Glenn flow to LPA via external suture ligature sized around 6mm Hegar.
CATH (1/20, 6 y, Porras): HD

 Cardiac diagnosis: Other hypoplastic right ventricle or small right-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 2.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 2.7
 Patient height: 99.0
 Patient weight: 13.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6152860368906081
 Heart rate: 87.0
 Upper limb systolic blood pressure: 75.0
 Upper limb diastolic blood pressure: 27.0
 Upper limb mean blood pressure: 46.0
 Left ventricle end-diastolic volume: 66.4
 Left ventricle end-systolic volume: 25.5
 Left ventricular mass: 33.6
 Right ventricular end-diastolic volume: 30.7
 Right ventricular end-systolic volume: 8.2
 Right ventricle mass: 10.0
 Native aorta flow rate: 4.48
 Ascending aorta, above the Stansel flow rate: 4.48
 Descending aorta flow rate: 1.08
 Right superior vena cava flow rate: 1.24
 Inferior vena cava, below the fenestration flow rate: 0.59
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.63
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.44
 Total right pulmonary vein flow rate: 2.13
 Total left pulmonary vein flow rate: 1.45
 Right atrioventricular valve/tricuspid inflow rate: 2.0
 Left atrioventricular valve/mitral inflow rate: 2.32
 Single ventricle ejection fraction 0.6529351184346035
 Single ventricle systolic volume 63.400000000000006
 Body mass index 14.080195898377717
 Mass to height volume indexed on BSA (exp = 2.7) 44.79932431978035
 Systemic ventricle end-systolic volume: 33.7
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.771273813241976
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.36212349011767
 Systemic ventricle end-diastolic volume: 97.10000000000001
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 157.8127800375607
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 182.56564364660017
 Systemic ventricle mass: 43.6
 Systemic ventricle mass indexed on BSA (exp=1) 70.8613512836009
 Systemic ventricle mass indexed on BSA (exp=1.3) 81.97592237890593
 Systemic ventricle mass to volume ratio: 0.8317569954083435
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.3518216659225468
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 1.5638542865528988
 Contrast type: Gadavist
 Description of late gadolinium enhancement: There are 2 small regions of late gadolinium enhancement in the mid anterior wall; the more basal one is associated with regional hypokinesis.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: device related artifact=========================None
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01406133].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data, I predict that the missing clinical outcome for the patient is ""no,"" meaning the patient has not died. This conclusion is supported by several key factors: the patient has undergone multiple corrective surgeries, and recent MRI findings show reasonable cardiac function with a single-ventricle ejection fraction of approximately 65%, which is indicative of stability and preserved heart function. Furthermore, the patient's low probability of adverse outcomes calculated by the XGBoost model (0.014) suggests a very low likelihood of mortality. The absence of significant complications such as cardiac arrests or severe arrhythmias also points towards a relatively stable clinical status.","Based on the provided data, I predict that the main patient has not died. The patient has experienced a complicated surgical history with multiple interventions, including a biventricular repair and an extracardiac Fontan procedure, but there is no history of severe complications that typically lead to mortality, such as cardiac arrest or significant thrombus formation. Furthermore, the estimated probability of the occluded outcome being 'yes' is very low (0.014) according to the XGBoost model, suggesting that the risk of death in this case is deemed quite minimal. When assessing similar patients, while there are cases of mortality, such outcomes are associated with significant complications not present in this patient's history. Overall, the combination of favorable surgical history, the absence of critical complications, and the low probability of mortality supports the conclusion that the main patient has not died.","Based on the information provided, the predicted clinical outcome for the main patient is ""no,"" indicating that the patient has not died. This conclusion is supported by the main patient's surgical history, which exhibits a complex course but does not list any life-threatening complications or mortality indicators, such as significant cardiac arrest or critical events leading to death. Additionally, an analysis of the similar patients shows a notable number who have endured significant postoperative complications and died; however, their presentations included severe cases of protein-losing enteropathy and major vascular issues which do not directly correlate with the main patient's current condition. Finally, the XGBoost model predicts a low probability (1.4%) of the occluded outcome being 'yes,' further reinforcing the likelihood that the patient remains alive, given the robust survival rate reflected in the validation set and the absence of critical events in the main patient’s profile.","Based on the provided data and the similarities observed among similar patients, the prediction is that the main patient **has not died**. The main patient has a complex surgical history characterized by multiple interventions related to managing congenital heart disease and benefited from biventricular repair, indicating that they may have improved hemodynamics and outcomes. In contrast, while some similar patients have had adverse outcomes (including death), many have not, particularly those who were also on managing medical therapies such as anticoagulants and had not demonstrated progressive complications typically associated with higher mortality risk (like protein-losing enteropathy or significant heart failure symptoms). The XGBoost model estimates a very low probability of the occluded outcome being 'yes' (0.014), further supporting the conclusion that this patient likely continues to survive as they navigate ongoing care.",1,1,1,1,0
BCH-MORMAX-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): anatomy: tricuspid atresia, transposition of the great arteries, severe aortic arch hypoplasia, and critical aortic coarctation
-twin pregnancy born at 35 weeks gestation by C-section. He was prenatally diagnosed with congenital heart disease. His birth weight was 2.36 kg.

SURG (5/14, 4 days, Baird): stage 1 Norwood with arch reconstruction and LBTS, central PA plasty, ASD creation, ligation of patent ductus arteriosus, and aberrant right subclavian artery. Postop c/b delayed chest closure and dysrhythmias, specifically ectopic atrial tachycardia requiring propranolol. 
CATH (6/14, 1 month): HD, persistent short, self-resolving episodes of ectopic atrial tachycardia. The arrhythmia persisted despite removal of all wires and catheters from the heart. He received epinephrine with improvement in blood pressures and temporary cessation of the tachycardia. Following sheath removal and extubation he continued to have brief episodes of EAT and was transferred to 8S for additional monitoring overnight.
CATH (11/14): APC (LIMA) coiled
SURG (11/14, 5 months, Baird): ligation of BTS, R BDG with central PA plasty
CATH (6/16, 2 yrs): APCs coiled c/b bleeding **
SURG (6/2016, 2 years): 4 mm fen Lateral tunnel Fontan and LPA plasty with pulmonary homograft
Cardioversion (4/2017): admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His HR was noted to be increased by his mother and he presented to the local ER with a HR between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter
EPS (8/2017, 3 years): ablation:Intra-atrial reentrant circuit with TCL ~ 305 ms that was able to be sufficiently mapped from within the Fontan baffle.
CATH (12/20, 6 years): VVCs coiled, fen test occlusion, LPA BD, fen device closure
COVID (1/22) admitted

 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 119.5
 Patient weight: 23.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8887344617993979
 Heart rate: 84.0
 Upper limb systolic blood pressure: 98.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 67.0
 Left ventricle end-diastolic volume: 64.9
 Left ventricle end-systolic volume: 30.0
 Left ventricular mass: 35.2
 Right ventricular end-diastolic volume: 2.3
 Right ventricular end-systolic volume: 0.5
 Native aorta flow rate: 3.06
 Ascending aorta, above the Stansel flow rate: 3.06
 Descending aorta flow rate: 1.31
 Right superior vena cava flow rate: 1.26
 Inferior vena cava, below the fenestration flow rate: 1.44
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.58
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.01
 Total right pulmonary vein flow rate: 1.88
 Total left pulmonary vein flow rate: 1.6
 Qp/Qs (enter a number, not a ratio): 1.35
 Single ventricle ejection fraction 0.5377503852080123
 Single ventricle systolic volume 34.900000000000006
 Body mass index 16.66637488839481
 Mass to height volume indexed on BSA (exp = 2.7) 21.759520416646037
 Systemic ventricle end-systolic volume: 30.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 33.755864422383006
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.97177114174064
 Systemic ventricle end-diastolic volume: 64.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 73.0251867004219
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.65559823663226
 Systemic ventricle mass: 35.2
 Systemic ventricle mass indexed on BSA (exp=1) 39.606880922262725
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.03354480630902
 Systemic ventricle mass to volume ratio: 0.5423728813559322
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6102755149809357
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6322580093422037
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.No Fontan fenestration or baffle leak detected.Unobstructed right and left pulmonary arteries.Unobstructed pulmonary venous return to the left atrium.Large interatrial communication.Unobstructed Stansel anastomosis.No significant aortic arch obstruction.Normal mitral and neo-aortic valve function.Normal left ventricular size. Low normal left ventricular systolic function.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His heart rate was noted to be increased by his mother and he presented to the local Emergency Room with a heart rate between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter to Boston Children's Hospital. 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00164473].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data, it is likely that the patient did not receive a heart transplant. The patient has a complex history of congenital heart disease, multiple surgeries including a Fontan procedure, and significant atrial arrhythmias, but there is no indication of either heart failure or severe complications that typically necessitate a heart transplant. The XGBoost model also suggests a very low probability (0.00164473) of the outcome being 'yes', indicating that the model does not expect this patient to have received a transplant compared to others in the dataset. The absence of significant clinical history related to hepatopulmonary syndrome or worsening ventricular function further supports this prediction. Thus, the prediction is a 'no' for heart transplant.","Based on the available data, the predicted outcome is **No, the patient did not receive a heart transplant**. The patient’s surgical history features a complex trajectory involving multiple surgeries, including a Fontan procedure, but there is no indication of dire complications that typically necessitate a transplant, such as severe heart failure or significant ventricular dysfunction, as evidenced by the reasonable parameters observed in his MRI report. Furthermore, the similar patients' data indicates that despite some complexities, a majority did not require transplantation, and the XGBoost model's predicted probability (0.00164473) also supports a strong likelihood that transplantation was not an outcome for this patient. This aligns with the overall trends showing that while complex heart disease may lead to the consideration of transplant, numerous patients manage to maintain adequate function without needing this intervention.","Based on the available data, we predict that the main patient did **not** receive a heart transplant. The main patient has a complex surgical history of multiple interventions including a Fontan procedure, which typically indicates that the patient's condition is being managed without the need for transplantation at this time. Furthermore, the similar patients' outcomes show a relatively low incidence of heart transplantation among those with comparable conditions, particularly given the main patient's low-risk factors like stable ventricular volumes and flow rates, despite some arrhythmias. The XGBoost model prediction of a very low likelihood (0.00164473) for a heart transplant further supports this conclusion, indicating that the overall risk in the cohort for requiring a transplant is low, especially for patients with ongoing management post-Fontan.","Based on the information provided, I predict that the main patient did **not** receive a heart transplant. The patient's extensive surgical history, including multiple surgeries such as a Fontan procedure, suggests a complex cardiac condition that often leads to higher risks associated with transplantation. Moreover, the analysis of similar patients indicates a low rate of heart transplant among this cohort; the XGBoost model yields a very low probability (0.00164473) for the outcome ""received heart transplant,"" which aligns with the pattern observed in analogous cases experiencing similar complications and histories. Additionally, given the main patient's existing arrhythmias and post-surgical history without indication of progressive failure that typically necessitates transplantation, it further supports the conclusion that the patient has not progressed to requiring a heart transplant.",1,1,1,1,0
BCH-MORMAX-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): anatomy: tricuspid atresia, transposition of the great arteries, severe aortic arch hypoplasia, and critical aortic coarctation
-twin pregnancy born at 35 weeks gestation by C-section. He was prenatally diagnosed with congenital heart disease. His birth weight was 2.36 kg.

SURG (5/14, 4 days, Baird): stage 1 Norwood with arch reconstruction and LBTS, central PA plasty, ASD creation, ligation of patent ductus arteriosus, and aberrant right subclavian artery. Postop c/b delayed chest closure and dysrhythmias, specifically ectopic atrial tachycardia requiring propranolol. 
CATH (6/14, 1 month): HD, persistent short, self-resolving episodes of ectopic atrial tachycardia. The arrhythmia persisted despite removal of all wires and catheters from the heart. He received epinephrine with improvement in blood pressures and temporary cessation of the tachycardia. Following sheath removal and extubation he continued to have brief episodes of EAT and was transferred to 8S for additional monitoring overnight.
CATH (11/14): APC (LIMA) coiled
SURG (11/14, 5 months, Baird): ligation of BTS, R BDG with central PA plasty
CATH (6/16, 2 yrs): APCs coiled c/b bleeding **
SURG (6/2016, 2 years): 4 mm fen Lateral tunnel Fontan and LPA plasty with pulmonary homograft
Cardioversion (4/2017): admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His HR was noted to be increased by his mother and he presented to the local ER with a HR between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter
EPS (8/2017, 3 years): ablation:Intra-atrial reentrant circuit with TCL ~ 305 ms that was able to be sufficiently mapped from within the Fontan baffle.
CATH (12/20, 6 years): VVCs coiled, fen test occlusion, LPA BD, fen device closure
COVID (1/22) admitted

 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 119.5
 Patient weight: 23.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8887344617993979
 Heart rate: 84.0
 Upper limb systolic blood pressure: 98.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 67.0
 Left ventricle end-diastolic volume: 64.9
 Left ventricle end-systolic volume: 30.0
 Left ventricular mass: 35.2
 Right ventricular end-diastolic volume: 2.3
 Right ventricular end-systolic volume: 0.5
 Native aorta flow rate: 3.06
 Ascending aorta, above the Stansel flow rate: 3.06
 Descending aorta flow rate: 1.31
 Right superior vena cava flow rate: 1.26
 Inferior vena cava, below the fenestration flow rate: 1.44
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.58
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.01
 Total right pulmonary vein flow rate: 1.88
 Total left pulmonary vein flow rate: 1.6
 Qp/Qs (enter a number, not a ratio): 1.35
 Single ventricle ejection fraction 0.5377503852080123
 Single ventricle systolic volume 34.900000000000006
 Body mass index 16.66637488839481
 Mass to height volume indexed on BSA (exp = 2.7) 21.759520416646037
 Systemic ventricle end-systolic volume: 30.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 33.755864422383006
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.97177114174064
 Systemic ventricle end-diastolic volume: 64.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 73.0251867004219
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.65559823663226
 Systemic ventricle mass: 35.2
 Systemic ventricle mass indexed on BSA (exp=1) 39.606880922262725
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.03354480630902
 Systemic ventricle mass to volume ratio: 0.5423728813559322
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6102755149809357
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6322580093422037
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.No Fontan fenestration or baffle leak detected.Unobstructed right and left pulmonary arteries.Unobstructed pulmonary venous return to the left atrium.Large interatrial communication.Unobstructed Stansel anastomosis.No significant aortic arch obstruction.Normal mitral and neo-aortic valve function.Normal left ventricular size. Low normal left ventricular systolic function.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His heart rate was noted to be increased by his mother and he presented to the local Emergency Room with a heart rate between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter to Boston Children's Hospital. 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.05693256].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided data and the XGBoost model's predicted probability of 0.05693256 (indicating a low likelihood of a positive outcome), it is reasonable to predict that the patient does not have a diagnosis of seizures requiring antiepileptic medications. The patient's surgical history and cardiac complications primarily focus on significant arrhythmias (such as atrial flutter and ectopic atrial tachycardia) rather than seizures or neurological issues, which are generally less common in this demographic and context. Additionally, no mention is made of neurologic symptoms, seizures, or the use of antiepileptic medications in the patient's extensive clinical profile, further supporting the prediction that the answer is ""no.""","**Prediction:** No, the patient does not have a diagnosis of seizures requiring antiepileptic medications.

**Reasoning:** The main patient's extensive surgical history involving complex congenital heart disease and the Fontan procedure has been associated with several complications, including arrhythmias. However, there is no documented history of seizures or neurological events in the main patient's records, which indicates a stable neurologic status. Furthermore, while examining the similar patients, none of the comparable clinical histories indicated a diagnosis of seizures, and a high percentage of them did not share complications related to seizures requiring interventions. Combined with the XGBoost model predicting a low probability for this diagnosis (0.0569), we conclude that the main patient is unlikely to have this diagnosis.","Based on the provided data, it is likely that the main patient does not have a diagnosis of seizures requiring antiepileptic medications. The patient has a complex surgical history involving multiple cardiac interventions typical of single-ventricle patients, with no reported instances of seizures in either their clinical history or subsequent updates. 

Analyzing similar patients, most notably those with comparable cardiac diagnoses and previous surgical histories, the majority did not present with a seizure diagnosis. Furthermore, the XGBoost model's prediction probability of the missing outcome indicates a very low likelihood of seizures in this patient, with a predicted probability of only 5.7%. Given these patterns and the electronic health record data, it seems reasonable to conclude that the main patient is also unlikely to have seizures requiring intervention.","Based on the data, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The main patient's history does not indicate any seizure activity, and his cardiac history primarily revolves around congenital heart defects and arrhythmias rather than neurological issues. Moreover, when comparing to similar patients, particularly those with tricuspid atresia and related surgical histories, the occurrence of seizures or the need for antiepileptic medication is relatively rare. The XGBoost model's predicted probability of the occluded outcome being 'yes' is only 5.69%, which reinforces the conclusion that it is less likely for the patient to have a diagnosis of seizures given the overall trends and available clinical evidence.",1,1,1,1,0
BCH-MORMAX-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): anatomy: tricuspid atresia, transposition of the great arteries, severe aortic arch hypoplasia, and critical aortic coarctation
-twin pregnancy born at 35 weeks gestation by C-section. He was prenatally diagnosed with congenital heart disease. His birth weight was 2.36 kg.

SURG (5/14, 4 days, Baird): stage 1 Norwood with arch reconstruction and LBTS, central PA plasty, ASD creation, ligation of patent ductus arteriosus, and aberrant right subclavian artery. Postop c/b delayed chest closure and dysrhythmias, specifically ectopic atrial tachycardia requiring propranolol. 
CATH (6/14, 1 month): HD, persistent short, self-resolving episodes of ectopic atrial tachycardia. The arrhythmia persisted despite removal of all wires and catheters from the heart. He received epinephrine with improvement in blood pressures and temporary cessation of the tachycardia. Following sheath removal and extubation he continued to have brief episodes of EAT and was transferred to 8S for additional monitoring overnight.
CATH (11/14): APC (LIMA) coiled
SURG (11/14, 5 months, Baird): ligation of BTS, R BDG with central PA plasty
CATH (6/16, 2 yrs): APCs coiled c/b bleeding **
SURG (6/2016, 2 years): 4 mm fen Lateral tunnel Fontan and LPA plasty with pulmonary homograft
Cardioversion (4/2017): admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His HR was noted to be increased by his mother and he presented to the local ER with a HR between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter
EPS (8/2017, 3 years): ablation:Intra-atrial reentrant circuit with TCL ~ 305 ms that was able to be sufficiently mapped from within the Fontan baffle.
CATH (12/20, 6 years): VVCs coiled, fen test occlusion, LPA BD, fen device closure
COVID (1/22) admitted

 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 119.5
 Patient weight: 23.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8887344617993979
 Heart rate: 84.0
 Upper limb systolic blood pressure: 98.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 67.0
 Left ventricle end-diastolic volume: 64.9
 Left ventricle end-systolic volume: 30.0
 Left ventricular mass: 35.2
 Right ventricular end-diastolic volume: 2.3
 Right ventricular end-systolic volume: 0.5
 Native aorta flow rate: 3.06
 Ascending aorta, above the Stansel flow rate: 3.06
 Descending aorta flow rate: 1.31
 Right superior vena cava flow rate: 1.26
 Inferior vena cava, below the fenestration flow rate: 1.44
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.58
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.01
 Total right pulmonary vein flow rate: 1.88
 Total left pulmonary vein flow rate: 1.6
 Qp/Qs (enter a number, not a ratio): 1.35
 Single ventricle ejection fraction 0.5377503852080123
 Single ventricle systolic volume 34.900000000000006
 Body mass index 16.66637488839481
 Mass to height volume indexed on BSA (exp = 2.7) 21.759520416646037
 Systemic ventricle end-systolic volume: 30.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 33.755864422383006
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.97177114174064
 Systemic ventricle end-diastolic volume: 64.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 73.0251867004219
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.65559823663226
 Systemic ventricle mass: 35.2
 Systemic ventricle mass indexed on BSA (exp=1) 39.606880922262725
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.03354480630902
 Systemic ventricle mass to volume ratio: 0.5423728813559322
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6102755149809357
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6322580093422037
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.No Fontan fenestration or baffle leak detected.Unobstructed right and left pulmonary arteries.Unobstructed pulmonary venous return to the left atrium.Large interatrial communication.Unobstructed Stansel anastomosis.No significant aortic arch obstruction.Normal mitral and neo-aortic valve function.Normal left ventricular size. Low normal left ventricular systolic function.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His heart rate was noted to be increased by his mother and he presented to the local Emergency Room with a heart rate between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter to Boston Children's Hospital. 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0012332].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided patient data, I predict that the patient does **not** have a history of pacemaker placement. The patient's surgical history includes multiple complex interventions and a notable presence of arrhythmias, particularly ectopic atrial tachycardia and atrial flutter, which were managed through medications and ablation rather than device therapy. Furthermore, there is no mention of pacemaker implantation or associated interventions in the surgical history, and the fact that the patient has undergone several electrophysiological studies suggests that arrhythmias have been addressed without resorting to permanently implantable devices such as pacemakers. The predicted probability of the occluded outcome being 'yes' is extremely low (0.0012332), aligning with the reasoning that a pacemaker has likely not been necessary in this case.","Based on the available data, the missing clinical outcome for the main patient is likely **no**, they do not have a history of pacemaker placement. The main patient has undergone multiple cardiac interventions, including successful management of atrial arrhythmias through electrophysiological studies and cardioversion, which suggests that rhythm control has been achieved without the need for a permanent pacemaker. Furthermore, among the similar patients analyzed, specifically one with an extensive cardiac history similar to that of our main patient, there was no indication of pacemaker placement despite other high-risk procedures, indicating a trend that in such cases, pacemaker placement might not often be necessary if arrhythmias can be effectively managed through other means. Additionally, the XGBoost model's prediction of a low probability (0.0012332) for a positive history of pacemaker placement aligns with the idea that such interventions would be rare in this context, reinforcing the conclusion.","Based on the detailed surgical history and clinical data of the main patient, it is less likely that the patient has a history of pacemaker placement. The patient has undergone a series of complex interventions, including atrial tachycardia treatments and an electrophysiologic study, but there is no record indicating the need for a pacemaker within the provided information. Moreover, the similar patients included in the analysis, while having undergone similar surgeries and experiencing arrhythmias, did not show a significant prevalence of pacemaker placements unless indicated by specific cardiac dysfunction or arrhythmic events. The XGBoost model's prediction probability of 0.0012332 suggests a very low likelihood of this condition being true for the patient, indicating that the occluded outcome is probably 'no' for having a history of pacemaker placement. Thus, it would be reasonable to predict that the patient does not have a history of pacemaker placement.","Based on the provided data, it is predicted that the main patient does **not** have a history of pacemaker placement. The main patient has undergone multiple surgeries and had episodes of arrhythmias, specifically atrial flutter and ectopic atrial tachycardia, but these have been managed without the permanent implantation of a pacemaker, as indicated by their surgery and catheterization history. In contrast, among the similar patients, none of them reported the need for a pacemaker despite complex surgical interventions and arrhythmias, suggesting that the absence of pacemaker placement may be a common trend within this specific cohort. Moreover, the estimated probability of the occluded outcome being 'yes' is exceedingly low (0.0012332), which further supports the conclusion that a history of pacemaker placement is unlikely for the main patient.",1,1,1,1,0
BCH-MORMAX-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): anatomy: tricuspid atresia, transposition of the great arteries, severe aortic arch hypoplasia, and critical aortic coarctation
-twin pregnancy born at 35 weeks gestation by C-section. He was prenatally diagnosed with congenital heart disease. His birth weight was 2.36 kg.

SURG (5/14, 4 days, Baird): stage 1 Norwood with arch reconstruction and LBTS, central PA plasty, ASD creation, ligation of patent ductus arteriosus, and aberrant right subclavian artery. Postop c/b delayed chest closure and dysrhythmias, specifically ectopic atrial tachycardia requiring propranolol. 
CATH (6/14, 1 month): HD, persistent short, self-resolving episodes of ectopic atrial tachycardia. The arrhythmia persisted despite removal of all wires and catheters from the heart. He received epinephrine with improvement in blood pressures and temporary cessation of the tachycardia. Following sheath removal and extubation he continued to have brief episodes of EAT and was transferred to 8S for additional monitoring overnight.
CATH (11/14): APC (LIMA) coiled
SURG (11/14, 5 months, Baird): ligation of BTS, R BDG with central PA plasty
CATH (6/16, 2 yrs): APCs coiled c/b bleeding **
SURG (6/2016, 2 years): 4 mm fen Lateral tunnel Fontan and LPA plasty with pulmonary homograft
Cardioversion (4/2017): admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His HR was noted to be increased by his mother and he presented to the local ER with a HR between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter
EPS (8/2017, 3 years): ablation:Intra-atrial reentrant circuit with TCL ~ 305 ms that was able to be sufficiently mapped from within the Fontan baffle.
CATH (12/20, 6 years): VVCs coiled, fen test occlusion, LPA BD, fen device closure
COVID (1/22) admitted

 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 119.5
 Patient weight: 23.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8887344617993979
 Heart rate: 84.0
 Upper limb systolic blood pressure: 98.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 67.0
 Left ventricle end-diastolic volume: 64.9
 Left ventricle end-systolic volume: 30.0
 Left ventricular mass: 35.2
 Right ventricular end-diastolic volume: 2.3
 Right ventricular end-systolic volume: 0.5
 Native aorta flow rate: 3.06
 Ascending aorta, above the Stansel flow rate: 3.06
 Descending aorta flow rate: 1.31
 Right superior vena cava flow rate: 1.26
 Inferior vena cava, below the fenestration flow rate: 1.44
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.58
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.01
 Total right pulmonary vein flow rate: 1.88
 Total left pulmonary vein flow rate: 1.6
 Qp/Qs (enter a number, not a ratio): 1.35
 Single ventricle ejection fraction 0.5377503852080123
 Single ventricle systolic volume 34.900000000000006
 Body mass index 16.66637488839481
 Mass to height volume indexed on BSA (exp = 2.7) 21.759520416646037
 Systemic ventricle end-systolic volume: 30.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 33.755864422383006
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.97177114174064
 Systemic ventricle end-diastolic volume: 64.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 73.0251867004219
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.65559823663226
 Systemic ventricle mass: 35.2
 Systemic ventricle mass indexed on BSA (exp=1) 39.606880922262725
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.03354480630902
 Systemic ventricle mass to volume ratio: 0.5423728813559322
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6102755149809357
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6322580093422037
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.No Fontan fenestration or baffle leak detected.Unobstructed right and left pulmonary arteries.Unobstructed pulmonary venous return to the left atrium.Large interatrial communication.Unobstructed Stansel anastomosis.No significant aortic arch obstruction.Normal mitral and neo-aortic valve function.Normal left ventricular size. Low normal left ventricular systolic function.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His heart rate was noted to be increased by his mother and he presented to the local Emergency Room with a heart rate between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter to Boston Children's Hospital. 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.03090512].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided data, it is predicted that the patient does **not** have a history of ascites (> trace) (answer: **no**). The patient has undergone multiple surgical procedures, including a successful Fontan operation, and has shown a pattern of managing arrhythmias effectively with interventions such as catheter ablation. The MRI report indicates unobstructed venous return and no significant effusions, which further supports the likelihood of normal fluid balance, reducing the risk of ascites. Additionally, the predicted probability of developing such complications indicated by the XGBoost model is relatively low (0.0309), suggesting that the patient is unlikely to have a problematic fluid accumulation history.","Based on the main patient's profile and the relevant historical and clinical data available, it seems likely that this patient does **not** have a history of ascites. The main patient has not documented any instances of ascites—either trace or otherwise—despite significant cardiac surgeries and a history of atrial tachyarrhythmias. 

When analyzing the similar patients' data, most of them also lacked a history of ascites, with only one of them showing non-chylous pleural effusions but still no history of significant ascitic episodes. Furthermore, the low predicted probability of 0.0309 according to the XGBoost model suggests a strong improbability of ascites in this patient’s condition. Contrasting these observations with the known outcomes in this group, it appears to align with the assertion that the main patient likely does not have a history of ascites.","Based on the available data, I predict that the main patient does **not** have a history of ascites (> trace). The main patient’s clinical history indicates no significant complications such as protein-losing enteropathy or other gastrointestinal issues that often correlate with ascites. Additionally, reviewing the outcomes of the similar patients, none of them reported a history of ascites, which suggests that this may not be a common complication among this cohort. The findings in the similar patients, coupled with the absence of related symptoms in the main patient’s data, lead to a conclusion that ascites is unlikely present in this case.","Based on the information provided, I predict that the main patient **does not have a history of ascites (> trace)**. The main patient underwent multiple cardiac surgeries, including a lateral tunnel Fontan, which often aims to enhance venous drainage and decrease complications such as ascites. Furthermore, among the similar patients, most do not report a history of ascites despite having undergone similar surgical interventions, suggesting that this outcome might be less common. The XGBoost model predicts a very low probability (3.09%) of the occluded outcome being 'yes,' further supporting the inference that the main patient likely does not experience ascites following their surgical history.",1,1,1,1,0
BCH-MORMAX-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): anatomy: tricuspid atresia, transposition of the great arteries, severe aortic arch hypoplasia, and critical aortic coarctation
-twin pregnancy born at 35 weeks gestation by C-section. He was prenatally diagnosed with congenital heart disease. His birth weight was 2.36 kg.

SURG (5/14, 4 days, Baird): stage 1 Norwood with arch reconstruction and LBTS, central PA plasty, ASD creation, ligation of patent ductus arteriosus, and aberrant right subclavian artery. Postop c/b delayed chest closure and dysrhythmias, specifically ectopic atrial tachycardia requiring propranolol. 
CATH (6/14, 1 month): HD, persistent short, self-resolving episodes of ectopic atrial tachycardia. The arrhythmia persisted despite removal of all wires and catheters from the heart. He received epinephrine with improvement in blood pressures and temporary cessation of the tachycardia. Following sheath removal and extubation he continued to have brief episodes of EAT and was transferred to 8S for additional monitoring overnight.
CATH (11/14): APC (LIMA) coiled
SURG (11/14, 5 months, Baird): ligation of BTS, R BDG with central PA plasty
CATH (6/16, 2 yrs): APCs coiled c/b bleeding **
SURG (6/2016, 2 years): 4 mm fen Lateral tunnel Fontan and LPA plasty with pulmonary homograft
Cardioversion (4/2017): admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His HR was noted to be increased by his mother and he presented to the local ER with a HR between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter
EPS (8/2017, 3 years): ablation:Intra-atrial reentrant circuit with TCL ~ 305 ms that was able to be sufficiently mapped from within the Fontan baffle.
CATH (12/20, 6 years): VVCs coiled, fen test occlusion, LPA BD, fen device closure
COVID (1/22) admitted

 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 119.5
 Patient weight: 23.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8887344617993979
 Heart rate: 84.0
 Upper limb systolic blood pressure: 98.0
 Upper limb diastolic blood pressure: 58.0
 Upper limb mean blood pressure: 67.0
 Left ventricle end-diastolic volume: 64.9
 Left ventricle end-systolic volume: 30.0
 Left ventricular mass: 35.2
 Right ventricular end-diastolic volume: 2.3
 Right ventricular end-systolic volume: 0.5
 Native aorta flow rate: 3.06
 Ascending aorta, above the Stansel flow rate: 3.06
 Descending aorta flow rate: 1.31
 Right superior vena cava flow rate: 1.26
 Inferior vena cava, below the fenestration flow rate: 1.44
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.58
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.01
 Total right pulmonary vein flow rate: 1.88
 Total left pulmonary vein flow rate: 1.6
 Qp/Qs (enter a number, not a ratio): 1.35
 Single ventricle ejection fraction 0.5377503852080123
 Single ventricle systolic volume 34.900000000000006
 Body mass index 16.66637488839481
 Mass to height volume indexed on BSA (exp = 2.7) 21.759520416646037
 Systemic ventricle end-systolic volume: 30.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 33.755864422383006
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 34.97177114174064
 Systemic ventricle end-diastolic volume: 64.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 73.0251867004219
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 75.65559823663226
 Systemic ventricle mass: 35.2
 Systemic ventricle mass indexed on BSA (exp=1) 39.606880922262725
 Systemic ventricle mass indexed on BSA (exp=1.3) 41.03354480630902
 Systemic ventricle mass to volume ratio: 0.5423728813559322
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.6102755149809357
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6322580093422037
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed inferior vena cava, superior vena cava, and Fontan baffle.No Fontan fenestration or baffle leak detected.Unobstructed right and left pulmonary arteries.Unobstructed pulmonary venous return to the left atrium.Large interatrial communication.Unobstructed Stansel anastomosis.No significant aortic arch obstruction.Normal mitral and neo-aortic valve function.Normal left ventricular size. Low normal left ventricular systolic function.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: admitted to the CICU via transport from an outside hospital. He had a 2 day history of nausea and vomiting. His heart rate was noted to be increased by his mother and he presented to the local Emergency Room with a heart rate between 230 and 240 beats per minute. He was given adenosine x 2 and diltiazem x 1 without response and was transferred in a narrow complex tachycardia, atrial flutter to Boston Children's Hospital. 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00904842].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided information, the prediction for the missing clinical outcome—whether the patient has died—is ""no"". The low predicted probability of the occluded outcome being 'yes' (0.009) from the XGBoost model suggests a very low likelihood of death. Furthermore, the detailed surgical history exhibits successful interventions and ongoing management post-surgery, with no documented occurrences of severe complications or critical conditions that typically lead to mortality, such as cardiac arrest, significant thromboembolic events, or major organ dysfunction. The patient is receiving routine monitoring and management, indicating a stable trajectory, further supporting the prediction that the patient is alive.","Based on the available data, I predict that the main patient has **not died**. The main patient has a complex history of congenital heart disease with multiple surgeries but has shown some stability in recent evaluations, including unobstructed circulation in the Fontan anatomy and no significant pulmonary or cardiac complications. Compared to similar patients, many of whom have had severe comorbidities and negative outcomes, this patient’s relatively better status—evident from their functional MRI results and a low predicted probability of poor outcomes (0.00904842)—supports the conclusion that they remain alive. The success of interventions also aligns more closely with similar living patients, reinforcing that the likelihood of death is low.","Based on the provided information, I predict that the missing clinical outcome for the main patient is ""no,"" indicating that the patient has not died. Despite the complexity of this patient's cardiac history, including significant surgical interventions and the presence of atrial tachyarrhythmias, the reported MRI findings suggest stable hemodynamic status, with unobstructed blood flow from key vascular structures. Additionally, the similar patients with lower ejection fractions and higher volumes had minimal mortality associated with comparable clinical presentations and interventions. The estimated probability of the occluded outcome being 'yes' is low (0.009), and the overall profile of the patient does not align with the high-risk factors observed in deceased patients from the similar cohort.","Based on the information provided, the predicted clinical outcome for the main patient is ""no,"" they have not died. The patient's extensive surgical history, including a successful Lateral Tunnel Fontan and ongoing management of atrial tachyarrhythmias, suggests that they are under close monitoring and their conditions are actively managed. Additionally, the XGBoost model estimates the probability of the outcome being 'yes' (indicating death) to be very low at 0.00904842, highlighting that the patient has favorable odds against mortality. Compared to similar patients, many who underwent similar procedures and have demonstrated survival, reinforce that there is no indication of imminent risk regarding this patient’s lifespan.",1,1,1,1,0
BCH-MOSSTA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 1.0
 Other relevant surgical or clinical history (optional): CATH ( 6/1979): HD
CATH (7/1985): HD
SURG (11/1986, BHC) Patient underwent a modified Fontan operation with RA to PA connection.  
SURG (12/1986, BCH): prolonged pleuro-cardial effusions post Fontan --> peluro-pericardial window
CATH (3/2009, Rhodes, Duke ) Initially, angiography revealed a widely patent confluence of the hepatic veins with classic Fontan connection and no obstruction despite mild tapering of the connection to the right atrial appendage to the main PA. Saturation hemodynamics included a systemic saturation of 65%, a mixed venous saturation of 91%, and Qp/Qs equal to 1. Cardiac index was calculated at 2.1 L/min/m2. The main Fontan pressures were 13 mmHg. An AP collateral off the descending aorta was coiled at this procedure. 
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 13.2
 Patient height: 154.0
 Patient weight: 87.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.9830097979853916
 Heart rate: 83.0
 Upper limb systolic blood pressure: 123.0
 Upper limb diastolic blood pressure: 69.0
 Upper limb mean blood pressure: 81.0
 Left ventricle end-diastolic volume: 167.3
 Left ventricle end-systolic volume: 83.1
 Left ventricular mass: 87.4
 Right ventricular end-diastolic volume: 8.0
 Right ventricular end-systolic volume: 4.3
 Right ventricle mass: 8.0
 Native aorta flow rate: 5.1
 Ascending aorta, above the Stansel flow rate: 5.1
 Descending aorta flow rate: 3.6
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 3.7
 Single ventricle ejection fraction 0.5014261266400457
 Single ventricle systolic volume 87.90000000000002
 Body mass index 37.021420138303256
 Mass to height volume indexed on BSA (exp = 2.7) 29.733253148214516
 Systemic ventricle end-systolic volume: 87.39999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.074416621033684
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.89129385173553
 Systemic ventricle end-diastolic volume: 175.3
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.40097521358359
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 71.98791547150161
 Systemic ventricle mass: 95.4
 Systemic ventricle mass indexed on BSA (exp=1) 48.10868816529307
 Systemic ventricle mass indexed on BSA (exp=1.3) 39.17653814022392
 Systemic ventricle mass to volume ratio: 1.5224148236700539
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7677293502113444
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6251880755215109
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Relatively large artifact from a presumed steel coil is present in the upper left thorax that obscures adjacent structures including the arch, pulmonary arteries, and left upper pulmonary vein.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00420892].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided information, I predict that the missing clinical outcome—whether the patient has died—is ""no."" The patient has a history of atrial tachyarrhythmias and has undergone several interventions without any indication of severe complications such as recurring thromboembolism or major arrhythmias that would lead to mortality. Moreover, the XGBoost model estimates the probability of the occluded outcome being 'yes' (death) at only 0.0042, which supports a very low likelihood of mortality based on the patient's clinical profile and MRI findings. Additionally, the absence of serious complications like protein-losing enteropathy or a heart transplant further corroborates a stable clinical condition.","Based on the provided data, I predict that the main patient has not died. The main patient's surgical history indicates a single surgical procedure (a Fontan operation) and stable hemodynamic parameters, along with a notable lack of significant complications such as pleural effusions, cardiac arrest, or thrombus formation. In contrast, the similar patients showed a higher incidence of severe complications, such as severe regurgitation and significant cardiac issues leading to death, particularly in patients with complex surgical histories and more advanced morbidity. The XGBoost model predicts a very low probability (0.42%) of the occluded outcome indicating death, further supporting the reasoning that the main patient is likely to have a better prognosis compared to the worsening outcomes observed in the similar cohort.","The predicted clinical outcome for the main patient regarding death is ""no."" This prediction is based on several factors. First, the main patient's MRI report indicates relatively stable hemodynamics post-Fontan surgery, with a single ventricle ejection fraction of approximately 50%. Additionally, the similar patients who experienced death generally had severe complications, such as substantial protein-losing enteropathy, malignant arrhythmias, and other critical conditions that are not present in the main patient's history. Furthermore, the XGBoost model suggests a very low predicted probability of negative outcomes, emphasizing the low likelihood of mortality given the stability observed in the main patient's clinical and MRI data.","Based on the longitudinal data of the main patient and comparisons to similar patients, it is predicted that the main patient has not died. The patient has a relatively stable cardiac status post-Fontan surgery, without significant complications such as protein-losing enteropathy or a history of severe arrhythmias reported. While the XGBoost model presents a very low predicted probability (0.0042) for the adverse outcome of death, reflecting similarity with the low incidence of deaths among patients with comparable cardiac anatomy and stable post-operative profiles. In contrast, similar patients, especially those with known complications like significant ventricular dysfunction or severe arrhythmias, showed higher mortality risk. Additionally, the main patient has had a series of favorable evaluations in MRI and surgical history, indicating a better clinical trajectory. Thus, while it remains critical to continuously monitor, the data suggests that the main patient is likely still alive.",1,1,1,1,0
BCH-MOSSTA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 1.0
 Other relevant surgical or clinical history (optional): CATH ( 6/1979): HD
CATH (7/1985): HD
SURG (11/1986, BHC) Patient underwent a modified Fontan operation with RA to PA connection.  
SURG (12/1986, BCH): prolonged pleuro-cardial effusions post Fontan --> peluro-pericardial window
CATH (3/2009, Rhodes, Duke ) Initially, angiography revealed a widely patent confluence of the hepatic veins with classic Fontan connection and no obstruction despite mild tapering of the connection to the right atrial appendage to the main PA. Saturation hemodynamics included a systemic saturation of 65%, a mixed venous saturation of 91%, and Qp/Qs equal to 1. Cardiac index was calculated at 2.1 L/min/m2. The main Fontan pressures were 13 mmHg. An AP collateral off the descending aorta was coiled at this procedure. 
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 13.2
 Patient height: 154.0
 Patient weight: 87.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.9830097979853916
 Heart rate: 83.0
 Upper limb systolic blood pressure: 123.0
 Upper limb diastolic blood pressure: 69.0
 Upper limb mean blood pressure: 81.0
 Left ventricle end-diastolic volume: 167.3
 Left ventricle end-systolic volume: 83.1
 Left ventricular mass: 87.4
 Right ventricular end-diastolic volume: 8.0
 Right ventricular end-systolic volume: 4.3
 Right ventricle mass: 8.0
 Native aorta flow rate: 5.1
 Ascending aorta, above the Stansel flow rate: 5.1
 Descending aorta flow rate: 3.6
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 3.7
 Single ventricle ejection fraction 0.5014261266400457
 Single ventricle systolic volume 87.90000000000002
 Body mass index 37.021420138303256
 Mass to height volume indexed on BSA (exp = 2.7) 29.733253148214516
 Systemic ventricle end-systolic volume: 87.39999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.074416621033684
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.89129385173553
 Systemic ventricle end-diastolic volume: 175.3
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.40097521358359
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 71.98791547150161
 Systemic ventricle mass: 95.4
 Systemic ventricle mass indexed on BSA (exp=1) 48.10868816529307
 Systemic ventricle mass indexed on BSA (exp=1.3) 39.17653814022392
 Systemic ventricle mass to volume ratio: 1.5224148236700539
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7677293502113444
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6251880755215109
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Relatively large artifact from a presumed steel coil is present in the upper left thorax that obscures adjacent structures including the arch, pulmonary arteries, and left upper pulmonary vein.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.02400114].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the data provided, it is predicted that the patient does **not** have a diagnosis of seizures requiring antiepileptic medications ('no'). The patient's MRI findings show no evidence of late gadolinium enhancement, which may suggest healthy myocardial tissue and a lower likelihood of structural changes associated with seizure risks. Additionally, there is no documented history of seizures or neurological issues in the patient's clinical update, and while there is a history of atrial arrhythmias, these do not directly imply a seizure disorder. The estimated probability of the outcome being 'yes' is very low (0.024), further supporting the prediction of 'no'.","Based on the information provided, it is predicted that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The main patient has no documented history of seizures, and despite the presence of atrial tachyarrhythmias, no other complications typical of seizure disorders have been noted. Additionally, the similar patient cohort revealed a considerably low incidence of seizure diagnosis among patients with comparable clinical histories (only 1 out of many similar cases). Furthermore, the XGBoost model's predicted probability for the occluded outcome denoting a seizure diagnosis is very low (0.024), suggesting that the correlation for seizures among this patient group is minimal and thus, aligns with the absence of seizure history in the main patient.","Based on the provided information, it is predicted that the main patient does not have a diagnosis of seizures requiring antiepileptic medications. This conclusion is supported by the patient's stable hemodynamics and absence of significant complications following their Fontan surgery. Comparatively, the similar patients who experienced seizures or related complications often had more complex underlying conditions, such as significant ventricular dysfunction or a history of major cardiac interventions (e.g., undergoing heart/liver transplants), which are not present in the main patient's profile. Furthermore, the XGBoost model's estimated probability of the occluded outcome being 'yes' (0.024) reflects a very low likelihood of seizure diagnosis, aligning with the observed outcomes in the similar patient cohort.","Based on the provided data, it is predicted that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The main patient has a history of atrial tachyarrhythmias and has undergone certain interventions on their Fontan pathway without reported complications like seizures, renal dysfunction, or significant intracardiac thrombus that could inform such a diagnosis. Additionally, examining similar patients, many of whom have complex surgical histories and some incidence of seizures, it appears that those with a history of comorbidities (e.g., protein-losing enteropathy or elevated liver fibrosis) have a higher incidence of seizures. Since the main patient shows a clean history with no such comorbidities or significant neurological issues reported, the likelihood of them having seizures appears low, especially given the predicted probability of the occluded outcome being 'yes' is only 0.024, which indicates a strong tendency towards 'no'.",1,1,1,1,0
BCH-MOSSTA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 1.0
 Other relevant surgical or clinical history (optional): CATH ( 6/1979): HD
CATH (7/1985): HD
SURG (11/1986, BHC) Patient underwent a modified Fontan operation with RA to PA connection.  
SURG (12/1986, BCH): prolonged pleuro-cardial effusions post Fontan --> peluro-pericardial window
CATH (3/2009, Rhodes, Duke ) Initially, angiography revealed a widely patent confluence of the hepatic veins with classic Fontan connection and no obstruction despite mild tapering of the connection to the right atrial appendage to the main PA. Saturation hemodynamics included a systemic saturation of 65%, a mixed venous saturation of 91%, and Qp/Qs equal to 1. Cardiac index was calculated at 2.1 L/min/m2. The main Fontan pressures were 13 mmHg. An AP collateral off the descending aorta was coiled at this procedure. 
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 13.2
 Patient height: 154.0
 Patient weight: 87.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.9830097979853916
 Heart rate: 83.0
 Upper limb systolic blood pressure: 123.0
 Upper limb diastolic blood pressure: 69.0
 Upper limb mean blood pressure: 81.0
 Left ventricle end-diastolic volume: 167.3
 Left ventricle end-systolic volume: 83.1
 Left ventricular mass: 87.4
 Right ventricular end-diastolic volume: 8.0
 Right ventricular end-systolic volume: 4.3
 Right ventricle mass: 8.0
 Native aorta flow rate: 5.1
 Ascending aorta, above the Stansel flow rate: 5.1
 Descending aorta flow rate: 3.6
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 3.7
 Single ventricle ejection fraction 0.5014261266400457
 Single ventricle systolic volume 87.90000000000002
 Body mass index 37.021420138303256
 Mass to height volume indexed on BSA (exp = 2.7) 29.733253148214516
 Systemic ventricle end-systolic volume: 87.39999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.074416621033684
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.89129385173553
 Systemic ventricle end-diastolic volume: 175.3
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.40097521358359
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 71.98791547150161
 Systemic ventricle mass: 95.4
 Systemic ventricle mass indexed on BSA (exp=1) 48.10868816529307
 Systemic ventricle mass indexed on BSA (exp=1.3) 39.17653814022392
 Systemic ventricle mass to volume ratio: 1.5224148236700539
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7677293502113444
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6251880755215109
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Relatively large artifact from a presumed steel coil is present in the upper left thorax that obscures adjacent structures including the arch, pulmonary arteries, and left upper pulmonary vein.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00092633].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided information, the patient likely does not have a history of pacemaker placement. The MRI reports and clinical history reveal a complex cardiac situation, including arrhythmias that have required emergent intervention, but the lack of documented significant tachyarrhythmias or other complications that often necessitate pacemaker insertion suggests that pacing support has not been needed. Furthermore, the model's estimated probability for the occluded outcome is very low (0.00092633), indicating that it is unlikely for the patient to require a pacemaker given their clinical situation and outcomes in the cohort studied. Therefore, I would predict that the answer is ""no.""","Based on the available information, the predicted outcome for the main patient is **no**, they do not have a history of pacemaker placement. The main patient's surgical history indicates only one cardiac surgery (the Fontan operation) and no mention of arrhythmias that would typically necessitate a pacemaker. In contrast, among the similar patients, those with a history of pacemaker placement either had more complex morphological and surgical histories, which often included multiple interventions, or significant complications such as arrhythmias. While the main patient does have a history of atrial tachyarrhythmias and was treated with defibrillation, their stable hemodynamics and relatively straightforward surgical history suggest that pacing was not required, aligning with the observed low rate of pacemaker necessity in the cohort with similar simpler surgical backgrounds. Additionally, the calculated probability from the XGBoost model (0.00092633), indicating a low likelihood of having had a pacemaker placement, supports this conclusion.","Based on the available data, it is likely that the main patient does not have a history of pacemaker placement. The main patient has a history of atrial tachyarrhythmias but has not undergone any recorded electrophysiologic studies, which suggests that their arrhythmias may have been managed without the need for permanent pacing interventions. Furthermore, among the similar patients, those with significant surgical histories and the presence of cardiac arrhythmias either had pacemakers in place or were monitored closely, indicating a potential pattern that patients with more severe arrhythmias commonly require pacing devices. Given the low probability (approximately 0.00092633) suggested by the XGBoost model for the patient’s adverse outcome, it further reinforces the notion that they may not require a pacemaker at this stage of their clinical history. Hence, the most reasonable prediction is that the main patient does not have a history of pacemaker placement.","Based on the provided data, it is predicted that the patient **does not** have a history of pacemaker placement. The main patient has a complex surgical history surrounding Fontan surgery and exhibits atrial tachyarrhythmias, which are sometimes managed without pacemaker implantation. Moreover, the similar patients in the cohort with comparable surgical histories and complications, including those with atrial arrhythmias, have not demonstrated a common trend of requiring pacemaker placement. Additionally, the XGBoost model's predicted probability (0.00092633) suggests a very low likelihood of this outcome, reinforcing the assessment that pacemaker placement is not a typical intervention for this patient profile.",1,1,1,1,0
BCH-MOSSTA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 1.0
 Other relevant surgical or clinical history (optional): CATH ( 6/1979): HD
CATH (7/1985): HD
SURG (11/1986, BHC) Patient underwent a modified Fontan operation with RA to PA connection.  
SURG (12/1986, BCH): prolonged pleuro-cardial effusions post Fontan --> peluro-pericardial window
CATH (3/2009, Rhodes, Duke ) Initially, angiography revealed a widely patent confluence of the hepatic veins with classic Fontan connection and no obstruction despite mild tapering of the connection to the right atrial appendage to the main PA. Saturation hemodynamics included a systemic saturation of 65%, a mixed venous saturation of 91%, and Qp/Qs equal to 1. Cardiac index was calculated at 2.1 L/min/m2. The main Fontan pressures were 13 mmHg. An AP collateral off the descending aorta was coiled at this procedure. 
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 13.2
 Patient height: 154.0
 Patient weight: 87.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.9830097979853916
 Heart rate: 83.0
 Upper limb systolic blood pressure: 123.0
 Upper limb diastolic blood pressure: 69.0
 Upper limb mean blood pressure: 81.0
 Left ventricle end-diastolic volume: 167.3
 Left ventricle end-systolic volume: 83.1
 Left ventricular mass: 87.4
 Right ventricular end-diastolic volume: 8.0
 Right ventricular end-systolic volume: 4.3
 Right ventricle mass: 8.0
 Native aorta flow rate: 5.1
 Ascending aorta, above the Stansel flow rate: 5.1
 Descending aorta flow rate: 3.6
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 3.7
 Single ventricle ejection fraction 0.5014261266400457
 Single ventricle systolic volume 87.90000000000002
 Body mass index 37.021420138303256
 Mass to height volume indexed on BSA (exp = 2.7) 29.733253148214516
 Systemic ventricle end-systolic volume: 87.39999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.074416621033684
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.89129385173553
 Systemic ventricle end-diastolic volume: 175.3
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.40097521358359
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 71.98791547150161
 Systemic ventricle mass: 95.4
 Systemic ventricle mass indexed on BSA (exp=1) 48.10868816529307
 Systemic ventricle mass indexed on BSA (exp=1.3) 39.17653814022392
 Systemic ventricle mass to volume ratio: 1.5224148236700539
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7677293502113444
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6251880755215109
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Relatively large artifact from a presumed steel coil is present in the upper left thorax that obscures adjacent structures including the arch, pulmonary arteries, and left upper pulmonary vein.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00159513].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data, I predict that the main patient did **not** receive a heart transplant. The patient's MRI report indicates stable hemodynamics with a systemic saturation of 65% and relatively low cardiac output, which suggests some level of adaptation to the Fontan physiology rather than progressing toward transplant. Furthermore, the patient has no significant history of complications commonly associated with the need for transplantation, such as protein-losing enteropathy or severe heart failure, and has maintained a NYHA status consistent with manageable heart function. The XGBoost model's prediction probability (0.0016) also suggests a strong indication that a transplant has not occurred, corroborating clinical features that do not typically lead to transplantation.","Based on the provided data, I would predict that the main patient did **not** receive a heart transplant. This conclusion is drawn from the main patient's clinical history, which indicates a single Fontan surgery with no significant postoperative complications such as protein-losing enteropathy or cardiac arrests, both of which are common precursors to the need for transplantation in similar patients. Additionally, the similar patients' experiences highlight that those with more complex surgical histories or significant complications, indicated by multiple interventions and deteriorated conditions, were more likely to receive transplants. The estimated probability of the occluded outcome being 'yes' (0.0016) further supports the likelihood that the main patient's condition remains stable enough to avoid transplantation.","Given the main patient's single-ventricle condition, surgical history, and current status, the prediction is that the patient did **not** receive a heart transplant. The patient has a history of atrial tachyarrhythmias and has undergone limited surgical intervention, specifically a modified Fontan operation. In contrast, in the similar patients, those who received transplants often had severe complications such as protein-losing enteropathy or malignant arrhythmias, which were not documented for the main patient. The predictive model's low probability of heart transplant at 0.0016 and the high validation accuracy suggest that, although heart transplants are critical for some patients, the main patient's stable hemodynamic status with satisfactory saturation levels and absence of severe complications point towards a decision against transplant.","Based on the available information, I predict that the main patient did not receive a heart transplant. This conclusion is supported by the fact that, despite some cardiovascular complications indicated in the MRI report and surgical history, the patient has not exhibited severe clinical deterioration typically associated with heart transplant necessity. Moreover, a significant percentage of similar patients who did not experience heart transplant manifested complications such as significant atrial arrhythmias or developmental issues without requiring transplantation as indicated in their histories. Additionally, the XGBoost estimate of the occluded outcome probability being very low (0.00159513) reinforces the likelihood that this patient remains stable enough to avoid a heart transplant.",1,1,1,1,0
BCH-MOSSTA-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 1.0
 Other relevant surgical or clinical history (optional): CATH ( 6/1979): HD
CATH (7/1985): HD
SURG (11/1986, BHC) Patient underwent a modified Fontan operation with RA to PA connection.  
SURG (12/1986, BCH): prolonged pleuro-cardial effusions post Fontan --> peluro-pericardial window
CATH (3/2009, Rhodes, Duke ) Initially, angiography revealed a widely patent confluence of the hepatic veins with classic Fontan connection and no obstruction despite mild tapering of the connection to the right atrial appendage to the main PA. Saturation hemodynamics included a systemic saturation of 65%, a mixed venous saturation of 91%, and Qp/Qs equal to 1. Cardiac index was calculated at 2.1 L/min/m2. The main Fontan pressures were 13 mmHg. An AP collateral off the descending aorta was coiled at this procedure. 
 Cardiac diagnosis: Double inlet left ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Atrial-pulmonary Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 13.2
 Patient height: 154.0
 Patient weight: 87.8
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.9830097979853916
 Heart rate: 83.0
 Upper limb systolic blood pressure: 123.0
 Upper limb diastolic blood pressure: 69.0
 Upper limb mean blood pressure: 81.0
 Left ventricle end-diastolic volume: 167.3
 Left ventricle end-systolic volume: 83.1
 Left ventricular mass: 87.4
 Right ventricular end-diastolic volume: 8.0
 Right ventricular end-systolic volume: 4.3
 Right ventricle mass: 8.0
 Native aorta flow rate: 5.1
 Ascending aorta, above the Stansel flow rate: 5.1
 Descending aorta flow rate: 3.6
 Right superior vena cava flow rate: 1.1
 Inferior vena cava, below the fenestration flow rate: 3.7
 Single ventricle ejection fraction 0.5014261266400457
 Single ventricle systolic volume 87.90000000000002
 Body mass index 37.021420138303256
 Mass to height volume indexed on BSA (exp = 2.7) 29.733253148214516
 Systemic ventricle end-systolic volume: 87.39999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 44.074416621033684
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 35.89129385173553
 Systemic ventricle end-diastolic volume: 175.3
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 88.40097521358359
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 71.98791547150161
 Systemic ventricle mass: 95.4
 Systemic ventricle mass indexed on BSA (exp=1) 48.10868816529307
 Systemic ventricle mass indexed on BSA (exp=1.3) 39.17653814022392
 Systemic ventricle mass to volume ratio: 1.5224148236700539
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7677293502113444
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6251880755215109
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Relatively large artifact from a presumed steel coil is present in the upper left thorax that obscures adjacent structures including the arch, pulmonary arteries, and left upper pulmonary vein.=========================Artifact limited anatomy
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.12282468].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided information, the predicted outcome for whether the patient has a history of ascites is **no**. The MRI findings indicate normal hemodynamics with main Fontan pressures at a reasonable level (13 mmHg) and no significant signs of elevated pressures or volume overload that might typically suggest ascites. Furthermore, the patient also has a history free from significant complications post-surgery, such as pleural effusions, protein-losing enteropathy, or marked hepatic dysfunction, which are often associated with ascites. The XGBoost model's estimated probability of having ascites is low at 0.1228, aligning with this conclusion.","Based on the assessment of the main patient's surgical history, MRI findings, and the historical data of similar patients, it is likely that the main patient does not have a history of ascites. The main patient has undergone a modified Fontan operation with no significant post-operative complications such as pleural effusion or protein-losing enteropathy, which are often associated with ascites. Additionally, similar patients, including one who had a history of significant surgical interventions without ascites, show contrasts in outcomes, suggesting that the main patient's stable hemodynamics and absence of liver dysfunction indicators further support the prediction. The XGBoost model's output indicates a low probability of having ascites, corroborating this inference. Thus, the most reasonable prediction is that the main patient does not have a history of ascites (> trace).","Based on the provided data, I predict that the main patient does not have a history of ascites. The main patient exhibited stable hemodynamics with a systemic saturation of 65%, which, although low, suggests that there have been managed pressures post-Fontan, indicated by the absence of significant pleural or pericardial effusions, as noted in their history. Furthermore, among the similar patients, those who had a history of ascites often had worse overall prognoses, including complex surgeries and significant complications, such as protein-losing enteropathy or the need for transplants, which have not been reported for the main patient. The XGBoost model also indicates a low predicted probability (0.1228) for the occluded outcome being 'yes,' consistent with a lower likelihood of complications such as ascites in the main patient. Thus, the evidence leans towards the absence of a history of ascites.","Based on the provided data, I predict that the main patient does **not** have a history of ascites (i.e., the answer is ""no""). The patient's medical history indicates no ongoing issues like protein-losing enteropathy or significant pleural effusions that could lead to ascites. Furthermore, among the similar patients, those with a relevant surgical history (e.g., Fontan procedures) and with documented ascites frequently had complications like protein-losing enteropathy or other significant histories. Since the main patient does not have any of these complications, and given the model's prediction of a low probability (0.12282468) for the occurrence of the occluded outcome, it suggests that their risk is also lower regarding ascites. Therefore, the absence of related clinical features strengthens the conclusion that the main patient likely does not have a history of ascites.",1,1,1,1,0
BCH-NUSPIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 5.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 5.0
 Patient height: 93.0
 Patient weight: 12.6
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.5715657750077818
 Heart rate: 141.0
 Upper limb systolic blood pressure: 84.0
 Upper limb diastolic blood pressure: 51.0
 Upper limb mean blood pressure: 59.0
 Right ventricular end-diastolic volume: 181.5
 Right ventricular end-systolic volume: 146.5
 Right ventricle mass: 61.7
 Native aorta flow rate: 2.24
 Ascending aorta, above the Stansel flow rate: 2.24
 Right superior vena cava flow rate: 0.9
 Inferior vena cava, below the fenestration flow rate: 0.18
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.76
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.32
 Total right pulmonary vein flow rate: 1.13
 Total left pulmonary vein flow rate: 0.49
 Right atrioventricular valve/tricuspid inflow rate: 4.81
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.1928374655647383
 Single ventricle systolic volume 35.0
 Body mass index 14.5681581685744
 Mass to height volume indexed on BSA (exp = 2.7) 75.05527195877701
 Systemic ventricle end-systolic volume: 146.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 256.3134575333966
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 303.1457921798476
 Systemic ventricle end-diastolic volume: 181.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 317.5487545550272
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 375.56970157435046
 Systemic ventricle mass: 61.7
 Systemic ventricle mass indexed on BSA (exp=1) 107.94908074956021
 Systemic ventricle mass indexed on BSA (exp=1.3) 127.67300598973787
 Systemic ventricle mass to volume ratio: 0.3399449035812672
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5947607754796705
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.703432539888363
 Contrast type: Magnevist
 Description of late gadolinium enhancement: Regional wall motion abnormalities include thinning and dyskinesis
in the infundibular free wall at the expected site of the previous Sano shunt insertion as well as in the posterior and inferior right ventricular free wall. Late gadolinium
enhancement is present in the infundibular free wall. In the posterior-inferior wall, the LGE is epicardial and mid-wall with a very thin subendocardial layer of non-enhancing tissue.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00370407].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided data, the prediction is **no**, the patient does not have a history of pacemaker placement. This conclusion is drawn from the patient's surgical history and MRI findings, which indicate significant structural and functional cardiac issues consistent with their complex congenital heart condition (Hypoplastic Left Heart Syndrome). The patient does, however, have a history of intracardiac thrombus and severe tricuspid regurgitation with late gadolinium enhancement, but there's no documented mention of arrhythmias or the need for pacing support, which are common reasons for pacemaker placement in similar patients. Additionally, the very low estimated probability (0.00370407) for the occluded outcome suggests that pacemaker placement is unlikely in this particular case.","Based on the provided data, it is likely that the main patient does not have a history of pacemaker placement (""no""). This reasoning is supported by the patient's surgical history indicating that they have undergone multiple interventions typical for a single-ventricle patient, but there is no specific mention of electrical issues requiring such a device, unlike some of the similar patients in which pacemaker placement was noted. Furthermore, the XGBoost model, which predicts the probability of the occluded outcome being 'yes' to be very low (0.00370407), aligns with the absence of complications in the similar cohort regarding pacemaker placement. Hence, these factors suggest that the main patient has not undergone this intervention.","Based on the provided data for the main patient, it is reasonable to predict that the patient does not have a history of pacemaker placement. The patient has undergone multiple surgeries and exhibits some concerning cardiac metrics, such as severe tricuspid regurgitation and late gadolinium enhancement indicative of myocardial scarring; however, there is no prior indication in the surgical history of interventions specifically addressing rhythm issues. Additionally, among the similar patients, while there were variations in clinical histories, none indicated a history of pacemaker placement for patients sharing comparable surgical backgrounds and cardiac profiles, coupled with the fact that they had not been documented with significant arrhythmias or conductive abnormalities. This supports the inference that the main patient likely has not needed a pacemaker based on their clinical presentation and the outcomes observed in similar cases.","Based on the provided data and the similarity metrics of the cohort, it can be predicted that the main patient does **not** have a history of pacemaker placement. The justification for this inference lies in the comprehensive surgical history of similar patients, particularly those with Hypoplastic Left Heart Syndrome, which show no instances of pacemaker placement despite complex surgical interventions. Moreover, the main patient exhibits a stable hemodynamic profile, such as not having a significant history of atrioventricular or ventricular arrhythmias—a common reason for needing a pacemaker. Additionally, considering the XGBoost model's low predicted probability (0.0037) of the patient having a positive outcome in terms of pacemaker placement reinforces the notion that it is unlikely for this patient.",1,1,1,1,0
BCH-NUSPIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 5.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 5.0
 Patient height: 93.0
 Patient weight: 12.6
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.5715657750077818
 Heart rate: 141.0
 Upper limb systolic blood pressure: 84.0
 Upper limb diastolic blood pressure: 51.0
 Upper limb mean blood pressure: 59.0
 Right ventricular end-diastolic volume: 181.5
 Right ventricular end-systolic volume: 146.5
 Right ventricle mass: 61.7
 Native aorta flow rate: 2.24
 Ascending aorta, above the Stansel flow rate: 2.24
 Right superior vena cava flow rate: 0.9
 Inferior vena cava, below the fenestration flow rate: 0.18
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.76
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.32
 Total right pulmonary vein flow rate: 1.13
 Total left pulmonary vein flow rate: 0.49
 Right atrioventricular valve/tricuspid inflow rate: 4.81
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.1928374655647383
 Single ventricle systolic volume 35.0
 Body mass index 14.5681581685744
 Mass to height volume indexed on BSA (exp = 2.7) 75.05527195877701
 Systemic ventricle end-systolic volume: 146.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 256.3134575333966
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 303.1457921798476
 Systemic ventricle end-diastolic volume: 181.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 317.5487545550272
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 375.56970157435046
 Systemic ventricle mass: 61.7
 Systemic ventricle mass indexed on BSA (exp=1) 107.94908074956021
 Systemic ventricle mass indexed on BSA (exp=1.3) 127.67300598973787
 Systemic ventricle mass to volume ratio: 0.3399449035812672
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5947607754796705
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.703432539888363
 Contrast type: Magnevist
 Description of late gadolinium enhancement: Regional wall motion abnormalities include thinning and dyskinesis
in the infundibular free wall at the expected site of the previous Sano shunt insertion as well as in the posterior and inferior right ventricular free wall. Late gadolinium
enhancement is present in the infundibular free wall. In the posterior-inferior wall, the LGE is epicardial and mid-wall with a very thin subendocardial layer of non-enhancing tissue.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.23069319].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? yes\n'],"Based on the provided data, it is likely that the patient does have a history of ascites (> trace). The significant findings in the MRI report indicate issues such as severe tricuspid regurgitation (53% regurgitation fraction) and late gadolinium enhancement in the right ventricular myocardium, which could point to volume overload conditions. Additionally, the patient's clinical status shows a positive liver fibrosis test, which is commonly associated with hepatic congestion due to fluid retention often seen in patients with Fontan physiology, further supporting the likelihood of ascites. The estimated probability (23.07%) for having this clinical outcome suggests a reasonable chance of ascites history being present, aligning with the clinical presentation of this patient cohort.","Based on the provided data, it is predicted that the main patient does **not** have a history of ascites (> trace). This conclusion is supported by the fact that both the main patient and the similar patients share a common cardiac diagnosis, specifically Hypoplastic Left Heart Syndrome, and have undergone similar surgical interventions. The MRI report for the main patient indicates significant tricuspid regurgitation (53%) and myocardial enhancement, which suggests potential heart failure symptoms, but not ascites as a documented outcome. Moreover, out of the similar patients examined, none reported a history of ascites, reinforcing the likelihood that this main patient is also free from such complications. The XGBoost model’s prediction probability of 0.23069319 further substantiates the idea that the occurrence of ascites is relatively low in this context.","Based on the provided data, I predict that the main patient **does not have a history of ascites (> trace)**. The main patient has significant cardiovascular issues, including severe tricuspid regurgitation and late gadolinium enhancement indicating myocardial damage, which could predispose them to fluid accumulation. However, the similar patients, particularly those with comparable surgical histories and similar cardiac diagnoses, show a low incidence of ascites. Specifically, none of the similar patients reported a history of ascites, suggesting a trend that may apply to the main patient as well. Additionally, the prediction probabilities derived from the XGBoost model indicate a lower likelihood of adverse outcomes like ascites being present, aligning with the data patterns observed in other patients with similar profiles.","Based on the information provided for the main patient and the trends observed in similar patients, it is reasonable to predict that the main patient does not have a history of ascites (> trace) (no). The main patient has a history of significant clinical features such as elevated liver fibrosis markers and a known history of intracardiac thrombus, but no documented history of fluid accumulation or ascites. In contrast, among the similar patients, ascites has not been reported as a common feature, which suggests that fluid retention post-Fontan is not a prevailing issue within this cohort and could indicate a better functional status for the main patient. Moreover, the XGBoost model indicates a low probability of the occluded outcome being 'yes,' further supporting the notion that this patient likely does not have significant complications such as ascites.",1,0,0,0,1
BCH-NUSPIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 5.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 5.0
 Patient height: 93.0
 Patient weight: 12.6
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.5715657750077818
 Heart rate: 141.0
 Upper limb systolic blood pressure: 84.0
 Upper limb diastolic blood pressure: 51.0
 Upper limb mean blood pressure: 59.0
 Right ventricular end-diastolic volume: 181.5
 Right ventricular end-systolic volume: 146.5
 Right ventricle mass: 61.7
 Native aorta flow rate: 2.24
 Ascending aorta, above the Stansel flow rate: 2.24
 Right superior vena cava flow rate: 0.9
 Inferior vena cava, below the fenestration flow rate: 0.18
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.76
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.32
 Total right pulmonary vein flow rate: 1.13
 Total left pulmonary vein flow rate: 0.49
 Right atrioventricular valve/tricuspid inflow rate: 4.81
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.1928374655647383
 Single ventricle systolic volume 35.0
 Body mass index 14.5681581685744
 Mass to height volume indexed on BSA (exp = 2.7) 75.05527195877701
 Systemic ventricle end-systolic volume: 146.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 256.3134575333966
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 303.1457921798476
 Systemic ventricle end-diastolic volume: 181.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 317.5487545550272
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 375.56970157435046
 Systemic ventricle mass: 61.7
 Systemic ventricle mass indexed on BSA (exp=1) 107.94908074956021
 Systemic ventricle mass indexed on BSA (exp=1.3) 127.67300598973787
 Systemic ventricle mass to volume ratio: 0.3399449035812672
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5947607754796705
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.703432539888363
 Contrast type: Magnevist
 Description of late gadolinium enhancement: Regional wall motion abnormalities include thinning and dyskinesis
in the infundibular free wall at the expected site of the previous Sano shunt insertion as well as in the posterior and inferior right ventricular free wall. Late gadolinium
enhancement is present in the infundibular free wall. In the posterior-inferior wall, the LGE is epicardial and mid-wall with a very thin subendocardial layer of non-enhancing tissue.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.06353018].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided clinical data, the prediction for the missing clinical outcome is ""no,"" indicating that the patient does not have a diagnosis of seizures requiring antiepileptic medications. This conclusion is supported by the absence of any reported history of seizures or related neurological events in the patient's status updates, as well as the relatively low probability estimate (approximately 6.35%) produced by the XGBoost model for this outcome. Additionally, the patient's significant history of intracardiac thrombus and elevated liver fibrosis could suggest systemic complications rather than direct neurological issues, further contributing to the conclusion that seizures are not a present concern for this patient.","Based on the information provided, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The main patient has a complex cardiac history with multiple surgeries but no history of seizures noted in their status updates. Furthermore, among the similar patients, only a small percentage had a diagnosis of seizures (with most being unaffected), suggesting that the occurrence of seizures may be relatively rare in this cohort. The XGBoost model also indicates a low predicted probability (approximately 6.35%) for having seizures, aligning with the observed trends in the patient data, which further supports that it is unlikely the main patient has this diagnosis.","Based on the provided data, the predicted diagnosis of seizures requiring antiepileptic medications for the main patient is **no**. The main patient's surgical history reveals multiple cardiac interventions associated with hypoplastic left heart syndrome, but they do not indicate any significant neurological complications such as seizures. Additionally, in the similar patients, the majority did not have a diagnosis of seizures despite sharing similar cardiac histories. The XGBoost model predicted a very low probability (0.0635) of the occluded outcome being 'yes,' further supporting the likelihood that this patient does not have a seizure diagnosis requiring antiepileptic medications. This combination of clinical evidence and statistical prediction leads to the conclusion that the patient likely does not have this diagnosis.","Based on the analysis of the main patient's data and the trends in the similar patient cohort, it is likely that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The XGBoost model predicts a low probability (approximately 6.35%) for the outcome of ""yes"" regarding seizures, which indicates that this outcome is considered rare in the dataset. Furthermore, in the similar patients, none recorded a diagnosis of seizures, suggesting minimal association with the clinical characteristics shared by the main patient, such as a history of significant interventions or any noted neurological issues. Thus, the evidence suggests a lower likelihood of seizures in this patient.",1,1,1,1,0
BCH-NUSPIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 5.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 5.0
 Patient height: 93.0
 Patient weight: 12.6
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.5715657750077818
 Heart rate: 141.0
 Upper limb systolic blood pressure: 84.0
 Upper limb diastolic blood pressure: 51.0
 Upper limb mean blood pressure: 59.0
 Right ventricular end-diastolic volume: 181.5
 Right ventricular end-systolic volume: 146.5
 Right ventricle mass: 61.7
 Native aorta flow rate: 2.24
 Ascending aorta, above the Stansel flow rate: 2.24
 Right superior vena cava flow rate: 0.9
 Inferior vena cava, below the fenestration flow rate: 0.18
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.76
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.32
 Total right pulmonary vein flow rate: 1.13
 Total left pulmonary vein flow rate: 0.49
 Right atrioventricular valve/tricuspid inflow rate: 4.81
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.1928374655647383
 Single ventricle systolic volume 35.0
 Body mass index 14.5681581685744
 Mass to height volume indexed on BSA (exp = 2.7) 75.05527195877701
 Systemic ventricle end-systolic volume: 146.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 256.3134575333966
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 303.1457921798476
 Systemic ventricle end-diastolic volume: 181.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 317.5487545550272
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 375.56970157435046
 Systemic ventricle mass: 61.7
 Systemic ventricle mass indexed on BSA (exp=1) 107.94908074956021
 Systemic ventricle mass indexed on BSA (exp=1.3) 127.67300598973787
 Systemic ventricle mass to volume ratio: 0.3399449035812672
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5947607754796705
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.703432539888363
 Contrast type: Magnevist
 Description of late gadolinium enhancement: Regional wall motion abnormalities include thinning and dyskinesis
in the infundibular free wall at the expected site of the previous Sano shunt insertion as well as in the posterior and inferior right ventricular free wall. Late gadolinium
enhancement is present in the infundibular free wall. In the posterior-inferior wall, the LGE is epicardial and mid-wall with a very thin subendocardial layer of non-enhancing tissue.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.6036864].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Considering the patient's clinical history, surgical history, and MRI report, it is reasonable to predict that the patient did not receive a heart transplant. The MRI findings reveal significant cardiovascular complications, including severe atrioventricular valve regurgitation and late gadolinium enhancement indicative of myocardial scarring. Additionally, the presence of an intracardiac thrombus and evidence of potential heart failure (as suggested by the low single ventricle ejection fraction) further complicates their condition, but they are still alive and being managed with current medications, likely indicating that their myocardium has not deteriorated to the point necessitating a transplant. Moreover, the XGBoost model's predicted probability of 0.6036864 leans towards a ""no"" for transplant, suggesting a more stable condition that can be managed without surgical intervention at this time.","Based on the patient's surgical history, which includes undergoing multiple cardiac surgeries but not receiving a heart transplant thus far, it is reasonable to predict that the main patient has not received a heart transplant. The similar patients analyzed share a diagnosis of hypoplastic left heart syndrome and have similar surgical histories, yet none had undergone a heart transplant either, suggesting that the combined characteristics of these single-ventricle patients do not typically lead to heart transplantation. Additionally, the XGBoost model predicts a probability of 0.6036864 for the occluded outcome being 'yes,' which is relatively moderate but does not outweigh the evidence pointing towards the likely outcome of 'no' for this patient's transplant status, particularly considering their other known complications like intracardiac thrombus and elevated liver fibrosis tests. Therefore, the outcome is likely **no**, the patient did not receive a heart transplant.","Based on the data analysis, I predict that the main patient **did not receive a heart transplant**. This conclusion is supported by the patient's surgical history, which includes multiple interventions typical for single-ventricle patients, without indication of a transplant or prior listing for one. Furthermore, the similar patients’ data, particularly those that also underwent Fontan surgery and exhibited significant characteristics such as elevated systemic pressures, late gadolinium enhancement, and historical complications like thrombus formation, did not show evidence of having received a transplant either. The XGBoost model's predicted probability of 0.6036864 leaning towards ""no"" also reinforces this inference, given its context in a well-performing validation set.","Based on the patient's clinical and surgical history, there are several indicators that suggest a relatively higher likelihood of the patient receiving a heart transplant. The patient has a complex history consistent with hypoplastic left heart syndrome, characterized by multiple surgical interventions, including a Fontan procedure with fenestration. Notably, there is also evidence of significant cardiac complications, including elevated tricuspid regurgitation and late gadolinium enhancement indicative of myocardial damage, which could push the patient toward transplant candidacy. 

Additionally, evaluating similar patients shows a trend where individuals with comparable surgical histories and clinical presentations (including a history of significant cardiac dysfunction and complications) have often led to heart transplant requirements, especially with the low single ventricle ejection fraction observed in this patient. 

The XGBoost model further supports this hypothesis with a predicted probability of receiving a transplant at 60.37%. Given the aggregated information about the main patient and trends in similar patients, it is reasonable to predict that this patient did receive a heart transplant.",1,1,0,0,0
BCH-NUSPIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 5.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 5.0
 Patient height: 93.0
 Patient weight: 12.6
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.5715657750077818
 Heart rate: 141.0
 Upper limb systolic blood pressure: 84.0
 Upper limb diastolic blood pressure: 51.0
 Upper limb mean blood pressure: 59.0
 Right ventricular end-diastolic volume: 181.5
 Right ventricular end-systolic volume: 146.5
 Right ventricle mass: 61.7
 Native aorta flow rate: 2.24
 Ascending aorta, above the Stansel flow rate: 2.24
 Right superior vena cava flow rate: 0.9
 Inferior vena cava, below the fenestration flow rate: 0.18
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.76
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.32
 Total right pulmonary vein flow rate: 1.13
 Total left pulmonary vein flow rate: 0.49
 Right atrioventricular valve/tricuspid inflow rate: 4.81
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.1928374655647383
 Single ventricle systolic volume 35.0
 Body mass index 14.5681581685744
 Mass to height volume indexed on BSA (exp = 2.7) 75.05527195877701
 Systemic ventricle end-systolic volume: 146.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 256.3134575333966
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 303.1457921798476
 Systemic ventricle end-diastolic volume: 181.5
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 317.5487545550272
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 375.56970157435046
 Systemic ventricle mass: 61.7
 Systemic ventricle mass indexed on BSA (exp=1) 107.94908074956021
 Systemic ventricle mass indexed on BSA (exp=1.3) 127.67300598973787
 Systemic ventricle mass to volume ratio: 0.3399449035812672
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.5947607754796705
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.703432539888363
 Contrast type: Magnevist
 Description of late gadolinium enhancement: Regional wall motion abnormalities include thinning and dyskinesis
in the infundibular free wall at the expected site of the previous Sano shunt insertion as well as in the posterior and inferior right ventricular free wall. Late gadolinium
enhancement is present in the infundibular free wall. In the posterior-inferior wall, the LGE is epicardial and mid-wall with a very thin subendocardial layer of non-enhancing tissue.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Limited study Pt coop
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Positive
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? yes
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.6600426].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data, I predict that the missing clinical outcome for the main patient is ""no"" (the patient has not died). The patient's clinical status indicates several concerns, including a diagnosis of intracardiac thrombus, a positive fibrosure suggesting potential liver issues, and a history of ascites, which may contribute to morbidity. However, the patient's current medication regimen, including anticoagulants, along with a significant predicted probability (0.66) from the XGBoost model, suggests that while there are serious health challenges, the risks have not yet culminated in mortality. Considering the additional clinical features and outcomes from a similar cohort, it seems likely this patient has continued to survive post-Fontan despite significant complications.","**Prediction: No, the patient has not died.**

The main patient has undergone multiple surgeries due to hypoplastic left heart syndrome, has significant Fontan anatomy, and presents with various cardiac and MRI findings, but there is no history of severe complications such as protein-losing enteropathy or plastic bronchitis—common precursors that negatively impact longevity in this population. Additionally, among the similar patients, the majority also demonstrated resilience, with no reported deaths, despite having similar cardiac diagnoses, concomitant conditions, and surgical histories. The estimated probability of 0.66 from the XGBoost model, although not overwhelmingly high, still leans towards survival, especially given the high accuracy rate of the model and the patterns observed in similar patients. Hence, I infer that the likelihood of the main patient having died is low.","Based on the information provided, the prediction for the occluded clinical outcome ""Has the patient died?"" is likely **no**. The main patient's profile shows notable success indicators, including a history of multiple cardiac surgeries and a well-documented Fontan procedure with a fenestration, which can positively influence overall prognosis. Furthermore, the XGBoost model's predicted probability of the occluded outcome being 'yes' is approximately 66%, indicating a higher likelihood of survival than the risk of death. 

When considering similar patients, many exhibited similar surgical histories and had not experienced mortality, despite some complications such as intracardiac thrombus and elevated liver fibrosis tests, which suggests that such factors may not be deterministically fatal. Hence, synthesizing the trends from both the main patient and the similar cohort leads to a reasoned prediction of survival.","Based on the analysis, I predict that the main patient has not died. The main patient has a surgical history consistent with hypoplastic left heart syndrome, with multiple surgeries including a Fontan procedure and no history of significant complications that typically lead to mortality, such as a recent myocardium infarction or severe arrhythmias. The XGBoost model predicts a 66% probability of the occluded outcome being 'yes' (indicating death), but the high accuracy (96%) and AUC score (0.87) of the model suggests it can differentiate well between outcomes in this specific cohort. The trends in similar patients show they also had features indicative of survival, such as successful management of post-surgical complications and the absence of life-threatening conditions in the dataset provided. Therefore, integrating these insights indicates that the main patient likely remains alive.",1,1,1,1,0
BCH-PATMAR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 7.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt after: 1. PAB 2. tightening of PAB 3. Left BT shunt 4.classic right BT shunt 5. reoperation for thrombosis
 Other relevant surgical or clinical history (optional): SURG (4/1979)- left lateral thoracotomy, right Blalock-Hanlon atrial septectomy, PAB
SURG (5/1979)- tightening of PAB
SURG (12/1979)- left posterolateral thoractomy, 6 mm Gote-Tex tube graft placed between left subclavian and LPA, c/b thrombus and reoperation 7 days later to address that. 
SURG (12/1982)- classic right BTS performed because of dysfunctional left modified BTS
SURG (1/1983)- Placement of a 7 mm central Gore-Tex shunt 
SURG (8/1987)- Closure of central shunt and BTS, modified Fontan, central PA plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 17.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 17.0
 Patient height: 159.0
 Patient weight: 55.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5753323301442939
 Heart rate: 63.0
 Upper limb systolic blood pressure: 106.0
 Upper limb diastolic blood pressure: 55.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 106.4
 Left ventricle end-systolic volume: 35.5
 Left ventricular mass: 45.6
 Right ventricular end-diastolic volume: 32.3
 Right ventricular end-systolic volume: 17.9
 Right ventricle mass: 20.0
 Single ventricle ejection fraction 0.6663533834586466
 Single ventricle systolic volume 70.9
 Body mass index 22.111467109687116
 Mass to height volume indexed on BSA (exp = 2.7) 13.037448532832059
 Systemic ventricle end-systolic volume: 35.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 22.534927596355715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 19.662761489894958
 Systemic ventricle end-diastolic volume: 106.4
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 67.54130411978164
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 58.932896409149954
 Systemic ventricle mass: 45.6
 Systemic ventricle mass indexed on BSA (exp=1) 28.94627319419213
 Systemic ventricle mass indexed on BSA (exp=1.3) 25.25695560392141
 Systemic ventricle mass to volume ratio: 0.42857142857142855
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2720514397950388
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.23737740229249443
 Contrast type: Magnevist
 Description of veno-venous collaterals: Large veno-venous collateral vessels presumably originating above the bidirectional Glenn and decompressing below the diaphragm (the vessels taper as they head inferiorly). 
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Significant stainless steel artifact from coils in the right upper thorax obscuring the right superior vena cava, bidirectional Glenn anastomosis, pulmonary arteries, superior baffle, and atria. No flow measurements obtained.=========================Artifact no flow
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: BT shunt (reoperation was performed 7 days later)
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: cardioverted x2 due to A fib
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.03586051].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,"[' Please provide any known details regarding the death: Sudden death, presumed EP arrest. Found sitting in chair at home.  So depends on how you code things. Real cause could be arrhythmia or hyperkalemia or PE or stroke or bleeding or other stuff.  Most likely arrhythmia. \n Has the patient died? yes\n If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest\n']","Based on the information provided, the prediction for the missing clinical outcome of whether the patient has died is ""no."" This conclusion is supported by the patient’s extensive surgical history, which includes multiple interventions and careful management of their condition. Notably, the absence of critical complications such as heart transplant, significant arrhythmias requiring device placement, positive liver fibrosis tests, and acute episodes leading to cardiac arrest all suggest that the patient has been maintaining a level of stability. Additionally, the low predicted probability (0.03586051) from the XGBoost model indicates a marginal chance of mortality, further reinforcing the inference that the patient has not died.","Based on the information provided, I predict that the main patient **has not died**. Despite a complex surgical history with multiple cardiac surgeries and interventions, the patient currently exhibits no significant signs of critical deterioration, such as severe arrhythmias or major thromboembolic events. The similar patients, particularly those identified in the cohort, show a higher survival rate, with significant instances of ongoing management and treatment rather than a need for end-of-life interventions. Additionally, the XGBoost model’s probability of the occluded outcome being 'yes' (indicating death) is relatively low at approximately 3.6%, further supporting the notion that survival is likely for the main patient.","Based on the provided data, the prediction for the main patient's missing clinical outcome ""Has the patient died?"" is **no**. The main patient has a complex surgical history with significant intervention but currently shows stability in their clinical status, including successful imaging without significant obstructions or late gadolinium enhancement, indicating good myocardial health. Additionally, similar patients with comparable surgical profiles and MRI reports exhibited trends where few had died, particularly those with lower systemic ventricular function and a history of severe complications. The very low predicted probability of the occluded outcome being 'yes' (0.03586051) further supports the conclusion that it is likely the patient has not died.","**Prediction:** No, the patient has not died.

**Reasoning:** The main patient has a complex surgical history including multiple interventions related to tricuspid atresia, but shows no history of severe complications commonly associated with mortality in similar patients, such as protein-losing enteropathy or hepatocellular carcinoma. The assessed MRI results indicate preserved single ventricle ejection fraction and no significant myocardial damage. Comparatively, in the similar patients’ cohort, despite facing challenges such as arrhythmias and thrombus formation, a substantial majority survived, and the occluded outcome (death) in this instance has been predicted with a low probability of 3.59%. The consistent follow-up of the main patient without a death report further supports this conclusion.",0,0,0,0,1
BCH-PATMAR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 7.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt after: 1. PAB 2. tightening of PAB 3. Left BT shunt 4.classic right BT shunt 5. reoperation for thrombosis
 Other relevant surgical or clinical history (optional): SURG (4/1979)- left lateral thoracotomy, right Blalock-Hanlon atrial septectomy, PAB
SURG (5/1979)- tightening of PAB
SURG (12/1979)- left posterolateral thoractomy, 6 mm Gote-Tex tube graft placed between left subclavian and LPA, c/b thrombus and reoperation 7 days later to address that. 
SURG (12/1982)- classic right BTS performed because of dysfunctional left modified BTS
SURG (1/1983)- Placement of a 7 mm central Gore-Tex shunt 
SURG (8/1987)- Closure of central shunt and BTS, modified Fontan, central PA plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 17.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 17.0
 Patient height: 159.0
 Patient weight: 55.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5753323301442939
 Heart rate: 63.0
 Upper limb systolic blood pressure: 106.0
 Upper limb diastolic blood pressure: 55.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 106.4
 Left ventricle end-systolic volume: 35.5
 Left ventricular mass: 45.6
 Right ventricular end-diastolic volume: 32.3
 Right ventricular end-systolic volume: 17.9
 Right ventricle mass: 20.0
 Single ventricle ejection fraction 0.6663533834586466
 Single ventricle systolic volume 70.9
 Body mass index 22.111467109687116
 Mass to height volume indexed on BSA (exp = 2.7) 13.037448532832059
 Systemic ventricle end-systolic volume: 35.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 22.534927596355715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 19.662761489894958
 Systemic ventricle end-diastolic volume: 106.4
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 67.54130411978164
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 58.932896409149954
 Systemic ventricle mass: 45.6
 Systemic ventricle mass indexed on BSA (exp=1) 28.94627319419213
 Systemic ventricle mass indexed on BSA (exp=1.3) 25.25695560392141
 Systemic ventricle mass to volume ratio: 0.42857142857142855
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2720514397950388
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.23737740229249443
 Contrast type: Magnevist
 Description of veno-venous collaterals: Large veno-venous collateral vessels presumably originating above the bidirectional Glenn and decompressing below the diaphragm (the vessels taper as they head inferiorly). 
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Significant stainless steel artifact from coils in the right upper thorax obscuring the right superior vena cava, bidirectional Glenn anastomosis, pulmonary arteries, superior baffle, and atria. No flow measurements obtained.=========================Artifact no flow
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: BT shunt (reoperation was performed 7 days later)
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: cardioverted x2 due to A fib
 Please provide any known details regarding the death: Sudden death, presumed EP arrest. Found sitting in chair at home.  So depends on how you code things. Real cause could be arrhythmia or hyperkalemia or PE or stroke or bleeding or other stuff.  Most likely arrhythmia. 
 Has the patient died? yes
 If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00107643].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided information, it is reasonable to predict that the patient does **not** have a history of pacemaker placement. The patient's surgical history indicates numerous interventions, particularly associated with heart rhythm management post-Fontan, but there is no mention of pacemaker placement or a corresponding diagnosis that reliably suggests the need for one, such as significant bradycardia or complete heart block. Furthermore, the cardiac MRI report reveals multiple complexities and some arrhythmias, but these do not necessarily result in pacemaker dependency. The low predicted probability (0.00107643) generated from the XGBoost model further supports the unlikely presence of this outcome in the patient's history.","Based on the analysis of the main patient's clinical and surgical history, it is unlikely that this patient has a history of pacemaker placement. The patient has undergone multiple cardiac surgeries and has a complex history, including a Fontan procedure; however, they have no documented issues with sinus node dysfunction or sustained arrhythmias, which are common indications for pacemaker placement. Additionally, the similar patients analyzed show a trend where those with significant arrhythmias or documented sinus dysfunction have received pacemakers, whereas the main patient has not displayed such complications. Furthermore, the very low predicted probability (0.00107643) from the XGBoost model suggests that the occluded outcome of having a pacemaker is improbable in this case.","Based on the clinical delineation provided for the main patient, they do not have a documented history of pacemaker placement, nor does their surgical history suggest significant arrhythmia that would necessitate such an intervention. However, in reviewing the similar patients, there is a noticeable trend where patients with complex cardiac histories, particularly those with significant arrhythmias or complications following surgeries, are more likely to have received pacemakers. Although the main patient experiences atrial fibrillation—an arrhythmia commonly leading to pacemaker placement—the patient did not undergo this intervention, which could suggest either a certain level of managed rhythm control or that their arrhythmias were not deemed sufficient to warrant permanent pacing measures. Therefore, it is reasonable to predict that the main patient does not have a history of pacemaker placement.","Based on the provided data, it is unlikely that the main patient has a history of pacemaker placement, and I predict ""no"". The patient has a significant surgical history with multiple complex interventions, but there is no indication of pacing device utilization or associated diagnoses in the clinical history provided. Furthermore, the similar patients with outcomes related to pacemaker placement exhibit a higher occurrence of atrial arrhythmias and programmed interventions such as electrophysiological studies, which the main patient does not appear to have directly documented. The model's predicted probability of ""yes"" for this outcome is extremely low (0.00107643), further supporting that the patient does not have a history of pacemaker placement.",1,1,1,1,0
BCH-PATMAR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 7.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt after: 1. PAB 2. tightening of PAB 3. Left BT shunt 4.classic right BT shunt 5. reoperation for thrombosis
 Other relevant surgical or clinical history (optional): SURG (4/1979)- left lateral thoracotomy, right Blalock-Hanlon atrial septectomy, PAB
SURG (5/1979)- tightening of PAB
SURG (12/1979)- left posterolateral thoractomy, 6 mm Gote-Tex tube graft placed between left subclavian and LPA, c/b thrombus and reoperation 7 days later to address that. 
SURG (12/1982)- classic right BTS performed because of dysfunctional left modified BTS
SURG (1/1983)- Placement of a 7 mm central Gore-Tex shunt 
SURG (8/1987)- Closure of central shunt and BTS, modified Fontan, central PA plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 17.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 17.0
 Patient height: 159.0
 Patient weight: 55.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5753323301442939
 Heart rate: 63.0
 Upper limb systolic blood pressure: 106.0
 Upper limb diastolic blood pressure: 55.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 106.4
 Left ventricle end-systolic volume: 35.5
 Left ventricular mass: 45.6
 Right ventricular end-diastolic volume: 32.3
 Right ventricular end-systolic volume: 17.9
 Right ventricle mass: 20.0
 Single ventricle ejection fraction 0.6663533834586466
 Single ventricle systolic volume 70.9
 Body mass index 22.111467109687116
 Mass to height volume indexed on BSA (exp = 2.7) 13.037448532832059
 Systemic ventricle end-systolic volume: 35.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 22.534927596355715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 19.662761489894958
 Systemic ventricle end-diastolic volume: 106.4
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 67.54130411978164
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 58.932896409149954
 Systemic ventricle mass: 45.6
 Systemic ventricle mass indexed on BSA (exp=1) 28.94627319419213
 Systemic ventricle mass indexed on BSA (exp=1.3) 25.25695560392141
 Systemic ventricle mass to volume ratio: 0.42857142857142855
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2720514397950388
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.23737740229249443
 Contrast type: Magnevist
 Description of veno-venous collaterals: Large veno-venous collateral vessels presumably originating above the bidirectional Glenn and decompressing below the diaphragm (the vessels taper as they head inferiorly). 
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Significant stainless steel artifact from coils in the right upper thorax obscuring the right superior vena cava, bidirectional Glenn anastomosis, pulmonary arteries, superior baffle, and atria. No flow measurements obtained.=========================Artifact no flow
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: BT shunt (reoperation was performed 7 days later)
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: cardioverted x2 due to A fib
 Please provide any known details regarding the death: Sudden death, presumed EP arrest. Found sitting in chair at home.  So depends on how you code things. Real cause could be arrhythmia or hyperkalemia or PE or stroke or bleeding or other stuff.  Most likely arrhythmia. 
 Has the patient died? yes
 If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.19984475].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? yes\n'],"Based on the provided data and the history of the patient, it is reasonable to predict that the patient does not have a history of ascites (> trace). The patient's MRI report indicates a single ventricle ejection fraction of approximately 66.6%, which suggests reasonable ventricular function, unlikely to lead to significant fluid overload or ascites. Additionally, the patient has no history of chylous pleural effusion or significant hepatic conditions, which are often associated with ascites. The predicted probability from the XGBoost model (approximately 19.98%) further supports the inference that ascites is unlikely, considering that lower probabilities in similar cohorts are indicative of the absence rather than the presence of complications. Therefore, it is predicted that the patient does not have a history of ascites (> trace): **No**.","Based on the data provided, the prediction for the main patient's history of ascites (> trace) is **no**. The main patient has a complex surgical history with multiple cardiac interventions but no documented history of ascites. In contrast, among the similar patients, while some reported incidences of pleural effusion and ascites, the presence of significant long-term complications such as ascites was not common in the cohort. Furthermore, the XGBoost model indicates a low estimated probability of the occluded outcome being 'yes' (0.1998), which suggests that ascites is likely not a prevalent condition in this cohort. Considering these patterns together, it is reasonable to predict that the main patient does not have a significant history of ascites.","Based on the provided data, I predict that the main patient does not have a history of ascites (> trace). The main patient has extensive prior surgeries, including multiple interventions related to their tricuspid atresia, but no mention of ascites has been documented in their clinical history. In contrast, among the similar patients, particularly the one with a diagnosis highlighting the potential for fluid retention (e.g., Fontan physiology), while some do have ascites, key metrics suggesting that an adverse outcome (like fluid overload) may not align with the main patient's lower right ventricular end-systolic volume and preserved single ventricle ejection fraction. Furthermore, the occluded outcome is predicted to have a 19.98% chance of being 'yes,' indicating a lack of strong indicators in the analysis that would push for a significant presumption toward fluid retention like ascites in the main patient. Thus, given the data points and predictive model, I conclude that it is more probabilistically aligned for the main patient to not exhibit a history of ascites.","Based on the provided data and the XGBoost model's prediction, I would predict that the main patient does **not** have a history of ascites (> trace). The model gives a probability of 0.1998 for the outcome being 'yes', which suggests a low likelihood of ascites. Additionally, among the similar patients, those with more extensive surgical histories and complications appear to have greater incidences of ascites; however, the main patient has not demonstrated this association. Their surgical interventions primarily related to other congenital heart defects without reported ascites episodes, indicating a potentially more stable post-operative course compared to the similar patients who showed higher rates of fluid retention and related complications.",0,0,0,0,1
BCH-PATMAR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 7.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt after: 1. PAB 2. tightening of PAB 3. Left BT shunt 4.classic right BT shunt 5. reoperation for thrombosis
 Other relevant surgical or clinical history (optional): SURG (4/1979)- left lateral thoracotomy, right Blalock-Hanlon atrial septectomy, PAB
SURG (5/1979)- tightening of PAB
SURG (12/1979)- left posterolateral thoractomy, 6 mm Gote-Tex tube graft placed between left subclavian and LPA, c/b thrombus and reoperation 7 days later to address that. 
SURG (12/1982)- classic right BTS performed because of dysfunctional left modified BTS
SURG (1/1983)- Placement of a 7 mm central Gore-Tex shunt 
SURG (8/1987)- Closure of central shunt and BTS, modified Fontan, central PA plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 17.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 17.0
 Patient height: 159.0
 Patient weight: 55.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5753323301442939
 Heart rate: 63.0
 Upper limb systolic blood pressure: 106.0
 Upper limb diastolic blood pressure: 55.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 106.4
 Left ventricle end-systolic volume: 35.5
 Left ventricular mass: 45.6
 Right ventricular end-diastolic volume: 32.3
 Right ventricular end-systolic volume: 17.9
 Right ventricle mass: 20.0
 Single ventricle ejection fraction 0.6663533834586466
 Single ventricle systolic volume 70.9
 Body mass index 22.111467109687116
 Mass to height volume indexed on BSA (exp = 2.7) 13.037448532832059
 Systemic ventricle end-systolic volume: 35.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 22.534927596355715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 19.662761489894958
 Systemic ventricle end-diastolic volume: 106.4
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 67.54130411978164
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 58.932896409149954
 Systemic ventricle mass: 45.6
 Systemic ventricle mass indexed on BSA (exp=1) 28.94627319419213
 Systemic ventricle mass indexed on BSA (exp=1.3) 25.25695560392141
 Systemic ventricle mass to volume ratio: 0.42857142857142855
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2720514397950388
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.23737740229249443
 Contrast type: Magnevist
 Description of veno-venous collaterals: Large veno-venous collateral vessels presumably originating above the bidirectional Glenn and decompressing below the diaphragm (the vessels taper as they head inferiorly). 
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Significant stainless steel artifact from coils in the right upper thorax obscuring the right superior vena cava, bidirectional Glenn anastomosis, pulmonary arteries, superior baffle, and atria. No flow measurements obtained.=========================Artifact no flow
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: BT shunt (reoperation was performed 7 days later)
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: cardioverted x2 due to A fib
 Please provide any known details regarding the death: Sudden death, presumed EP arrest. Found sitting in chair at home.  So depends on how you code things. Real cause could be arrhythmia or hyperkalemia or PE or stroke or bleeding or other stuff.  Most likely arrhythmia. 
 Has the patient died? yes
 If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.06891212].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided data and the XGBoost model prediction, it is reasonable to predict that the occluded clinical outcome—whether the patient has a diagnosis of seizures requiring antiepileptic medications—is ""no."" The patient has a history of significant cardiac interventions, including multiple surgeries and issues such as arrhythmias, thrombus, and ascites, but there is no documented history of seizures or neurological complications. Additionally, the predicted probability of 0.06891212 for the patient indicating they do not have seizures aligns with the model's stronger performance in predicting negative outcomes (not having a specific diagnosis). Thus, the evidence suggests a lower likelihood of seizure diagnosis.","Based on the provided data, it is likely that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. This conclusion stems from the absence of reported seizures in the main patient's clinical history, despite a complex surgical background and several interventions that can predispose to such neurological events. Moreover, the similar patients identified through the MRI-centered retrieval framework exhibit an alarming trend: while some have documented histories of seizures, the majority do not seem to experience them, particularly those with comparable surgeries and anatomical considerations. The XGBoost model also indicates a very low predicted probability (0.0689) for the presence of seizures, reinforcing the inference that seizure diagnosis is unlikely for this patient.","Based on the available data, it is likely that the main patient does *not* have a diagnosis of seizures requiring antiepileptic medications. The main patient has a complex surgical history associated with tricuspid atresia and a series of significant interventions, including multiple surgeries and a Fontan procedure. Although patients with similar histories may face neurological challenges, including seizures, the similar patients’ data show that while some have a history of stroke and other complications, there is no consistent prevalence of epilepsy or the need for antiepileptic medications among them. Additionally, the XGBoost model predicts a low probability (around 6.9%) for the occluded outcome, suggesting it is relatively unlikely for this particular patient when considering the validation cohort's accuracy and trends. Therefore, it appears that the main patient does not have a diagnosis of seizures requiring antiepileptic medications.","Based on the data available, it is likely that the main patient does not have a diagnosis of seizures requiring antiepileptic medications (prediction: **no**). The main patient has a history of complex surgeries, including multiple interventions for tricuspid atresia, but no documented history of seizures or neurological events, which usually leads to such a diagnosis. 

In contrast, similar patients who have a seizure diagnosis often have additional risk factors, including prior strokes or specific genetic syndromes, which are not present in the main patient's profile. Furthermore, the suggested probability from the XGBoost model (0.06891212) indicates a very low likelihood of seizures, reflecting the trends observed in the similar cohort where they have significantly lower rates of seizure disorders compared to the general population of single-ventricle patients. Thus, it's reasonable to conclude that the main patient is less likely to have this diagnosis.",1,1,1,1,0
BCH-PATMAR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 7.0
 Please describe additional cardiac pre-Fontan surgery: Central shunt after: 1. PAB 2. tightening of PAB 3. Left BT shunt 4.classic right BT shunt 5. reoperation for thrombosis
 Other relevant surgical or clinical history (optional): SURG (4/1979)- left lateral thoracotomy, right Blalock-Hanlon atrial septectomy, PAB
SURG (5/1979)- tightening of PAB
SURG (12/1979)- left posterolateral thoractomy, 6 mm Gote-Tex tube graft placed between left subclavian and LPA, c/b thrombus and reoperation 7 days later to address that. 
SURG (12/1982)- classic right BTS performed because of dysfunctional left modified BTS
SURG (1/1983)- Placement of a 7 mm central Gore-Tex shunt 
SURG (8/1987)- Closure of central shunt and BTS, modified Fontan, central PA plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? yes
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? yes
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 17.0
 Gadopentetate dimeglumine (Magnevist) contrast dose: 17.0
 Patient height: 159.0
 Patient weight: 55.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.5753323301442939
 Heart rate: 63.0
 Upper limb systolic blood pressure: 106.0
 Upper limb diastolic blood pressure: 55.0
 Upper limb mean blood pressure: 66.0
 Left ventricle end-diastolic volume: 106.4
 Left ventricle end-systolic volume: 35.5
 Left ventricular mass: 45.6
 Right ventricular end-diastolic volume: 32.3
 Right ventricular end-systolic volume: 17.9
 Right ventricle mass: 20.0
 Single ventricle ejection fraction 0.6663533834586466
 Single ventricle systolic volume 70.9
 Body mass index 22.111467109687116
 Mass to height volume indexed on BSA (exp = 2.7) 13.037448532832059
 Systemic ventricle end-systolic volume: 35.5
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 22.534927596355715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 19.662761489894958
 Systemic ventricle end-diastolic volume: 106.4
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 67.54130411978164
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 58.932896409149954
 Systemic ventricle mass: 45.6
 Systemic ventricle mass indexed on BSA (exp=1) 28.94627319419213
 Systemic ventricle mass indexed on BSA (exp=1.3) 25.25695560392141
 Systemic ventricle mass to volume ratio: 0.42857142857142855
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.2720514397950388
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.23737740229249443
 Contrast type: Magnevist
 Description of veno-venous collaterals: Large veno-venous collateral vessels presumably originating above the bidirectional Glenn and decompressing below the diaphragm (the vessels taper as they head inferiorly). 
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Significant stainless steel artifact from coils in the right upper thorax obscuring the right superior vena cava, bidirectional Glenn anastomosis, pulmonary arteries, superior baffle, and atria. No flow measurements obtained.=========================Artifact no flow
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V LV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: BT shunt (reoperation was performed 7 days later)
 If other critical findings and/or intervention of first post-Fontan electrophysiologic study study, please specify: cardioverted x2 due to A fib
 Please provide any known details regarding the death: Sudden death, presumed EP arrest. Found sitting in chair at home.  So depends on how you code things. Real cause could be arrhythmia or hyperkalemia or PE or stroke or bleeding or other stuff.  Most likely arrhythmia. 
 Has the patient died? yes
 If yes to death, primary cause of death Malignant Arrhythmia/Arrhythmia arrest
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? yes
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? yes
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.04131616].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided clinical details and MRI findings, it is reasonable to predict that the main patient did not receive a heart transplant. The patient has a significant history of cardiac surgeries related to tricuspid atresia, including multiple interventions aimed at improving systemic circulation through various shunts and a Fontan procedure. The absence of a Fontan revision or significant valve interventions suggests stable management without a need for transplant, further supported by the XGBoost model’s low predicted probability (0.04131616) suggesting the outcome of needing a heart transplant is unlikely. While the presence of complications, such as arrhythmias and thrombus history, indicates ongoing cardiac challenges, they do not correlate directly with undergoing a heart transplant, especially given the patient's overall history of managing single-ventricle physiology through surgical means.","Based on the information provided, I predict that the main patient did not receive a heart transplant (no). The patient has undergone multiple cardiac interventions, including a modified Fontan procedure, but there is no indication or historical trend of heart transplantation in the extensive surgical history provided. Moreover, the XGBoost model estimates a very low predicted probability (0.0413) for receiving a heart transplant, which suggests that such an outcome is not prominent in cases similar to this patient's profile. Additionally, among the similar patients reviewed, none had undergone a heart transplant, reinforcing the notion that this patient likely did not either, given their complex surgical history and current status.","Based on the information provided, I would predict that the main patient did **not** receive a heart transplant. This is supported by the significant surgical history, indicating multiple interventions primarily focused on managing the progression of tricuspid atresia without advancing to heart transplantation. The presence of significant arrhythmias and cardiac complications, such as thrombus and sudden death, might suggest a complex clinical picture that could lead to increased surgical risk, making transplantation less viable. Furthermore, the model's prediction of only a 4.13% probability for a heart transplant aligns with the low occurrence rates observed in the similar patient cohort, which further supports the conclusion that this patient did not receive a heart transplant.","Based on the provided data and pattern recognition, it is reasonable to predict that the main patient did not receive a heart transplant. The patient has a history of multiple cardiac surgeries including a Fontan procedure for tricuspid atresia, which is often associated with significant morbidity and late complications, reducing the likelihood of heart transplant eligibility. Furthermore, among similar patients, those with a comparable history of complex surgeries and complications associated with single-ventricle anatomy also show a low incidence of heart transplantation, as evidenced by the average predicted probabilities and the clinical status of the cohort. The XGBoost model’s prediction probability of 0.041 suggests a low chance of transplant in light of their overall clinical profiles.",1,1,1,1,0
BCH-ROCAID-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): Ex 35 weekeer 
SURG (9/2004, PDN):  Stage 1 with Sano modification (4mm).
CATH (1/05): BD of proximal RPA and proximal RV-PA conduit. RIMA coiled. C/B coil protruding into RSCA which was removed 
SURG (2/05, PDN): BDG and T/D of RV-PA conduit C/B R hemidiaphragm paralysis
CATH (3/05): poor weight gain.Coiling of APCx3 and dilation of  possible coil-related thrombus in RSCA. Filling defect in RSCA possibly representing clot.*****
CATH (3/06): LIMA coiled.
CATH (4/07): LIMA coiled. Due to abnl HD, Fontan delayed.
SURG (5/2007, PDN): Lateral tunneled fenestrated Fontan
CATH (08/2009): APCs coil occluded. Complication: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm******
CATH (7/11): fenestration closure
CATH (4/2015): One hepatic VVC was closed with coils 
CATH (5/22): HD and angiographic evaluation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 171.5
 Patient weight: 61.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7088330375546557
 Heart rate: 65.0
 Upper limb systolic blood pressure: 109.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 70.0
 O2 Saturation: 96
 Left ventricle end-diastolic volume: 9.5
 Left ventricle end-systolic volume: 5.6
 Left ventricular mass: 12.0
 Right ventricular end-diastolic volume: 233.4
 Right ventricular end-systolic volume: 122.3
 Right ventricle mass: 98.6
 Neo-aorta flow rate: 4.96
 Descending aorta flow rate: 2.45
 Right superior vena cava flow rate: 1.27
 Inferior vena cava, below the fenestration flow rate: 1.69
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.59
 Total right pulmonary vein flow rate: 2.09
 Total left pulmonary vein flow rate: 2.18
 Right atrioventricular valve/tricuspid inflow rate: 6.08
 Left atrioventricular valve/mitral inflow rate: 0.06
 Qp/Qs (enter a number, not a ratio): 0.6
 Tricuspid regurgitation fraction: 22.0
 Single ventricle ejection fraction 0.4734458624948539
 Single ventricle systolic volume 115.00000000000001
 Body mass index 20.90965499069265
 Mass to height volume indexed on BSA (exp = 2.7) 25.777570965811254
 Systemic ventricle end-systolic volume: 127.89999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 74.84639937850524
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.73251004752808
 Systemic ventricle end-diastolic volume: 242.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.14378740452636
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 121.0369561418653
 Systemic ventricle mass: 110.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.72253144067771
 Systemic ventricle mass indexed on BSA (exp=1.3) 55.11192815681475
 Systemic ventricle mass to volume ratio: 1.6856086231001668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9864091962502533
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.8399379867703781
 Description of aortopulmonary collaterals: moderate burden of aortopulmonary collateral flow is estimated.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Mild artifact from the fenestration closure devices are present that somewhat limits evaluation. Given this artifact, unable to
perform direct visual assessment for residual Fontan fenestration flow. There is no significant residual fenestration flow based on the difference of net vena cavae flows with net branch pulmonary artery flows (a calculated 3% right-to-left flow is obtained during this study at rest, which is within the margin of error for no flow).=========================Artifact limited anatomy
 Other relevant report comments or concerns: Lymphatic abnormality
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild to moderate
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: possible coil-related thrombus in RSCA duringcath
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm.An atrial stimulation study at the end of the case demonstrated a brisk AV node with appropriate conduction to rates of 230bpm. Etiology of tachycardia likely atrial with aberrant conduction. Hemodynamically stable following initial episode.
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.03295961].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided data, it is more likely that the patient does **not** have a history of ascites. The patient has no documented history of pleural effusions or significant fluid overload post-surgery, as indicated by the absence of chylous or non-chylous effusions greater than 30 days after surgery. Additionally, the patient's clinical management includes the use of anticoagulants, diuretics, and medications for arrhythmias, but there is no indication of ascites-related treatments. Lastly, the low predicted probability (0.0329) for the occluded outcome suggests a lower likelihood of issues such as ascites that could typically arise from heart failure or significant venous return problems in similar patients.","Based on the provided information, the main patient is unlikely to have a history of ascites (> trace). The patient has experienced multiple interventions and complications post-Fontan surgery, including the presence of an intracardiac thrombus, but no direct indication of ascites in the clinical history or MRI report. Moreover, when considering the similar patients, particularly patient #1, while they share similar complexities in surgical history and a diagnosis of Hypoplastic Left Heart Syndrome, the actual singular incidence of ascites was not reported, suggesting limited occurrence among this cohort. Additionally, the model predicts a low probability (0.0329) of the occluded outcome being 'yes', reinforcing the likelihood that the main patient does not have significant ascites. Thus, I predict the outcome of ""no"" for the question regarding a history of ascites.","Based on the data provided, the main patient has a complex surgical history, primarily indicating interventions related to hypoplastic left heart syndrome, including multiple cardiac surgeries and catheterizations. Notably, there is a history of potential complications such as the possible coil-related thrombus and wide-complex tachycardia, which could suggest heightened systemic and pulmonary complications. The patient’s MRI report also mentions lymphatic abnormalities, which could predispose to fluid-related issues, including ascites.

In contrast, similar patients with hypoplastic left heart syndrome or related diagnoses (who were also studied) have not reported histories of ascites or significant fluid retention. The XGBoost model predicts a very low probability (3.30%) of the occluded outcome being 'yes,' supporting the likelihood that the main patient does not have a history of ascites, aligning with trends observed in similar cases. Overall, it seems more consistent with the clinical patterns seen previously, leading to the prediction that the patient does not have a history of ascites (> trace). Thus, the answer is **no**.","Based on the data provided, I would predict that the main patient does not have a history of ascites (> trace). The patient's MRI results and surgical history indicate multiple interventions over the years, but there are no recorded complications related to ascites or fluid retention. Additionally, among the similar patients, none indicated a history of ascites, and the predicted probability from the XGBoost model for having such a history is very low at 0.03296, suggesting it is rare among comparable cases. Therefore, both the main patient's specific characteristics and patterns in similar patients support the conclusion that the patient likely does not have a history of ascites.",1,1,1,1,0
BCH-ROCAID-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): Ex 35 weekeer 
SURG (9/2004, PDN):  Stage 1 with Sano modification (4mm).
CATH (1/05): BD of proximal RPA and proximal RV-PA conduit. RIMA coiled. C/B coil protruding into RSCA which was removed 
SURG (2/05, PDN): BDG and T/D of RV-PA conduit C/B R hemidiaphragm paralysis
CATH (3/05): poor weight gain.Coiling of APCx3 and dilation of  possible coil-related thrombus in RSCA. Filling defect in RSCA possibly representing clot.*****
CATH (3/06): LIMA coiled.
CATH (4/07): LIMA coiled. Due to abnl HD, Fontan delayed.
SURG (5/2007, PDN): Lateral tunneled fenestrated Fontan
CATH (08/2009): APCs coil occluded. Complication: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm******
CATH (7/11): fenestration closure
CATH (4/2015): One hepatic VVC was closed with coils 
CATH (5/22): HD and angiographic evaluation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 171.5
 Patient weight: 61.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7088330375546557
 Heart rate: 65.0
 Upper limb systolic blood pressure: 109.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 70.0
 O2 Saturation: 96
 Left ventricle end-diastolic volume: 9.5
 Left ventricle end-systolic volume: 5.6
 Left ventricular mass: 12.0
 Right ventricular end-diastolic volume: 233.4
 Right ventricular end-systolic volume: 122.3
 Right ventricle mass: 98.6
 Neo-aorta flow rate: 4.96
 Descending aorta flow rate: 2.45
 Right superior vena cava flow rate: 1.27
 Inferior vena cava, below the fenestration flow rate: 1.69
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.59
 Total right pulmonary vein flow rate: 2.09
 Total left pulmonary vein flow rate: 2.18
 Right atrioventricular valve/tricuspid inflow rate: 6.08
 Left atrioventricular valve/mitral inflow rate: 0.06
 Qp/Qs (enter a number, not a ratio): 0.6
 Tricuspid regurgitation fraction: 22.0
 Single ventricle ejection fraction 0.4734458624948539
 Single ventricle systolic volume 115.00000000000001
 Body mass index 20.90965499069265
 Mass to height volume indexed on BSA (exp = 2.7) 25.777570965811254
 Systemic ventricle end-systolic volume: 127.89999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 74.84639937850524
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.73251004752808
 Systemic ventricle end-diastolic volume: 242.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.14378740452636
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 121.0369561418653
 Systemic ventricle mass: 110.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.72253144067771
 Systemic ventricle mass indexed on BSA (exp=1.3) 55.11192815681475
 Systemic ventricle mass to volume ratio: 1.6856086231001668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9864091962502533
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.8399379867703781
 Description of aortopulmonary collaterals: moderate burden of aortopulmonary collateral flow is estimated.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Mild artifact from the fenestration closure devices are present that somewhat limits evaluation. Given this artifact, unable to
perform direct visual assessment for residual Fontan fenestration flow. There is no significant residual fenestration flow based on the difference of net vena cavae flows with net branch pulmonary artery flows (a calculated 3% right-to-left flow is obtained during this study at rest, which is within the margin of error for no flow).=========================Artifact limited anatomy
 Other relevant report comments or concerns: Lymphatic abnormality
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild to moderate
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: possible coil-related thrombus in RSCA duringcath
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm.An atrial stimulation study at the end of the case demonstrated a brisk AV node with appropriate conduction to rates of 230bpm. Etiology of tachycardia likely atrial with aberrant conduction. Hemodynamically stable following initial episode.
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.07443175].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided patient data and the predicted probability of the occluded outcome being 'yes' at 0.07443175, it is reasonable to predict that the patient does **not** have a diagnosis of seizures requiring antiepileptic medications. This is supported by the fact that the patient has a history of intra-cardiac thrombus and arrhythmias requiring management through cardioversion but no documented evidence of seizure activity or treatment with antiepileptic medications. Moreover, the patient's overall clinical status, including factors like normal liver function and absence of significant neurological history, further strengthens the likelihood that seizures are not a concern in this case. The low estimated probability of the occluded outcome being 'yes' aligns with this reasoning, indicating a low risk for the diagnosis of seizures.","Based on the information provided, it is reasonable to predict that the main patient does not have a diagnosis of seizures requiring antiepileptic medications (""no""). The main patient's MRI report shows significant concerns regarding cardiac function and various interventions without any direct mention of neurological issues or seizures. Additionally, the similar patients, particularly one with a high cosine similarity, exhibit a higher tendency for seizure diagnoses, particularly with significant clinical histories linked to seizure outcomes (like intracardiac thrombus). 

However, the occluded outcome prediction from the XGBoost model indicates a low probability (approximately 7.44%) of seizure diagnosis in the similar cohort, reflecting a broader pattern in single-ventricle patients post-Fontan, wherein seizures are relatively uncommon. Given these factors, the absence of any documented seizure-related history for the main patient and the low correlation in the context of similar patients, it leads to the conclusion that the patient likely does not have a diagnosis of seizures.","Based on the available data, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The analysis of the main patient's surgical history and MRI findings reveals no significant neurological complications or history of seizures. Additionally, among the similar patients, one does have a diagnosis of seizures, but the majority do not show any overlap in neurological issues. Moreover, the XGBoost model indicates a low predicted probability (7.44%) for the occlusion outcome being positive for seizures, which further suggests that it is more likely the main patient does not require antiepileptic treatment. Hence, evaluating both the patient-specific data and the trends reveals a consistent picture that aligns with the prediction of no seizure diagnosis.","Based on the provided data, I predict that the main patient does not have a diagnosis of seizures requiring antiepileptic medications. In the main patient's clinical history, there is no mention of seizures, which aligns with the overall trend observed in the similar patients, most of whom also do not exhibit this diagnosis. Additionally, the XGBoost model estimates a low predicted probability (0.074) for the occluded outcome ('yes', for seizure diagnosis), suggesting a limited likelihood that seizures would be an issue for this patient. Given the patient's previous interventions and cardiac complications unrelated to seizures or neurological problems, it appears more consistent with the absence of such a diagnosis in this cohort.",1,1,1,1,0
BCH-ROCAID-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): Ex 35 weekeer 
SURG (9/2004, PDN):  Stage 1 with Sano modification (4mm).
CATH (1/05): BD of proximal RPA and proximal RV-PA conduit. RIMA coiled. C/B coil protruding into RSCA which was removed 
SURG (2/05, PDN): BDG and T/D of RV-PA conduit C/B R hemidiaphragm paralysis
CATH (3/05): poor weight gain.Coiling of APCx3 and dilation of  possible coil-related thrombus in RSCA. Filling defect in RSCA possibly representing clot.*****
CATH (3/06): LIMA coiled.
CATH (4/07): LIMA coiled. Due to abnl HD, Fontan delayed.
SURG (5/2007, PDN): Lateral tunneled fenestrated Fontan
CATH (08/2009): APCs coil occluded. Complication: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm******
CATH (7/11): fenestration closure
CATH (4/2015): One hepatic VVC was closed with coils 
CATH (5/22): HD and angiographic evaluation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 171.5
 Patient weight: 61.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7088330375546557
 Heart rate: 65.0
 Upper limb systolic blood pressure: 109.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 70.0
 O2 Saturation: 96
 Left ventricle end-diastolic volume: 9.5
 Left ventricle end-systolic volume: 5.6
 Left ventricular mass: 12.0
 Right ventricular end-diastolic volume: 233.4
 Right ventricular end-systolic volume: 122.3
 Right ventricle mass: 98.6
 Neo-aorta flow rate: 4.96
 Descending aorta flow rate: 2.45
 Right superior vena cava flow rate: 1.27
 Inferior vena cava, below the fenestration flow rate: 1.69
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.59
 Total right pulmonary vein flow rate: 2.09
 Total left pulmonary vein flow rate: 2.18
 Right atrioventricular valve/tricuspid inflow rate: 6.08
 Left atrioventricular valve/mitral inflow rate: 0.06
 Qp/Qs (enter a number, not a ratio): 0.6
 Tricuspid regurgitation fraction: 22.0
 Single ventricle ejection fraction 0.4734458624948539
 Single ventricle systolic volume 115.00000000000001
 Body mass index 20.90965499069265
 Mass to height volume indexed on BSA (exp = 2.7) 25.777570965811254
 Systemic ventricle end-systolic volume: 127.89999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 74.84639937850524
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.73251004752808
 Systemic ventricle end-diastolic volume: 242.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.14378740452636
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 121.0369561418653
 Systemic ventricle mass: 110.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.72253144067771
 Systemic ventricle mass indexed on BSA (exp=1.3) 55.11192815681475
 Systemic ventricle mass to volume ratio: 1.6856086231001668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9864091962502533
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.8399379867703781
 Description of aortopulmonary collaterals: moderate burden of aortopulmonary collateral flow is estimated.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Mild artifact from the fenestration closure devices are present that somewhat limits evaluation. Given this artifact, unable to
perform direct visual assessment for residual Fontan fenestration flow. There is no significant residual fenestration flow based on the difference of net vena cavae flows with net branch pulmonary artery flows (a calculated 3% right-to-left flow is obtained during this study at rest, which is within the margin of error for no flow).=========================Artifact limited anatomy
 Other relevant report comments or concerns: Lymphatic abnormality
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild to moderate
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: possible coil-related thrombus in RSCA duringcath
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm.An atrial stimulation study at the end of the case demonstrated a brisk AV node with appropriate conduction to rates of 230bpm. Etiology of tachycardia likely atrial with aberrant conduction. Hemodynamically stable following initial episode.
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00093131].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided patient data and the estimated probability from the XGBoost model, it can be predicted that the missing clinical outcome, ""Did the patient receive a heart transplant?"" is **no**. The patient's surgical history indicates multiple interventions, including a fenestrated Fontan, and a significant burden of aortopulmonary collateral flow, which are often associated with complications but not definitive end-stage heart failure that would necessitate transplantation. Additionally, the very low predicted probability (0.00093131) for the outcome suggests that the likelihood of requiring a heart transplant is extremely low, further supported by the fact that the patient has not suffered any significant complications that would typically lead to listing for transplantation, such as significant protein-losing enteropathy or severe ventricular dysfunction.","Based on the provided data, it is predicted that the main patient did not receive a heart transplant (no). The main patient has undergone multiple surgical interventions related to hypoplastic left heart syndrome but demonstrates a specific pattern of ongoing management without listing or receiving a transplant, evident from the historical interventions detailed in their surgical history. 

Moreover, when examining the similar patients, especially those who share comparable conditions and surgical histories, the likelihood of undergoing a transplant appears to correlate with the severity of cardiac complications, including significant arrhythmias and a history of intracardiac thrombi. Given the low predicted probability from the XGBoost model (0.00093131), which indicates a very low likelihood of any significant deterioration requiring transplant consideration, this supports the conclusion that the main patient is highly likely not to have received a heart transplant. Thus, the absence of transplant-related indicators in the patient’s history further corroborates this prediction.","Based on the provided data, I predict that the main patient **did not receive a heart transplant**. The patient's surgical history indicates multiple cardiac interventions, including staged surgeries like a lateral tunneled fenestrated Fontan and a history of complications such as arrhythmias but without evidence of a heart transplant being performed. Furthermore, the similar patients, who also had hypoplastic left heart syndrome and underwent similar surgical procedures, showed a low proportion of heart transplants; this aligns with the XGBoost model's predicted low probability (0.00093131) of the patient receiving a transplant, suggesting a strong correlation with the overall cohort outcomes. Hence, continuity of care and attempts to manage their condition, rather than opting for transplantation, seems more likely.","Based on the provided information, I predict that the main patient did not receive a heart transplant (no). The patient's surgical history, characterized by multiple interventions involving stenting and catheterizations, suggests ongoing management for complex congenital heart disease, typical in patients with hypoplastic left heart syndrome, and does not indicate a need for transplantation at this point. Additionally, the XGBoost model prediction probability of the occlusion outcome being 'yes' is extremely low at 0.00093131, which indicates a strong likelihood that the patient has not reached a critical state necessitating transplantation. Furthermore, similar patients with comparable surgical histories and outcomes have not received a heart transplant, reinforcing the idea that the current management strategies are effective enough to avoid transplantation for this cohort.",1,1,1,1,0
BCH-ROCAID-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): Ex 35 weekeer 
SURG (9/2004, PDN):  Stage 1 with Sano modification (4mm).
CATH (1/05): BD of proximal RPA and proximal RV-PA conduit. RIMA coiled. C/B coil protruding into RSCA which was removed 
SURG (2/05, PDN): BDG and T/D of RV-PA conduit C/B R hemidiaphragm paralysis
CATH (3/05): poor weight gain.Coiling of APCx3 and dilation of  possible coil-related thrombus in RSCA. Filling defect in RSCA possibly representing clot.*****
CATH (3/06): LIMA coiled.
CATH (4/07): LIMA coiled. Due to abnl HD, Fontan delayed.
SURG (5/2007, PDN): Lateral tunneled fenestrated Fontan
CATH (08/2009): APCs coil occluded. Complication: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm******
CATH (7/11): fenestration closure
CATH (4/2015): One hepatic VVC was closed with coils 
CATH (5/22): HD and angiographic evaluation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 171.5
 Patient weight: 61.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7088330375546557
 Heart rate: 65.0
 Upper limb systolic blood pressure: 109.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 70.0
 O2 Saturation: 96
 Left ventricle end-diastolic volume: 9.5
 Left ventricle end-systolic volume: 5.6
 Left ventricular mass: 12.0
 Right ventricular end-diastolic volume: 233.4
 Right ventricular end-systolic volume: 122.3
 Right ventricle mass: 98.6
 Neo-aorta flow rate: 4.96
 Descending aorta flow rate: 2.45
 Right superior vena cava flow rate: 1.27
 Inferior vena cava, below the fenestration flow rate: 1.69
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.59
 Total right pulmonary vein flow rate: 2.09
 Total left pulmonary vein flow rate: 2.18
 Right atrioventricular valve/tricuspid inflow rate: 6.08
 Left atrioventricular valve/mitral inflow rate: 0.06
 Qp/Qs (enter a number, not a ratio): 0.6
 Tricuspid regurgitation fraction: 22.0
 Single ventricle ejection fraction 0.4734458624948539
 Single ventricle systolic volume 115.00000000000001
 Body mass index 20.90965499069265
 Mass to height volume indexed on BSA (exp = 2.7) 25.777570965811254
 Systemic ventricle end-systolic volume: 127.89999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 74.84639937850524
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.73251004752808
 Systemic ventricle end-diastolic volume: 242.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.14378740452636
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 121.0369561418653
 Systemic ventricle mass: 110.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.72253144067771
 Systemic ventricle mass indexed on BSA (exp=1.3) 55.11192815681475
 Systemic ventricle mass to volume ratio: 1.6856086231001668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9864091962502533
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.8399379867703781
 Description of aortopulmonary collaterals: moderate burden of aortopulmonary collateral flow is estimated.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Mild artifact from the fenestration closure devices are present that somewhat limits evaluation. Given this artifact, unable to
perform direct visual assessment for residual Fontan fenestration flow. There is no significant residual fenestration flow based on the difference of net vena cavae flows with net branch pulmonary artery flows (a calculated 3% right-to-left flow is obtained during this study at rest, which is within the margin of error for no flow).=========================Artifact limited anatomy
 Other relevant report comments or concerns: Lymphatic abnormality
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild to moderate
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: possible coil-related thrombus in RSCA duringcath
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm.An atrial stimulation study at the end of the case demonstrated a brisk AV node with appropriate conduction to rates of 230bpm. Etiology of tachycardia likely atrial with aberrant conduction. Hemodynamically stable following initial episode.
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.03895076].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data and analysis from the XGBoost model, the estimated probability of the patient’s outcome being ""yes"" (indicating death) is approximately 0.03895, which suggests a low likelihood of that outcome. Additionally, the patient's medical history shows significant interventions including multiple cardiac surgeries and issues such as arrhythmias and possible thrombus formation, yet they are still alive and stable enough to not require a heart transplant or exhibit critical complications like protein-losing enteropathy or significant heart failure, as noted in their NYHA classification not being reported. Given these factors, I would predict that the clinical outcome is ""no,"" the patient has not died.","Based on the available data, I predict that the main patient has not died (no). The main patient has a history of complex surgeries and interventions, typical for those with hypoplastic left heart syndrome, but they also demonstrate good O2 saturation (96%) and a functioning Fontan circulation with only mild issues like possible thrombus and arrhythmias. Furthermore, the prognosis appears favorable given the similar patients, who have historical outcomes reflective of their survival status, with the XGBoost model indicating a very low probability (0.03895076) of the occluded outcome being 'yes' (indicating death). The strong accuracy (0.96) and decent recall (0.27) for detecting poor outcomes in the validation set further support this conclusion, suggesting that while complications do exist, survival is much more likely.","Based on the provided data, the predicted clinical outcome for the main patient is ""no,"" indicating that the patient has not died. This conclusion stems from several key observations: the main patient has undergone multiple surgeries without significant late complications reported, such as severe arrhythmias or systemic deterioration that could lead to mortality. Furthermore, the similar patients demonstrate a relatively low mortality rate, and the estimated probability of 0.03895076 from the XGBoost model supports a low likelihood for death. Additionally, both the surgical history and the MRI findings for the main patient are consistent with stable outcomes, which aligns with the observed low mortality among similar cases, particularly considering the absence of serious new complications or deteriorating health.","**Prediction: No, the patient has not died.**

The main patient's history reveals multiple surgeries and interventions, including a complex series involving a Fontan procedure, but there are no significant indicators of deteriorating health or imminent mortality from their records. While there is a noted history of intracardiac thrombus and atrial tachyarrhythmias, these conditions are effectively managed and do not directly imply a fatal outcome. Additionally, the similar patients exhibit a survival rate and present with comparable clinical profiles. Notably, the XGBoost predictive probability of dying is quite low (0.03895076), suggesting that given the patient's clinical features and the trends observed among similar patients, it is unlikely that they have died.",1,1,1,1,0
BCH-ROCAID-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): Ex 35 weekeer 
SURG (9/2004, PDN):  Stage 1 with Sano modification (4mm).
CATH (1/05): BD of proximal RPA and proximal RV-PA conduit. RIMA coiled. C/B coil protruding into RSCA which was removed 
SURG (2/05, PDN): BDG and T/D of RV-PA conduit C/B R hemidiaphragm paralysis
CATH (3/05): poor weight gain.Coiling of APCx3 and dilation of  possible coil-related thrombus in RSCA. Filling defect in RSCA possibly representing clot.*****
CATH (3/06): LIMA coiled.
CATH (4/07): LIMA coiled. Due to abnl HD, Fontan delayed.
SURG (5/2007, PDN): Lateral tunneled fenestrated Fontan
CATH (08/2009): APCs coil occluded. Complication: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm******
CATH (7/11): fenestration closure
CATH (4/2015): One hepatic VVC was closed with coils 
CATH (5/22): HD and angiographic evaluation
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 171.5
 Patient weight: 61.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.7088330375546557
 Heart rate: 65.0
 Upper limb systolic blood pressure: 109.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 70.0
 O2 Saturation: 96
 Left ventricle end-diastolic volume: 9.5
 Left ventricle end-systolic volume: 5.6
 Left ventricular mass: 12.0
 Right ventricular end-diastolic volume: 233.4
 Right ventricular end-systolic volume: 122.3
 Right ventricle mass: 98.6
 Neo-aorta flow rate: 4.96
 Descending aorta flow rate: 2.45
 Right superior vena cava flow rate: 1.27
 Inferior vena cava, below the fenestration flow rate: 1.69
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.45
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.59
 Total right pulmonary vein flow rate: 2.09
 Total left pulmonary vein flow rate: 2.18
 Right atrioventricular valve/tricuspid inflow rate: 6.08
 Left atrioventricular valve/mitral inflow rate: 0.06
 Qp/Qs (enter a number, not a ratio): 0.6
 Tricuspid regurgitation fraction: 22.0
 Single ventricle ejection fraction 0.4734458624948539
 Single ventricle systolic volume 115.00000000000001
 Body mass index 20.90965499069265
 Mass to height volume indexed on BSA (exp = 2.7) 25.777570965811254
 Systemic ventricle end-systolic volume: 127.89999999999999
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 74.84639937850524
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 63.73251004752808
 Systemic ventricle end-diastolic volume: 242.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 142.14378740452636
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 121.0369561418653
 Systemic ventricle mass: 110.6
 Systemic ventricle mass indexed on BSA (exp=1) 64.72253144067771
 Systemic ventricle mass indexed on BSA (exp=1.3) 55.11192815681475
 Systemic ventricle mass to volume ratio: 1.6856086231001668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9864091962502533
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.8399379867703781
 Description of aortopulmonary collaterals: moderate burden of aortopulmonary collateral flow is estimated.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Mild artifact from the fenestration closure devices are present that somewhat limits evaluation. Given this artifact, unable to
perform direct visual assessment for residual Fontan fenestration flow. There is no significant residual fenestration flow based on the difference of net vena cavae flows with net branch pulmonary artery flows (a calculated 3% right-to-left flow is obtained during this study at rest, which is within the margin of error for no flow).=========================Artifact limited anatomy
 Other relevant report comments or concerns: Lymphatic abnormality
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qp/Qs calculation method: Comparison of pulmonary artery and systemic outflow
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild to moderate
 Qualitative or quantitative total semi-lunar valve regurgitation: Unable to determine
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Where there visible aortopulmonary collaterals? yes
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify: possible coil-related thrombus in RSCA duringcath
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: Wide-complex tachycardia for 2-3 min unresponsive to adenosine and therefore cardioverted once with 50J with revision to sinus rhythm.An atrial stimulation study at the end of the case demonstrated a brisk AV node with appropriate conduction to rates of 230bpm. Etiology of tachycardia likely atrial with aberrant conduction. Hemodynamically stable following initial episode.
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00080105].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided clinical history and MRI report, the patient does not have a history of pacemaker placement. This reasoning is supported by the absence of documented arrhythmias, indicating a lack of persistent or significant conduction issues that would typically necessitate pacemaker implantation. While there was a history of wide-complex tachycardia requiring cardioversion, this was treated acutely and did not lead to a long-term solution such as pacemaker placement, particularly since the patient remains hemodynamically stable. Furthermore, the patient's ongoing management does not include any mention of implantable devices such as pacemakers. Thus, the predicted outcome is ""no.""","Based on the provided data, I predict that the main patient does **not** have a history of pacemaker placement. This conclusion is supported by the absence of pacemaker-related history in the main patient's records, along with similar patients who also underwent complex surgical histories related to single ventricle conditions. Furthermore, while the similar patients had varying complications, the presence of a pacemaker was not a common finding, especially considering that both the main patient and the cohort have histories of atrial tachyarrhythmias but did not require such interventions. Additionally, the low predicted probability (0.00080105) from the XGBoost model for the occluded outcome suggests that the risk of requiring a pacemaker is minimal.","**Prediction:** No, the patient does not have a history of pacemaker placement.

**Reasoning:** The main patient has undergone multiple cardiac interventions but does not show any documentation of pacemaker placement compared to similar patients, none of whom indicated a history of pacemaker implantation either. The data from similar patients with hypoplastic left heart syndrome shows a relatively low incidence of pacemaker placement, particularly since the main patient's surgical history includes interventions aimed at managing complications without explicit mention of pacing issues. Additionally, the low predicted probability from the XGBoost model (0.00080105) supports the likelihood that the occluded outcome, indicating a history of pacemaker placement, is negative, aligning with the trends observed in this cohort.","Based on the available data, it is highly likely that the main patient does not have a history of pacemaker placement, leading to the prediction of ""no"" for this outcome. The main patient's numerous interventions, particularly around the time of Fontan surgery and subsequent catheterizations, suggest that while they have had some complications (such as arrhythmias), they have not needed a permanent pacemaker, as there is no documented history of such in their records. 

In contrast, the similar patients often exhibited indications for pacing due to arrhythmias (like sustained ventricular tachyarrhythmias) or other complications leading to pacemaker placement. Given the reported patient cohort's outcomes, which highlight both a history of significant interventions and subsequent needs for pacing devices, it appears that the main patient is on a different path, supported further by low incidences of related complications that would typically necessitate pacing support. Additionally, the XGBoost model's estimate of the occluded outcome being 'no' for a pacemaker also aligns with this assessment, indicating a broader trend against pacer placements among patients with similar profiles.",1,1,1,1,0
BCH-RUTNEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 180.0
 Patient weight: 67.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.8313438135382463
 Heart rate: 106.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 71.0
 Upper limb mean blood pressure: 86.0
 O2 Saturation: 93
 Left ventricle end-diastolic volume: 195.2
 Left ventricle end-systolic volume: 95.8
 Left ventricular mass: 89.1
 Right ventricular end-diastolic volume: 13.5
 Right ventricular end-systolic volume: 7.3
 Right ventricle mass: 15.5
 Native aorta flow rate: 6.34
 Descending aorta flow rate: 4.19
 Right superior vena cava flow rate: 1.95
 Fontan, above the fenestration flow rate: 3.74
 Inferior vena cava, below the fenestration flow rate: 4.25
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.85
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.46
 Total right pulmonary vein flow rate: 3.9
 Total left pulmonary vein flow rate: 2.89
 Qp/Qs (enter a number, not a ratio): 0.897
 Single ventricle ejection fraction 0.5059894585529469
 Single ventricle systolic volume 105.6
 Body mass index 20.833333333333332
 Mass to height volume indexed on BSA (exp = 2.7) 21.39419356332943
 Systemic ventricle end-systolic volume: 103.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 56.29745722121164
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 46.95240188960921
 Systemic ventricle end-diastolic volume: 208.7
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 113.9600322217931
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 95.04331982891797
 Systemic ventricle mass: 104.6
 Systemic ventricle mass indexed on BSA (exp=1) 57.11652788883353
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.63551151942894
 Systemic ventricle mass to volume ratio: 1.604603066180935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.8761888697899729
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.730746537697638
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed superior vena cava, inferior vena cava, and superior cavopulmonary anastomosis. Trivial relative narrowing of the Fontan pathway at the level of the atria relative to the portions above and below this point.Tiny Fontan fenestration with net flow directed into the atria. Qp:Qs of ~0.84-0.9.Unobstructed branch pulmonary arteries.Unobstructed pulmonary venous egress.Small ventricular septal defect.Probably mild mitral regurgitation.The left ventricular end-diastolic volume measures near the upper limits of normal with borderline depressed systolic function.Severely hypoplastic right ventricle.Combined ventricular end-diastolic volume of ~114 mL/m2 and ejection fraction of ~51%.Unobstructed left aortic arch. Probably isolated right subclavian artery, described below.Trivially dilated aortic root and mildly dilated ascending aorta.Signs of collateral vessels, described below.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00752685].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided information, it is highly likely that the missing clinical outcome, ""Has the patient died?"" is ""no."" The patient has not exhibited any of the significant complications commonly associated with high mortality rates in single-ventricle patients, such as a diagnosis of protein-losing enteropathy, cardiac arrest, or significant thrombus history. The MRI report indicates a mildly dilated aorta, trivial mitral regurgitation, and generally stable hemodynamics with a good systemic ejection fraction of approximately 51%. Additionally, the XGBoost model predicts a very low probability (0.00752685) of the occluded outcome being 'yes,' which further supports the conclusion that the patient is alive.","Based on the provided information, the predicted clinical outcome for the main patient, specifically regarding whether they have died, is **no**. The main patient has undergone Fontan surgery without any significant post-operative complications, such as the common issues of protein-losing enteropathy or plastic bronchitis, which were reported in some similar patients. Furthermore, the XGBoost model predicts a very low probability (0.0075) of the occluded outcome being 'yes,' indicating that the likelihood of the patient having died is very low. Additionally, analysis of the similar patients shows a generally positive survival trend, with no deaths reported among them despite varying surgical histories and complications. Thus, synthesizing these insights leads to the conclusion that the main patient is likely alive.","**Prediction:** No, the patient has not died.

**Reasoning:** The main patient has a history of complex heart surgery due to tricuspid atresia and underwent a lateral tunnel Fontan procedure with a fenestration, which can provide some hemodynamic advantage. Importantly, they have not exhibited any severe complications such as protein-losing enteropathy, significant thrombus formation, or recurrent cardiac events, which are associated with higher mortality risk in similar patients. Additionally, the XGBoost model's predicted probability of death is quite low (0.0075), and the similar patients' data shows a predominant trend of survival, as indicated by their clinical statuses. This is further supported by statistical validation showing a high accuracy and reliability in predicting outcomes within the studied cohort.","Based on the data provided, I predict that the main patient has **not died**. The patient's medical history shows a relatively stable condition, with no indications of significant complications such as stroke, thrombus, or the need for heart transplantation, which are often associated with increased mortality risk in similar patients. The comparative analysis with similar patients, who although faced some challenges, further supports this prediction—many of them displayed more severe histories but still maintained survival, especially those without critical complications or conditions like protein-losing enteropathy. Additionally, the XGBoost model's prediction of a very low probability of a fatal outcome (0.00752685) also suggests a high likelihood that the patient remains alive, reinforcing the conclusion from the clinical history and comparison.",1,1,1,1,0
BCH-RUTNEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 180.0
 Patient weight: 67.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.8313438135382463
 Heart rate: 106.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 71.0
 Upper limb mean blood pressure: 86.0
 O2 Saturation: 93
 Left ventricle end-diastolic volume: 195.2
 Left ventricle end-systolic volume: 95.8
 Left ventricular mass: 89.1
 Right ventricular end-diastolic volume: 13.5
 Right ventricular end-systolic volume: 7.3
 Right ventricle mass: 15.5
 Native aorta flow rate: 6.34
 Descending aorta flow rate: 4.19
 Right superior vena cava flow rate: 1.95
 Fontan, above the fenestration flow rate: 3.74
 Inferior vena cava, below the fenestration flow rate: 4.25
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.85
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.46
 Total right pulmonary vein flow rate: 3.9
 Total left pulmonary vein flow rate: 2.89
 Qp/Qs (enter a number, not a ratio): 0.897
 Single ventricle ejection fraction 0.5059894585529469
 Single ventricle systolic volume 105.6
 Body mass index 20.833333333333332
 Mass to height volume indexed on BSA (exp = 2.7) 21.39419356332943
 Systemic ventricle end-systolic volume: 103.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 56.29745722121164
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 46.95240188960921
 Systemic ventricle end-diastolic volume: 208.7
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 113.9600322217931
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 95.04331982891797
 Systemic ventricle mass: 104.6
 Systemic ventricle mass indexed on BSA (exp=1) 57.11652788883353
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.63551151942894
 Systemic ventricle mass to volume ratio: 1.604603066180935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.8761888697899729
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.730746537697638
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed superior vena cava, inferior vena cava, and superior cavopulmonary anastomosis. Trivial relative narrowing of the Fontan pathway at the level of the atria relative to the portions above and below this point.Tiny Fontan fenestration with net flow directed into the atria. Qp:Qs of ~0.84-0.9.Unobstructed branch pulmonary arteries.Unobstructed pulmonary venous egress.Small ventricular septal defect.Probably mild mitral regurgitation.The left ventricular end-diastolic volume measures near the upper limits of normal with borderline depressed systolic function.Severely hypoplastic right ventricle.Combined ventricular end-diastolic volume of ~114 mL/m2 and ejection fraction of ~51%.Unobstructed left aortic arch. Probably isolated right subclavian artery, described below.Trivially dilated aortic root and mildly dilated ascending aorta.Signs of collateral vessels, described below.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01098996].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the given data, the prediction for the missing clinical outcome regarding whether the patient has a history of ascites (> trace) is ""no."" The patient's MRI report indicates unobstructed venous return pathways and no evidence of significant complications such as protein-losing enteropathy or chylothorax, which are commonly associated with ascites in Fontan patients. Furthermore, the XGBoost model predicts a low probability (around 1.1%) for the occurrence of ascites in similar cohorts, suggesting that this patient, who has demonstrated reasonable overall hemodynamics (with a single ventricle ejection fraction of approximately 51%), is less likely to have a significant history of ascites. Hence, based on these indicators, the absence of a history of ascites is the most reasonable conclusion.","Based on the provided data, the predicted clinical outcome for the main patient regarding a history of ascites (> trace) is **no**. The main patient's MRI report indicates normal flow rates and the absence of chylous pleural effusions or significant pericardial effusions, suggesting effective circulatory dynamics post-Fontan. In contrast, the similar patients, although presenting some complications, do not demonstrate a direct correlation with ascites for those without active diagnoses of fluid issues or a history of significant complications. Additionally, the XGBoost model predicts a low probability (1.1%) for the occluded outcome being 'yes', reinforcing that significant complications like ascites are unlikely for this patient when considering aggregated outcomes from similar cohorts.","Based on the provided data, it is reasonable to predict that the main patient does **not** have a history of ascites (> trace). The main patient exhibits a relatively stable cardiac status without significant complications such as pleural effusion or signs of hepatic involvement, as indicated by normal O2 saturation and absence of other concerning histories like protein-losing enteropathy. In comparison, the similar patients show inconsistent histories of ascites, with some having a higher complexity in their surgeries and cardiac conditions (e.g., those diagnosed with hypoplastic left heart syndrome). Furthermore, the XGBoost model predicts a low probability (0.01098996) for the occluded outcome of a history of ascites, which further supports the likelihood that the main patient does not have this condition. Thus, taking into account their surgical history, MRI findings, and the statistical outcome trends from similar patients, the prediction is that the main patient does not have a history of ascites.","The predicted clinical outcome for the main patient regarding the history of ascites (> trace) is **no**. This conclusion is supported by the main patient's MRI data, which does not reflect significant abnormalities typically related to ascites and lacks any documented history of pleural effusions greater than 30 days after surgery. Additionally, a review of the similar patients reveals that those with complex congenital heart conditions and relevant surgical histories, such as Fontan physiology, often report a higher incidence of ascites. However, none of the similar patients in the dataset have a history of ascites, supporting the assertion that the main patient is likely not to have this issue either, especially since their clinical status and indices indicate stable hemodynamics. Furthermore, the XGBoost model's probability of the occluded outcome being 'yes' is very low (0.011), further substantiating the likelihood that the main patient does not have a relevant history of ascites.",1,1,1,1,0
BCH-RUTNEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 180.0
 Patient weight: 67.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.8313438135382463
 Heart rate: 106.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 71.0
 Upper limb mean blood pressure: 86.0
 O2 Saturation: 93
 Left ventricle end-diastolic volume: 195.2
 Left ventricle end-systolic volume: 95.8
 Left ventricular mass: 89.1
 Right ventricular end-diastolic volume: 13.5
 Right ventricular end-systolic volume: 7.3
 Right ventricle mass: 15.5
 Native aorta flow rate: 6.34
 Descending aorta flow rate: 4.19
 Right superior vena cava flow rate: 1.95
 Fontan, above the fenestration flow rate: 3.74
 Inferior vena cava, below the fenestration flow rate: 4.25
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.85
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.46
 Total right pulmonary vein flow rate: 3.9
 Total left pulmonary vein flow rate: 2.89
 Qp/Qs (enter a number, not a ratio): 0.897
 Single ventricle ejection fraction 0.5059894585529469
 Single ventricle systolic volume 105.6
 Body mass index 20.833333333333332
 Mass to height volume indexed on BSA (exp = 2.7) 21.39419356332943
 Systemic ventricle end-systolic volume: 103.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 56.29745722121164
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 46.95240188960921
 Systemic ventricle end-diastolic volume: 208.7
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 113.9600322217931
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 95.04331982891797
 Systemic ventricle mass: 104.6
 Systemic ventricle mass indexed on BSA (exp=1) 57.11652788883353
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.63551151942894
 Systemic ventricle mass to volume ratio: 1.604603066180935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.8761888697899729
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.730746537697638
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed superior vena cava, inferior vena cava, and superior cavopulmonary anastomosis. Trivial relative narrowing of the Fontan pathway at the level of the atria relative to the portions above and below this point.Tiny Fontan fenestration with net flow directed into the atria. Qp:Qs of ~0.84-0.9.Unobstructed branch pulmonary arteries.Unobstructed pulmonary venous egress.Small ventricular septal defect.Probably mild mitral regurgitation.The left ventricular end-diastolic volume measures near the upper limits of normal with borderline depressed systolic function.Severely hypoplastic right ventricle.Combined ventricular end-diastolic volume of ~114 mL/m2 and ejection fraction of ~51%.Unobstructed left aortic arch. Probably isolated right subclavian artery, described below.Trivially dilated aortic root and mildly dilated ascending aorta.Signs of collateral vessels, described below.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0008895].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided patient information, it is predicted that the patient did not receive a heart transplant (no). This conclusion is supported by the absence of significant complications such as protein-losing enteropathy, plastic bronchitis, or sustained arrhythmias that often lead to transplantation. Additionally, the XGBoost model estimated a very low probability (0.0008895) for the occluded outcome, indicating that the likelihood of requiring a heart transplant is minimal, especially since the patient has been stable without major vascular thrombus or cardiac arrest events. Furthermore, the patient's cardiac status is relatively stable, as indicated by MRI findings, which show manageable functional metrics and no critical warnings necessitating transplant intervention at this time.","Based on the available data, it is likely that the main patient did **not** receive a heart transplant. The majority of the similar patients, who also have complex congenital heart conditions requiring Fontan procedures, have not undergone heart transplants, and importantly, they tend to exhibit a low probability of requiring such an intervention after a successful Fontan pathway, as indicated by the low prediction probability from the XGBoost model (0.0008895). Furthermore, this patient’s cardiac evaluation—showing contributions from both ventricles to the systemic circulation, a functioning fenestration, and a relatively stable cardiac status without major complications—suggests a low likelihood of deterioration that would necessitate transplantation. Thus, the evidence supports a conclusion of ""no"" for heart transplantation in this instance.","Based on the data provided, it is predicted that the main patient did not receive a heart transplant. The patient has undergone two cardiac surgeries, with a recent Fontan procedure involving a lateral tunnel and a fenestration, which indicates a relatively stable heart condition that typically mitigates the need for transplantation. Additionally, none of the similar patients with comparable surgical histories, such as those who had successful Fontan surgery, resulted in requiring a heart transplant. Furthermore, the XGBoost model prediction indicates a very low probability (0.0008895) of needing a transplant, suggesting that the model aligns with clinical observations of stability in patients with backgrounds like that of the main patient. Thus, considering both the derived model's output and the clinical features, the conclusion supports no heart transplant being necessary.","Based on the provided data and analysis, it is predicted that the main patient did **not** receive a heart transplant. The patient's medical history indicates a complex surgical background with tricuspid atresia, predominantly left ventricular morphology, and a previous lateral tunnel Fontan procedure. Among the similar patients, those who underwent similar surgical interventions (Fenestrated Fontan without significant comorbidities) did not typically require heart transplantation. Additionally, the XGBoost model output, which estimates the probability of heart transplant being 'yes' at just 0.0008895, reinforces this conclusion, showing a very low likelihood of heart transplant among similar patients with the available features. Thus, the substantial evidence from patient characteristics and modeling supports the prediction of the main patient not having undergone a heart transplant.",1,1,1,1,0
BCH-RUTNEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 180.0
 Patient weight: 67.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.8313438135382463
 Heart rate: 106.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 71.0
 Upper limb mean blood pressure: 86.0
 O2 Saturation: 93
 Left ventricle end-diastolic volume: 195.2
 Left ventricle end-systolic volume: 95.8
 Left ventricular mass: 89.1
 Right ventricular end-diastolic volume: 13.5
 Right ventricular end-systolic volume: 7.3
 Right ventricle mass: 15.5
 Native aorta flow rate: 6.34
 Descending aorta flow rate: 4.19
 Right superior vena cava flow rate: 1.95
 Fontan, above the fenestration flow rate: 3.74
 Inferior vena cava, below the fenestration flow rate: 4.25
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.85
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.46
 Total right pulmonary vein flow rate: 3.9
 Total left pulmonary vein flow rate: 2.89
 Qp/Qs (enter a number, not a ratio): 0.897
 Single ventricle ejection fraction 0.5059894585529469
 Single ventricle systolic volume 105.6
 Body mass index 20.833333333333332
 Mass to height volume indexed on BSA (exp = 2.7) 21.39419356332943
 Systemic ventricle end-systolic volume: 103.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 56.29745722121164
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 46.95240188960921
 Systemic ventricle end-diastolic volume: 208.7
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 113.9600322217931
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 95.04331982891797
 Systemic ventricle mass: 104.6
 Systemic ventricle mass indexed on BSA (exp=1) 57.11652788883353
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.63551151942894
 Systemic ventricle mass to volume ratio: 1.604603066180935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.8761888697899729
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.730746537697638
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed superior vena cava, inferior vena cava, and superior cavopulmonary anastomosis. Trivial relative narrowing of the Fontan pathway at the level of the atria relative to the portions above and below this point.Tiny Fontan fenestration with net flow directed into the atria. Qp:Qs of ~0.84-0.9.Unobstructed branch pulmonary arteries.Unobstructed pulmonary venous egress.Small ventricular septal defect.Probably mild mitral regurgitation.The left ventricular end-diastolic volume measures near the upper limits of normal with borderline depressed systolic function.Severely hypoplastic right ventricle.Combined ventricular end-diastolic volume of ~114 mL/m2 and ejection fraction of ~51%.Unobstructed left aortic arch. Probably isolated right subclavian artery, described below.Trivially dilated aortic root and mildly dilated ascending aorta.Signs of collateral vessels, described below.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00071394].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided patient data and the XGBoost model's predicted probability of the occluded outcome being 'yes' at 0.00071394, it is highly unlikely that the patient has a history of pacemaker placement. The patient has undergone two cardiac surgeries related to tricuspid atresia, with significant residual features suggesting a stable hemodynamic state. Furthermore, the absence of any arrhythmias or indications of electrical abnormalities in the cardiac history, along with a current NYHA class status without any indication of symptomatic heart failure or arrhythmias, supports the conclusion that the likelihood of requiring a pacemaker is low. The combination of these factors points strongly towards the outcome being 'no' for the history of pacemaker placement.","Based on the information provided, the prediction for the missing clinical outcome—whether the patient has a history of pacemaker placement—would be ""no."" The main patient has undergone a limited surgical history with no significant interventions such as a pacemaker placement, and the MRI report suggests only minor issues, such as trivial mitral regurgitation and a small ventricular septal defect. 

When examining the similar patients, those who had a history of pacemaker placement typically exhibited more complex cardiac surgeries and significant complications leading to rhythm disturbances, which are not evident in the main patient's records. Furthermore, the XGBoost model's predicted probability of needing a pacemaker placement is extremely low at 0.00071394, reinforcing the conclusion that the main patient is unlikely to require such an intervention.","Based on the provided data, it is likely that the main patient does **not** have a history of pacemaker placement. The patient has a relatively stable cardiac profile following Fontan surgery, as indicated by their reported parameters such as a single ventricle ejection fraction of 0.51 and no history of complications like arrhythmias which often lead to pacemaker implantation. Additionally, similar patients, particularly those with comparable surgical histories and anatomical considerations, show variable outcomes but also do not reflect a pattern of frequent pacemaker placements. The XGBoost model's low predicted probability (0.00071394) further supports that the likelihood of requiring a pacemaker is minimal for this patient. Overall, assimilating these insights suggests that the main patient is less likely to have had a pacemaker placed.","Based on the provided data, I predict that the main patient does **not** have a history of pacemaker placement. The main patient's surgical history indicates no interventions related to device placement, and they have not experienced significant arrhythmias or cardiac events that would typically necessitate a pacemaker. 

Furthermore, examining the outcomes in similar patients, many with more complex surgical histories (including multiple cardiac procedures), also demonstrate no history of pacemaker placement, suggesting a common trend of avoiding such interventions among successfully managed patients. The computed probability from the XGBoost model also supports the conclusion that this patient is unlikely to have such a history, indicated by a very low estimated probability of the occluded outcome being 'yes'.",1,1,1,1,0
BCH-RUTNEL-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Left
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) no
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 180.0
 Patient weight: 67.5
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.8313438135382463
 Heart rate: 106.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 71.0
 Upper limb mean blood pressure: 86.0
 O2 Saturation: 93
 Left ventricle end-diastolic volume: 195.2
 Left ventricle end-systolic volume: 95.8
 Left ventricular mass: 89.1
 Right ventricular end-diastolic volume: 13.5
 Right ventricular end-systolic volume: 7.3
 Right ventricle mass: 15.5
 Native aorta flow rate: 6.34
 Descending aorta flow rate: 4.19
 Right superior vena cava flow rate: 1.95
 Fontan, above the fenestration flow rate: 3.74
 Inferior vena cava, below the fenestration flow rate: 4.25
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.85
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.46
 Total right pulmonary vein flow rate: 3.9
 Total left pulmonary vein flow rate: 2.89
 Qp/Qs (enter a number, not a ratio): 0.897
 Single ventricle ejection fraction 0.5059894585529469
 Single ventricle systolic volume 105.6
 Body mass index 20.833333333333332
 Mass to height volume indexed on BSA (exp = 2.7) 21.39419356332943
 Systemic ventricle end-systolic volume: 103.1
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 56.29745722121164
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 46.95240188960921
 Systemic ventricle end-diastolic volume: 208.7
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 113.9600322217931
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 95.04331982891797
 Systemic ventricle mass: 104.6
 Systemic ventricle mass indexed on BSA (exp=1) 57.11652788883353
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.63551151942894
 Systemic ventricle mass to volume ratio: 1.604603066180935
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.8761888697899729
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.730746537697638
 Any significant metallic artifact that obscures anatomy? If yes, please describe: none
 Other relevant report comments or concerns: Unobstructed superior vena cava, inferior vena cava, and superior cavopulmonary anastomosis. Trivial relative narrowing of the Fontan pathway at the level of the atria relative to the portions above and below this point.Tiny Fontan fenestration with net flow directed into the atria. Qp:Qs of ~0.84-0.9.Unobstructed branch pulmonary arteries.Unobstructed pulmonary venous egress.Small ventricular septal defect.Probably mild mitral regurgitation.The left ventricular end-diastolic volume measures near the upper limits of normal with borderline depressed systolic function.Severely hypoplastic right ventricle.Combined ventricular end-diastolic volume of ~114 mL/m2 and ejection fraction of ~51%.Unobstructed left aortic arch. Probably isolated right subclavian artery, described below.Trivially dilated aortic root and mildly dilated ascending aorta.Signs of collateral vessels, described below.No pericardial or pleural effusion.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01765855].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided data, the predicted clinical outcome for the main patient regarding the diagnosis of seizures requiring antiepileptic medications is **no**. This conclusion is supported by the patient's medical history, which shows no history of strokes, transient ischemic attacks, or other neurological issues that could be associated with seizures. Additionally, the logical flow of the patient's overall condition and the cluster of existing outcomes hint at stable health, as indicated by the high values in cardiac function metrics (e.g., heart rate, end-diastolic volumes, and low incidence of complications such as protein-losing enteropathy or pleural effusions). The estimated low probability of 1.77% from the XGBoost model further reinforces the conclusion that seizures are unlikely in this patient.","Based on the analysis of the main patient's data and the information derived from similar patients, the prediction for a diagnosis of seizures requiring antiepileptic medications is **no**. The main patient has a total of two cardiac surgeries and an overall favorable MRI profile with no signs indicative of neurological complications, such as stroke or defined neurological deficits. Among similar patients, those with a diagnosis requiring antiepileptic medications generally exhibited more complex cardiac histories or signs of hypoxia, which are not present in the main patient’s evaluation. Additionally, the predicted probability from the XGBoost model for seizures being 'yes' is only 0.018, suggesting that the odds of the main patient having such a diagnosis are quite low, consistent with the observations from the similar cohort.","Based on the data provided, I would predict **no** for the main patient having a diagnosis of seizures requiring antiepileptic medications. The patient's MRI report indicates a relatively stable cardiac function despite the presence of a small ventricular septal defect and mild mitral regurgitation. Additionally, among the similar patients analyzed, none had a history of seizures, including those who exhibited some of the more complex ventricular morphologies and surgical histories, suggesting that seizures are likely infrequent in this cohort. Coupled with the XGBoost model's low predicted probability (0.0177) of a positive outcome for the seizure diagnosis, it further reinforces the likelihood that this patient does not have a seizure condition requiring treatment.","Based on the provided data and the similarity observed in other patients, the most reasonable prediction is that the main patient **does not have a diagnosis of seizures requiring antiepileptic medications**. The XGBoost model predicts a low probability (1.77%) for the outcome 'yes,' indicating that seizures are relatively uncommon in this cohort following Fontan surgery. Additionally, similar patients, despite having various cardiac surgeries and complications, also demonstrated a low incidence of seizure diagnoses. The main patient's MRI findings and surgical history do not present significant factors, such as atrial arrhythmias or other risk factors typically associated with seizures, further supporting this prediction.",1,1,1,1,0
BCH-SILFIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 If other Fontan pathway or fenestration intervention, please describe: surg (berlin heart VAD placed):  Restriction of Fontan fenestration from 5mm to 4mm.
 Other relevant surgical or clinical history (optional): SURG (2/2017, 3d): Stage I palliation with RV-PA composite conduit with proximal 5mm Gore-Tex graft and distal 7mm femoral vein graft with 8mm external stent. Atrial septectomy. Chest closed on POD#3.
CATH (2/2017, 24d): Sano with an acute angle/obstruction proximally, stented and dilated. Post sats increased from 60s to 80%
CATH (5/2017, 3m): APCs: Coil occlusion of RIMA.
SURG (5/2017, 3m): RV-PA conduit takedown, BDG anastomosis.
CATH (5/2019, 2y 3m):  Coiled VVC from left innominate vein to CS.
SURG (4/2020, 3y): Fenestrated lateral tunnel Fontan with 4-5 mm fenestration, tricuspid valvuloplasty
CATH (9/2020, 3y): Right chest tube placement. 200 cc chylous fluid RFV. Admitted to CICU on  milrinone
****Currently admitted on 8E for management of fluid overload on lasix.  Sildenafil started on 9/2020.  CMR showed severe TR and right pleural effusion.  Chest tube placed and drained 200cc chylous effusions, admitted to 8S for post-anesthesia care. 
CATH (9/2020, 3 y): Particle occlusion of APCs from the left internal mammary artery and the left lateral thoracic artery.  Two coils were deployed in a larger APC originating from the right subclavian artery.  
**SURG (10/2020, 3y): Berlin heart VAD placement (30cc system). Venous cannula in the common atrium, arterial cannula in the DKS near the neoaortic valve. Restriction of Fontan fenestration from 5mm to 4mm.
SURG (10/2020, 3y): Delayed sternal closure.
SURG (11/3/2020, 3y): Inflow cannula fibrin swabbed out.
****CATH (11/2020): drainage of the left pleural effusion
****SURG (7//2021, 4y): ***TRANSPLANT***
SURG (8/2021, 4y): Ex-lap, primary closure of Morgagni hernia, intraoperative fluoroscopy
CATH (8/2021, 4y): HD
CATH (8/2021, 4y): HD
CATH (9/2021, 4y):  HD
CATH (9/2021, 4y): Trivial APCs off R lateral thoracic artery, R and L subclavian artery. G0 cellular rejection, +AMR, CD68 with mild interstitial macrophages, CD4 negative
CATH (10/2021, 4y):  By angio: unobstructed RPA, obstructed LPA stenosis and decreased flow. EMB performed. C4D negative. +AMR. C68 similar to prior. Mild myocyte fibrosis and focal endocardial fibrosis.
CATH (10/2021): proximal LPA BD and stented 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 92.5
 Patient weight: 14.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6128105406291536
 Heart rate: 123.0
 Upper limb systolic blood pressure: 88.0
 Upper limb diastolic blood pressure: 42.0
 Upper limb mean blood pressure: 54.0
 Left ventricle end-diastolic volume: 6.7
 Left ventricle end-systolic volume: 5.0
 Left ventricular mass: 8.6
 Right ventricular end-diastolic volume: 104.6
 Right ventricular end-systolic volume: 62.0
 Right ventricle mass: 25.8
 Native aorta flow rate: 1.85
 Ascending aorta, above the Stansel flow rate: 1.85
 Right superior vena cava flow rate: 0.81
 Inferior vena cava, below the fenestration flow rate: 0.57
 Right atrioventricular valve/tricuspid inflow rate: 3.9
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.4072657743785851
 Single ventricle systolic volume 42.599999999999994
 Body mass index 16.82980277574872
 Mass to height volume indexed on BSA (exp = 2.7) 31.84469015196504
 Systemic ventricle end-systolic volume: 62.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 101.17319446944649
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 117.18380476137348
 Systemic ventricle end-diastolic volume: 104.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 170.6889700242597
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 197.70041900063976
 Systemic ventricle mass: 25.8
 Systemic ventricle mass indexed on BSA (exp=1) 42.10110350502774
 Systemic ventricle mass indexed on BSA (exp=1.3) 48.763583271668324
 Systemic ventricle mass to volume ratio: 0.2466539196940727
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4024962094170912
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.4661910446622211
 Other relevant report comments or concerns: Examination abbreviated due to unexpected large right pleural effusion. Quantification of differential branch pulmonary artery flow and
pulmonary venous return was not performed because of significant associated right lung collapse.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: EP was called urgently to the cath lab after a long sheath was placed across the RVOT and SANO caused heart block.  Afterwards the patient went into a narrow complex SVT which did not respond to adenosine or DCCV
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? yes
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? yes
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.92140007].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? yes\n Did the patient receive a heart transplant? yes\n'],"Based on the information provided, the patient underwent significant cardiac interventions, including the placement of a Berlin heart VAD in October 2020 and ultimately received a heart transplant in July 2021. The surgical history indicates a progression of care aimed at managing severe complications, including tricuspid regurgitation and pleural effusions. Additionally, the high probability of the occluded outcome being 'yes' (0.9214) from the XGBoost model suggests a strong likelihood that the patient did indeed receive a heart transplant. Therefore, I predict that the patient did receive a heart transplant (yes).","Based on the provided information, I predict that the main patient did receive a heart transplant (yes). This conclusion is supported by the fact that the main patient underwent multiple surgeries, including significant interventions related to heart failure management, such as the placement of a Berlin Heart VAD and the restriction of Fontan fenestration. Furthermore, similar patients with comparable clinical histories, particularly those who had deteriorating conditions requiring advanced interventions, also exhibited a trend towards receiving transplants. The high predicted probability (0.9214) from the XGBoost model, along with the evidence of worsening clinical parameters over time, reinforces this likelihood, suggesting the need for transplantation to address ongoing severe cardiac dysfunction.","**Prediction:** Yes, the patient received a heart transplant.

**Reasoning:** The main patient has a complex surgical history, including multiple heart interventions and a recent status involving severe tricuspid regurgitation (TR) and fluid overload. The placement of the Berlin heart VAD indicates significant clinical deterioration, often necessitating a heart transplant in these patients. Furthermore, the analysis of similar patients reveals a trend where those with similar surgical histories and complications, including severe echocardiographic findings and complications such as protein-losing enteropathy or significant heart function decline, commonly progressed to receiving a heart transplant. The XGBoost model's prediction of a 92.14% probability supports this likelihood, indicating that the occluded outcome is very likely to be affirmative.",1,1,1,1,1,1
BCH-SILFIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 If other Fontan pathway or fenestration intervention, please describe: surg (berlin heart VAD placed):  Restriction of Fontan fenestration from 5mm to 4mm.
 Other relevant surgical or clinical history (optional): SURG (2/2017, 3d): Stage I palliation with RV-PA composite conduit with proximal 5mm Gore-Tex graft and distal 7mm femoral vein graft with 8mm external stent. Atrial septectomy. Chest closed on POD#3.
CATH (2/2017, 24d): Sano with an acute angle/obstruction proximally, stented and dilated. Post sats increased from 60s to 80%
CATH (5/2017, 3m): APCs: Coil occlusion of RIMA.
SURG (5/2017, 3m): RV-PA conduit takedown, BDG anastomosis.
CATH (5/2019, 2y 3m):  Coiled VVC from left innominate vein to CS.
SURG (4/2020, 3y): Fenestrated lateral tunnel Fontan with 4-5 mm fenestration, tricuspid valvuloplasty
CATH (9/2020, 3y): Right chest tube placement. 200 cc chylous fluid RFV. Admitted to CICU on  milrinone
****Currently admitted on 8E for management of fluid overload on lasix.  Sildenafil started on 9/2020.  CMR showed severe TR and right pleural effusion.  Chest tube placed and drained 200cc chylous effusions, admitted to 8S for post-anesthesia care. 
CATH (9/2020, 3 y): Particle occlusion of APCs from the left internal mammary artery and the left lateral thoracic artery.  Two coils were deployed in a larger APC originating from the right subclavian artery.  
**SURG (10/2020, 3y): Berlin heart VAD placement (30cc system). Venous cannula in the common atrium, arterial cannula in the DKS near the neoaortic valve. Restriction of Fontan fenestration from 5mm to 4mm.
SURG (10/2020, 3y): Delayed sternal closure.
SURG (11/3/2020, 3y): Inflow cannula fibrin swabbed out.
****CATH (11/2020): drainage of the left pleural effusion
****SURG (7//2021, 4y): ***TRANSPLANT***
SURG (8/2021, 4y): Ex-lap, primary closure of Morgagni hernia, intraoperative fluoroscopy
CATH (8/2021, 4y): HD
CATH (8/2021, 4y): HD
CATH (9/2021, 4y):  HD
CATH (9/2021, 4y): Trivial APCs off R lateral thoracic artery, R and L subclavian artery. G0 cellular rejection, +AMR, CD68 with mild interstitial macrophages, CD4 negative
CATH (10/2021, 4y):  By angio: unobstructed RPA, obstructed LPA stenosis and decreased flow. EMB performed. C4D negative. +AMR. C68 similar to prior. Mild myocyte fibrosis and focal endocardial fibrosis.
CATH (10/2021): proximal LPA BD and stented 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 92.5
 Patient weight: 14.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6128105406291536
 Heart rate: 123.0
 Upper limb systolic blood pressure: 88.0
 Upper limb diastolic blood pressure: 42.0
 Upper limb mean blood pressure: 54.0
 Left ventricle end-diastolic volume: 6.7
 Left ventricle end-systolic volume: 5.0
 Left ventricular mass: 8.6
 Right ventricular end-diastolic volume: 104.6
 Right ventricular end-systolic volume: 62.0
 Right ventricle mass: 25.8
 Native aorta flow rate: 1.85
 Ascending aorta, above the Stansel flow rate: 1.85
 Right superior vena cava flow rate: 0.81
 Inferior vena cava, below the fenestration flow rate: 0.57
 Right atrioventricular valve/tricuspid inflow rate: 3.9
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.4072657743785851
 Single ventricle systolic volume 42.599999999999994
 Body mass index 16.82980277574872
 Mass to height volume indexed on BSA (exp = 2.7) 31.84469015196504
 Systemic ventricle end-systolic volume: 62.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 101.17319446944649
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 117.18380476137348
 Systemic ventricle end-diastolic volume: 104.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 170.6889700242597
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 197.70041900063976
 Systemic ventricle mass: 25.8
 Systemic ventricle mass indexed on BSA (exp=1) 42.10110350502774
 Systemic ventricle mass indexed on BSA (exp=1.3) 48.763583271668324
 Systemic ventricle mass to volume ratio: 0.2466539196940727
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4024962094170912
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.4661910446622211
 Other relevant report comments or concerns: Examination abbreviated due to unexpected large right pleural effusion. Quantification of differential branch pulmonary artery flow and
pulmonary venous return was not performed because of significant associated right lung collapse.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: EP was called urgently to the cath lab after a long sheath was placed across the RVOT and SANO caused heart block.  Afterwards the patient went into a narrow complex SVT which did not respond to adenosine or DCCV
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? yes
 Did the patient receive a heart transplant? yes
  diagnosis of protein-losing enteropathy? yes
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? yes
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.0012969].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided clinical and surgical history of the patient, it can be predicted that the patient does **not** have a history of pacemaker placement. The information indicates that the patient has experienced significant complications, including severe tricuspid regurgitation and arrhythmias, but there is no explicit mention or documentation of a pacemaker insertion. Additionally, the patient underwent numerous interventions and finally a heart transplant, which would typically address any intrinsic conduction issues, reducing the likelihood of requiring a pacemaker. The low predicted probability of the occluded outcome being 'yes' (0.0012969) further supports that a history of pacemaker placement is unlikely in this case.","Based on the available information, I predict that the main patient does **not** have a history of pacemaker placement. The patient's surgical history, which includes multiple interventions such as a tension pneumothorax repair and fenestration interventions, but notably lacks any mention of pacemaker implantation, suggests that this patient may maintain a normal electrical conduction capable of avoiding such a device. Furthermore, when examining the similar patients, none appear to have a pacemaker placement history reported either, indicating a potential trend among this cohort. Additionally, the XGBoost model indicates an extremely low probability (0.0012969) for positive outcomes related to pacemaker placement, further supporting the conclusion that the patient likely does not have this history.","Based on the available information, it is predicted that the main patient does **not** have a history of pacemaker placement. The main patient has a detailed surgical history indicating multiple interventions, including a Berlin heart VAD placement and transplant, but there is no mention of a pacemaker being used or placed. In contrast, among the similar cohort, pacemaker placements are somewhat common, specifically in patients with severe atrial tachyarrhythmias or significant arrhythmias, but they also demonstrate a diverse range of clinical statuses and histories. Given the XGBoost model’s predicted low probability of the occluded outcome being 'yes' (0.0012969), this further suggests that the main patient's profile aligns more with those who do not have a pacemaker, as such devices are typically indicated for chronic arrhythmias or dysfunction not evident in this specific patient.",1,1,1,1,1,0
BCH-SILFIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 If other Fontan pathway or fenestration intervention, please describe: surg (berlin heart VAD placed):  Restriction of Fontan fenestration from 5mm to 4mm.
 Other relevant surgical or clinical history (optional): SURG (2/2017, 3d): Stage I palliation with RV-PA composite conduit with proximal 5mm Gore-Tex graft and distal 7mm femoral vein graft with 8mm external stent. Atrial septectomy. Chest closed on POD#3.
CATH (2/2017, 24d): Sano with an acute angle/obstruction proximally, stented and dilated. Post sats increased from 60s to 80%
CATH (5/2017, 3m): APCs: Coil occlusion of RIMA.
SURG (5/2017, 3m): RV-PA conduit takedown, BDG anastomosis.
CATH (5/2019, 2y 3m):  Coiled VVC from left innominate vein to CS.
SURG (4/2020, 3y): Fenestrated lateral tunnel Fontan with 4-5 mm fenestration, tricuspid valvuloplasty
CATH (9/2020, 3y): Right chest tube placement. 200 cc chylous fluid RFV. Admitted to CICU on  milrinone
****Currently admitted on 8E for management of fluid overload on lasix.  Sildenafil started on 9/2020.  CMR showed severe TR and right pleural effusion.  Chest tube placed and drained 200cc chylous effusions, admitted to 8S for post-anesthesia care. 
CATH (9/2020, 3 y): Particle occlusion of APCs from the left internal mammary artery and the left lateral thoracic artery.  Two coils were deployed in a larger APC originating from the right subclavian artery.  
**SURG (10/2020, 3y): Berlin heart VAD placement (30cc system). Venous cannula in the common atrium, arterial cannula in the DKS near the neoaortic valve. Restriction of Fontan fenestration from 5mm to 4mm.
SURG (10/2020, 3y): Delayed sternal closure.
SURG (11/3/2020, 3y): Inflow cannula fibrin swabbed out.
****CATH (11/2020): drainage of the left pleural effusion
****SURG (7//2021, 4y): ***TRANSPLANT***
SURG (8/2021, 4y): Ex-lap, primary closure of Morgagni hernia, intraoperative fluoroscopy
CATH (8/2021, 4y): HD
CATH (8/2021, 4y): HD
CATH (9/2021, 4y):  HD
CATH (9/2021, 4y): Trivial APCs off R lateral thoracic artery, R and L subclavian artery. G0 cellular rejection, +AMR, CD68 with mild interstitial macrophages, CD4 negative
CATH (10/2021, 4y):  By angio: unobstructed RPA, obstructed LPA stenosis and decreased flow. EMB performed. C4D negative. +AMR. C68 similar to prior. Mild myocyte fibrosis and focal endocardial fibrosis.
CATH (10/2021): proximal LPA BD and stented 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 92.5
 Patient weight: 14.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6128105406291536
 Heart rate: 123.0
 Upper limb systolic blood pressure: 88.0
 Upper limb diastolic blood pressure: 42.0
 Upper limb mean blood pressure: 54.0
 Left ventricle end-diastolic volume: 6.7
 Left ventricle end-systolic volume: 5.0
 Left ventricular mass: 8.6
 Right ventricular end-diastolic volume: 104.6
 Right ventricular end-systolic volume: 62.0
 Right ventricle mass: 25.8
 Native aorta flow rate: 1.85
 Ascending aorta, above the Stansel flow rate: 1.85
 Right superior vena cava flow rate: 0.81
 Inferior vena cava, below the fenestration flow rate: 0.57
 Right atrioventricular valve/tricuspid inflow rate: 3.9
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.4072657743785851
 Single ventricle systolic volume 42.599999999999994
 Body mass index 16.82980277574872
 Mass to height volume indexed on BSA (exp = 2.7) 31.84469015196504
 Systemic ventricle end-systolic volume: 62.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 101.17319446944649
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 117.18380476137348
 Systemic ventricle end-diastolic volume: 104.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 170.6889700242597
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 197.70041900063976
 Systemic ventricle mass: 25.8
 Systemic ventricle mass indexed on BSA (exp=1) 42.10110350502774
 Systemic ventricle mass indexed on BSA (exp=1.3) 48.763583271668324
 Systemic ventricle mass to volume ratio: 0.2466539196940727
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4024962094170912
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.4661910446622211
 Other relevant report comments or concerns: Examination abbreviated due to unexpected large right pleural effusion. Quantification of differential branch pulmonary artery flow and
pulmonary venous return was not performed because of significant associated right lung collapse.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: EP was called urgently to the cath lab after a long sheath was placed across the RVOT and SANO caused heart block.  Afterwards the patient went into a narrow complex SVT which did not respond to adenosine or DCCV
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? yes
 Did the patient receive a heart transplant? yes
  diagnosis of protein-losing enteropathy? yes
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? yes
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.8911593].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided information, it is predicted that the occluded outcome ""Has the patient died?"" is **no**. This prediction is supported by the patient's surgical history, which includes multiple interventions, such as heart transplant and management of complications like chylous effusions, but does not indicate a recent deterioration leading to mortality. Moreover, the XGBoost model indicates a high probability (0.891) for a positive outcome, suggesting that similar patients tend to survive post-Fontan surgery despite complications. Additionally, the patient has been listed for a transplant, underwent successful surgery, and is receiving ongoing medical management, indicating stability despite prior health challenges.","Based on the provided data, I predict that the clinical outcome for the main patient, ""Has the patient died?"" is **no**. Despite the complexity of the patient's surgical history, including severe tricuspid regurgitation and repeated interventions, such as the placement of a Berlin heart VAD, they managed to undergo a successful heart transplant. Additionally, the similar patients exhibited a notable survival trend, with the XGBoost model predicting a 89.12% probability of a 'no' outcome for death. Their low mortality rates observed in patients with comparable characteristics strengthen the inference that the main patient is likely still alive.","Based on the data provided, the predicted outcome for the main patient regarding whether they have died is ""no."" The main patient experienced multiple surgeries and complications but ultimately underwent a heart transplant, which suggests a significant ongoing medical intervention aimed at survival. 

Looking at the similar patients, those who received transplants and had closely related complications often reported positive outcomes post-surgery. Moreover, the XGBoost model predicts a high probability (approximately 89%) that the occluded outcome is 'yes,' suggesting that most cases similar to this patient did not result in death. Therefore, considering their surgical history, the high likelihood indicated by the model, and the outcomes of similar patients, it is reasonable to conclude that this patient survived.",1,1,1,1,1,0
BCH-SILFIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 If other Fontan pathway or fenestration intervention, please describe: surg (berlin heart VAD placed):  Restriction of Fontan fenestration from 5mm to 4mm.
 Other relevant surgical or clinical history (optional): SURG (2/2017, 3d): Stage I palliation with RV-PA composite conduit with proximal 5mm Gore-Tex graft and distal 7mm femoral vein graft with 8mm external stent. Atrial septectomy. Chest closed on POD#3.
CATH (2/2017, 24d): Sano with an acute angle/obstruction proximally, stented and dilated. Post sats increased from 60s to 80%
CATH (5/2017, 3m): APCs: Coil occlusion of RIMA.
SURG (5/2017, 3m): RV-PA conduit takedown, BDG anastomosis.
CATH (5/2019, 2y 3m):  Coiled VVC from left innominate vein to CS.
SURG (4/2020, 3y): Fenestrated lateral tunnel Fontan with 4-5 mm fenestration, tricuspid valvuloplasty
CATH (9/2020, 3y): Right chest tube placement. 200 cc chylous fluid RFV. Admitted to CICU on  milrinone
****Currently admitted on 8E for management of fluid overload on lasix.  Sildenafil started on 9/2020.  CMR showed severe TR and right pleural effusion.  Chest tube placed and drained 200cc chylous effusions, admitted to 8S for post-anesthesia care. 
CATH (9/2020, 3 y): Particle occlusion of APCs from the left internal mammary artery and the left lateral thoracic artery.  Two coils were deployed in a larger APC originating from the right subclavian artery.  
**SURG (10/2020, 3y): Berlin heart VAD placement (30cc system). Venous cannula in the common atrium, arterial cannula in the DKS near the neoaortic valve. Restriction of Fontan fenestration from 5mm to 4mm.
SURG (10/2020, 3y): Delayed sternal closure.
SURG (11/3/2020, 3y): Inflow cannula fibrin swabbed out.
****CATH (11/2020): drainage of the left pleural effusion
****SURG (7//2021, 4y): ***TRANSPLANT***
SURG (8/2021, 4y): Ex-lap, primary closure of Morgagni hernia, intraoperative fluoroscopy
CATH (8/2021, 4y): HD
CATH (8/2021, 4y): HD
CATH (9/2021, 4y):  HD
CATH (9/2021, 4y): Trivial APCs off R lateral thoracic artery, R and L subclavian artery. G0 cellular rejection, +AMR, CD68 with mild interstitial macrophages, CD4 negative
CATH (10/2021, 4y):  By angio: unobstructed RPA, obstructed LPA stenosis and decreased flow. EMB performed. C4D negative. +AMR. C68 similar to prior. Mild myocyte fibrosis and focal endocardial fibrosis.
CATH (10/2021): proximal LPA BD and stented 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 92.5
 Patient weight: 14.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6128105406291536
 Heart rate: 123.0
 Upper limb systolic blood pressure: 88.0
 Upper limb diastolic blood pressure: 42.0
 Upper limb mean blood pressure: 54.0
 Left ventricle end-diastolic volume: 6.7
 Left ventricle end-systolic volume: 5.0
 Left ventricular mass: 8.6
 Right ventricular end-diastolic volume: 104.6
 Right ventricular end-systolic volume: 62.0
 Right ventricle mass: 25.8
 Native aorta flow rate: 1.85
 Ascending aorta, above the Stansel flow rate: 1.85
 Right superior vena cava flow rate: 0.81
 Inferior vena cava, below the fenestration flow rate: 0.57
 Right atrioventricular valve/tricuspid inflow rate: 3.9
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.4072657743785851
 Single ventricle systolic volume 42.599999999999994
 Body mass index 16.82980277574872
 Mass to height volume indexed on BSA (exp = 2.7) 31.84469015196504
 Systemic ventricle end-systolic volume: 62.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 101.17319446944649
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 117.18380476137348
 Systemic ventricle end-diastolic volume: 104.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 170.6889700242597
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 197.70041900063976
 Systemic ventricle mass: 25.8
 Systemic ventricle mass indexed on BSA (exp=1) 42.10110350502774
 Systemic ventricle mass indexed on BSA (exp=1.3) 48.763583271668324
 Systemic ventricle mass to volume ratio: 0.2466539196940727
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4024962094170912
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.4661910446622211
 Other relevant report comments or concerns: Examination abbreviated due to unexpected large right pleural effusion. Quantification of differential branch pulmonary artery flow and
pulmonary venous return was not performed because of significant associated right lung collapse.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: EP was called urgently to the cath lab after a long sheath was placed across the RVOT and SANO caused heart block.  Afterwards the patient went into a narrow complex SVT which did not respond to adenosine or DCCV
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? yes
 Did the patient receive a heart transplant? yes
  diagnosis of protein-losing enteropathy? yes
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? yes
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.63075835].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? yes\n'],"Based on the provided data, it is likely that the patient has a history of ascites (> trace). The patient's clinical history indicates multiple instances of significant pleural effusions and fluid overload, as noted in various MRI reports and cath lab encounters. These findings suggest a compromised circulation and fluid management, which often accompany conditions leading to ascites in single-ventricle patients post-Fontan. Additionally, the model's prediction probability (0.63075835) indicates a relatively high likelihood of the patient having this outcome, aligning with the established patterns of fluid retention typically seen in this cohort.","Based on the provided data, I predict that the main patient **does have a history of ascites (> trace)**. The main patient has undergone multiple cardiac surgeries, including a heart transplant, and has a history of significant postoperative complications such as fluid overload and drainage of pleural effusions. Additionally, the similar patients show a trend where those with complex surgical histories, such as complications post-Fontan or transplant recipients, often report conditions like ascites due to changes in venous pressure and fluid dynamics. Moreover, the XGBoost model indicates a probability of 0.63075835 for a positive outcome regarding ascites, suggesting a reasonable likelihood that the main patient has this complication.","**Prediction:** Yes, the patient has a history of ascites (> trace).

**Reasoning:** The main patient has a complex surgical history, including multiple interventions post-Fontan surgery, and has presented with severe issues such as chylous effusions and fluid overload, which is closely linked to ascites. Among the similar patients, ascites was also noted in cases with significant surgical complexity or repeated catheterizations, suggesting a correlation between extensive interventions and fluid retention issues, including ascites. Furthermore, the probability from the XGBoost model indicates a substantial risk for ascites, given its output of 0.63075835, which reflects a meaningful likelihood that the main patient mirrors the presentation of similar cases interlinked with ascites.",1,1,1,1,1,1
BCH-SILFIN-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 If other Fontan pathway or fenestration intervention, please describe: surg (berlin heart VAD placed):  Restriction of Fontan fenestration from 5mm to 4mm.
 Other relevant surgical or clinical history (optional): SURG (2/2017, 3d): Stage I palliation with RV-PA composite conduit with proximal 5mm Gore-Tex graft and distal 7mm femoral vein graft with 8mm external stent. Atrial septectomy. Chest closed on POD#3.
CATH (2/2017, 24d): Sano with an acute angle/obstruction proximally, stented and dilated. Post sats increased from 60s to 80%
CATH (5/2017, 3m): APCs: Coil occlusion of RIMA.
SURG (5/2017, 3m): RV-PA conduit takedown, BDG anastomosis.
CATH (5/2019, 2y 3m):  Coiled VVC from left innominate vein to CS.
SURG (4/2020, 3y): Fenestrated lateral tunnel Fontan with 4-5 mm fenestration, tricuspid valvuloplasty
CATH (9/2020, 3y): Right chest tube placement. 200 cc chylous fluid RFV. Admitted to CICU on  milrinone
****Currently admitted on 8E for management of fluid overload on lasix.  Sildenafil started on 9/2020.  CMR showed severe TR and right pleural effusion.  Chest tube placed and drained 200cc chylous effusions, admitted to 8S for post-anesthesia care. 
CATH (9/2020, 3 y): Particle occlusion of APCs from the left internal mammary artery and the left lateral thoracic artery.  Two coils were deployed in a larger APC originating from the right subclavian artery.  
**SURG (10/2020, 3y): Berlin heart VAD placement (30cc system). Venous cannula in the common atrium, arterial cannula in the DKS near the neoaortic valve. Restriction of Fontan fenestration from 5mm to 4mm.
SURG (10/2020, 3y): Delayed sternal closure.
SURG (11/3/2020, 3y): Inflow cannula fibrin swabbed out.
****CATH (11/2020): drainage of the left pleural effusion
****SURG (7//2021, 4y): ***TRANSPLANT***
SURG (8/2021, 4y): Ex-lap, primary closure of Morgagni hernia, intraoperative fluoroscopy
CATH (8/2021, 4y): HD
CATH (8/2021, 4y): HD
CATH (9/2021, 4y):  HD
CATH (9/2021, 4y): Trivial APCs off R lateral thoracic artery, R and L subclavian artery. G0 cellular rejection, +AMR, CD68 with mild interstitial macrophages, CD4 negative
CATH (10/2021, 4y):  By angio: unobstructed RPA, obstructed LPA stenosis and decreased flow. EMB performed. C4D negative. +AMR. C68 similar to prior. Mild myocyte fibrosis and focal endocardial fibrosis.
CATH (10/2021): proximal LPA BD and stented 
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 92.5
 Patient weight: 14.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.6128105406291536
 Heart rate: 123.0
 Upper limb systolic blood pressure: 88.0
 Upper limb diastolic blood pressure: 42.0
 Upper limb mean blood pressure: 54.0
 Left ventricle end-diastolic volume: 6.7
 Left ventricle end-systolic volume: 5.0
 Left ventricular mass: 8.6
 Right ventricular end-diastolic volume: 104.6
 Right ventricular end-systolic volume: 62.0
 Right ventricle mass: 25.8
 Native aorta flow rate: 1.85
 Ascending aorta, above the Stansel flow rate: 1.85
 Right superior vena cava flow rate: 0.81
 Inferior vena cava, below the fenestration flow rate: 0.57
 Right atrioventricular valve/tricuspid inflow rate: 3.9
 Tricuspid regurgitation fraction: 53.0
 Single ventricle ejection fraction 0.4072657743785851
 Single ventricle systolic volume 42.599999999999994
 Body mass index 16.82980277574872
 Mass to height volume indexed on BSA (exp = 2.7) 31.84469015196504
 Systemic ventricle end-systolic volume: 62.0
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 101.17319446944649
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 117.18380476137348
 Systemic ventricle end-diastolic volume: 104.6
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 170.6889700242597
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 197.70041900063976
 Systemic ventricle mass: 25.8
 Systemic ventricle mass indexed on BSA (exp=1) 42.10110350502774
 Systemic ventricle mass indexed on BSA (exp=1.3) 48.763583271668324
 Systemic ventricle mass to volume ratio: 0.2466539196940727
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.4024962094170912
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.4661910446622211
 Other relevant report comments or concerns: Examination abbreviated due to unexpected large right pleural effusion. Quantification of differential branch pulmonary artery flow and
pulmonary venous return was not performed because of significant associated right lung collapse.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: Severe
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: EP was called urgently to the cath lab after a long sheath was placed across the RVOT and SANO caused heart block.  Afterwards the patient went into a narrow complex SVT which did not respond to adenosine or DCCV
 Has the patient died? no
 Prior listing for a heart transplant? yes
 Did the patient receive a heart transplant? yes
  diagnosis of protein-losing enteropathy? yes
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? yes
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? yes
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.05658219].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided data, it is predicted that the patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The patient's surgical history indicates multiple cardiac interventions, with significant complications such as severe tricuspid regurgitation and pleural effusions, but there is no direct mention of neurological complications or seizures. Additionally, the predicted probability of 0.056 is quite low, suggesting a minimal likelihood of this outcome. Given the high accuracy and AUC of the model and the absence of related symptoms or historical data associated with seizures in the clinical status event updates, it aligns with this inference.","Given the information provided, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The main patient's history includes significant surgical interventions and complications related to Fontan physiology, but no direct indication of seizures is noted. Additionally, among the similar patients, the absence of seizure diagnoses correlates with those undergoing comparable surgical histories, particularly those without severe central nervous system complications or a history of transient ischemic events. The XGBoost model further supports this prediction, providing a low probability (0.05658219) for the presence of seizures in the patient. Overall, the patterns in the medical histories of both the main patient and similar cases do not support a diagnosis of seizures requiring medication.","Based on the data provided, the prediction for the main patient regarding the diagnosis of seizures requiring antiepileptic medications is **""no.""** 

This conclusion stems from several observations. First, the main patient's extensive surgical history, including significant interventions post-Fontan surgery, has not indicated any prior seizures or related interventions. In the cohort of similar patients, while some had histories of seizures or required antiepileptic medications, the majority did not demonstrate such a diagnosis, particularly those without a significant number of arrhythmias or neurologic events. The low predicted probability (5.66%) from the XGBoost model, combined with the main patient's clinical features—specifically the lack of neurological complications or seizures mentioned—supports this prediction.",1,1,1,1,1,0
BCH-TARJOS-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? yes
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 125.0
 Patient weight: 23.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8944569422129799
 Heart rate: 88.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 148.9
 Right ventricular end-systolic volume: 63.41
 Right ventricle mass: 41.1
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right superior vena cava flow rate: 1.14
 Inferior vena cava, below the fenestration flow rate: 1.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.94
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.42
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.95
 Right atrioventricular valve/tricuspid inflow rate: 5.7
 Single ventricle ejection fraction 0.5741437206178643
 Single ventricle systolic volume 85.49000000000001
 Body mass index 14.912
 Mass to height volume indexed on BSA (exp = 2.7) 22.500117534534567
 Systemic ventricle end-systolic volume: 63.41
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 70.89217714954175
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 73.30447408744034
 Systemic ventricle end-diastolic volume: 148.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 166.46972366451297
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 172.13430360542293
 Systemic ventricle mass: 41.1
 Systemic ventricle mass indexed on BSA (exp=1) 45.94966851988907
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.51322953782997
 Systemic ventricle mass to volume ratio: 0.27602417730020146
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.30859414721214956
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.31909489279939535
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Localized signal artifact in the left superior mediastinum, and stents in the pulmonary artery, left pulmonary veins and Fontan fenestration precludes assessment of those
structures.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify:  thrombosed LUPV stent
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00177462].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided patient data, I predict that the patient does **not** have a history of pacemaker placement (no). This conclusion is supported by the patient’s surgical history and clinical outcomes, as there is no indication of significant arrhythmias or interventions for rhythm disturbances, which are often the primary reasons for pacemaker placement in other patients. Additionally, the absence of documented history of sustained ventricular arrhythmias or sinus node dysfunction further suggests that the patient's cardiac function has remained stable, reducing the likelihood of requiring a pacing intervention. The very low predicted probability (0.00177) from the XGBoost model also supports the likelihood that this patient does not have a history of pacemaker placement.","Based on the provided information, it is unlikely that the main patient has a history of pacemaker placement. First, the main patient’s medical history indicates they have not experienced sustained ventricular arrhythmias, which often necessitate the use of a pacemaker. Additionally, when considering the similar patients, particularly the one with substantial overlap in surgical history and diagnosis who did not have a pacemaker, the data suggests a pattern where non-pacemaker patients tend to have stable arrhythmias or do not face complications severe enough to warrant device implantation. The XGBoost model’s prediction for the occluded outcome being ""no"" also aligns with this clinical observation, reinforcing the conclusion that the main patient likely does not have a history of pacemaker placement.","Based on the available information, it is predicted that the main patient does **not** have a history of pacemaker placement. The patient has undergone multiple surgeries including a Fontan procedure and has a complex surgical history indicative of significant cardiac management without a documented need for a pacemaker. Furthermore, the similar patients, who also have critical congenital heart defects and have undergone similar surgical interventions, exhibit a trend where they display either no need for pacemaker placement or have not recorded any such interventions. Given the low probability of a positive outcome for pacemaker placement indicated by the XGBoost model (0.00177462), it aligns with the absence of pacemaker history in both the main patient and the similar patients.","Based on the available data, it is unlikely that the main patient has a history of pacemaker placement. The patient has undergone multiple significant surgeries, including atrioventricular valve procedures, yet does not show documentation for any arrhythmia that would typically necessitate a pacemaker, such as sustained tachyarrhythmias or symptoms indicative of arrhythmias. Furthermore, among the similar patients, those who had similar cardiac diagnoses and surgeries (such as Hypoplastic Left Heart Syndrome) have not shown a high incidence of pacemaker placement, suggesting that this option may not be common in their profiles. Additionally, the XGBoost model predicts a very low probability (0.00177462) for the outcome indicating that pacemaker placement is likely not a factor for this patient. Thus, the prediction would be ""no.""",1,1,1,1,0
BCH-TARJOS-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? yes
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 125.0
 Patient weight: 23.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8944569422129799
 Heart rate: 88.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 148.9
 Right ventricular end-systolic volume: 63.41
 Right ventricle mass: 41.1
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right superior vena cava flow rate: 1.14
 Inferior vena cava, below the fenestration flow rate: 1.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.94
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.42
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.95
 Right atrioventricular valve/tricuspid inflow rate: 5.7
 Single ventricle ejection fraction 0.5741437206178643
 Single ventricle systolic volume 85.49000000000001
 Body mass index 14.912
 Mass to height volume indexed on BSA (exp = 2.7) 22.500117534534567
 Systemic ventricle end-systolic volume: 63.41
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 70.89217714954175
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 73.30447408744034
 Systemic ventricle end-diastolic volume: 148.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 166.46972366451297
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 172.13430360542293
 Systemic ventricle mass: 41.1
 Systemic ventricle mass indexed on BSA (exp=1) 45.94966851988907
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.51322953782997
 Systemic ventricle mass to volume ratio: 0.27602417730020146
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.30859414721214956
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.31909489279939535
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Localized signal artifact in the left superior mediastinum, and stents in the pulmonary artery, left pulmonary veins and Fontan fenestration precludes assessment of those
structures.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify:  thrombosed LUPV stent
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00865501].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data, the prediction for the missing clinical outcome—whether the patient received a heart transplant—would be ""no."" This conclusion stems from several factors in the patient's surgical history and clinical evaluation. Firstly, the patient has undergone a significant number of corrective surgeries (four), including a Fontan procedure, which suggests efforts to optimize the function of the existing anatomy rather than transitioning to transplant. Additionally, the patient's cardiac MRI report indicates a single ventricle ejection fraction of 0.57 and a relatively stable clinical status, with no history of serious post-operative complications other than a thrombus, suggesting sufficient cardiac function to maintain circulation without necessitating transplantation at this point. Moreover, the XGBoost probability output of 0.00865501 strongly suggests a low likelihood of the outcome ""yes,"" supporting the prediction that a heart transplant was not needed.","Based on the analysis of the main patient's clinical and surgical history, and considering the data from similar patients, the prediction is that the main patient did **not** receive a heart transplant. This conclusion is supported by the relatively low predicted probability (0.0087) from the XGBoost model indicating a high likelihood of the absence of the outcome. Furthermore, similar patients with comparable surgical histories, particularly those who did not develop complications like protein-losing enteropathy, had a lower incidence of heart transplants, with many remaining stable without requiring such interventions. These factors, including the main patient’s current status with known intracardiac thrombus and relatively stable function metrics, suggest that a heart transplant was not pursued or needed at this time.","The predicted outcome for the main patient regarding the question of whether they received a heart transplant is **no**. The main patient has a complex surgical history that includes multiple cardiac surgeries, an extracardiac Fontan procedure with fenestration, and a history of intracardiac thrombus. The lower estimated probability of receiving a heart transplant (0.0087) suggests a low likelihood of this intervention based on the XGBoost model’s findings.

Moreover, in the cohort of similar patients, those with deceased status often exhibited additional critical complications leading to transplant necessity, such as significant valvular regurgitation and severe thrombotic issues. In contrast, the main patient has no history of key complications like protein-losing enteropathy or confirmed arrhythmias that would typically prompt transplant consideration in similar patients. Thus, the patterns in both the patient’s clinical features and the similar cohort indicate a low risk of requiring a heart transplant at this stage.","Based on the provided data, it is predicted that the main patient did **not** receive a heart transplant. The XGBoost model's predicted probability of the occluded outcome being 'yes' is very low at 0.0087, suggesting that the likelihood of this patient receiving a transplant is minimal. Additionally, among the similar patients, only a small fraction had undergone heart transplantation, with most having complications like protein-losing enteropathy, which can often complicate the candidacy for transplant. The main patient's clinical history indicates potential risks for transplant candidacy, such as an intracardiac thrombus and a complicated surgical history, further supporting the prediction that a heart transplant is unlikely.",1,1,1,1,0
BCH-TARJOS-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? yes
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 125.0
 Patient weight: 23.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8944569422129799
 Heart rate: 88.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 148.9
 Right ventricular end-systolic volume: 63.41
 Right ventricle mass: 41.1
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right superior vena cava flow rate: 1.14
 Inferior vena cava, below the fenestration flow rate: 1.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.94
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.42
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.95
 Right atrioventricular valve/tricuspid inflow rate: 5.7
 Single ventricle ejection fraction 0.5741437206178643
 Single ventricle systolic volume 85.49000000000001
 Body mass index 14.912
 Mass to height volume indexed on BSA (exp = 2.7) 22.500117534534567
 Systemic ventricle end-systolic volume: 63.41
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 70.89217714954175
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 73.30447408744034
 Systemic ventricle end-diastolic volume: 148.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 166.46972366451297
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 172.13430360542293
 Systemic ventricle mass: 41.1
 Systemic ventricle mass indexed on BSA (exp=1) 45.94966851988907
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.51322953782997
 Systemic ventricle mass to volume ratio: 0.27602417730020146
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.30859414721214956
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.31909489279939535
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Localized signal artifact in the left superior mediastinum, and stents in the pulmonary artery, left pulmonary veins and Fontan fenestration precludes assessment of those
structures.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify:  thrombosed LUPV stent
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.02600487].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided data, the prediction for the occluded outcome, ""Does the patient have a history of ascites (> trace)?"", is **no**. The patient has undergone multiple surgeries and has complex cardiac history, including an Extracardiac Fontan and documented interventions such as thrombus management, but there is no indication of ascites or its complications mentioned in the patient status event update section. Furthermore, the XGBoost model prediction probability of 0.026 suggests a low likelihood of the patient having a history of ascites, reinforcing the conclusion that ascites is not likely to be a significant issue for this particular patient.","Based on the information provided, I predict that the main patient does **not** have a history of ascites (> trace). The main patient has undergone multiple complex cardiac surgeries but has not demonstrated significant issues with fluid retention or documented symptoms often associated with ascites, such as cardiac-related liver dysfunction, as indicated by their lack of prior diagnoses like protein-losing enteropathy or elevated liver fibrosis tests. 

When reviewing similar patients, particularly patient #1, there was a prominent diagnosis of protein-losing enteropathy, indicating issues with fluid regulation that could lead to ascites; however, the majority did not report a history of ascites, suggesting that this may not be a prevalent complication in patients with similar profiles. Moreover, the XGBoost model estimates a very low probability (2.6%) for the occluded outcome being 'yes,' reinforcing the conclusion that the patient likely does not have a significant history of ascites.","Based on the analysis of both the main patient's data and the trends observed in similar patients, it is predicted that the main patient does **not** have a history of ascites (> trace). The main patient’s previous cardiac surgeries and MRI reports indicate some complexity, such as a history of intracardiac thrombus and the presence of a fenestration, but not a clear history of ascites or fluid-related issues. In contrast, some similar patients do have a history of ascites, though the overall data shows that a majority do not, aligning with the XGBoost model’s predicted low probability (0.02600487) for the outcome being ""yes."" Therefore, considering the main patient's absence of relevant symptoms and the trends in the similar cohort, the prediction leans towards ""no.""","**Prediction:** No, the patient does not have a history of ascites (> trace).

**Reasoning:** The main patient has a complex surgical history due to hypoplastic left heart syndrome and has undergone multiple surgeries without a record of experiencing ascites. Among similar patients, especially those identified with comparable anatomical and surgical characteristics (such as having undergone a Fontan procedure), ascites was reported in only a few cases. Given that the predicted probability of the occluded outcome being 'yes' is only 0.02600487—indicating a low likelihood of ascites—this aligns with the observed patterns in the data of similar patients, where the majority were managed without ascitic complications.",1,1,1,1,0
BCH-TARJOS-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? yes
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 125.0
 Patient weight: 23.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8944569422129799
 Heart rate: 88.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 148.9
 Right ventricular end-systolic volume: 63.41
 Right ventricle mass: 41.1
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right superior vena cava flow rate: 1.14
 Inferior vena cava, below the fenestration flow rate: 1.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.94
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.42
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.95
 Right atrioventricular valve/tricuspid inflow rate: 5.7
 Single ventricle ejection fraction 0.5741437206178643
 Single ventricle systolic volume 85.49000000000001
 Body mass index 14.912
 Mass to height volume indexed on BSA (exp = 2.7) 22.500117534534567
 Systemic ventricle end-systolic volume: 63.41
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 70.89217714954175
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 73.30447408744034
 Systemic ventricle end-diastolic volume: 148.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 166.46972366451297
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 172.13430360542293
 Systemic ventricle mass: 41.1
 Systemic ventricle mass indexed on BSA (exp=1) 45.94966851988907
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.51322953782997
 Systemic ventricle mass to volume ratio: 0.27602417730020146
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.30859414721214956
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.31909489279939535
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Localized signal artifact in the left superior mediastinum, and stents in the pulmonary artery, left pulmonary veins and Fontan fenestration precludes assessment of those
structures.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify:  thrombosed LUPV stent
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01556012].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided information, I would predict that the patient does **not** have a diagnosis of seizures requiring antiepileptic medications ('no'). The patient's cardiac history indicates multiple surgeries with a focus on structural issues rather than neurological complications, and there is no prior mention of a significant thromboembolic event or neurological symptoms that would indicate a risk for seizures. Additionally, the XGBoost model's predicted probability of the occluded outcome being 'yes' is relatively low (0.01556012), suggesting a very low likelihood of this patient having a seizure disorder that necessitates medication. Therefore, considering both the clinical features and the model output, the evidence supports a 'no' conclusion regarding the diagnosis of seizures.","Based on the provided data, I predict that the main patient does not have a diagnosis of seizures requiring antiepileptic medications. The main patient’s history does not indicate any seizures or neurological complications, and there is no evidence of related issues such as stroke or transient ischemic attacks. Furthermore, the similar patients' data suggest that the majority do not have a diagnosis of seizures; notably, one similar patient had intracardiac thrombus but did not report seizures, showcasing variability in complications. Additionally, the XGBoost model predicts a very low probability (1.6%) for the occluded outcome to be 'yes' (indicating seizures), further supporting the likelihood that the main patient is not experiencing this condition.","Based on the provided data, the predicted clinical outcome for the main patient regarding the diagnosis of seizures requiring antiepileptic medications is **no**. The main patient shows a complex but stable post-Fontan course with no prior history of seizures or significant neurological issues, suggesting a lower likelihood of developing such complications. 

In comparison, the similar patients exhibit a mixed spectrum of outcomes; while some had severe complications like protein-losing enteropathy or major vascular thrombi, none of the patient profiles directly correlated a diagnosis of seizures with the provided surgical history or MRI findings. Additionally, the XGBoost model yields a very low predicted probability of seizures (approximately 1.56%), indicating it is highly unlikely for this patient to have a diagnosis of seizures requiring antiepileptic medications. Overall, this points to a more stable neurological status for the main patient compared to the risks observed in similar cases.","The prediction for the main patient is **no** regarding a diagnosis of seizures requiring antiepileptic medications. Upon reviewing the main patient’s surgical history and MRI data, there is no documented evidence of seizures or previous neurological complications, which align with similar patients in the cohort. Most notably, the XGBoost model outputs a low probability (0.01556012) for the occlusion outcome being 'yes' (seizures), suggesting that this condition is rare among the group. Additionally, in the data from similar patients, those who did have seizures also experienced severe complications like heart transplants, which the main patient has avoided thus far, indicating a more favorable neurological condition. Overall, the combination of low predictive probability and favorable status suggests that the main patient is unlikely to have a seizure diagnosis.",1,1,1,1,0
BCH-TARJOS-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Type of branch pulmonary artery intervention: yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? yes
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 125.0
 Patient weight: 23.3
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.8944569422129799
 Heart rate: 88.0
 Upper limb systolic blood pressure: 116.0
 Upper limb diastolic blood pressure: 60.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 148.9
 Right ventricular end-systolic volume: 63.41
 Right ventricle mass: 41.1
 Native aorta flow rate: 4.5
 Ascending aorta, above the Stansel flow rate: 4.5
 Right superior vena cava flow rate: 1.14
 Inferior vena cava, below the fenestration flow rate: 1.15
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.94
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.42
 Total right pulmonary vein flow rate: 2.5
 Total left pulmonary vein flow rate: 1.95
 Right atrioventricular valve/tricuspid inflow rate: 5.7
 Single ventricle ejection fraction 0.5741437206178643
 Single ventricle systolic volume 85.49000000000001
 Body mass index 14.912
 Mass to height volume indexed on BSA (exp = 2.7) 22.500117534534567
 Systemic ventricle end-systolic volume: 63.41
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 70.89217714954175
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 73.30447408744034
 Systemic ventricle end-diastolic volume: 148.9
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 166.46972366451297
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 172.13430360542293
 Systemic ventricle mass: 41.1
 Systemic ventricle mass indexed on BSA (exp=1) 45.94966851988907
 Systemic ventricle mass indexed on BSA (exp=1.3) 47.51322953782997
 Systemic ventricle mass to volume ratio: 0.27602417730020146
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.30859414721214956
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.31909489279939535
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Localized signal artifact in the left superior mediastinum, and stents in the pulmonary artery, left pulmonary veins and Fontan fenestration precludes assessment of those
structures.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 If other location of first intracardiac thrombus, please specify:  thrombosed LUPV stent
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? yes
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): yes
 Diuretic: yes
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.07301246].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided information, it is reasonable to predict that the patient has not died, as the estimated probability of the occluded outcome (i.e., death) is only 7.3%, which indicates a low likelihood. Furthermore, the patient's clinical profile shows a history of stable cardiac interventions, such as successful Fontan surgery with a fenestration and no significant complications like arrhythmias or a severe decline in functional status, which would suggest a relatively favorable prognosis. The model's validation metrics also support the reliability of its predictions, indicating that while there may be some risk factors present, they do not significantly elevate the likelihood of death for this patient. Overall, the combination of clinical data and model predictions leads to the conclusion that the patient has not died.","Based on the provided information, I predict that the main patient has **not** died. This conclusion is drawn from the main patient's clinical data, where there are no indications of severe complications such as protein-losing enteropathy, major vascular thrombus, or previous heart transplant, which correlate with higher mortality rates in similar patients. Additionally, the similar patients' data indicates that despite having similar surgical histories and demographics, the majority of similar patients without severe complications did not report death. The XGBoost model's predicted probability of the occluded outcome being ‘yes’ (death) is very low (0.073), suggesting that the risk of mortality for the main patient is also relatively low, supporting the conclusion that they are still alive.","Based on the provided data, it is predicted that the main patient has not died. The patient has experienced complex surgical interventions and has a relatively stable clinical profile, with no significant features such as protein-losing enteropathy or significant pulmonary complications that could exacerbate their condition. 

In contrast, the similar patients who did succumb often had the histories of protein-losing enteropathy, severe thrombus, and multiple complications following Fontan surgery. The XGBoost model's estimated probability of the occluded outcome being 'yes' (indicating the potential of death) is low at 0.07301246, and the high accuracy rate (0.96) of the model suggests confidence in predicting survivability based on available clinical features. Together, these observations lead to the conclusion that while the patient is at risk, current data suggests they have not yet passed away.","Based on the available data for the main patient, there is an estimated probability of 7.3% for the occluded outcome of death. The patient has undergone four cardiac surgeries and has a notably complex medical history, which includes an intracardiac thrombus diagnosis, highlighting significant cardiac concerns. Furthermore, similar patients, especially those with hypoplastic left heart syndrome (HLHS) or similar conditions and a history of complex surgeries, experienced a range of outcomes including death related to transplantation or post-operative complications. These trends in similar patients, coupled with the main patient's compromised clinical situation indicated by the MRI findings and surgical history, suggest a concerning trajectory that increases the likelihood of potential mortality despite the model's lower probability estimation. Thus, it's reasonable to predict that the outcome is more likely to be ""yes,"" the patient has died, reflecting the complex interplay of their medical challenges.",1,1,1,0,0
BCH-TOMCHR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 If other genetic diagnoses, please describe: Pentalogy of Cantrell with omphalocele and partial ectopia cordis
 If other semilunar valve procedure please describe oversewing of pulmonary valve, left pulmonary artery patch plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 7.6
 Patient height: 160.1
 Patient weight: 50.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.490868980284426
 Heart rate: 76.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 74.0
 Upper limb mean blood pressure: 98.0
 O2 Saturation: 97
 Left ventricle end-diastolic volume: 110.3
 Left ventricle end-systolic volume: 62.0
 Left ventricular mass: 76.9
 Right ventricular end-diastolic volume: 43.8
 Right ventricular end-systolic volume: 19.2
 Right ventricle mass: 17.6
 Native aorta flow rate: 5.34
 Ascending aorta, above the Stansel flow rate: 5.34
 Descending aorta flow rate: 3.57
 Right superior vena cava flow rate: 1.65
 Inferior vena cava, below the fenestration flow rate: 1.65
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.69
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.01
 Total right pulmonary vein flow rate: 4.02
 Total left pulmonary vein flow rate: 2.22
 Left atrioventricular valve/mitral inflow rate: 5.55
 Single ventricle ejection fraction 0.4730694354315379
 Single ventricle systolic volume 72.89999999999999
 Body mass index 19.5848862418515
 Mass to height volume indexed on BSA (exp = 2.7) 26.52010335772917
 Systemic ventricle end-systolic volume: 81.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.464879928287715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 48.31530293858998
 Systemic ventricle end-diastolic volume: 154.1
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.3625369082406
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.69197269503343
 Systemic ventricle mass: 94.5
 Systemic ventricle mass indexed on BSA (exp=1) 63.38585164067967
 Systemic ventricle mass indexed on BSA (exp=1.3) 56.22901635094523
 Systemic ventricle mass to volume ratio: 1.0990159672458262
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7371646883659471
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6539321353673593
 Any significant metallic artifact that obscures anatomy? If yes, please describe: patient motion, Metallic artifact from the left pulmonary artery stent precludes evaluation for stenosis, and impacts assessment of flow.
 Other relevant report comments or concerns: Hepatic changes consistent with Fontan associated liver disease.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00116448].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data and the XGBoost model's predicted probability of the occluded outcome being 'yes' (0.00116448), it is reasonable to predict that the patient **did not receive a heart transplant**. The very low probability indicates that, in similar cases, heart transplants are rare among patients who share the same clinical features as this patient. Additionally, their surgical history—including the fact that they have completed a lateral tunnel Fontan without subsequent revisions or significant complications, along with a lack of major adverse events such as arrhythmias or thrombus—suggests that their heart function has been stable enough to avoid the necessity for transplantation. The effective management indicated by controlled O2 saturation, normal systemic blood pressures, and preserved ventricular function further supports an outcome of not requiring heart transplantation.","Based on the provided information, I predict that the main patient did **not** receive a heart transplant. The patient has a complex surgical history, including a lateral tunnel Fontan and a fenestration, without a record of significant complications such as protein-losing enteropathy or severe arrhythmias, which are often indications for transplantation. Additionally, among the similar patients, there is a noted trend of those who underwent heart transplantation displaying more significant adverse conditions and complications that the main patient does not currently exhibit. Coupled with the low predicted probability of the occluded outcome being 'yes' (0.00116448), it strongly suggests that transplantation is unlikely for this patient.","Based on the provided data and the predicted probability from the XGBoost model, I would predict that the main patient did *not* receive a heart transplant. The model estimates a very low probability (0.0012) of the occluded outcome being 'yes' (indicative of having received a transplant), which suggests that the majority of patients in similar clinical contexts did not require this intervention. Additionally, the main patient has multiple factors indicating a relatively stable condition, such as a reasonable single ventricle ejection fraction of approximately 47% and no history of severe complications like thrombus or significant arrhythmias, which also trends towards non-transplantation in similar patients who maintained their hemodynamics adequately post Fontan.","Given the information provided, I predict that the missing clinical outcome for the main patient, regarding whether they received a heart transplant, is ""no."" The main patient has a surgical history indicating no heart transplant has occurred and has undergone a series of complex surgeries characteristic of single-ventricle management (Fontan and Glenn procedures) without prior re-transplantation. 

Furthermore, the similar cohort of patients indicates a relatively low incidence (0.00116448 probability) of heart transplants among them. Although some similar patients with cardiac diagnoses like tricuspid atresia underwent cardiac surgery, the data indicates that they did not trend towards receiving a heart transplant when comparing similar outcomes within the cohort. This reinforces the idea that the main patient would likely not have undergone transplant surgery either.",1,1,1,1,0
BCH-TOMCHR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 If other genetic diagnoses, please describe: Pentalogy of Cantrell with omphalocele and partial ectopia cordis
 If other semilunar valve procedure please describe oversewing of pulmonary valve, left pulmonary artery patch plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 7.6
 Patient height: 160.1
 Patient weight: 50.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.490868980284426
 Heart rate: 76.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 74.0
 Upper limb mean blood pressure: 98.0
 O2 Saturation: 97
 Left ventricle end-diastolic volume: 110.3
 Left ventricle end-systolic volume: 62.0
 Left ventricular mass: 76.9
 Right ventricular end-diastolic volume: 43.8
 Right ventricular end-systolic volume: 19.2
 Right ventricle mass: 17.6
 Native aorta flow rate: 5.34
 Ascending aorta, above the Stansel flow rate: 5.34
 Descending aorta flow rate: 3.57
 Right superior vena cava flow rate: 1.65
 Inferior vena cava, below the fenestration flow rate: 1.65
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.69
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.01
 Total right pulmonary vein flow rate: 4.02
 Total left pulmonary vein flow rate: 2.22
 Left atrioventricular valve/mitral inflow rate: 5.55
 Single ventricle ejection fraction 0.4730694354315379
 Single ventricle systolic volume 72.89999999999999
 Body mass index 19.5848862418515
 Mass to height volume indexed on BSA (exp = 2.7) 26.52010335772917
 Systemic ventricle end-systolic volume: 81.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.464879928287715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 48.31530293858998
 Systemic ventricle end-diastolic volume: 154.1
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.3625369082406
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.69197269503343
 Systemic ventricle mass: 94.5
 Systemic ventricle mass indexed on BSA (exp=1) 63.38585164067967
 Systemic ventricle mass indexed on BSA (exp=1.3) 56.22901635094523
 Systemic ventricle mass to volume ratio: 1.0990159672458262
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7371646883659471
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6539321353673593
 Any significant metallic artifact that obscures anatomy? If yes, please describe: patient motion, Metallic artifact from the left pulmonary artery stent precludes evaluation for stenosis, and impacts assessment of flow.
 Other relevant report comments or concerns: Hepatic changes consistent with Fontan associated liver disease.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00193613].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data, it is predicted that the missing clinical outcome, ""Has the patient died?"", is **no**. The patient has a complex cardiac history but no significant evidence of morbidity that would typically lead to mortality, such as severe arrhythmias, thrombus, or pulmonary complications. Furthermore, the XGBoost model indicates a very low predicted probability (0.00193613) of adverse outcomes, reflecting the clinical stability suggested by the overall MRI evaluation and lack of major complications recorded. With a strong performance (accuracy of 0.96 and AUC of 0.87) in the model, this supports the likelihood that the patient is alive.","Based on the provided data, it is predicted that the main patient has **not died**. The patient's medical history is significant, but they show no indications of severe complications that typically lead to mortality, such as cardiac arrest, thrombosis, or liver disease. Furthermore, similar patients with comparable profiles, especially those who have undergone similar surgical interventions and Fontan procedures, predominantly maintained stable health statuses without mortality. The low predicted probability from the XGBoost model (0.0019) further supports this conclusion, suggesting a very low likelihood of mortality for this patient.","Based on the analysis of the main patient's clinical data and the results from the similar patients, I predict that the missing clinical outcome, ""Has the patient died?"" is **no**. The main patient has a history of successful surgical interventions and relatively stable hemodynamic status, as indicated by their MRI report showing adequate ejection fractions and flow rates. Furthermore, the cohort of similar patients reflects a favorable prognosis, with most having not experienced mortality, especially considering they share similar surgical and anatomical profiles, including Fontan procedures and similar hemodynamic challenges. Additionally, the XGBoost model estimates a very low probability (0.00193613) of the occluded outcome being 'yes', which aligns with the clinical history of the main patient and provides further support for a favorable outcome.","Based on the available data, I predict that the missing clinical outcome for the main patient is ""no,"" indicating that the patient has not died. This conclusion is supported by the patient's stable MRI results, including a single ventricle ejection fraction of approximately 47% and an absence of significant atrioventricular or semilunar valve regurgitation, which suggests adequate cardiac function despite the patient's underlying complex congenital heart condition. Furthermore, the similar patients, particularly those with comparable surgical histories and diagnoses, mostly demonstrate a lack of mortality events; the XGBoost model predicts a very low probability of death at 0.0019, indicating a strong tendency for survival in these cases. Collectively, these observations imply a protective trend against mortality for this cohort, supporting the prediction that the main patient has not died.",1,1,1,1,0
BCH-TOMCHR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 If other genetic diagnoses, please describe: Pentalogy of Cantrell with omphalocele and partial ectopia cordis
 If other semilunar valve procedure please describe oversewing of pulmonary valve, left pulmonary artery patch plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 7.6
 Patient height: 160.1
 Patient weight: 50.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.490868980284426
 Heart rate: 76.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 74.0
 Upper limb mean blood pressure: 98.0
 O2 Saturation: 97
 Left ventricle end-diastolic volume: 110.3
 Left ventricle end-systolic volume: 62.0
 Left ventricular mass: 76.9
 Right ventricular end-diastolic volume: 43.8
 Right ventricular end-systolic volume: 19.2
 Right ventricle mass: 17.6
 Native aorta flow rate: 5.34
 Ascending aorta, above the Stansel flow rate: 5.34
 Descending aorta flow rate: 3.57
 Right superior vena cava flow rate: 1.65
 Inferior vena cava, below the fenestration flow rate: 1.65
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.69
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.01
 Total right pulmonary vein flow rate: 4.02
 Total left pulmonary vein flow rate: 2.22
 Left atrioventricular valve/mitral inflow rate: 5.55
 Single ventricle ejection fraction 0.4730694354315379
 Single ventricle systolic volume 72.89999999999999
 Body mass index 19.5848862418515
 Mass to height volume indexed on BSA (exp = 2.7) 26.52010335772917
 Systemic ventricle end-systolic volume: 81.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.464879928287715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 48.31530293858998
 Systemic ventricle end-diastolic volume: 154.1
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.3625369082406
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.69197269503343
 Systemic ventricle mass: 94.5
 Systemic ventricle mass indexed on BSA (exp=1) 63.38585164067967
 Systemic ventricle mass indexed on BSA (exp=1.3) 56.22901635094523
 Systemic ventricle mass to volume ratio: 1.0990159672458262
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7371646883659471
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6539321353673593
 Any significant metallic artifact that obscures anatomy? If yes, please describe: patient motion, Metallic artifact from the left pulmonary artery stent precludes evaluation for stenosis, and impacts assessment of flow.
 Other relevant report comments or concerns: Hepatic changes consistent with Fontan associated liver disease.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01077081].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided data and the XGBoost model's prediction, it is reasonable to predict that the patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The model indicates a very low predicted probability (0.01077081) for the occurrence of this outcome, suggesting that seizures are uncommon within similar patient cohorts. Additionally, the MRI report indicates no history of significant vascular complications, strokes, or arrhythmias that might contribute to seizure risk, and the patient's current medication regimen does not include antiepileptic drugs, reinforcing the prediction that seizures are unlikely in this case.","Based on the patient's clinical history and the data from similar patients, it is reasonable to predict that the main patient does not have a diagnosis of seizures requiring antiepileptic medications (no). The main patient has a complex medical history with tricuspid atresia and undergone a series of surgeries, but there is no indication of a seizure history. The similar patients, while exhibiting various complications, did not show a significant prevalence of seizures; particularly, none of the three similar patients had a seizure diagnosis, which suggests that it is infrequent in this cohort. Given the low estimated probability of seizures as inferred from the model prediction (0.01077081) and the lack of evidence for seizure episodes or antiepileptic treatment in similar cases, the prediction leans heavily towards 'no'.","Based on the information provided, it is predicted that the main patient does not have a diagnosis of seizures requiring antiepileptic medications (no). The main patient has undergone a series of surgeries including a lateral tunnel Fontan, but there is no indication of neurological issues in their medical history. Furthermore, the analysis of similar patients indicates that the majority did not report seizures, despite experiencing various complications associated with single-ventricle anatomy. The XGBoost model's low probability prediction of the occluded outcome (0.01077081) aligns with this conclusion, suggesting that the risk of developing seizures is minimal in this specific clinical context.","Based on the available data, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. The main patient has a complex surgical history, including a Lateral Tunnel Fontan and a history of pulmonary interventions, but there is no reported history of seizures or related neurological issues in their clinical updates. The similar patients also exhibit a low incidence of seizures; in fact, most displayed no neurological complications despite comparable cardiac conditions. Furthermore, the XGBoost model’s prediction probability of 0.0108 indicates a very low likelihood of seizures associated with this cohort, which aligns with the lack of seizure diagnoses in both the patient and similar cases.",1,1,1,1,0
BCH-TOMCHR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 If other genetic diagnoses, please describe: Pentalogy of Cantrell with omphalocele and partial ectopia cordis
 If other semilunar valve procedure please describe oversewing of pulmonary valve, left pulmonary artery patch plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 7.6
 Patient height: 160.1
 Patient weight: 50.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.490868980284426
 Heart rate: 76.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 74.0
 Upper limb mean blood pressure: 98.0
 O2 Saturation: 97
 Left ventricle end-diastolic volume: 110.3
 Left ventricle end-systolic volume: 62.0
 Left ventricular mass: 76.9
 Right ventricular end-diastolic volume: 43.8
 Right ventricular end-systolic volume: 19.2
 Right ventricle mass: 17.6
 Native aorta flow rate: 5.34
 Ascending aorta, above the Stansel flow rate: 5.34
 Descending aorta flow rate: 3.57
 Right superior vena cava flow rate: 1.65
 Inferior vena cava, below the fenestration flow rate: 1.65
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.69
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.01
 Total right pulmonary vein flow rate: 4.02
 Total left pulmonary vein flow rate: 2.22
 Left atrioventricular valve/mitral inflow rate: 5.55
 Single ventricle ejection fraction 0.4730694354315379
 Single ventricle systolic volume 72.89999999999999
 Body mass index 19.5848862418515
 Mass to height volume indexed on BSA (exp = 2.7) 26.52010335772917
 Systemic ventricle end-systolic volume: 81.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.464879928287715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 48.31530293858998
 Systemic ventricle end-diastolic volume: 154.1
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.3625369082406
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.69197269503343
 Systemic ventricle mass: 94.5
 Systemic ventricle mass indexed on BSA (exp=1) 63.38585164067967
 Systemic ventricle mass indexed on BSA (exp=1.3) 56.22901635094523
 Systemic ventricle mass to volume ratio: 1.0990159672458262
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7371646883659471
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6539321353673593
 Any significant metallic artifact that obscures anatomy? If yes, please describe: patient motion, Metallic artifact from the left pulmonary artery stent precludes evaluation for stenosis, and impacts assessment of flow.
 Other relevant report comments or concerns: Hepatic changes consistent with Fontan associated liver disease.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00066778].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided patient data and the low estimated probability of 'yes' for having a history of pacemaker placement (0.00066778), it is reasonable to predict that the patient does not have a history of pacemaker placement (no). The patient's surgical history reveals no significant arrhythmias or related postoperative interventions, which would typically precede pacemaker placement. Additionally, the patient's current status indicates a lack of any relevant cardiac issues such as sustained arrhythmias or syncope that might necessitate such management. Therefore, the combination of the patient's stable clinical condition and the model's prediction supports the conclusion that they do not have a pacemaker history.","Based on the provided data, it is predicted that the main patient does not have a history of pacemaker placement (no). This inference is supported by the fact that the main patient has a relatively low single ventricle ejection fraction of 47.3%, which might increase the need for close monitoring and potentially interventions, but there are no indications of sustained or significant arrhythmias that would typically necessitate pacemaker implantation. Additionally, among the similar patients, despite some having undergone various interventions, the lack of a pacemaker history is prevalent, indicating that it may not be a common necessity for patients with comparable surgical histories and ventricular performance. The low predicted probability of 0.00066778 further aligns with this assumption, suggesting a very low likelihood of a pacemaker placement.","Based on the available data regarding the main patient and similar patients, I predict that the main patient does **not** have a history of pacemaker placement. The main patient exhibits a variety of cardiac interventions, including lateral tunnel Fontan surgery, but there is no indication of sinus node dysfunction or sustained ventricular arrhythmias, which are common triggers for pacemaker placement. Additionally, amongst the similar patients, those with comparable surgical histories, such as tricuspid atresia and similar Fontan procedures, showed no significant prevalence of pacemaker placements. Moreover, the XGBoost model's output, with a very low predicted probability (0.00066778) of having such a history, supports the inference that it is unlikely for this patient to have undergone pacemaker placement.","The predicted outcome for the main patient regarding whether they have a history of pacemaker placement is **no**. 

The main patient has undergone two cardiac surgeries and has been documented with various interventions; however, there is no indication of a pacemaker placement in their surgical history. Additionally, within the cohort of similar patients, those with a history of pacemaker placement often presented with more complex surgical histories or complications requiring such an intervention, which is not seen in this patient's profile. The XGBoost model's low predicted probability of 0.00066778 for the occluded outcome further supports the likelihood that the answer is no, as patients without significant arrhythmias or postoperative complications (which lead to the need for pacing) were generally not reported to need pacemaker placements.",1,1,1,1,0
BCH-TOMCHR-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 2.0
 If other genetic diagnoses, please describe: Pentalogy of Cantrell with omphalocele and partial ectopia cordis
 If other semilunar valve procedure please describe oversewing of pulmonary valve, left pulmonary artery patch plasty
 Cardiac diagnosis: Tricuspid atresia
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Balanced or mixed
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? no
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? no
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? no
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): yes
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? no
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Gadobutrol (Gadavist, Gadovist) contrast dose: 7.6
 Patient height: 160.1
 Patient weight: 50.2
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.490868980284426
 Heart rate: 76.0
 Upper limb systolic blood pressure: 122.0
 Upper limb diastolic blood pressure: 74.0
 Upper limb mean blood pressure: 98.0
 O2 Saturation: 97
 Left ventricle end-diastolic volume: 110.3
 Left ventricle end-systolic volume: 62.0
 Left ventricular mass: 76.9
 Right ventricular end-diastolic volume: 43.8
 Right ventricular end-systolic volume: 19.2
 Right ventricle mass: 17.6
 Native aorta flow rate: 5.34
 Ascending aorta, above the Stansel flow rate: 5.34
 Descending aorta flow rate: 3.57
 Right superior vena cava flow rate: 1.65
 Inferior vena cava, below the fenestration flow rate: 1.65
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.69
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 2.01
 Total right pulmonary vein flow rate: 4.02
 Total left pulmonary vein flow rate: 2.22
 Left atrioventricular valve/mitral inflow rate: 5.55
 Single ventricle ejection fraction 0.4730694354315379
 Single ventricle systolic volume 72.89999999999999
 Body mass index 19.5848862418515
 Mass to height volume indexed on BSA (exp = 2.7) 26.52010335772917
 Systemic ventricle end-systolic volume: 81.2
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 54.464879928287715
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 48.31530293858998
 Systemic ventricle end-diastolic volume: 154.1
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 103.3625369082406
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 91.69197269503343
 Systemic ventricle mass: 94.5
 Systemic ventricle mass indexed on BSA (exp=1) 63.38585164067967
 Systemic ventricle mass indexed on BSA (exp=1.3) 56.22901635094523
 Systemic ventricle mass to volume ratio: 1.0990159672458262
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.7371646883659471
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.6539321353673593
 Any significant metallic artifact that obscures anatomy? If yes, please describe: patient motion, Metallic artifact from the left pulmonary artery stent precludes evaluation for stenosis, and impacts assessment of flow.
 Other relevant report comments or concerns: Hepatic changes consistent with Fontan associated liver disease.
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? no
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers yes
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01096194].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided data, I predict that the missing clinical outcome for the main patient is ""no"" for the history of ascites (> trace). The patient's clinical history lacks signs indicative of fluid accumulation, such as ""history of pleural effusion, chylous greater than 30 days after surgery"" being marked as ""no."" Moreover, the Cardiac Magnetic Resonance (CMR) report mentions liver changes consistent with Fontan associated liver disease, which may indicate hepatic congestion rather than ascites itself. The low predicted probability of the occluded outcome (0.01096194) also suggests that the likelihood of the patient experiencing ascites is minimal, further supporting the conclusion that the patient does not have a significant history of ascites.","Based on the provided data, I predict that the main patient does not have a history of ascites (> trace) (""no""). The main patient's MRI report indicates hepatic changes consistent with Fontan-associated liver disease, which could raise concern for potential complications, but there is no direct evidence of ascites in the current status update. In comparison with similar patients, particularly those with a history of complications post-Fontan surgery, none reported significant issues with ascites (> trace). Furthermore, the patient's low predicted probability (0.01096194) from the XGBoost model for the outcome suggests a very low likelihood of developing ascites, aligning with the absence of reported complications in this particular cohort.","Based on the provided data, I predict that the main patient does not have a history of ascites (> trace). The main patient underwent a Lateral Tunnel Fontan and has multiple interventions, including a fenestration, but shows no clinical signs such as elevated liver fibrosis or pleural effusions, which often accompany ascites. In comparison, the similar patients with ascites histories either had evidence of pleural effusion or variations in arterial flow indicating significant complications, which this patient does not exhibit. Additionally, the XGBoost model provides a very low probability (0.01096) for a positive outcome regarding ascites, aligning with the absence of significant clinical indicators in the patient's records.","Based on the provided data, the main patient has a complex surgical history involving tricuspid atresia and multiple interventions, including a lateral tunnel Fontan procedure with a fenestration. The MRI report indicated ""hepatic changes consistent with Fontan-associated liver disease,"" which could be indicative of fluid overload or venous congestion, commonly associated with ascites. Furthermore, among similar patients, some with similar backgrounds and a history of significant hepatic changes showed occurrences of pleural effusions and ascites. The predictive model's probability estimation of 0.01096194 for a history of ascites being positive is quite low, suggesting that while the patient may be at risk due to prevailing factors, the overall indicator is not strongly in favor of a history of ascites.

Thus, I would predict that the main patient does **not** have a history of ascites exceeding trace levels, mainly due to the low probability estimate combined with the existing patterns among similar patients.",1,1,1,1,0
BCH-TRATRI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURGERY (10/2002):  Stage 1 Norwood with right modified BT shunt.
CATH (5/2003):  Balloon dilation of coarctation.
SURGERY (7/2003):  Bidirectional Glenn with takedown of BT shunt and reconstruction of PA confluence with patch of cryopreserved pulmonary allograft.
SURGERY (8/2004):  Fontan procedure with extracardiac conduit.
CATH (2/2017): Hemodynamic
CATH (5/2017, CHB):  Coil occlusion of an innominate VVC.
*SURGERY (5/2017, CHB):  Biventricular conversion.  Takedown of Stansel connection.  Takedown of Fontan and Glenn connections.  
CATH (10/2017):  Balloon dilation of LPA
CATH (6/2019) - balloon dilation of proximal LPA, RFA and RFV perclosed
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 8.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 8.7
 Patient height: 168.0
 Patient weight: 58.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.6484270181251144
 Heart rate: 85.0
 Upper limb systolic blood pressure: 127.0
 Upper limb diastolic blood pressure: 88.0
 Upper limb mean blood pressure: 103.0
 Left ventricle end-diastolic volume: 85.8
 Left ventricle end-systolic volume: 33.1
 Left ventricular mass: 82.8
 Right ventricular end-diastolic volume: 92.4
 Right ventricular end-systolic volume: 44.8
 Right ventricle mass: 70.2
 Native aorta flow rate: 4.9
 Ascending aorta, above the Stansel flow rate: 4.9
 Descending aorta flow rate: 3.3
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.8
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.2
 Total right pulmonary vein flow rate: 3.2
 Total left pulmonary vein flow rate: 1.8
 Right atrioventricular valve/tricuspid inflow rate: 1.8
 Left atrioventricular valve/mitral inflow rate: 3.5
 Aortic or native aortic regurgitation fraction: 17.0
 Pulmonary or neo-aortic regurgitation fraction: 15.0
 Mitral or common atrioventricular regurgitation fraction: 10.0
 Single ventricle ejection fraction 0.5628507295173961
 Single ventricle systolic volume 100.29999999999998
 Body mass index 20.691609977324266
 Mass to height volume indexed on BSA (exp = 2.7) 37.701303866397225
 Systemic ventricle end-systolic volume: 77.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 47.25717253081777
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 40.67680339251185
 Systemic ventricle end-diastolic volume: 178.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.10305706022754
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 93.05014588633647
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 92.81575606181154
 Systemic ventricle mass indexed on BSA (exp=1.3) 79.89153939735961
 Systemic ventricle mass to volume ratio: 1.7247752247752248
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.0463157942757741
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9006205739981675
 Contrast type: Gadavist
 Description of veno-venous collaterals: Prominent decompressing venous collateral from the left innominate vein to a reconstituted azygous and hemiazygous venous system.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Part of the LPA is obscured by a metallic artifact from the stent. Non-stented portion is unobstructed.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.04286864].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided information, I predict that the missing clinical outcome for the patient is ""no"" regarding the diagnosis of seizures requiring antiepileptic medications. This prediction is supported by the patient's overall clinical history and the absence of any reported neurologic complications, including seizures. Additionally, the patient's MRI findings show no late gadolinium enhancement, which often indicates less likelihood of significant brain pathology that could lead to seizures. Lastly, the very low predicted probability (0.04286864) from the XGBoost model suggesting that there's a 4.29% chance of having seizures aligns with the clinical history of no significant neuromuscular or neurologic issues.","Based on the information provided, I predict that the main patient does not have a diagnosis of seizures requiring antiepileptic medications. The main patient has a history of significant cardiac surgeries and interventions, yet there are no records or indications of neurological issues or seizures in their clinical events update, which is a reassuring sign. In contrast, the similar patients, particularly patient #1, also do not have a diagnosis of seizures. Additionally, the predicted probability of a seizure diagnosis, with a low estimation of only 4.29%, suggests that such a condition is rare in this cohort. Therefore, it is reasonable to conclude that the main patient likely does not have a seizure diagnosis warranting antiepileptic treatment.","Based on the provided information, I predict that the main patient does not have a diagnosis of seizures requiring antiepileptic medications (no). The main patient has a complex surgical history related to congenital heart disease, but there are no documented incidents of seizures or neurological events in their medical records. An analysis of similar patients shows that while some had complex histories with some instances of seizures, the overall frequency appears low in this context, particularly for patients who have not experienced significant complications like protein-losing enteropathy or plastic bronchitis. Furthermore, the probability of having a seizure diagnosis according to the model is quite low (4.29%), indicating that it is not a common outcome in this cohort of similar patients.","Based on the analysis of the main patient's data and the trends observed in the similar patients, the prediction for whether the patient has a diagnosis of seizures requiring antiepileptic medications is **no**. The main patient has a history of significant cardiac procedures including a Fontan operation and subsequent revisions but has no documented seizures or related complications in their medical history. Furthermore, the similar cohort shows a low incidence of seizures with only a few patients having this diagnosis, which coincides with the overall low predicted probability generated by the XGBoost model (approximately 4.29%). Given this context and the stability in the heart function indicated by their CMR results, the risk for the current patient appears minimal for developing seizure disorders.",1,1,1,1,0
BCH-TRATRI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURGERY (10/2002):  Stage 1 Norwood with right modified BT shunt.
CATH (5/2003):  Balloon dilation of coarctation.
SURGERY (7/2003):  Bidirectional Glenn with takedown of BT shunt and reconstruction of PA confluence with patch of cryopreserved pulmonary allograft.
SURGERY (8/2004):  Fontan procedure with extracardiac conduit.
CATH (2/2017): Hemodynamic
CATH (5/2017, CHB):  Coil occlusion of an innominate VVC.
*SURGERY (5/2017, CHB):  Biventricular conversion.  Takedown of Stansel connection.  Takedown of Fontan and Glenn connections.  
CATH (10/2017):  Balloon dilation of LPA
CATH (6/2019) - balloon dilation of proximal LPA, RFA and RFV perclosed
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 8.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 8.7
 Patient height: 168.0
 Patient weight: 58.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.6484270181251144
 Heart rate: 85.0
 Upper limb systolic blood pressure: 127.0
 Upper limb diastolic blood pressure: 88.0
 Upper limb mean blood pressure: 103.0
 Left ventricle end-diastolic volume: 85.8
 Left ventricle end-systolic volume: 33.1
 Left ventricular mass: 82.8
 Right ventricular end-diastolic volume: 92.4
 Right ventricular end-systolic volume: 44.8
 Right ventricle mass: 70.2
 Native aorta flow rate: 4.9
 Ascending aorta, above the Stansel flow rate: 4.9
 Descending aorta flow rate: 3.3
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.8
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.2
 Total right pulmonary vein flow rate: 3.2
 Total left pulmonary vein flow rate: 1.8
 Right atrioventricular valve/tricuspid inflow rate: 1.8
 Left atrioventricular valve/mitral inflow rate: 3.5
 Aortic or native aortic regurgitation fraction: 17.0
 Pulmonary or neo-aortic regurgitation fraction: 15.0
 Mitral or common atrioventricular regurgitation fraction: 10.0
 Single ventricle ejection fraction 0.5628507295173961
 Single ventricle systolic volume 100.29999999999998
 Body mass index 20.691609977324266
 Mass to height volume indexed on BSA (exp = 2.7) 37.701303866397225
 Systemic ventricle end-systolic volume: 77.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 47.25717253081777
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 40.67680339251185
 Systemic ventricle end-diastolic volume: 178.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.10305706022754
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 93.05014588633647
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 92.81575606181154
 Systemic ventricle mass indexed on BSA (exp=1.3) 79.89153939735961
 Systemic ventricle mass to volume ratio: 1.7247752247752248
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.0463157942757741
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9006205739981675
 Contrast type: Gadavist
 Description of veno-venous collaterals: Prominent decompressing venous collateral from the left innominate vein to a reconstituted azygous and hemiazygous venous system.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Part of the LPA is obscured by a metallic artifact from the stent. Non-stented portion is unobstructed.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00150152].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? no\n Reason for pacemaker placement: Other\n'],"Based on the provided clinical history and MRI report of the patient, it is unlikely that the patient has a history of pacemaker placement. The patient's surgical history, particularly involving multiple cardiac surgeries, including the Fontan procedure and biventricular conversion, typically suggests significant monitoring and management of potential arrhythmias that could necessitate a pacemaker. However, the available data shows no recorded history of arrhythmias, and there are no mentions of interventions related to arrhythmias that might indicate pacemaker placement. Additionally, the XGBoost model estimates a very low probability (0.0015) of the occluded outcome (history of pacemaker placement) being 'yes,' further supporting the conclusion that the patient likely does not have this history. Thus, the predicted outcome is 'no.'","Based on the provided information, it is likely that the main patient does not have a history of pacemaker placement. The main patient exhibits a clinical history that includes multiple surgeries and interventions but does not indicate any prior conditions or complications that would typically warrant the implantation of a pacemaker, such as sustained arrhythmias or significant hemodynamic instability. Additionally, the similar patients do not show a high prevalence of pacemaker placement despite having comparable surgical histories and clinical features, suggesting that it is relatively uncommon among this cohort. Furthermore, the XGBoost model predicts a very low probability (0.00150152) of the occluded outcome being 'yes', reinforcing the notion that a pacemaker is unlikely to be required for this patient.","**Prediction:** No, the patient does not have a history of pacemaker placement.

**Reasoning:** The main patient's surgical history and MRI report suggest a relatively stable hemodynamic status, with no episodes of sustained arrhythmias or significant complications that typically necessitate pacemaker placement. Additionally, among the similar patients analyzed, many have undergone complex surgeries like Fontan procedures without a history of needing a pacemaker, indicating that such intervention may not be common in this demographic with comparable surgical histories. Furthermore, the predicted probability of the occluded outcome being 'yes' is exceedingly low (0.0015), suggesting that the likelihood of pacemaker placement is minimal among patients with similar clinical profiles.","Based on the analysis of the patient's clinical and surgical history, it is predicted that the main patient does **not** have a history of pacemaker placement. The main patient has undergone multiple surgeries and catheterizations but does not show signs of arrhythmias, which are often a primary indication for pacemaker placement. Furthermore, the similar cohort of patients displays a trend among those undergoing extensive surgeries, including Fontan revisions and atrioventricular valve interventions, where only a minor subset required pacemaker placements. The low probability of the occluded outcome being 'yes' (0.0015) from the XGBoost model further supports the prediction that it is unlikely for the patient to have had a pacemaker placed, as most individuals in similar circumstances did not report such history.",1,1,1,1,0
BCH-TRATRI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURGERY (10/2002):  Stage 1 Norwood with right modified BT shunt.
CATH (5/2003):  Balloon dilation of coarctation.
SURGERY (7/2003):  Bidirectional Glenn with takedown of BT shunt and reconstruction of PA confluence with patch of cryopreserved pulmonary allograft.
SURGERY (8/2004):  Fontan procedure with extracardiac conduit.
CATH (2/2017): Hemodynamic
CATH (5/2017, CHB):  Coil occlusion of an innominate VVC.
*SURGERY (5/2017, CHB):  Biventricular conversion.  Takedown of Stansel connection.  Takedown of Fontan and Glenn connections.  
CATH (10/2017):  Balloon dilation of LPA
CATH (6/2019) - balloon dilation of proximal LPA, RFA and RFV perclosed
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 8.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 8.7
 Patient height: 168.0
 Patient weight: 58.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.6484270181251144
 Heart rate: 85.0
 Upper limb systolic blood pressure: 127.0
 Upper limb diastolic blood pressure: 88.0
 Upper limb mean blood pressure: 103.0
 Left ventricle end-diastolic volume: 85.8
 Left ventricle end-systolic volume: 33.1
 Left ventricular mass: 82.8
 Right ventricular end-diastolic volume: 92.4
 Right ventricular end-systolic volume: 44.8
 Right ventricle mass: 70.2
 Native aorta flow rate: 4.9
 Ascending aorta, above the Stansel flow rate: 4.9
 Descending aorta flow rate: 3.3
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.8
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.2
 Total right pulmonary vein flow rate: 3.2
 Total left pulmonary vein flow rate: 1.8
 Right atrioventricular valve/tricuspid inflow rate: 1.8
 Left atrioventricular valve/mitral inflow rate: 3.5
 Aortic or native aortic regurgitation fraction: 17.0
 Pulmonary or neo-aortic regurgitation fraction: 15.0
 Mitral or common atrioventricular regurgitation fraction: 10.0
 Single ventricle ejection fraction 0.5628507295173961
 Single ventricle systolic volume 100.29999999999998
 Body mass index 20.691609977324266
 Mass to height volume indexed on BSA (exp = 2.7) 37.701303866397225
 Systemic ventricle end-systolic volume: 77.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 47.25717253081777
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 40.67680339251185
 Systemic ventricle end-diastolic volume: 178.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.10305706022754
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 93.05014588633647
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 92.81575606181154
 Systemic ventricle mass indexed on BSA (exp=1.3) 79.89153939735961
 Systemic ventricle mass to volume ratio: 1.7247752247752248
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.0463157942757741
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9006205739981675
 Contrast type: Gadavist
 Description of veno-venous collaterals: Prominent decompressing venous collateral from the left innominate vein to a reconstituted azygous and hemiazygous venous system.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Part of the LPA is obscured by a metallic artifact from the stent. Non-stented portion is unobstructed.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00720092].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided data, the predicted missing clinical outcome for the patient regarding a history of ascites is **""no.""** This prediction is supported by the absence of relevant clinical events in the status update, specifically there is no report of fluid accumulation such as pleural effusions or an explicit mention of ascites, which are common complications in single-ventricle patients post-Fontan. Furthermore, the patient's MRI findings indicate stable hemodynamics and only mild regurgitation, suggesting a relatively favorable status without significant signs of congestion that would typically be associated with ascites. The expectation of very low probability for the occluded outcome (0.72%) further strengthens the rationale that ascites is not present in this case.","Based on the provided data for the main patient, it is reasonable to predict that the patient does not have a history of ascites (> trace) (answer: **no**). The main patient has undergone several significant surgeries without documented complications such as protein-losing enteropathy or significant pleural effusions, which are often associated with ascites in patients with single-ventricle physiology. Furthermore, analyzing the similar patients reveals that a majority have not reported such complications either; specifically, one similar patient with comparable surgical history also shows no signs of ascites. The XGBoost model's predicted probability of the occluded outcome being 'yes' (0.0072) further suggests that the likelihood of this patient facing such complications is very low, thus supporting the conclusion that the patient most likely does not have a history of ascites.","Based on the provided data, I predict that the main patient does not have a history of ascites (> trace). The main patient has undergone multiple heart surgeries, including a Fontan procedure and revisions, with no recorded history of ascites after these interventions, as indicated in their status updates. Additionally, the similar patients share a lack of ascites in their histories, with some indicating elevated liver fibrosis tests but still no ascites, suggesting that while liver health may be compromised in this cohort, it does not necessarily lead to ascites. The model’s prediction probability of 0.0072 strongly suggests that ascites is unlikely, aligning with the main patient’s history and the outcomes observed in similar patients.","Based on the information, I predict that the main patient does not have a history of ascites (> trace). The absence of ascites is supported by both the main patient's clinical data, which explicitly states there is no history of ascites, and the wider cohort of similar patients. In the cohort of similar patients, there are instances where ascites was reported, particularly in those with underlying conditions such as significant thrombosis or elevated liver pressures, which do not seem to apply to the main patient given their current status and past interventions. Additionally, the low predicted probability of 0.0072 from the XGBoost model indicates that the clinical features of the main patient strongly suggest the absence of this condition, given that the model successfully identified similar patterns in the training data.",1,1,1,1,0
BCH-TRATRI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURGERY (10/2002):  Stage 1 Norwood with right modified BT shunt.
CATH (5/2003):  Balloon dilation of coarctation.
SURGERY (7/2003):  Bidirectional Glenn with takedown of BT shunt and reconstruction of PA confluence with patch of cryopreserved pulmonary allograft.
SURGERY (8/2004):  Fontan procedure with extracardiac conduit.
CATH (2/2017): Hemodynamic
CATH (5/2017, CHB):  Coil occlusion of an innominate VVC.
*SURGERY (5/2017, CHB):  Biventricular conversion.  Takedown of Stansel connection.  Takedown of Fontan and Glenn connections.  
CATH (10/2017):  Balloon dilation of LPA
CATH (6/2019) - balloon dilation of proximal LPA, RFA and RFV perclosed
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 8.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 8.7
 Patient height: 168.0
 Patient weight: 58.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.6484270181251144
 Heart rate: 85.0
 Upper limb systolic blood pressure: 127.0
 Upper limb diastolic blood pressure: 88.0
 Upper limb mean blood pressure: 103.0
 Left ventricle end-diastolic volume: 85.8
 Left ventricle end-systolic volume: 33.1
 Left ventricular mass: 82.8
 Right ventricular end-diastolic volume: 92.4
 Right ventricular end-systolic volume: 44.8
 Right ventricle mass: 70.2
 Native aorta flow rate: 4.9
 Ascending aorta, above the Stansel flow rate: 4.9
 Descending aorta flow rate: 3.3
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.8
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.2
 Total right pulmonary vein flow rate: 3.2
 Total left pulmonary vein flow rate: 1.8
 Right atrioventricular valve/tricuspid inflow rate: 1.8
 Left atrioventricular valve/mitral inflow rate: 3.5
 Aortic or native aortic regurgitation fraction: 17.0
 Pulmonary or neo-aortic regurgitation fraction: 15.0
 Mitral or common atrioventricular regurgitation fraction: 10.0
 Single ventricle ejection fraction 0.5628507295173961
 Single ventricle systolic volume 100.29999999999998
 Body mass index 20.691609977324266
 Mass to height volume indexed on BSA (exp = 2.7) 37.701303866397225
 Systemic ventricle end-systolic volume: 77.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 47.25717253081777
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 40.67680339251185
 Systemic ventricle end-diastolic volume: 178.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.10305706022754
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 93.05014588633647
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 92.81575606181154
 Systemic ventricle mass indexed on BSA (exp=1.3) 79.89153939735961
 Systemic ventricle mass to volume ratio: 1.7247752247752248
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.0463157942757741
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9006205739981675
 Contrast type: Gadavist
 Description of veno-venous collaterals: Prominent decompressing venous collateral from the left innominate vein to a reconstituted azygous and hemiazygous venous system.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Part of the LPA is obscured by a metallic artifact from the stent. Non-stented portion is unobstructed.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00189202].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided information, I predict that the patient did not receive a heart transplant (no). The patient's MRI findings indicate mild valve regurgitation and a relatively stable cardiac function, with a single ventricle ejection fraction of 56.3%, and no history of significant complications such as severe arrhythmias, organ dysfunction, or other issues that frequently lead to transplant eligibility. Furthermore, the XGBoost model predicts an extremely low probability of the occluded outcome being 'yes' (0.00189202), suggesting that the likelihood of needing a transplant is minimal. Additionally, the patient's intact systemic circulation and improvements following surgical interventions indicate a compensation sufficient to avoid immediate transplantation needs.","Based on the information provided, it is predicted that the main patient **did not receive a heart transplant**. This conclusion is supported by the main patient's extensive surgical history, which indicates multiple complex interventions including the Fontan procedure and a recent biventricular conversion, suggesting ongoing treatment strategies aimed at optimizing function rather than proceeding to transplant. Additionally, similar patients who have undergone substantial surgeries without a reported transplant tend to maintain stability without severe complications, as evidenced by the significant majority of similar patients also classified as ""no"" for heart transplant events. Furthermore, the XGBoost model's probability of the occluded outcome being 'yes' (0.00189202) reflects a low likelihood of the patient receiving a transplant, aligning with all the observed data trends.","Based on the data, it is predicted that the main patient did not receive a heart transplant (outcome: ""no""). The main patient has a complex surgical history involving multiple procedures but has managed to maintain adequate cardiac function as evidenced by the MRI findings, including good ejection fraction and manageable regurgitation fractions. Additionally, the XGBoost model predicts a very low probability (0.00189202) of the outcome being 'yes', indicating that heart transplantation is unlikely for this patient. Comparatively, while some similar patients with more severe outcomes have undergone transplantation, the majority did not, particularly those with characteristics such as the main patient's heart function metrics and history of surgical interventions which suggest ongoing stability without the need for transplant.","Based on the presented data, the occluded clinical outcome ""Did the patient receive a heart transplant?"" is likely to be ""no."" The main patient exhibits a complex surgical history typical of a single-ventricle physiology, having undergone multiple surgeries including a Fontan procedure and subsequent biventricular conversion. Given the patient's stable status, as indicated by no history of major complications such as cardiac arrest, thrombus, or significant heart failure symptoms, and the fact that they have not been listed for transplantation, it appears the current management has been effective.

Moreover, among the similar patients, most did not undergo heart transplantation despite complex histories, and those that did show associated significant complications or declining status prior to transplant. The XGBoost model's predicted probability (0.00189202) reinforces this, suggesting that the likelihood of requiring a heart transplant is very low in this cohort, further supporting the prediction that the main patient did not receive a heart transplant.",1,1,1,1,0
BCH-TRATRI-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 4.0
 Other relevant surgical or clinical history (optional): SURGERY (10/2002):  Stage 1 Norwood with right modified BT shunt.
CATH (5/2003):  Balloon dilation of coarctation.
SURGERY (7/2003):  Bidirectional Glenn with takedown of BT shunt and reconstruction of PA confluence with patch of cryopreserved pulmonary allograft.
SURGERY (8/2004):  Fontan procedure with extracardiac conduit.
CATH (2/2017): Hemodynamic
CATH (5/2017, CHB):  Coil occlusion of an innominate VVC.
*SURGERY (5/2017, CHB):  Biventricular conversion.  Takedown of Stansel connection.  Takedown of Fontan and Glenn connections.  
CATH (10/2017):  Balloon dilation of LPA
CATH (6/2019) - balloon dilation of proximal LPA, RFA and RFV perclosed
 Cardiac diagnosis: Double outlet right ventricle
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Extracardiac Fontan
 Did the patient have a fenestration during the initial Fontan surgery? no
  history of Fontan revision? yes
 Type of Fontan revision: Biventricular repair
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? no
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? no
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? no
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Contrast dose: 8.7
 Gadobutrol (Gadavist, Gadovist) contrast dose: 8.7
 Patient height: 168.0
 Patient weight: 58.4
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.6484270181251144
 Heart rate: 85.0
 Upper limb systolic blood pressure: 127.0
 Upper limb diastolic blood pressure: 88.0
 Upper limb mean blood pressure: 103.0
 Left ventricle end-diastolic volume: 85.8
 Left ventricle end-systolic volume: 33.1
 Left ventricular mass: 82.8
 Right ventricular end-diastolic volume: 92.4
 Right ventricular end-systolic volume: 44.8
 Right ventricle mass: 70.2
 Native aorta flow rate: 4.9
 Ascending aorta, above the Stansel flow rate: 4.9
 Descending aorta flow rate: 3.3
 Right superior vena cava flow rate: 1.2
 Inferior vena cava, below the fenestration flow rate: 2.8
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 3.1
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.2
 Total right pulmonary vein flow rate: 3.2
 Total left pulmonary vein flow rate: 1.8
 Right atrioventricular valve/tricuspid inflow rate: 1.8
 Left atrioventricular valve/mitral inflow rate: 3.5
 Aortic or native aortic regurgitation fraction: 17.0
 Pulmonary or neo-aortic regurgitation fraction: 15.0
 Mitral or common atrioventricular regurgitation fraction: 10.0
 Single ventricle ejection fraction 0.5628507295173961
 Single ventricle systolic volume 100.29999999999998
 Body mass index 20.691609977324266
 Mass to height volume indexed on BSA (exp = 2.7) 37.701303866397225
 Systemic ventricle end-systolic volume: 77.9
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 47.25717253081777
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 40.67680339251185
 Systemic ventricle end-diastolic volume: 178.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 108.10305706022754
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 93.05014588633647
 Systemic ventricle mass: 153.0
 Systemic ventricle mass indexed on BSA (exp=1) 92.81575606181154
 Systemic ventricle mass indexed on BSA (exp=1.3) 79.89153939735961
 Systemic ventricle mass to volume ratio: 1.7247752247752248
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.0463157942757741
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9006205739981675
 Contrast type: Gadavist
 Description of veno-venous collaterals: Prominent decompressing venous collateral from the left innominate vein to a reconstituted azygous and hemiazygous venous system.
 Any significant metallic artifact that obscures anatomy? If yes, please describe: Part of the LPA is obscured by a metallic artifact from the stent. Non-stented portion is unobstructed.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Mild
 Qualitative or quantitative total semi-lunar valve regurgitation: Mild
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Negative
 Were there visible veno-venous collaterals? yes
 Where there visible aortopulmonary collaterals? no
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? no
  history of pacemaker placement? no
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00420783].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the information provided, it is predicted that the patient has not died (outcome: ""no""). The XGBoost model yields a very low predicted probability of 0.00420783 for the outcome being ""yes,"" indicating a strong likelihood of survival. Additionally, the patient's extensive surgical history and the absence of critical complications like significant thrombus, severe arrhythmias, or chronic conditions (e.g., protein-losing enteropathy or heart transplant listing) further support the conclusion that the patient is likely alive post-Fontan surgery. The high accuracy and AUC of the predictive model suggest that patients with similar profiles tend to have favorable outcomes, reinforcing the belief in this patient's continuing survival.","**Prediction**: No, the patient has not died.

**Reasoning**: The main patient has undergone multiple cardiac surgeries, including a complex surgical history indicative of careful management over the years, with no documented history of severe complications like cardiac arrest or significant thrombus, which are often linked to mortality. Furthermore, in the cohort of similar patients, despite the overall complexity of their conditions, a significant majority had not died, indicating a relatively favorable outcome among those with high similarity measures. The XGBoost model also produces a very low predicted probability (0.42%) for the outcome of death, suggesting that the risk is minimal based on the clinical features, reinforcing the conclusion that the main patient is likely still alive.","Based on the provided information, I predict that the occluded outcome, ""Has the patient died?"" is **no**. The main patient has a complex surgical history with multiple interventions including a Fontan procedure, and their imaging and clinical status suggest stable hemodynamics, as reflected in the normal ejection fraction (0.562) and absence of severe complications such as arrhythmias, strokes, or significant symptoms. 

Moreover, similar patients, particularly those with comparable surgical histories and cardiac diagnoses, often exhibit resilience with a high proportion remaining alive without severe complications. The XGBoost model probability indicating a low likelihood of the outcome being ""yes"" (0.004) supports this conclusion, considering that similar patients also showed favorable outcomes, evidenced by conditioning factors such as good baseline hemodynamics and low rates of mortality in the cohort data. Thus, it seems reasonable to conclude that the patient has not died.","Based on the provided data, I predict that the outcome ""Has the patient died?"" for the main patient is **no**. The patient has a comprehensive surgical history with multiple successful interventions, including a recent biventricular conversion, which suggests effective management of their condition. Furthermore, the patient’s MRI report indicates a lack of significant late gadolinium enhancement, which is a positive sign regarding myocardial viability. 

Comparing this patient to similar patients with similarly complex cardiac histories, the majority did not experience mortality and the XGBoost model indicates an extremely low probability of mortality (0.42%). This strong performance alongside the management trends in similar cases underscores the likelihood that the patient has survived.",1,1,1,1,0
BCH-VAZAGU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): 1/23 update: {S,D,S} w/ DORV, hypoplastic LV palliated to lateral tunneled Fontan s/p EP ablation for IART on 12/22 c/b  L AV (superficial femoral artery to common femoral vein) fistula now s/p repair for another post-op wound evaluation.
 Cardiac diagnosis: Mitral atresia (including mitral atresia with DORV)
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 123.0
 Patient weight: 23.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9009922865134855
 Heart rate: 60.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 117.2
 Right ventricular end-systolic volume: 43.6
 Right ventricle mass: 97.0
 Native aorta flow rate: 2.1
 Ascending aorta, above the Stansel flow rate: 2.1
 Right superior vena cava flow rate: 1.06
 Inferior vena cava, below the fenestration flow rate: 1.29
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.08
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.86
 Total right pulmonary vein flow rate: 1.61
 Total left pulmonary vein flow rate: 1.2
 Right atrioventricular valve/tricuspid inflow rate: 3.6
 Qp/Qs (enter a number, not a ratio): 1.2
 Single ventricle ejection fraction 0.6279863481228668
 Single ventricle systolic volume 73.6
 Body mass index 15.79747504792121
 Mass to height volume indexed on BSA (exp = 2.7) 55.466138706756546
 Systemic ventricle end-systolic volume: 43.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 48.39109130303018
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 49.9285661814198
 Systemic ventricle end-diastolic volume: 117.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 130.07880506227377
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 134.211650377578
 Systemic ventricle mass: 97.0
 Systemic ventricle mass indexed on BSA (exp=1) 107.65907927509006
 Systemic ventricle mass indexed on BSA (exp=1.3) 111.07960824765414
 Systemic ventricle mass to volume ratio: 0.8276450511945392
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9185928265792668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9477782273690626
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: soccer ball impact to chest with immediate syncope. EMS found him in a wide complex tachycardia~ 240 bpm which was terminated with cardioversion
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? yes
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.9956909].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? yes\n Reason for pacemaker placement: Other\n'],"Based on the provided data, I predict that the patient does have a history of pacemaker placement (yes). The patient has a history of cardiac arrest and has undergone emergency cardioversion due to significant arrhythmias, which may indicate underlying electrical conduction issues that could necessitate a pacemaker for rhythm stabilization. Additionally, the presence of sinus node dysfunction and atrial tachyarrhythmias further support the need for a device to manage potential bradycardia or irregular heart rhythms. The XGBoost model's estimated probability of 0.9956909 for a 'yes' outcome substantiates this prediction, indicating a very high likelihood that the patient has indeed required pacemaker intervention.","Based on the provided information, I predict that the main patient **does have a history of pacemaker placement**. This prediction is supported by the patient's complex surgical history, which includes multiple interventions such as a Stansel procedure and electrophysiologic study, suggesting the likelihood of arrhythmias or conduction issues, particularly given the reported wide complex tachycardia incident and subsequent cardioversion. Furthermore, the similar patient data shows that many patients with comparable profiles, especially those who have undergone similar surgeries and experienced arrhythmias, frequently resulted in pacemaker placements. These observations, combined with the XGBoost model probability of 0.995, strongly indicate that it is very likely that this patient has a history of pacemaker placement to manage their cardiac rhythm.","**Predicted Outcome: Yes, the patient has a history of pacemaker placement.**

The main patient shows a complex cardiac history with multiple interventions, including arrhythmogenic events necessitating cardioversion, which suggests a significant risk for arrhythmias. Additionally, the presence of atrial tachyarrhythmias and prior electrophysiologic studies implies ongoing cardiac monitoring and possible interventions. Analysis of similar patients reveals a trend where those with comparable surgical histories and arrhythmic complications often require pacemaker placement to manage their cardiac rhythm effectively. Coupled with the high probability estimate (0.9956909) from the XGBoost model, this strengthens the case for concluding that the main patient has a history of undergoing pacemaker placement.","Based on the provided information, I predict that the main patient does **not** have a history of pacemaker placement ('no'). The main patient has undergone multiple surgical interventions including a Fontan procedure and electrophysiologic studies but does not have a documented history of arrhythmias or other complications that typically necessitate pacemaker placement, such as significant symptomatic bradycardia or advanced heart block. 

Furthermore, among the similar patients, those who had pacemakers often had higher rates of arrhythmias or more complicated histories, such as recurring tachyarrhythmias or significant structural heart disease requiring strict rhythm control. In contrast, the main patient's MRI and clinical data suggest stable cardiac function and absence of severe symptoms that would commonly lead to the decision for pacemaker implantation. The robust prediction from the XGBoost model with a probability of 0.99569 reinforces this conclusion by emphasizing the low likelihood of the main patient needing a pacemaker.",1,1,1,0,1
BCH-VAZAGU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): 1/23 update: {S,D,S} w/ DORV, hypoplastic LV palliated to lateral tunneled Fontan s/p EP ablation for IART on 12/22 c/b  L AV (superficial femoral artery to common femoral vein) fistula now s/p repair for another post-op wound evaluation.
 Cardiac diagnosis: Mitral atresia (including mitral atresia with DORV)
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 123.0
 Patient weight: 23.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9009922865134855
 Heart rate: 60.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 117.2
 Right ventricular end-systolic volume: 43.6
 Right ventricle mass: 97.0
 Native aorta flow rate: 2.1
 Ascending aorta, above the Stansel flow rate: 2.1
 Right superior vena cava flow rate: 1.06
 Inferior vena cava, below the fenestration flow rate: 1.29
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.08
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.86
 Total right pulmonary vein flow rate: 1.61
 Total left pulmonary vein flow rate: 1.2
 Right atrioventricular valve/tricuspid inflow rate: 3.6
 Qp/Qs (enter a number, not a ratio): 1.2
 Single ventricle ejection fraction 0.6279863481228668
 Single ventricle systolic volume 73.6
 Body mass index 15.79747504792121
 Mass to height volume indexed on BSA (exp = 2.7) 55.466138706756546
 Systemic ventricle end-systolic volume: 43.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 48.39109130303018
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 49.9285661814198
 Systemic ventricle end-diastolic volume: 117.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 130.07880506227377
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 134.211650377578
 Systemic ventricle mass: 97.0
 Systemic ventricle mass indexed on BSA (exp=1) 107.65907927509006
 Systemic ventricle mass indexed on BSA (exp=1.3) 111.07960824765414
 Systemic ventricle mass to volume ratio: 0.8276450511945392
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9185928265792668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9477782273690626
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: soccer ball impact to chest with immediate syncope. EMS found him in a wide complex tachycardia~ 240 bpm which was terminated with cardioversion
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? yes
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01524258].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data, I predict that the patient has not died (""no""). The patient has relatively stable MRI results with a single ventricle ejection fraction of approximately 62.8% and no significant issues noted in the cardiac history, such as severe regurgitation or ongoing complications like pleural effusions or significant thrombus formation. Although the patient has undergone multiple interventions and has a history of arrhythmias and an ECMO instance, they have not shown evidence of severe chronic complications commonly associated with poor outcomes in single-ventricle patients. Additionally, the XGBoost model predicts a very low probability (1.52%) for the outcome of death, suggesting that, based on similar cohort data, the patient's risk of mortality appears minimal.","Based on the information provided, it is likely that the main patient has not died. The predicted probability of the occluded outcome being 'yes' (i.e., that the patient has died) is only 0.015, which suggests a very low likelihood of this outcome. Furthermore, the main patient has a relatively extensive surgical history with a successful Fontan procedure, and there are no significant complications reported such as protein-losing enteropathy, stroke, or major thrombus that are common indicators of poorer survival. The similar patients, particularly patient #1 with a comparable surgical history, have remained alive and demonstrate no critical complications that would suggest an imminent risk of mortality, reinforcing the conclusion that the main patient is likely still alive.","Based on the provided data, I predict that the missing clinical outcome for the main patient, ""Has the patient died?"", is **no**. The main patient's surgical history indicates they have undergone multiple cardiac procedures, including successful Fontan surgery and interventions, and they have not exhibited significant complications such as protein-losing enteropathy, major thrombosis, or severe arrhythmias that would commonly correlate with poor outcomes. 

Regarding similar patients, while some have exhibited issues like post-operative complications and arrhythmias, the overall trends show that many patients with similar surgical histories and MRI findings continue to survive, especially given the high accuracy and AUC of the XGBoost model (96% accuracy, AUC 0.87) which includes these types of patients. Additionally, the predicted probability (1.524%) from the XGBoost model for the occluded outcome being 'yes' corroborates a low likelihood of mortality. Hence, the combination of favorable past interventions, stable clinical status updates, and the model's output strongly suggests that this patient has not died.","Based on the analysis of the main patient's data and the characteristics of similar patients, I would predict that the outcome for ""Has the patient died?"" is **no**. The main patient has a complex medical history with a total of three cardiac surgeries, including a lateral tunnel Fontan, and currently shows stable physiological parameters, such as a single ventricle ejection fraction of 0.63 and no significant complications like protein-losing enteropathy or major thrombus. The similar patients, who also underwent multiple cardiac interventions and had comparable metrics, generally exhibited low mortality rates, particularly among those with similar diagnoses and interventions. The probability estimate from the XGBoost model (0.015) reinforces the notion that the likelihood of death in this cohort is quite low, aligning with the absence of critical complications indicated in the main patient's status and history. Thus, given these factors, it appears unlikely that the patient has experienced a fatal outcome.",1,1,1,1,0
BCH-VAZAGU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): 1/23 update: {S,D,S} w/ DORV, hypoplastic LV palliated to lateral tunneled Fontan s/p EP ablation for IART on 12/22 c/b  L AV (superficial femoral artery to common femoral vein) fistula now s/p repair for another post-op wound evaluation.
 Cardiac diagnosis: Mitral atresia (including mitral atresia with DORV)
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 123.0
 Patient weight: 23.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9009922865134855
 Heart rate: 60.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 117.2
 Right ventricular end-systolic volume: 43.6
 Right ventricle mass: 97.0
 Native aorta flow rate: 2.1
 Ascending aorta, above the Stansel flow rate: 2.1
 Right superior vena cava flow rate: 1.06
 Inferior vena cava, below the fenestration flow rate: 1.29
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.08
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.86
 Total right pulmonary vein flow rate: 1.61
 Total left pulmonary vein flow rate: 1.2
 Right atrioventricular valve/tricuspid inflow rate: 3.6
 Qp/Qs (enter a number, not a ratio): 1.2
 Single ventricle ejection fraction 0.6279863481228668
 Single ventricle systolic volume 73.6
 Body mass index 15.79747504792121
 Mass to height volume indexed on BSA (exp = 2.7) 55.466138706756546
 Systemic ventricle end-systolic volume: 43.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 48.39109130303018
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 49.9285661814198
 Systemic ventricle end-diastolic volume: 117.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 130.07880506227377
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 134.211650377578
 Systemic ventricle mass: 97.0
 Systemic ventricle mass indexed on BSA (exp=1) 107.65907927509006
 Systemic ventricle mass indexed on BSA (exp=1.3) 111.07960824765414
 Systemic ventricle mass to volume ratio: 0.8276450511945392
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9185928265792668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9477782273690626
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: soccer ball impact to chest with immediate syncope. EMS found him in a wide complex tachycardia~ 240 bpm which was terminated with cardioversion
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? yes
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.01184468].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided data, the prediction for the missing clinical outcome regarding whether the patient has a history of ascites (> trace) is **no**. The main patient has undergone multiple cardiac surgeries, including significant interventions such as Fontan-related procedures and a history of arrhythmias that could complicate fluid management; however, there are no documented incidences of pleural effusions, renal dysfunction, or protein-losing enteropathy, which often accompany ascites development in this patient population. The low predicted probability (0.0118) from the XGBoost model further supports this interpretation, indicating that, given the patient’s profile, ascites is unlikely to be a significant concern. Furthermore, the absence of a diagnosis of chylous effusions post-surgery suggests an effective management of fluid overload, reducing the likelihood of ascites.","Based on the provided data, it is reasonable to predict that the main patient does not have a history of ascites (> trace), answering 'no.' The main patient exhibits a complex surgical history but does not show any signs of hepatic or fluid retention complications such as protein-losing enteropathy or pleural effusions. In the similar patients, while some had varied surgical experiences, none reported a history of ascites, suggesting that this outcome may be less common in this cohort. Moreover, the XGBoost model's low predicted probability (0.0118) for the occluded outcome further supports the inference that the incidence of ascites might be low within this specific patient demographic.","Based on the available data, I predict that the main patient does **not** have a history of ascites (> trace). The primary patient has undergone a series of surgical interventions, including a lateral tunnel Fontan and interventions on their superior vena cava, with no reported complications or notes suggesting ascitic conditions. Furthermore, among the similar patients, none exhibited a history of ascites either, despite various cardiac conditions and multiple surgeries. The XGBoost model outputs a low predicted probability (0.0118) for the occluded outcome of ascites, reflecting an overall trend that suggests this patient is unlikely to develop complications related to ascites post-surgery.","Based on the information provided, the main patient has undergone multiple complex cardiac surgeries, including a lateral tunnel Fontan with fenestration and Stansel procedure, which are factors that could predispose them to complications such as ascites. However, the patient’s history notably does not include documentation of any ascites or fluid-related complications. In contrast, similar patients with situations comparable in terms of diagnosis and surgical history (particularly those with Fontan physiology) often experienced varying degrees of pleural effusion, but many did not present with ascites. Furthermore, the XGBoost model predicts a low probability (0.0118) of the occluded outcome being 'yes,' suggesting that the likelihood of the patient having a history of ascites is substantially low. Therefore, it is predicted that this patient does not have a history of ascites (> trace).",1,1,1,1,0
BCH-VAZAGU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): 1/23 update: {S,D,S} w/ DORV, hypoplastic LV palliated to lateral tunneled Fontan s/p EP ablation for IART on 12/22 c/b  L AV (superficial femoral artery to common femoral vein) fistula now s/p repair for another post-op wound evaluation.
 Cardiac diagnosis: Mitral atresia (including mitral atresia with DORV)
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 123.0
 Patient weight: 23.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9009922865134855
 Heart rate: 60.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 117.2
 Right ventricular end-systolic volume: 43.6
 Right ventricle mass: 97.0
 Native aorta flow rate: 2.1
 Ascending aorta, above the Stansel flow rate: 2.1
 Right superior vena cava flow rate: 1.06
 Inferior vena cava, below the fenestration flow rate: 1.29
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.08
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.86
 Total right pulmonary vein flow rate: 1.61
 Total left pulmonary vein flow rate: 1.2
 Right atrioventricular valve/tricuspid inflow rate: 3.6
 Qp/Qs (enter a number, not a ratio): 1.2
 Single ventricle ejection fraction 0.6279863481228668
 Single ventricle systolic volume 73.6
 Body mass index 15.79747504792121
 Mass to height volume indexed on BSA (exp = 2.7) 55.466138706756546
 Systemic ventricle end-systolic volume: 43.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 48.39109130303018
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 49.9285661814198
 Systemic ventricle end-diastolic volume: 117.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 130.07880506227377
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 134.211650377578
 Systemic ventricle mass: 97.0
 Systemic ventricle mass indexed on BSA (exp=1) 107.65907927509006
 Systemic ventricle mass indexed on BSA (exp=1.3) 111.07960824765414
 Systemic ventricle mass to volume ratio: 0.8276450511945392
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9185928265792668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9477782273690626
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: soccer ball impact to chest with immediate syncope. EMS found him in a wide complex tachycardia~ 240 bpm which was terminated with cardioversion
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? yes
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00091276].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided data, it is predicted that the patient did **not** receive a heart transplant. The patient has undergone three cardiac surgeries, including a lateral tunnel Fontan and has a history of electrophysiological intervention, indicating significant cardiac management without a transplant. Additionally, the low predicted probability (0.00091276) of the occluded outcome being 'yes' suggests that, in the context of similar patients, the likelihood of needing a heart transplant is minimal given their current condition. The absence of complications such as protein-losing enteropathy or significant cardiac arrhythmias, alongside stable hemodynamics indicated by favorable MRI findings, supports this prediction.","Based on the available data, it is predicted that the main patient did not receive a heart transplant ('no'). The main patient has a complex surgical history, including multiple surgeries and a noted history of arrhythmias and defibrillation, which are often risk factors that deter transplant candidacy. Additionally, similar patients who also underwent lateral tunnel Fontan surgeries and had comparable clinical presentations largely exhibited a low incidence of heart transplants, with outcomes not suggesting a need for transplant. The XGBoost model's predicted probability of receiving a heart transplant is very low at 0.00091276, reinforcing the lack of strong evidence to suggest this patient underwent transplantation.","Based on the provided data, the prediction for whether the main patient received a heart transplant is ""no."" The main patient has undergone multiple cardiac surgeries, including a Fontan procedure and has a complex surgical history with arrhythmias, but they currently show no signs of critical complications typically leading to transplantation, such as significant end-organ dysfunction or severe cardiac deterioration. Additionally, the similar patient cohort indicates a low incidence of transplantation among those with a similar profile, especially considering that clinical features and pathways leading to transplantation are notably different among patients with complex conditions. The XGBoost model's predicted probability of 0.00091276 for the outcome being 'yes' strongly supports the conclusion that the likelihood of receiving a heart transplant is minimal.","Based on the analysis of the main patient's surgical history and MRI findings, as well as the data from similar patients, it is reasonable to predict that this patient did not receive a heart transplant. The main patient has undergone multiple corrective surgeries indicative of challenging anatomy (mitral atresia with DORV and other complex interventions) but has maintained a relatively stable status without significant long-term complications such as those commonly leading to transplantation (e.g., severe arrhythmias, end-stage heart failure). 

Moreover, the similar patients identified had comparable cardiac conditions but none were listed as having received a transplant either, suggesting a trend in this cohort where surgical interventions effectively managed their conditions without necessitating transplantation. Additionally, the XGBoost model's predicted probability (0.00091276) of the occluded outcome being 'yes' (i.e., having received a transplant) strongly supports this assessment, indicating a very low likelihood of transplantation in this patient population. Hence, the predicted outcome is **no**.",1,1,1,1,0
BCH-VAZAGU-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 3.0
 Other relevant surgical or clinical history (optional): 1/23 update: {S,D,S} w/ DORV, hypoplastic LV palliated to lateral tunneled Fontan s/p EP ablation for IART on 12/22 c/b  L AV (superficial femoral artery to common femoral vein) fistula now s/p repair for another post-op wound evaluation.
 Cardiac diagnosis: Mitral atresia (including mitral atresia with DORV)
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? no
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Type of ascending aorta or arch intervention: yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Type of Fontan pathway or fenestration intervention: yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 123.0
 Patient weight: 23.9
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 0.9009922865134855
 Heart rate: 60.0
 Upper limb systolic blood pressure: 121.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 74.0
 Right ventricular end-diastolic volume: 117.2
 Right ventricular end-systolic volume: 43.6
 Right ventricle mass: 97.0
 Native aorta flow rate: 2.1
 Ascending aorta, above the Stansel flow rate: 2.1
 Right superior vena cava flow rate: 1.06
 Inferior vena cava, below the fenestration flow rate: 1.29
 Right pulmonary artery, distal to the superior cavopulmonary connection flow rate: 1.08
 Left pulmonary artery, distal to the superior cavopulmonary connection flow rate: 0.86
 Total right pulmonary vein flow rate: 1.61
 Total left pulmonary vein flow rate: 1.2
 Right atrioventricular valve/tricuspid inflow rate: 3.6
 Qp/Qs (enter a number, not a ratio): 1.2
 Single ventricle ejection fraction 0.6279863481228668
 Single ventricle systolic volume 73.6
 Body mass index 15.79747504792121
 Mass to height volume indexed on BSA (exp = 2.7) 55.466138706756546
 Systemic ventricle end-systolic volume: 43.6
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 48.39109130303018
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 49.9285661814198
 Systemic ventricle end-diastolic volume: 117.2
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 130.07880506227377
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 134.211650377578
 Systemic ventricle mass: 97.0
 Systemic ventricle mass indexed on BSA (exp=1) 107.65907927509006
 Systemic ventricle mass indexed on BSA (exp=1.3) 111.07960824765414
 Systemic ventricle mass to volume ratio: 0.8276450511945392
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 0.9185928265792668
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9477782273690626
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? yes
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V RV only
 Qp/Qs calculation method: Comparison of pulmonary venous and caval flow
 Qualitative or quantitative total atrioventricular valve regurgitation: None
 Qualitative or quantitative total semi-lunar valve regurgitation: None
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Details of first emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest: soccer ball impact to chest with immediate syncope. EMS found him in a wide complex tachycardia~ 240 bpm which was terminated with cardioversion
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? no
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? yes
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? yes
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? yes
  history of post-Fontan electrophysiologic study? yes
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: no
 Beta blocker: no
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: yes
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.03238112].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? no\n'],"Based on the provided data, it is reasonable to predict that the patient does not have a diagnosis of seizures requiring antiepileptic medications (no). This conclusion is supported by the absence of any reported history of seizures in the patient's status event update, which includes a comprehensive review of cardiovascular and neurological complications. Furthermore, the patient has experienced a significant cardiac issue with wide complex tachycardia leading to syncope, which may have been misinterpreted as a seizure but was likely arrhythmogenic in nature, further suggesting that seizures are not present. Additionally, the low probability estimate from the XGBoost model (0.03238112) indicates that seizures are unlikely, aligning with the clinical characteristics observed in this single-ventricle patient following Fontan surgery.","Based on the available data, the prediction for whether the main patient has a diagnosis of seizures requiring antiepileptic medications is ""no."" The main patient has a complex surgical history involving multiple interventions for congenital heart defects but shows no indicators in the clinical or surgical history that suggest a seizure disorder. 

Additionally, the similar patient cohort demonstrates a notable absence of seizure diagnoses, with only one of the similar patients having such a diagnosis, which appeared to be unrelated to any evident cardiac complications arising from the surgical procedures typically associated with single-ventricle physiology. The low predicted probability (3.24%) from the XGBoost model indicates a strong likelihood that seizures are unlikely given the established patterns in other comparable patient outcomes, reinforcing the conclusion that a seizure diagnosis is not present in this case.","Based on the provided information, I predict that the main patient does **not** have a diagnosis of seizures requiring antiepileptic medications. This prediction is supported by the fact that the patient has a relatively complex surgical history with multiple interventions, including electrophysiologic studies and cardioversions related to arrhythmias, but no prior history of seizures is noted. Additionally, the similar patients demonstrate a clear lack of seizure diagnoses, with most also lacking notable neurological complications, suggesting that such issues may not be prevalent in this cohort. Finally, the XGBoost model's predicted probability of the occluded outcome suggests a very low likelihood (approximately 3.24%), reinforcing the inference that seizures are unlikely to be a concern for this patient.","Based on the provided data, I predict that the missing clinical outcome, ""Does the patient have a diagnosis of seizures requiring antiepileptic medications?"" is likely **no**. The main patient has a history of atrial tachyarrhythmias and was involved in an emergent cardioversion following a soccer ball impact, which may contribute to a likelihood of seizure activity, but there is no indication of a seizure diagnosis in the medical history provided. Furthermore, the similar patients, most of whom did not report seizures or the need for antiepileptics, indicate a prevailing trend where seizure diagnoses are rare in this cohort. Moreover, the XGBoost model estimates a low probability of the occluded outcome being 'yes' (0.0324), reinforcing the likelihood that seizures are not present in this patient.",1,1,1,1,0
BCH-WEIALE-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other primary neonatal surgery, please describe: aortic valve commisurotomy
 If other semilunar valve procedure please describe valve sparing neoaortic root repair, Resection of sub-neoaortic valve tissue.
 If other ascending aorta or arch intervention please describe:   Valve-sparing neoaortic root repair with 20 millimeter Hemashield graft and leaflet thinning of the neo-aortic valve leaflets. 
 Other relevant surgical or clinical history (optional): CATH 8/1/1991, OSH- balloon aortic valvuloplasty
SURG 8/1/1991, OSH- aortic valve commisurotomy
SURG 10/16/1991: Stage I /BTS
CATH 3/27/1992- Hemodynamics
SURG 3/30/1992- Bi-directional glenn
CATH 4/15/1992- creation of arterial-pulmonary shunt
CATH 6/23/1992- Hemodynamics
CATH 3/24/1993- caval surgery
CATH 2/1/1994- coils placed
SURG 2/3/1994- fenestrated lateral tunnel fontan procedure
CATH 2/2007- Dilation and stent placement of fenestration
CATH 9/14- hemodynamic
SURG 9/14- Valve sparing root replacement. Take down of lateral fontan and creation of extracardiac fontan. Tricupid valve annuloplasty. Tricupid valve repair. Placement of epicardial lead
SURG 9/14- Connection of generator to existing atrial pacing leads.
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Extracardiac Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.5
 Patient weight: 50.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4964721470797968
 Heart rate: 95.0
 Upper limb systolic blood pressure: 95.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 76.0
 Left ventricle end-diastolic volume: 32.83
 Left ventricle end-systolic volume: 18.58
 Left ventricular mass: 41.23
 Right ventricular end-diastolic volume: 154.0
 Right ventricular end-systolic volume: 77.0
 Right ventricle mass: 60.18
 Aortic or native aortic regurgitation fraction: 23.0
 Single ventricle ejection fraction 0.488411925279666
 Single ventricle systolic volume 91.24999999999999
 Body mass index 18.93491124260355
 Mass to height volume indexed on BSA (exp = 2.7) 27.338626793243897
 Systemic ventricle end-systolic volume: 95.58
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 63.87021648649726
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 56.594965145472365
 Systemic ventricle end-diastolic volume: 186.82999999999998
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 124.84696114430093
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 110.62604455041432
 Systemic ventricle mass: 101.41
 Systemic ventricle mass indexed on BSA (exp=1) 67.7660457616205
 Systemic ventricle mass indexed on BSA (exp=1.3) 60.04703301320728
 Systemic ventricle mass to volume ratio: 1.6466427602248497
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1003497548805665
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9750124463482922
 Any significant metallic artifact that obscures anatomy? If yes, please describe: There is susceptibility artifact from the stents in the
Fontan pathway.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? no
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Moderate
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
  diagnosis of seizures requiring antiepileptic medications? yes
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.3319198].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.96
AUC (ROC Curve): 0.87

Classification Report:
              precision    recall  f1-score   support

         0.0       0.97      1.00      0.98       679
         1.0       0.73      0.27      0.39        30

    accuracy                           0.96       709
   macro avg       0.85      0.63      0.69       709
weighted avg       0.96      0.96      0.96       709


",Has the patient died?,[' Has the patient died? no\n'],"Based on the provided data for the main patient, it is predicted that the missing clinical outcome ""Has the patient died?"" is ""No."" The patient's fairly extensive surgical history, including multiple interventions such as the Fontan procedure and valve repairs, indicates that they are receiving continuous medical attention and management which is critical for single-ventricle patients. The patient also has a relatively stable hemodynamic profile, as suggested by their MRI results and absence of critical complications, such as thrombus formation or severe arrhythmias. Additionally, the predicted probability of the occluded outcome being 'yes' is only around 33%, which supports the likelihood of survival rather than mortality. Thus, the combination of these clinical factors strongly leans towards the conclusion that the patient is alive.","Based on the provided data, I would predict that the main patient has not died (""no""). The patient has undergone multiple cardiac interventions, including a lateral tunnel Fontan and subsequent extracardiac Fontan revision, without any documented fatal complications or a history of critical adverse events such as major strokes or cardiac arrests. Additionally, the data from the similar patients indicates a relatively low mortality rate in those with comparable profiles, as none reported a death. The XGBoost model also suggests a substantial probability (0.33) that the occluded outcome (death) is not true, corroborating the idea that survival is likely for the main patient when considering surgical history and clinical features together.","Based on the provided data, the most likely prediction for the main patient regarding the occluded outcome, ""Has the patient died?"", is **no**. The main patient has a complex surgical history, including five cardiac surgeries and a history of challenges post-Fontan, including a pacemaker placement and episodes of non-chylous pleural effusions. However, despite these issues, there is no indication of severe complications leading to death in their history, such as significant ventricular arrhythmias or heart transplant listing.

Examining the similar patients, there is a notable trend: while some in the cohort have died (particularly those with significant arrhythmias), the overall majority have not and exhibit a good clinical status. The XGBoost model estimates a relatively low probability of the outcome being 'yes' (33.19%), reflecting a general trend of survival among this cohort of patients. This reinforces the reasoning that the main patient is likely still alive given the lack of catastrophic events in their medical history compared to deceased patients in the similar cohort.","Based on the analysis of the main patient's surgical history and MRI data, as well as comparisons to similar patients, I predict that the clinical outcome for the main patient is likely ""no"" for having died. The patient has a complex history involving multiple cardiac surgeries and ongoing management for their condition, including seizure treatment and having a pacemaker, but no significant history of severe complications like thrombosis or arrhythmias that led to fatal outcomes. Furthermore, the estimated probability from the XGBoost model of 0.3319 suggests a moderate risk of death; however, this aligns with the lower incidence seen in the similar cohort—where most patients did not experience mortality despite serious situations, indicating that while caution is warranted, the prognosis for the main patient appears relatively stable compared to deceased counterparts.",1,1,1,1,0
BCH-WEIALE-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other primary neonatal surgery, please describe: aortic valve commisurotomy
 If other semilunar valve procedure please describe valve sparing neoaortic root repair, Resection of sub-neoaortic valve tissue.
 If other ascending aorta or arch intervention please describe:   Valve-sparing neoaortic root repair with 20 millimeter Hemashield graft and leaflet thinning of the neo-aortic valve leaflets. 
 Other relevant surgical or clinical history (optional): CATH 8/1/1991, OSH- balloon aortic valvuloplasty
SURG 8/1/1991, OSH- aortic valve commisurotomy
SURG 10/16/1991: Stage I /BTS
CATH 3/27/1992- Hemodynamics
SURG 3/30/1992- Bi-directional glenn
CATH 4/15/1992- creation of arterial-pulmonary shunt
CATH 6/23/1992- Hemodynamics
CATH 3/24/1993- caval surgery
CATH 2/1/1994- coils placed
SURG 2/3/1994- fenestrated lateral tunnel fontan procedure
CATH 2/2007- Dilation and stent placement of fenestration
CATH 9/14- hemodynamic
SURG 9/14- Valve sparing root replacement. Take down of lateral fontan and creation of extracardiac fontan. Tricupid valve annuloplasty. Tricupid valve repair. Placement of epicardial lead
SURG 9/14- Connection of generator to existing atrial pacing leads.
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Extracardiac Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.5
 Patient weight: 50.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4964721470797968
 Heart rate: 95.0
 Upper limb systolic blood pressure: 95.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 76.0
 Left ventricle end-diastolic volume: 32.83
 Left ventricle end-systolic volume: 18.58
 Left ventricular mass: 41.23
 Right ventricular end-diastolic volume: 154.0
 Right ventricular end-systolic volume: 77.0
 Right ventricle mass: 60.18
 Aortic or native aortic regurgitation fraction: 23.0
 Single ventricle ejection fraction 0.488411925279666
 Single ventricle systolic volume 91.24999999999999
 Body mass index 18.93491124260355
 Mass to height volume indexed on BSA (exp = 2.7) 27.338626793243897
 Systemic ventricle end-systolic volume: 95.58
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 63.87021648649726
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 56.594965145472365
 Systemic ventricle end-diastolic volume: 186.82999999999998
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 124.84696114430093
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 110.62604455041432
 Systemic ventricle mass: 101.41
 Systemic ventricle mass indexed on BSA (exp=1) 67.7660457616205
 Systemic ventricle mass indexed on BSA (exp=1.3) 60.04703301320728
 Systemic ventricle mass to volume ratio: 1.6466427602248497
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1003497548805665
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9750124463482922
 Any significant metallic artifact that obscures anatomy? If yes, please describe: There is susceptibility artifact from the stents in the
Fontan pathway.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? no
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Moderate
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? yes
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.9933822].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 1.00
AUC (ROC Curve): 1.00

Classification Report:
              precision    recall  f1-score   support

         0.0       1.00      1.00      1.00       665
         1.0       1.00      0.98      0.99        46

    accuracy                           1.00       711
   macro avg       1.00      0.99      0.99       711
weighted avg       1.00      1.00      1.00       711


",Does the patient have a history of pacemaker placement?,['  history of pacemaker placement? yes\n Reason for pacemaker placement: Other\n'],"Based on the provided data, I predict that the missing clinical outcome for the patient is **yes**, they have a history of pacemaker placement. Several indicators support this prediction: the patient has undergone multiple complex surgical interventions, including a “placement of epicardial lead” during Fontan revision surgery, which typically indicates the placement of a pacemaker. Additionally, the patient’s current NYHA (New York Heart Association) class indicates ongoing management of heart function, which may also warrant pacing support. Furthermore, the model's predicted probability of the occluded outcome being 'yes' (0.9933822) strongly suggests a high likelihood of the patient having a history of pacemaker placement.","Based on the provided data, it is likely that the main patient has a history of pacemaker placement (""yes""). The main patient has a complex surgical history, including multiple surgeries and interventions related to their cardiac condition, which is hypoplastic left heart syndrome. This condition often leads to arrhythmias or cardiac dysfunction requiring pacemaker support, especially considering their reported sinus node dysfunction. Additionally, among the similar patients, those who experienced comparable surgical histories and complications often required a pacemaker; this trend is reinforced by the XGBoost model, which predicts a high probability of the occluded outcome being 'yes' (0.9933822), indicating that a past pacemaker placement might be an expected outcome in this high-risk cohort.","Based on the information provided for the main patient, it is reasonable to predict that the patient has a history of pacemaker placement (yes). The main patient has a complex surgical history involving multiple interventions, including a Fontan pathway revision and indications of potential arrhythmias (e.g., sinus node dysfunction), which increases the likelihood of requiring a pacemaker. Additionally, similar patients with comparable surgical histories and complications have often required pacemaker placements due to their complex anatomy and potential conduction issues associated with single-ventricle physiology. The high predicted probability of 0.9933822 from the XGBoost model further supports this outcome, indicating a strong likelihood that the patient would have experienced arrhythmias necessitating a pacemaker.","Based on the comprehensive analysis of the main patient's data, including their significant surgical history, particularly multiple interventions involving fenestration and modifications to the Fontan pathway, it is highly probable that the patient has had a history of pacemaker placement. Additionally, the similar patients exhibited a notable trend, with many having a higher likelihood of requiring pacing support, especially after complex surgeries like Fontan revisions. Given the patient's specific conditions, including sinus node dysfunction, and the predicted high probability (0.9933822) from the XGBoost model indicating a strong likelihood of needing a pacemaker, it is reasonable to conclude that the answer to whether this patient has a history of pacemaker placement is ""yes.""",1,1,1,1,1
BCH-WEIALE-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other primary neonatal surgery, please describe: aortic valve commisurotomy
 If other semilunar valve procedure please describe valve sparing neoaortic root repair, Resection of sub-neoaortic valve tissue.
 If other ascending aorta or arch intervention please describe:   Valve-sparing neoaortic root repair with 20 millimeter Hemashield graft and leaflet thinning of the neo-aortic valve leaflets. 
 Other relevant surgical or clinical history (optional): CATH 8/1/1991, OSH- balloon aortic valvuloplasty
SURG 8/1/1991, OSH- aortic valve commisurotomy
SURG 10/16/1991: Stage I /BTS
CATH 3/27/1992- Hemodynamics
SURG 3/30/1992- Bi-directional glenn
CATH 4/15/1992- creation of arterial-pulmonary shunt
CATH 6/23/1992- Hemodynamics
CATH 3/24/1993- caval surgery
CATH 2/1/1994- coils placed
SURG 2/3/1994- fenestrated lateral tunnel fontan procedure
CATH 2/2007- Dilation and stent placement of fenestration
CATH 9/14- hemodynamic
SURG 9/14- Valve sparing root replacement. Take down of lateral fontan and creation of extracardiac fontan. Tricupid valve annuloplasty. Tricupid valve repair. Placement of epicardial lead
SURG 9/14- Connection of generator to existing atrial pacing leads.
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Extracardiac Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.5
 Patient weight: 50.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4964721470797968
 Heart rate: 95.0
 Upper limb systolic blood pressure: 95.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 76.0
 Left ventricle end-diastolic volume: 32.83
 Left ventricle end-systolic volume: 18.58
 Left ventricular mass: 41.23
 Right ventricular end-diastolic volume: 154.0
 Right ventricular end-systolic volume: 77.0
 Right ventricle mass: 60.18
 Aortic or native aortic regurgitation fraction: 23.0
 Single ventricle ejection fraction 0.488411925279666
 Single ventricle systolic volume 91.24999999999999
 Body mass index 18.93491124260355
 Mass to height volume indexed on BSA (exp = 2.7) 27.338626793243897
 Systemic ventricle end-systolic volume: 95.58
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 63.87021648649726
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 56.594965145472365
 Systemic ventricle end-diastolic volume: 186.82999999999998
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 124.84696114430093
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 110.62604455041432
 Systemic ventricle mass: 101.41
 Systemic ventricle mass indexed on BSA (exp=1) 67.7660457616205
 Systemic ventricle mass indexed on BSA (exp=1.3) 60.04703301320728
 Systemic ventricle mass to volume ratio: 1.6466427602248497
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1003497548805665
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9750124463482922
 Any significant metallic artifact that obscures anatomy? If yes, please describe: There is susceptibility artifact from the stents in the
Fontan pathway.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? no
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Moderate
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.17247081].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.94
AUC (ROC Curve): 0.86

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      1.00      0.97       665
         1.0       0.60      0.07      0.12        46

    accuracy                           0.94       711
   macro avg       0.77      0.53      0.54       711
weighted avg       0.92      0.94      0.91       711


",Does the patient have a diagnosis of seizures requiring antiepileptic medications?,['  diagnosis of seizures requiring antiepileptic medications? yes\n'],"Based on the available data, it is likely that the patient does not have a diagnosis of seizures requiring antiepileptic medications (""no""). The patient's cardiac history, including five surgeries and various cardiac interventions, reflects a complex but managed condition of hypoplastic left heart syndrome. Notably, there is no reported history of neurologic issues, such as strokes or transient ischemic attacks, which could indicate a higher risk for seizures. Additionally, the XGBoost model predicts only a 17.2% probability of the occluded outcome being 'yes,' suggesting a low likelihood of seizure diagnosis in this cohort of patients. Thus, the balance of the patient's clinical and MRI findings combined with the model output supports this conclusion.","Based on the provided information and analysis, it is likely that the main patient does not have a diagnosis of seizures requiring antiepileptic medications. The main patient has a complex surgical history including multiple interventions, but there are no reported cases of seizures or the need for antiepileptic medication. 

Additionally, evaluating the similar patients shows that none of the matched patients experienced seizures or required such medications, despite significant surgical histories akin to the main patient. Furthermore, the predicted probability of the occluded outcome being 'yes' based on the XGBoost model is relatively low (0.172), suggesting that the occurrence of seizures is uncommon in this cohort. Combined, these factors lead to a strong inference that the main patient is unlikely to have a diagnosis of seizures requiring antiepileptic treatment.","Based on the information provided, the predicted clinical outcome for the main patient regarding the diagnosis of seizures requiring antiepileptic medications is **no**. The main patient has a complex surgical history consistent with significant cardiac interventions but does not report any history of neurological complications, such as seizures. When comparing to similar patients, the majority also reflect no diagnosis of seizures, and importantly, the XGBoost model indicated a low predicted probability (0.17247081) for the outcome being 'yes'. Given the trends in the cohort, along with a strong performance of the predictive model, it seems unlikely that the main patient has a seizure disorder requiring medication.","Based on the main patient's clinical history and MRI findings, it is reasonable to predict that the patient does not have a diagnosis of seizures requiring antiepileptic medications. The absence of such a diagnosis in the patient's status update implies that there are no established seizures or related neurological issues reported. Additionally, examining similar patients, several demonstrate a lack of seizure history despite similar cardiac conditions and surgical histories, indicating that seizure-related complications may not be common across patients with comparable profiles. Furthermore, the XGBoost model's prediction of a low probability (approximately 17.2%) for the diagnosis of seizures suggests that this outcome is less likely based on aggregated clinical features, reinforcing the conclusion that the main patient likely does not have such a diagnosis.",0,0,0,0,1
BCH-WEIALE-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other primary neonatal surgery, please describe: aortic valve commisurotomy
 If other semilunar valve procedure please describe valve sparing neoaortic root repair, Resection of sub-neoaortic valve tissue.
 If other ascending aorta or arch intervention please describe:   Valve-sparing neoaortic root repair with 20 millimeter Hemashield graft and leaflet thinning of the neo-aortic valve leaflets. 
 Other relevant surgical or clinical history (optional): CATH 8/1/1991, OSH- balloon aortic valvuloplasty
SURG 8/1/1991, OSH- aortic valve commisurotomy
SURG 10/16/1991: Stage I /BTS
CATH 3/27/1992- Hemodynamics
SURG 3/30/1992- Bi-directional glenn
CATH 4/15/1992- creation of arterial-pulmonary shunt
CATH 6/23/1992- Hemodynamics
CATH 3/24/1993- caval surgery
CATH 2/1/1994- coils placed
SURG 2/3/1994- fenestrated lateral tunnel fontan procedure
CATH 2/2007- Dilation and stent placement of fenestration
CATH 9/14- hemodynamic
SURG 9/14- Valve sparing root replacement. Take down of lateral fontan and creation of extracardiac fontan. Tricupid valve annuloplasty. Tricupid valve repair. Placement of epicardial lead
SURG 9/14- Connection of generator to existing atrial pacing leads.
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Extracardiac Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.5
 Patient weight: 50.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4964721470797968
 Heart rate: 95.0
 Upper limb systolic blood pressure: 95.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 76.0
 Left ventricle end-diastolic volume: 32.83
 Left ventricle end-systolic volume: 18.58
 Left ventricular mass: 41.23
 Right ventricular end-diastolic volume: 154.0
 Right ventricular end-systolic volume: 77.0
 Right ventricle mass: 60.18
 Aortic or native aortic regurgitation fraction: 23.0
 Single ventricle ejection fraction 0.488411925279666
 Single ventricle systolic volume 91.24999999999999
 Body mass index 18.93491124260355
 Mass to height volume indexed on BSA (exp = 2.7) 27.338626793243897
 Systemic ventricle end-systolic volume: 95.58
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 63.87021648649726
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 56.594965145472365
 Systemic ventricle end-diastolic volume: 186.82999999999998
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 124.84696114430093
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 110.62604455041432
 Systemic ventricle mass: 101.41
 Systemic ventricle mass indexed on BSA (exp=1) 67.7660457616205
 Systemic ventricle mass indexed on BSA (exp=1.3) 60.04703301320728
 Systemic ventricle mass to volume ratio: 1.6466427602248497
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1003497548805665
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9750124463482922
 Any significant metallic artifact that obscures anatomy? If yes, please describe: There is susceptibility artifact from the stents in the
Fontan pathway.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? no
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Moderate
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? yes
 Prior listing for a heart transplant? no
 Did the patient receive a heart transplant? no
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.32011402].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.93
AUC (ROC Curve): 0.88

Classification Report:
              precision    recall  f1-score   support

         0.0       0.94      0.99      0.96       653
         1.0       0.67      0.25      0.36        57

    accuracy                           0.93       710
   macro avg       0.80      0.62      0.66       710
weighted avg       0.92      0.93      0.91       710


",Does the patient have a history of ascites (> trace)?,['  history of ascites (> trace)? no\n'],"Based on the provided details, it is reasonable to predict that the patient has a history of ascites (yes). The significant surgical history, particularly the multiple interventions and complications associated with Fontan physiology, suggests challenges with fluid management and venous return. Furthermore, the patient's MRI report indicates moderate semi-lunar valve regurgitation, which can lead to fluid overload and subsequent ascites in patients with single-ventricle physiology. Although the XGBoost model predicts a 32% probability for the occluded outcome, which is relatively low, the combination of the patient's history and the anatomical challenges makes a history of ascites plausible.","Based on the provided data, the prediction for the occluded clinical outcome, ""Does the patient have a history of ascites (> trace)?"", is **no**. The main patient has a history of non-chylous pleural effusions greater than 30 days after surgery, but no mention of ascites, suggesting that fluid retention may have been localized rather than systemic. Moreover, among the similar patients, none reported a history of ascites, which, along with the main patient's relatively stable hemodynamic and clinical status post-Fontan, further supports a lower likelihood of ascites. Additionally, the XGBoost model indicates that the probability of experiencing this outcome is relatively low (0.32), aligning with the absence of significant indications for ascites in this particular cohort.","**Prediction:** **Yes**, the patient has a history of ascites (> trace).

**Reasoning:** The main patient has undergone multiple cardiac surgeries, including a history of pleural effusions along with significant hemodynamic management post-Fontan. This suggests a complex clinical background that often correlates with fluid management issues, such as ascites. When considering the similar patients, one had a strong indication of pleural effusions, which can be associated with fluid overload and ascites in single-ventricle patients. Given the occluded outcome has a predicted probability of 0.32 for being 'yes', and the established trend of fluid-related complications in similar patients, it is reasonable to conclude that this patient could indeed have a history of ascites.","Based on the provided data, I predict that the main patient does **not** have a history of ascites (> trace). The patient has a surgical history with multiple interventions but no documented episodes of ascites or significant complications typically associated with ascites, such as protein-losing enteropathy or pleural effusions. In the cohort of similar patients, while some exhibit histories of ascites, those with comparable surgical profiles to the main patient, particularly those who underwent a Fontan procedure without subsequent major complications or noted ascites, did not report such a history. Furthermore, the model's output, which indicates a relatively low probability of the occluded outcome being 'yes' (0.32), supports the likelihood that conditions promoting ascites have not developed in this case. Consequently, I conclude that the main patient likely does not have a history of ascites.",0,1,0,1,0
BCH-WEIALE-1," Pt Clinical Surgical History 
 Total number of cardiac surgeries: 5.0
 If other primary neonatal surgery, please describe: aortic valve commisurotomy
 If other semilunar valve procedure please describe valve sparing neoaortic root repair, Resection of sub-neoaortic valve tissue.
 If other ascending aorta or arch intervention please describe:   Valve-sparing neoaortic root repair with 20 millimeter Hemashield graft and leaflet thinning of the neo-aortic valve leaflets. 
 Other relevant surgical or clinical history (optional): CATH 8/1/1991, OSH- balloon aortic valvuloplasty
SURG 8/1/1991, OSH- aortic valve commisurotomy
SURG 10/16/1991: Stage I /BTS
CATH 3/27/1992- Hemodynamics
SURG 3/30/1992- Bi-directional glenn
CATH 4/15/1992- creation of arterial-pulmonary shunt
CATH 6/23/1992- Hemodynamics
CATH 3/24/1993- caval surgery
CATH 2/1/1994- coils placed
SURG 2/3/1994- fenestrated lateral tunnel fontan procedure
CATH 2/2007- Dilation and stent placement of fenestration
CATH 9/14- hemodynamic
SURG 9/14- Valve sparing root replacement. Take down of lateral fontan and creation of extracardiac fontan. Tricupid valve annuloplasty. Tricupid valve repair. Placement of epicardial lead
SURG 9/14- Connection of generator to existing atrial pacing leads.
 Cardiac diagnosis: Hypoplastic left heart syndrome or small left-sided structures
 Suspected heterotaxy: No
 Interrupted Inferior Vena Cava (IVC)? no
 Patients dominant ventricular morphology: Right
 Did the patient undergo a primary neonatal surgery within the first 30 days of life? yes
 If primary neonatal surgery included placement of a pulmonary blood flow shunt, record type: no
 Did the patient undergo a primary Stage 2 Cardiac Surgery or Superior Cavopulmonary Connection Surgery?
(Glenn surgery not as part of the Fontan procedure) yes
 Type of superior cavopulmonary connection surgery: Bidirectional Glenn
 Did the patient undergo an additional cardiac pre-Fontan surgery? no
 Initial Fontan surgery/Total Cavopulmonary Connection: Lateral tunnel Fontan
 Did the patient have a fenestration during the initial Fontan surgery? yes
  history of Fontan revision? yes
 Type of Fontan revision: Extracardiac Fontan
 Did the patient have a fenestration during the Fontan revision? no
 Did the patient undergo a Stansel/Damus/DKS procedure? yes
 Did the patient undergo pulmonary artery band surgery (PAB)? no
 Did the patient undergo a systemic or pulmonary artery shunt surgery? yes
 Type of systemic or pulmonary artery shunt: yes
 Did the patient undergo a semilunar valve (pulmonary and/or aortic)  procedure? yes
 Did the patient undergo an atrioventricular (tricuspid and/or mitral) valve procedure? yes
 Did the patient undergo an ascending aorta or arch intervention (excluding an intervention at the time of a Stage I, Glenn, or Fontan surgery)? yes
 Did the patient undergo a branch pulmonary artery (PA)  intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery): no
 Did the patient undergo a pulmonary vein intervention (excluding interventions at the time of a Stage I, Glenn or Fontan surgery)? no
 Did the patient undergo a superior vena cava (SVC) intervention? no
 Did the patient undergo a Fontan pathway or fenestration intervention? yes
 Did the patient undergo an aortopulmonary collateral (APC) coil or gelfoam intervention? yes
 Did the patient undergo a  veno-venous collateral (VVC) coil or gelfoam intervention? yes
 Known genetic diagnosis: Other {dx_genetic_other}

 Cmr 
 Patient height: 162.5
 Patient weight: 50.0
 Record the patient's Body Surface Area (BSA) if your center does not report height/weight: 1.4964721470797968
 Heart rate: 95.0
 Upper limb systolic blood pressure: 95.0
 Upper limb diastolic blood pressure: 61.0
 Upper limb mean blood pressure: 76.0
 Left ventricle end-diastolic volume: 32.83
 Left ventricle end-systolic volume: 18.58
 Left ventricular mass: 41.23
 Right ventricular end-diastolic volume: 154.0
 Right ventricular end-systolic volume: 77.0
 Right ventricle mass: 60.18
 Aortic or native aortic regurgitation fraction: 23.0
 Single ventricle ejection fraction 0.488411925279666
 Single ventricle systolic volume 91.24999999999999
 Body mass index 18.93491124260355
 Mass to height volume indexed on BSA (exp = 2.7) 27.338626793243897
 Systemic ventricle end-systolic volume: 95.58
 Systemic ventricle end-systolic volume indexed on BSA (exp=1) 63.87021648649726
 Systemic ventricle end-systolic volume indexed on BSA (exp=1.3) 56.594965145472365
 Systemic ventricle end-diastolic volume: 186.82999999999998
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1) 124.84696114430093
 Systemic ventricle end-diastolic volume indexed on BSA (exp=1.3) 110.62604455041432
 Systemic ventricle mass: 101.41
 Systemic ventricle mass indexed on BSA (exp=1) 67.7660457616205
 Systemic ventricle mass indexed on BSA (exp=1.3) 60.04703301320728
 Systemic ventricle mass to volume ratio: 1.6466427602248497
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1) 1.1003497548805665
 Systemic ventricle mass to volume ratio indexed on BSA (exp=1.3) 0.9750124463482922
 Any significant metallic artifact that obscures anatomy? If yes, please describe: There is susceptibility artifact from the stents in the
Fontan pathway.=========================Minor artifact only
 Were the cardiac magnetic resonance images successfully uploaded to Ambra? no
 Cardiac magnetic resonance imaging vendor type: yes
 Tesla strength yes
 Was sedation used during the cardiac magnetic resonance imaging? no
 Was contrast used during cardiac magnetic resonance imaging? no
 What was the patients Fontan anatomy at the time of cardiovascular magnetic imaging? yes
 Fenestration or baffle leak status at CMR:
 yes
 Were both ventricles contoured using a single contour so the entered data above represents volumes from both ventricles? no
 Which ventricles contribute to the systemic circulation? 

1. If the patient has a ventricular septal defect both ventricles ALWAYS contribute
2. If there is NO ventricular septal defect and semilunar valve ATRESIA, the ventricle under that valve does NOT contribute to the systemic circulation 
Ex: HLHS with a. Aortic atresia--> 1V    b. Aortic stenosis--> 2V Both
 Qualitative or quantitative total atrioventricular valve regurgitation: Unable to determine
 Qualitative or quantitative total semi-lunar valve regurgitation: Moderate
 Late gadolinium enhancement present in the ventricular myocardium or papillary muscles at time of cardiovascular magnetic imaging? Not performed
 Gadolinium based contrast agents subtype (Exemplary Commercial name): Other
 Location and description of late gadolinium enhancement: Unable to determine

 Pt Status Event Update 
 Has the patient died? no
  diagnosis of seizures requiring antiepileptic medications? yes
  diagnosis of protein-losing enteropathy? no
  diagnosis of plastic bronchitis? no
  diagnosis of intracardiac or major vascular thrombus? no
  history of stroke (peri-op)? no
  history of stroke (non peri-op)? no
  history of transient ischemic attack (non peri-op)? no
  history of cardiac arrest (peri-op)? no
  history of cardiac arrest (non peri-op)? no
  history of pleural effusion, chylous greater than 30 days after surgery? no
  history of pleural effusions, non-chylous, greater than 30 days after surgery? yes
  history of a positive fibrosure or significantly elevated liver fibrosis test? no
  history of ascites (> trace)? no
  history of hepatocellular carcinoma? no
  history of renal dysfunction defined as a GFR < 60 or Dialysis; excluding peri-operative renal dysfunction? no
  history of hemoptysis? no
  history of Extra Corporeal Membrane Oxygenation (ECMO)? no
  history of atrial tachyarrhythmias, atrial fibrillation, atrial flutter, or atrial tachycardia? no
  history of non-sustained ventricular tachyarrhythmias? no
  history of sustained ventricular tachyarrhythmias, ventricular tachycardia, ventricular fibrillation, lasting more than 30 seconds? no
  history of elective cardioversion? no
  history of emergent cardioversion, defibrillation, or arrhythmogenic cardiac arrest? no
  history of post-Fontan electrophysiologic study? no
  history of sinus node dysfunction? yes
  history of pacemaker placement? yes
  history of defibrillator use? no
 Current NYHA class: yes
 Anticoagulant / anti-platelet: yes
 Angiotensin Converting Enzyme Inhibitor (ACE-I) / Angiotensin Receptor Blocker (ARB): no
 Diuretic: yes
 Beta blocker: yes
 Antidepressants, anti-anxiety, stimulants, antipsychotics, and/or mood stabilizers no
 Pulmonary Vasodilator: no
 Location of first intracardiac thrombus: Other {hx_thrombus_loc_other}
 Critical findings and/or intervention of first post-Fontan electrophysiologic study: Other
 Reason for pacemaker placement: Other
 Reason for defibrillator placement: Other
 Type(s) of anticoagulant / antiplatelet: Other {meds_anticoag_other}
","Additionally, an XGBoost model estimates the predicted probability of the occluded outcome being 'yes' to be: [0.00805685].
This prediction is based on a model trained and validated on the set of clinical features you were given. The dataset includes a similar cohort of patients, but not the patient in question.
Below are the results obtained on the similar cohort (excluding the test patient)
Accuracy on Validation Set: 0.98
AUC (ROC Curve): 0.93

Classification Report:
              precision    recall  f1-score   support

         0.0       0.99      1.00      0.99       695
         1.0       0.78      0.44      0.56        16

    accuracy                           0.98       711
   macro avg       0.88      0.72      0.78       711
weighted avg       0.98      0.98      0.98       711


",Did the patient receive or was listed for a heart transplant?,[' Prior listing for a heart transplant? no\n Did the patient receive a heart transplant? no\n'],"Based on the provided information, it is predicted that the patient did **not** receive a heart transplant. This conclusion is supported by the patient’s complex surgical history, including multiple heart surgeries and the specific details surrounding their Fontan procedure and revisions. The absence of significant acute complications, such as severe post-operative heart failure or major thrombotic events, combined with normal hemodynamic readings and relatively low single ventricle ejection fraction (48.84%), suggests the patient has managed their condition with the existing ventricular morphology without necessitating a transplant. Moreover, the low estimated probability (0.008) from the XGBoost model reinforces the likelihood that the occluded outcome is negative, indicating that a heart transplant was unlikely required in this patient's case.","Based on the available information, I predict that the main patient did **not** receive a heart transplant. This conclusion is supported by the XGBoost model's estimated probability of the occluded outcome being 'yes' at only 0.00805685, indicating a very low likelihood of transplant occurrence. Furthermore, the main patient's complex surgical history, including a series of interventions to address hypoplastic left heart syndrome and the need for Fontan revision, suggests that management has prioritized maintaining the existing anatomy rather than opting for transplantation, which is typically considered when patients experience significant deterioration. Additionally, similar patients with comparable surgical histories and outcomes did not show a high prevalence of heart transplant, reinforcing the idea that these patients often remain under ongoing medical management without resorting to transplant options.","Based on the provided data and patterns observed in the similar patients, it appears that the main patient is unlikely to have received a heart transplant. The main patient has undergone multiple complex cardiac surgeries typical for a single ventricle physiology, including a Fontan procedure with a history of interventions to manage complications, suggesting ongoing management rather than transplantation. The similarity with patients who did not receive transplants, especially those who have also experienced significant surgical histories without later undergoing transplantation, further supports this conclusion. Additionally, the XGBoost model indicates a very low probability (0.008) of the occluded outcome being 'yes,' reinforcing the likelihood that the patient did not receive a heart transplant.","Based on the provided data and analysis, the prediction for the main patient's outcome regarding whether they received a heart transplant is **no**. The main patient has a history of multiple surgeries for hypoplastic left heart syndrome and has undergone a complex surgical pathway, including a lateral tunnel Fontan and subsequent revisions, indicating that their condition has been managed without resorting to heart transplantation. Furthermore, similar patients with comparable surgical histories and cardiac diagnoses have shown a low incidence of transplantation, as evidenced by higher survival rates and the presence of moderate comorbidities. 

The XGBoost model's output, suggesting a very low probability (0.81%) that the patient received a heart transplant, strongly supports this conclusion. The models trained on similar cohorts show a high overall accuracy but also emphasize the need for careful consideration of various clinical features that indicate ongoing management of heart function without transplantation. Thus, it aligns with both the clinical history of the main patient and the observed patterns in the similar patient group.",1,1,1,1,0
